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Abstract	  	  	   The	  biological	  functions	  of	  the	  molecular	  components	  	  (genes,	  proteins,	  miRNAs,	  siRNAs,..etc)	   of	   biological	   cells	   and	   mutations/perturbations	   thereof	   are	   tightly	  connected	  with	  cellular	  malfunctions	  and	  disease	  pathways.	  Moreover,	  these	  molecular	  elements	  interact	  with	  each	  other	  forming	  a	  complex	  interwoven	  regulatory	  machinery	  that	   governs,	   on	   one	   hand,	   regular	   cellular	   pathways,	   and	   on	   the	   other	   hand,	   their	  dysregulation	   or	   malfunction	   in	   pathological	   processes.	   Therefore,	   revealing	   these	  critical	  molecular	   interactions	   in	  complex	   living	  systems	  is	  being	  considered	  as	  one	  of	  the	  major	  goals	  of	  current	  systems	  biology.	  	  	  In	   this	  dissertation,	  we	   introduce	  practical	  computational	  approaches	   implemented	  as	  freely	   available	   software	   tools	   to	   integrate	   heterogeneous	   sources	   of	   large-­‐scale	  genomic	  data	  and	  unravel	  the	  combinatorial	  regulatory	  interactions	  between	  different	  molecular	   elements.	   First,	  we	  present	   an	   automated	  GRN	  pipeline	   that	   constructs	   the	  genomic	   regulatory	  machinery	   of	   a	   cell	   from	   expression,	   sequencing,	   and	   annotation	  datasets	   through	   three	   modules	   implemented	   as	   separated	   software	   components	  (plugins)	   and	  hosted	  by	   our	   software	   framework	  Mebitoo	   that	   aims	   at	   automation	  of	  bioinformatics	   workflows.	   Then,	   we	   extended	   this	   pipeline	   to	   a	   general	   integrative	  network-­‐based	   approach	   that	   involves	   also	   post-­‐transcriptional	   interactions	   and	  reports	   the	   computational	   analysis	   of	   gene	   and	   miRNA	   transcriptomes,	   DNA	  methylome,	   and	   somatic	  mutations.	   This	  workflow	   enables	   users	   to	   identify	   putative	  disease	   drivers	   and	   novel	   targets	   for	   therapeutic	   treatment.	   Regarding	   the	  incorporation	  of	  somatic	  mutations	  with	  other	  genomic	  data	  sets,	  a	  stand-­‐alone	  pipeline	  named	   “SnvDMiR”	   was	   implemented	   to	   explore	   possible	   genomic	   proximity	  relationships	  between	  somatic	  variants	  and	  both	  differentially	  methylated	  CpG	  sites	  as	  well	  as	  differentially	  expressed	  miRNAs.	  Along	  the	  same	  lines,	  but	  targeting	  the	  effects	  of	   genomic	  mutations,	  we	  developed	  an	  NGS	  pipeline	   and	  applied	   it	   to	   two	  groups	  of	  bacterial	   isolates	   (nasal	   and	   invasive)	   to	   investigate	   the	  phylogenetic	   positions	   of	   the	  recently	  emerged	  t504	  clone	  (Spa-­‐type	  t504)	  in	  the	  Saarland	  province	  of	  Germany	  and	  to	  better	  understand	  the	  infectivity	  mechanism	  of	  the	  invasive	  group.	  Motivated	  by	  all	  of	   this,	  we	  developed	  TFmiR	  as	  a	   freely	  available	  web	  server	   for	  deep	  and	   integrative	  downstream	  analysis	  of	  combinatorial	  regulatory	  interactions	  between	  TFs/genes	  and	  miRNAs	  that	  are	  involved	  in	  the	  pathogenesis	  of	  human	  diseases.	  	  In	  the	  frame	  of	  this	  thesis,	  we	  employed	  these	  approaches	  to	  investigate	  the	  molecular	  mechanisms	   of	   cellular	   differentiation	   (namely	   hematopoiesis)	   as	   an	   example	   for	  biological	   processes	   and	   human	   breast	   cancer	   and	   diabetes	   as	   examples	   for	   complex	  diseases.	  	  	  In	  summary,	  the	  work	  presented	  in	  this	  thesis	  has	  led	  to	  the	  development	  of	  interesting	  computational	  approaches	  that	  have	  been	  made	  available	  as	  non-­‐commercial	  software	  toolkits.	   The	   provided	   topological	   and	   functional	   analyses	   of	   our	   approaches	   as	  validated	   on	   cellular	   differentiation	   and	   complex	   diseases	   promotes	   them	   as	   reliable	  systems	  biology	  tools	  for	  researchers	  across	  the	  life	  science	  communities.	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Deutsche	  Zusammenfassung	  
	  Die	   Funktionsweise	   verschiedener	   molekularer	   Elemente	   (Gene,	   Proteine,	   Mutationen,	  miRNAs,	   siRNAs,...	   etc.)	   ist	   	  mit	  den	  darunterliegenden	  zellulären	  Fehlfunktionen	  als	   auch	  mit	  Krankheits-­‐assoziierten	  zellulären	  Signalwegen	  verknüpft.	  Darüber	  hinaus	  interagieren	  diese	   molekularen	   Elemente	   auch	   miteinander	   und	   bilden	   eine	   komplexe	   ineinander	  verwobene	   regulatorische	   Maschinerie,	   die	   wiederum	   zelluläre	   Signalwege	   oder	   auch	  Krankheitsentwicklungen	  auf	  zellulärer	  Ebene	  beeinflusst.	  Aufgrund	  dessen	  ist	  heutzutage	  die	   Aufklärung	   dieser	  molekularen	   Interaktionen	   in	   komplexen	   lebenden	   Systemen	   eines	  der	  Hauptziele	  der	  Systembiologie.	  	  In	   dieser	   Dissertation	   stellen	   wir	   rechnerbasierte	   Ansätze	   vor	   welche	   als	   Software	   frei	  verfügbar	   sind	   und	   	   die	   Integration	   von	   großen	   genomischen	   Datensätzen	   als	   auch	   eine	  damit	   verbundene	   Aufklärung	   der	   kombinatorischen	   Vielfalt	   dieser	   regulatorischen	  Interaktionen	   zwischen	   den	   verschiedenen	   molekularen	   Elementen,	   ermöglichten.	   Dafür	  entwickelten	   wir	   anfangs	   eine	   automatisierte	   GRN	   Pipeline,	   welche	   die	   regulatorische	  Maschinerie	   einer	   Zelle	   auf	   der	   Grundlage	   von	   Daten	   zur	   Genexpression,	   über	  Sequenzierung	  als	  auch	  Annotierung	  von	  Datensätzen	  konstruiert.	  Diese	  Pipeline	  wurde	  in	  drei	  separate	  Module	  aufgeteilt,	  die	  alle	  als	  Software	  plugins	  verfügbar	  sind,	  und	   in	  unser	  Framework	   Mebitoo,	   welches	   bioinformatische	   Arbeitsabläufe	   automatisiert,	   integriert	  sind.	   Daraufhin	   erweiterten	  wir	   unser	   bisheriges	   Framework	   um	   einem	   allgemeinen	   und	  integrativen	   Netzwerk-­‐basierten	   Ansatz,	   welcher	   post-­‐transkriptionelle	   Interaktionen	  berücksichtigt	   und	   die	   rechnerbasierte	   Analyse	   von	   Genen	   als	   auch	   miRNA	  Transkriptomen,	   dem	  DNA	  Methylom	  und	   somatischen	  Mutationen	  mit	   einbezieht.	   Unser	  Ziel	  war	  es,	  dabei	  vermeintliche	  Verursacher	  von	  Krankheitsbildern	  als	  auch	  neue	  Ziele	  für	  die	   therapeutische	   Behandlung	   von	   Krankheiten	   zu	   identifizieren.	   Für	   die	   Integration	  somatischer	  Mutationen	  wurde	  eine	  eigenständige	  Pipeline	  namens	  „SnvDMiR“	  entwickelt,	  welche	   die	   Analyse	   von	   möglichen	   genomischen	   Nachbarschaftsbeziehungen	   zwischen	  somatischen	  Mutationen	  und	  differentiell	  methylierten	  CpG	  Positionen	  als	  auch	  differentiell	  exprimierten	   miRNAs,	   ermöglicht.	   Für	   die	   Analyse	   von	   somatischen	   Mutationen	  entwickelten	  wir	   zudem	  eine	  NGS	  Pipeline	  und	  wendeten	  diese	  auf	   zwei	  unterschiedliche	  Gruppen	   von	   bakteriellen	   Isolaten	   (nasale	   und	   invasive)	   an,	   um	   einerseits	   die	  phylogenetische	   Position	   des	   kürzlich	   im	   Saarland	   aufgekommenen	  Klons	   t504	   (Spa-­‐type	  t504)	   zu	   untersuchen,	   aber	   auch	   um	   den	   Mechanismus,	   der	   zu	   einer	   Infektion	   durch	  invasive	   Stämme	   führt,	   besser	   zu	   verstehen.	   All	   dies	   motivierte	   uns	   dazu	   TFmiR	   als	   frei	  verfügbare	  Web-­‐Applikation	   zu	   entwickeln,	   welche	   eine	   tief	   gehende	   integrative	   Analyse	  von	   den	   kombinatorischen	   regulatorischen	   Interaktionen	   zwischen	   TFs/Genen	   und	  miRNAs	  ermöglicht,	  die	  an	  der	  Krankheitsentwicklung	  im	  Menschen	  beteiligt	  sind.	  	  Die	   entwickelten	  Methoden	   wurden	   auf	   die	   zelluläre	   Differenzierung	   (Hämatopoese),	   als	  Beispiel	  für	  einen	  biologischen	  Prozess,	  als	  auch	  auf	  Brustkrebs	  und	  Diabetes,	  als	  Beispiele	  für	   komplexe	   Krankheiten,	   angewendet	   um	   deren	   molekulare	   Mechanismen	   zu	  untersuchen.	  	  	  Zusammenfassend	  hat	  diese	  Arbeit	  zur	  Entwicklung	  von	  interessanten,	  rechnergestützten	  Methoden	   geführt,	   welche	   als	   nicht-­‐kommerzielle	   Software	   publiziert	   wurden.	   Die	  Validierung	  unserer	  Methoden	  anhand	  von	  topologischen	  und	  funktionsbasierten	  Analysen	  sowohl	   in	   zellulärer	   Differenzierung	   als	   auch	   komplexen	   Krankheiten,	   machen	   diese	   zu	  verlässlichen	   systembiologischen	   Werkzeugen	   für	   Wissenschaftler	   aus	   den	  unterschiedlichsten	  Naturwissenschaftsbereichen.	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“The soul is of the affair of my lord. And mankind has not been given of knowledge except a 
little”     
 
“My Lord, Increase me in knowledge” 
 
Quran ,Ch17, vers 85 , and Ch20, vers 114 
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1. Introduction	  and	  biological	  
background	  	  	  	  	  	  
	  
Synopsis	  	  
In	   this	   chapter,	   we	   frame	   the	   problem	   of	   the	   multiple	   cellular	   factors	   affecting	   the	  
regulatory	  machinery	   inside	   the	   cell	   on	   different	  molecular	   levels	   such	   as	   transcription,	  
post-­‐transcription,	   and	   post-­‐translation	   and	   therefore	   the	   need	   for	   integrating	  
information	   from	  heterogeneous	   sources	   of	   genomic	  data.	  We	  discuss	   the	  biology	  of	   the	  
Gene	  Regulatory	  Network	  (GRN)	  and	  tackle	  its	  connection	  to	  biological	  processes	  as	  well	  
as	  to	  the	  pathology	  of	  diseases.	  Finally,	  we	  give	  an	  overview	  of	  the	  structure	  of	  this	  thesis,	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1.1 Introduction	  	  The	   ultimate	   goal	   of	   the	   genomic	   revolution	   and	   of	   modern	   systems	   biology	   is	  elucidating	  the	  genetic	  causes	  and	  drivers	  behind	  cellular	  processes,	  disease	  pathways,	  and	   phenotypic	   characteristics	   of	   organisms.	   This	   requires	   having	   a	   blueprint	   which	  states	  the	  different	  conditions	  in	  which	  genetic	  molecules,	  such	  as	  genes,	  proteins,	  and	  miRNAs,	   interact	   to	   make	   a	   complex	   living	   system	   [1].	   In	   the	   past,	   these	   molecular	  associations	  have	  been	  reported	  at	  a	  rather	  slow	  pace.	  For	  example,	  it	  took	  more	  than	  a	  decade	  from	  the	  discovery	  of	   the	  well-­‐known	  tumor	  suppressor	  gene	  p53	  to	  conclude	  that	  it	  formed	  a	  regulatory	  feedback	  loop	  with	  its	  key	  regulator	  MDM2	  [2].	  Nowadays,	  advances	  in	  sequencing	  and	  expression	  technologies	  enable	  the	  generation	  of	  large	  high	  throughput	  data	   sets	   that	  allow	   for	  genome	  wide	  association	   studies.	   Indeed,	   this	  has	  made	   at	   least	   a	   part	   of	   this	   goal	   closer	   within	   reach,	   namely	   that	   of	   unraveling	   the	  underlying	   regulatory	   interactions	   between	   genes	   in	   a	   living	   system,	   or	   the	   so-­‐called	  gene	  regulatory	  network	  (GRN).	  The	   identification	  of	  regulatory	  networks	  will	  help	   in	  identifying	  hundreds	  of	   genes	   that	   are	   responsible	   for	  most	  genetic	  diseases	  and	   that	  could	  serve	  as	  a	  starting	  point	  for	  new	  therapeutic	  intervention	  [3].	  
1.2 Gene	  Regulatory	  Networks	  (GRN)	  	  Gene	   regulation	   is	   a	   general	   name	   for	   the	   control	   of	   gene	   expression	   levels	   and	  ultimately	  relates	  the	  specific	  quantity	  of	  a	  target	  gene	  product	  (protein)	  to	  the	  context	  of	  biological	  processes	  in	  cellular	  organisms.	  	  In	  general,	  when	  a	  regulator	  protein	  binds	   to	   the	  regulatory	  sites	  of	  a	  gene,	  an	  mRNA	  transcript	   is	   produced	   that	   is	   in	   general	   translated	   into	   a	   specific	   protein	   or	   set	   of	  proteins.	  	  These	  proteins	  are	  either	  structural	  ones	  that	  colonize	  themselves	  at	  the	  cell	  membrane	  or	  enzymes	  that	  catalyze	  a	  certain	  reaction	  or	  regulators	  for	  the	  expression	  levels	  of	  other	  genes.	  The	  last	  groups	  of	  proteins	  generally	  bind	  to	  DNA	  and	  are	  known	  as	  transcription	  factors	  (TF),	  the	  main	  key	  players	  in	  the	  regulation	  machinery	  (Figure	  1-­‐1).	  	  	  These	   proteins	   either	   activate	   or	   repress	   other	   genes	   by	   binding	   to	   their	   promoter	  regions	  and	   in	   this	  way	   initiate	  or	   inhibit	   the	  production	  of	  other	  proteins,	  and	  so	  on.	  Such	  multiple	   and	   concurrent	   cellular	   events	   lead	   to	   a	   complex	   and	   interwoven	   gene	  regulation	  machinery.	  	  A	  gene	  regulation	  system	  consists	  of	  group	  of	  target	  genes,	  regulatory	  genomic	  regions	  	  (cis-­‐regions),	   group	   of	   regulators,	   and	   their	   interactions.	   The	   regulators	   are	   often	  proteins	  (TFs)	  if	  regulation	  occurs	  at	  the	  transcription	  level	  or	  small	  molecules	  such	  as	  miRNAs	   and	  metabolites	   if	   regulation	   occurs	   at	   post-­‐transcription	   or	   post-­‐translation	  levels,	  respectively.	  	  	  The	  cis-­‐regions	  serve	  as	  aggregators	  of	  the	  effects	  of	  all	  transcription	  factors	  involved	  in	  gene	  regulation.	  Through	  protein-­‐specific	  binding	  sites	  the	  cis-­‐regions	  recruit	  and	  bring	  in	   proximity	   single	   TFs	   or	   groups	   of	   TFs	   (TF	   complex)	   having	   specific	   regulatory	  properties,	  with	  the	  purpose	  of	  inducing	  precisely	  when,	  where,	  and	  at	  what	  rate	  a	  gene	  is	  to	  be	  transcribed	  [1].	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  A	  gene	  regulatory	  network	   is	   typically	  represented	  as	  a	  graph	   in	  which	   the	  nodes	  are	  genes	   and	   the	   edges	   between	   nodes	   represent	   gene	   interactions	   through	   which	   the	  products	  of	  one	  gene	  affect	  those	  of	  another.	  These	  regulatory	  links	  can	  be	  inducting	  or	  activating	   (the	   arrowheads),	   where	   an	   increase	   in	   the	   expression	   of	   one	   leads	   to	   an	  increase	  in	  the	  other,	  or	  inhibitory/	  repressing	  (the	  dull	  end),	  where	  an	  increase	  in	  one	  leading	   to	   a	   decrease	   in	   the	   other.	   A	   series	   of	   edges	   indicates	   a	   chain	   of	   such	  dependencies,	  with	  cycles	  corresponding	  to	  feedback	  loops	  [4].	  	  	  
	  
	  
Figure	  1-­‐1	  Regulation	  of	  gene	  transcription.	  Schematic	  diagram	  illustrating	  how	  a	  transcription	  factor	  binds	  to	  the	  DNA	  at	  specific	  binding	  motifs	  in	  the	  promoter	  region	  of	  a	  gene,	  and	  thereby	  regulates	  the	  activities	  (rate	  of	  transcription)	  of	  this	  gene.	  (b)	  Transcription	  of	  genes	  into	  mRNA	  and	  translation	  of	  mRNA	  into	  amino	  acid	  chains	  (proteins).	  	  A	  cell’s	  DNA	  carries	  the	  instructions,	  or	  genes,	  to	  make	  the	  proteins	  that	  are	  needed	  to	  build	  cell	  structures	  and	  to	  perform	  necessary	  functions.	  To	  make	  a	  protein,	  the	  instructions	  in	  the	  DNA	  are	  transcribed,	  or	  copied,	  to	  a	  molecule	  of	  messenger	  RNA	  (mRNA).	  Other	  molecules	  in	  the	  cell	  then	  help	  translating	  those	  instructions	  to	  assemble	  the	  protein	  by	  stringing	  together	  more	  than	  20	  different	  kinds	  of	  amino	  acids	   in	  a	  specific	   sequence.	  Messenger	  RNA	  provides	  vital	   clues	  about	   the	  processes	  a	  cell	  uses	   to	  survive,	   because	   it	   shows	   which	   genes	   are	   being	   used	   at	   a	   given	   time.	   Source:	  https://sbi4u2013.wordpress.com/author/viceteacher/,	   and	   http://www.whoi.edu/news-­‐release/DeepBiosphere_mRNA.	  	  
1.3 Biological	  properties	  of	  GRN	  	  Uncovering	   the	   architecture,	   dynamics,	   and	   the	   interwoven	   nature	   of	   the	   regulatory	  machinery	  in	  biological	  cells	  depends	  on	  our	  knowledge	  of	  the	  biological	  properties	  of	  gene	   networks.	   Noticeably	   more	   is	   known	   about	   the	   gene	   regulation	   circuitry	   today	  than	   few	  years	  ago,	  which	  helped	  scientists	   to	  effectively	  model	  GRNs	  and	  powerfully	  understand	  the	  underlying	  and	  controlled	  cellular	  behaviors	  of	  specific	  processes.	  	  For	   example,	   one	   of	   the	   important	   properties	   of	   gene	   network	   topology	   (structure),	  which	  defines	  the	  connections	  between	  nodes,	  is	  their	  sparseness.	  This	  means	  that	  each	  gene	  is	  regulated	  only	  by	  relatively	  few	  other	  genes	  and	  consecutively;	  there	  is	  a	  small	  number	  of	  edges	  per	  node,	  smaller	  than	  the	  total	  number	  of	  nodes	  [5].	  The	  sparseness	  property	   is	   often	   used	   to	   prune	   the	   search	   space	   and	   reduce	   the	   data	   dimensionality	  during	   network	   inference	   using	   data	   portioning	  methods	   (clustering	   and	   biclustering	  algorithms),	  as	  described	  later	  in	  chapter	  3	  of	  this	  thesis.	  It	  has	  been	  previously	  shown	  that	   the	  degree	  centrality	  distribution	  of	  biological	  networks	   tends	   to	  be	   longer	   tailed	  
(b) (a) 
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than	   the	  normal	  distribution	   [6].	  The	  appropriate	  distribution	   seems	   to	  belong	   to	   the	  so-­‐called	  scale-­‐free	  networks.	  This	   is	  a	  class	  of	  networks	  where	  the	   frequency	  P(N)	  of	  nodes	  with	  N	  connections	  in	  the	  GRN	  graph	  (i.e.	  the	  degree	  of	  the	  node)	  depends	  on	  N	  by	  a	  power-­‐law	  	  P(N)	  =	  N	  -­‐γ,	  where	  	  γ	  is	  some	  network	  specific	  constant.	  Such	  scale-­‐free	  networks	  exhibit	  one	  important	  characteristic	  that	  is	  the	  emergence	  of	  hubs,	  or	  highly	  connected	  nodes	   in	   the	  network.	  Such	  hub	  nodes	  are	  extremely	  unlikely	   to	  happen	   in	  standard	  random	  graphs.	   .	  These	  hub	  nodes	  correspond	  to	  highly	  central	  nodes	  in	  the	  gene	   network,	   i.e.	   genes	   that	   contribute	   a	   large	   amount	   of	   the	   overall	   regulation	   [1].	  They	   could	   in	   fact	   be	   potential	   candidates	   for	   master	   regulatory	   genes	   or	   essential	  genetic	   determinants	   of	   cell	   fate	   or	   probable	   targets	   for	   new	   drugs	   and	   treatment	   of	  complex	  diseases,	  as	  is	  demonstrated	  in	  chapter	  6	  and	  also	  in	  [7].	  	  	  Another	   important	   feature	   of	   GRNs	   is	   the	   network	   modularity.	   GRNS	   are	   often	  composed	   of	   inhomogeneous	   and	   different	   kinds	   of	   subcircuits	   or	  modules	   that	   each	  have	  a	  specific	  kind	  of	  cellular	  function	  [8].	  This	  concept	  is	  important,	  because	  it	  plays	  a	  key	  role	  for	  designing	  gene	  networks	  in	  synthetic	  biology	  which	  aims	  at	  designing	  novel	  biological	  circuits	  able	  to	  perform	  specific	  tasks	  (for	  example,	  the	  periodic	  expression	  of	  a	  gene	  of	  interest)	  [3].	  
1.4 Complexity	  of	  GRNs	  	  The	   complexity	   of	   gene	   regulatory	   systems	   goes	   back	   to	   the	   different	   cellular	   levels	  (transcription,	  post-­‐transcription,	  and	  post-­‐translation)	  at	  which	   they	  can	  be	  modeled	  as	   well	   as	   the	   huge	   number	   of	   genetic	   molecules	   (genes,	   proteins,	   metabolites,	  miRNAs…)	  involved	  at	  each	  level.	  A	  widely	  used	  approach	  is	  to	  reduce	  or	  subsume	  the	  regulatory	  system	  to	  the	  gene	  space	  at	  the	  transcription	  level	  for	  the	  sake	  of	  simplicity	  and	   research	   feasibility	   (Figure	   1-­‐2).	   This	   also	   depends	   on	   the	   existing	   biological	  knowledge	  and	  the	  availability	  of	  empirical	  data,	  as	  well	  as	  on	   the	  goal	  of	   the	  project,	  which	   can	   be	   as	   simple	   as	   hypothesis	   testing,	   or	   as	   complex	   as	   quantitative	   network	  modeling.	   Although	   modeling	   the	   GRN	   on	   the	   gene	   space	   is	   a	   common	   approach	  nowadays,	   it	   remains	   insufficient	   to	   puzzle	   the	   complete	   picture	   of	   regulatory	  mechanisms	  because	  other	   important	  genetic	   factors	   that	  affect	   the	  regulation	  system	  at	  other	  levels	  are	  ignored.	  In	  turn,	  this	  will	  not	  help	  in	  fully	  elucidating	  the	  associated	  biological	   processes	   and	   functions	   of	   genetic	   molecules.	   To	   this	   end,	   tackling	   this	  problem	  was	  the	  spirit	  behind	  the	  work	  in	  this	  thesis.	  
1.5 Levels	  of	  gene	  regulation	  
	  There	   are	   three	  main	   levels	   of	   controlling	   gene	  expression	   in	   living	   cells	   as	   shown	   in	  Figure	  1-­‐3.	  We	  summarize	  them	  as	  follows:	  
1.5.1 Transcriptional	  regulation	  	  Transcriptional	   regulation	   is	   the	  most	   common	   type	   of	   regulation.	   It	   regulates	  which	  genes	   are	   transcribed	   (from	  DNA	   to	  mRNA)	   and	   controls	   the	   rate	   of	   transcription	   or	  levels	   of	   gene	   expression.	   Transcription	   regulation	   includes	   two	  main	   cellular	   events.	  Firstly,	  the	  binding	  of	  a	  regulator	  molecule	  to	  the	  cis-­‐regulatory	  region	  of	  a	  target	  gene	  to	  initiate	  the	  transcription	  process	  as	  described	  above	  in	  section	  1-­‐2.	  Secondly	  and	  sole	  importantly,	  are	  epigenetic	  modifications.	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Figure	  1-­‐2	  Complexity	  of	  gene	  regulation	  machinery	  and	  reducing	  it	  into	  gene	  space.	  Shown	  on	  the	  left	  are	  the	  multiple	  levels	  at	  which	  genes	  are	  regulated	  by	  other	  genes,	  proteins	  and	  metabolites.	  On	  the	   right	   is	   a	   useful	   abstraction	   subsuming	   all	   the	   interactions	   into	   ones	   between	   genes	   only.	   The	   cis-­‐regions	   are	  shown	  next	   to	   the	   coding	   regions,	  which	   are	  marked	  with	  pattern	   fill	   and	   start	   at	   the	  bent	   arrows.	  The	   edges	   are	  marked	  with	  the	  name	  of	  the	  molecule	  that	  carries	  the	   interaction.	  Some	  reactions	  represent	  transcription	  factor	  –	  DNA	   binding,	   happen	   during	   transcription,	   and	   are	   localized	   on	   the	   cis-­‐regions.	   In	   those	   cases	   the	   corresponding	  protein-­‐specific	   binding	   sites,	   or	   cis-­‐elements,	   on	   the	   cis-­‐regions	   are	   shown	   (colored	   polygons).	   Otherwise,	   the	  interactions	   can	   take	   place	   during	   transcription	   or	   later	   (e.g.	   post-­‐translational	  modifications)	   as	  may	   be	   the	   case	  with	  Metabolite	  2	  interacting	  with	  Gene	  4.	  The	  nature	  of	  the	  interactions	  is	  inducing	  (arrow)	  or	  repressing	  (dull	  end).	  Source:	  modified	  from	  [1].	  	  	  
	  
Figure	  1-­‐3	  Different	  levels	  of	  gene	  regulation	  system.	  Source:	  modified	  from	  http://en.wikipedia.org/wiki/File:Gene_Regulation.svg	  	  
1.5.1.1 Epigenetic	  modifications	  	  The	  term	  “epigenetics”	  refers	  to	  the	  study	  of	  the	  heritable	  alterations	  and	  modifications	  in	   phenotypic	   expression	   that	   don’t	   involve	   changes	   in	   DNA	   sequence	   [9].	   These	  modifications	  were	   found	   to	   be	   highly	   correlated	  with	   the	   changes	   in	   DNA	   sequence	  through	  evolution	  [10].	  Furthermore,	  these	  epigenetic	  changes	  are	  essential	  for	  normal	  
lncRNA 
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Figure	  1-­‐4	  Epigenetic	  modifications.	  The	  genome	   is	   prone	   to	   direct	   methylation	   of	  DNA	   and	   histone	   modifications;	   which	  include	  histone	  acetylation	  and	  methylation.	  Other	  chromatin	  remodelers	  also	  come	  into	  play.	   Additionally,	   noncoding	   RNAs	   play	   a	  major	  role	   in	  DNA	  targeting	  by	  silencing	  or	  different	   mechanisms.	   Source:	   modified	  from	  [12].	  
	  
1.5.1.1.1 DNA	  methylation	  	  DNA	  methylation	   is	   the	  most	  extensively	  studied	  epigenetic	  modification	   that	   is	  being	  increasingly	  recognized	  to	  play	  an	  important	  role	   in	  the	  regulation	  of	  gene	  expression	  and	  is	  used	  as	  epigenetic	  marker	   for	  different	  disease	  pathways	  [13-­‐16].	   In	  mammals,	  DNA	  methylation	  typically	  occurs	  in	  a	  CpG	  dinucleotide	  context	  that	  is	  often	  grouped	  in	  clusters	   called	   CpG	   islands.	   More	   than	   half	   of	   the	   gene	   promoters	   in	   human	   are	  associated	   with	   CpG	   regions	   and	   are	   usually	   unmethylated	   in	   normal	   cells,	   although	  some	  of	  them	  become	  methylated	  in	  a	  tissue-­‐specific	  manner	  during	  early	  development	  [17].	  DNA	  methylation	  is	  also	  believed	  to	  be	  a	  crucial	  reason	  behind	  genomic	  imprinting	  (see	  next	  section),	  where	  hypermethylation	  at	  one	  of	   the	   two	  parental	  alleles	   leads	   to	  monoallelic	   expression	   [17].	   DNA	   methylation	   profiling	   unravels	   differentially	  methylated	   regions	   (DMRs)	   that	   are	   in	   principle	   CpG	   sites	   altered	   during	   disease	   or	  oncogenic	  processes	  [18,	  19]	  as	  shown	  in	  Figure	  1-­‐5.	  Hypermethylation	  of	  CpG	  islands	  located	   in	   promoter	   regions,	   for	   example,	   is	   involved	   in	   gene	   silencing	   at	   the	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transcriptional	  level	  [20]	  (Figure	  1-­‐6)	  and	  often	  leads	  to	  a	  high	  rate	  of	  C	  to	  T	  mutations	  at	  these	  sites	  [21].	  	  	  
	  
	  
Figure	  1-­‐5	  Altered DNA-methylation patterns in tumorigenesis. The	  hypermethylation	  of	  CpG	  islands	  of	  tumor	  suppressor	  genes	  is	  a	  common	  alteration	  in	  cancer	  cells,	  and	  leads	  to	  the	   transcriptional	   inactivation	   of	   these	   genes	   and	   the	   loss	   of	   their	   normal	   cellular	   functions.	   This	   contributes	   to	  many	   of	   the	   hallmarks	   of	   cancer	   cells.	   At	   the	   same	   time,	   the	   genome	   of	   the	   cancer	   cell	   undergoes	   global	  hypomethylation	   at	   repetitive	   sequences,	   and	   tissue-­‐specific	   and	   imprinted	   genes	   can	   also	   show	   loss	   of	   DNA	  methylation.	  In	  some	  cases,	  this	  hypomethylation	  is	  known	  to	  contribute	  to	  cancer	  cell	  phenotypes,	  causing	  changes	  such	  as	   loss	  of	   imprinting,	   and	  might	  also	   contribute	   to	   the	  genomic	   instability	   that	   characterizes	   tumors.	  E,	   exon.	  Source:	  modified	  from	  [19].	  
Genomic	  imprinting	  	  	  One	   of	   the	   important	   epigenetic	   phenomena	   in	   mammals	   is	   genomic	   imprinting,	   by	  which	   certain	   genes	   are	   expressed	   in	   a	   parent-­‐of-­‐origin-­‐specific	  manner.	   If	   the	   allele	  inherited	   from	   the	   father	   is	   imprinted,	   then	   it	   is	   silenced	   and	   the	   gene	   is	   called	  maternally	   expressed,	   and	   vice	   versa	   [22].	   To	   date,	   about	   100	   genes	   have	   been	  experimentally	   confirmed	   to	   be	   imprinted	   in	   mammals.	   	   Thus,	   the	   imprinting	  phenomenon	   affects	   a	   fairly	   small	   number	   of	   genes.	   Many	   studies	   showed	   that	  imprinted	   genes	   are	   not	   only	   important	   during	   embryonic	   development	   but	   possess	  also	   postnatal	   functions.	   Hence,	   the	   kinship	   theory	   with	   its	   focus	   on	   prenatal	  development	   might	   explain	   some	   but	   not	   all	   aspects	   of	   the	   evolution	   of	   genomic	  imprinting.	  	  	  During	  postnatal	  development,	  genomic	  imprinting	  affects	  endocrinal	  networks,	  energy	  metabolism,	  and	  behavior.	  Prominent	  examples	  for	  the	  functions	  of	  imprinted	  genes	  in	  endocrinal	   pathways	   are	   the	   imprinted	   transcripts	   of	   the	   Gnas	   locus.	   In	   the	   human,	  genetic	  and	  epigenetic	  aberrations	  in	  this	  region	  are	  associated	  with	  Albright	  hereditary	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osteodystrophy	   and	   pseudohypoparathyroidism	   type	   1A	   or	   1B	   [23].	   Behavioral	  abnormalities	  have	  been	  observed	  in	  human	  imprinting	  disorders	  and	  in	  various	  mouse	  models	   in	   which	   imprinted	   genes	   have	   been	   mutated.	   For	   example,	   the	   obesity	   of	  Prader-­‐Willi-­‐syndrome	   patients	   is,	   at	   least	   in	   parts,	   a	   result	   of	   an	   impaired	   eating	  behavior.	  Knock-­‐out	  studies	   in	  mouse	  showed	  that	   the	   two	  paternally	  expressed	  Peg1	  and	  Peg3	  genes	  have	  a	  clear	  behavioral	  phenotype	  [24].	  Females	  that	  inherit	  a	  null	  allele	  for	   these	   genes	   from	   their	   fathers	  behaved	   ‘deficiently’	  with	   respect	   to	  maternal	   care	  behavior	  including	  placentophagy	  and	  nest-­‐building.	  	  In	  this	  thesis,	  we	  will	  discuss	  the	  imprinting	  phenomena	  in	  details	  and	  investigate	  the	  association	   of	   imprinted	   genes	   with	   cell	   differentiation	   processes,	   namely	  hematopoiesis	  or	  blood	  cell	  development.	  
1.5.1.1.2 Histone	  modifications	  	  Histones	   are	  proteins	   that	   act	   as	   a	   spool	   around	  which	  DNA	   can	  wind.	  When	   specific	  amino	  acids	  of	  histones	  are	  modified	  with	  chemical	  tags	  (acetylation,	  methylation,	  and	  phosphorylation),	   these	   tags	   can	   influence	   the	   physical	   shape	   of	   chromatin	   structure,	  which	  in	  turn,	  determines	  the	  accessibility	  of	  the	  associated	  chromosomal	  segment	  for	  binding	  to	  DNA-­‐binding	  proteins	  (transcription	  factors)	  [11].	  If	  chromatin	  is	  condensed	  (heterochromatin	  structure),	  DNA	  transcription	  doesn’t	  occur	  and	  related	  genes	  will	  be	  inactive.	   If	   chromatin	   is	   relaxed,	  DNA	  will	  be	  easily	  accessible	  and	  can	  be	   transcribed	  and	  being	  active	  (Figure	  1-­‐6).	  	  	  
	  
	  
Figure	  1-­‐6	  Schematic	  of	  the	  reversible	  changes	  in	  chromatin	  organization	  that	  influence	  gene	  expression.	  Genes	  are	  expressed	  (switched	  on)	  when	  the	  chromatin	  is	  open	  (active),	  and	  they	  are	  inactivated	  (switched	  off)	  when	  the	  chromatin	  is	  condensed	  (silent).	  White	  circles	  =	  unmethylated	  cytosines;	  red	  circles	  =	  methylated	  cytosines.	  Source:	  modified	  from	  [25].	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1.5.2 Post-­‐transcriptional	  regulation	  	  Post-­‐transcriptional	   regulation	  is	   the	   control	   of	   gene	   expression	   at	   the	   RNA	   level,	   i.e	  after	   the	   transcription	   of	   a	   gene	   into	  mRNA	  and	  before	   the	   translation	   of	  RNA	   into	   a	  protein.	  The	  cellular	  events	  occurring	  at	   that	   level	  of	   regulation	  rely	  on	  specific	  RNA–protein	   interactions	   that	   either	   result	   in	   the	   targeted	   degradation	   of	   the	   mRNA	   or	  inhibit	  the	  translation	  process	  to	  make	  proteins	  [26].	  Gene	  expression	  can	  be	  controlled	  at	  this	  level	  through	  the	  following	  mechanisms:	  
1.5.2.1 mRNA	  processing,	  stability,	  and	  degradation	  	  Gene	  expression	  can	  be	  controlled	  by	  changes	  in	  pre-­‐mRNA	  processing	  and	  alternative	  splicing,	  which	  produces	   various	  mRNA	   forms	  by	   removing	  different	   combinations	   of	  introns	   based	   on	   which	   proteins	   are	   needed	   by	   the	   cell.	   Also,	   changes	   in	   mRNA	  stabilities	   contribute	   to	   the	   overall	   regulation	   of	   gene	   expression.	   Some	   mRNAs	   in	  eukaryotic	  cells	  are	  stable	  and	  have	  half-­‐lives	  of	  more	   than	  10	  hours.	  Many,	  however,	  have	  half-­‐lives	  of	  few	  minutes	  or	  less.	  These	  unstable	  mRNAs	  often	  code	  for	  regulatory	  proteins,	  such	  as	  growth	  factors	  and	  transcription	  factors,	  whose	  production	  rates	  need	  to	  change	  quickly	  in	  cells	  [27].	  Cheadle	  et	  al.2005	  investigated	  the	  effect	  of	  changes	  in	  mRNA	   stability	   on	   gene	   expression	   during	   T	   cell	   activation	   using	   microarray	  experiments.	  They	  concluded	  that	  regulation	  of	  mRNA	  stability	  contributes	  significantly	  to	  the	  observed	  changes	  in	  gene	  expression	  in	  response	  to	  external	  stimuli	  [28].	  In	  the	  same	   context,	   by	   binding	   to	   certain	   regulatory	   molecules	   like	   RNA	   binding	   proteins	  (RBP),	   mRNA	  will	   be	   directly	   or	   indirectly	   degraded	   or	   sequestrated	   in	   P-­‐bodies	   for	  storage.	  	  
1.5.2.2 Interaction	  with	  non-­‐coding	  RNAs	  	  Noncoding	  RNAs	  such	  as	  microRNA	  (miRNAs)	  and	  long	  non-­‐coding	  RNA	  (lncRNAs)	  have	  gained	  extensive	  attention	  in	  recent	  years	  as	  a	  potentially	  new	  and	  crucial	  layer	  of	  post-­‐transcriptional	  biological	  regulation	  [29].	  	  	  miRNAs	   are	   small	   non-­‐coding	  RNA	  molecules	   of	   about	  22	  nucleotides	   that	   have	  been	  characterized	  in	  	  virtually	  all	  animals	  and	  plants.	  miRNAs	  are	  transcribed	  from	  different	  genomic	   loci,	  which	   implies	   their	  regulation	  by	  other	  transcription	   factors	  [30].	  These	  genomic	   loci	   encode	   for	   long	   RNAs	   with	   a	   hairpin	   structure	   that	   when	   processed	  (cleavage)	  by	  a	  series	  of	  enzymes	  (Drosha	  and	  dicer)	  synthesizes	  a	  miRNA	  duplex	  of	  22	  nucleotides	  [31].	  miRNAs	  often	  repress	   target	  genes	  through	  translational	  silencing	  of	  the	  mRNA	  or	  through	  degradation	  of	  the	  mRNA,	  via	  complementary	  binding	  to	  specific	  sequences	  in	  the	  3'	  UTR	  region	  of	  the	  target	  gene's	  transcript	  [32]	  (Figure	  1-­‐7).	  	  	  A	   miRNA	   can	   target	   a	   plethora	   of	   mRNAs,	   creating	   a	   post-­‐transcriptional	   regulatory	  network	   [33]	   that	   has	   a	   critical	   role	   not	   only	   in	   cellular	   functions	   [34]	   but	   also	   in	  pathological	   processes	   [35]	   especially	   in	   human	   cancerogenesis	   [33,	   36-­‐38].	   A	  considerable	  amount	  of	  literature	  has	  been	  published	  on	  miRNA-­‐related	  mutations	  and	  on	   the	   impact	  of	  somatic	  mutations	  on	  miRNA	  functions.	  These	  studies	  have	  reported	  that	   genetic	   variants	  within	  miRNAs	  or	   their	   target	   sites	   can	   alter	  miRNA	   function	   in	  cancers	   [39-­‐43]	   and	   have	   been	   associated	   with	   cancer	   risk,	   treatment	   efficacy	   and	  patient	  prognosis	  [39],	  as	  well	  as	  genomic	  phenotypes	  [44].	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With	   respect	   to	   cell	   differentiation,	   miRNAs	   are	   substantial	   components	   of	   the	  molecular	   circuitry	   that	   controls	   blood	   cell	   differentiation	   and	   determines	  hematopoietic	  lineage	  commitment	  [45].	  	  Long	  non-­‐coding	   RNAs	  (lncRNA)	   are	   non-­‐protein	   coding	  transcripts	  longer	   than	   200	  nucleotides	   [29].	   Similar	   to	   the	   regulatory	   role	   of	   miRNAs,	   lncRNAs	   control	   various	  aspects	  of	  mRNA	  at	  the	  post-­‐transcriptional	  level.	  lncRNAs	  have	  a	  repressing	  regulatory	  effect	   when	   they	   bind	   to	   mRNA	   and	   facade	   key	   elements	   with	   mRNA	   required	   for	  processing,	  splicing,	  and	  translation.	  In	  other	  inducing	  or	  activation	  scenarios,	  lncRNAs	  can	  absorb	  and	  bind	  to	  the	  miRNA	  molecules	  enabling	  mRNA	  to	  be	  translated	  [46].	  	  	  
 
Figure	  1-­‐7	  post-­‐transcriptional	  regulation	  by	  miRNA	  interactions.	  The	   illustration	   shows	   how	   a	  microRNA	   (miRNA)	   silences	   genes.	   It	   is	   cut	   out	   of	   a	   precursor	   hairpin-­‐shaped	   pre-­‐miRNA	  to	  form	  a	  mature	  miRNA,	  which	  binds	  to	  the	  3'	  untranslated	  region	  (3'	  UTR)	  of	  a	  target	  gene's	  messenger	  RNA	  and	  turns	  off	  its	  activity.	  Source:	  http://www.laskerfoundation.org/awards/2008_b_description.htm.	  	  Other	   non-­‐coding	  RNAs	   such	   as	   piwi-­‐interacting	  RNAs	   (piRNAs),	   endogenous	   siRNAs,	  and	   intron-­‐derived	   miRNAs	   (miRtrons),	   were	   recently	   discovered	   and,	   yet,	   their	  regulatory	   roles	  were	   not	   deciphered.	   This	  will	   open	   new	   avenues	   of	   research	   in	   the	  field	   of	   RNA	   biology	   and,	   hence,	   will	   have	   a	   significant	   role	   in	   better	   understanding	  human	  development	  and	  complex	  diseases.	  
1.5.3 Post-­‐translational	  regulation	  	  Post-­‐translational	  regulation	  refers	  to	  the	  control	  of	  the	  levels	  of	  active	  proteins	  during	  and	  after	  protein	  biosynthesis	  and	  therefore	  limiting	  their	  functions	  and	  stability	  [47].	  This	  is	  achieved	  using	  two	  mechanisms:	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1.5.3.1 Chemical	  modifications	  	  Amino	  acid	  side	  chains	  may	  be	  chemically	  modified	  by	  attachment	  of	  chemical	  groups	  such	   as	   phosphate,	   acetate,	   amide,	   or	   methyl.	   Their	   addition	   or	   deletion	   may	   have	  severe	   effects	   on	   protein	   structure	   and	   function.	   The	   presence	   or	   absence	   of	   such	  chemicals	  can	  put	  also	  proteins	  in	  inactive	  state.	  
1.5.3.2 Degradation	  	  	  Degradation	  refers	  to	  the	  life	  span	  of	  a	  certain	  protein.	  Some	  proteins	  are	  used	  in	  cells	  only	  for	  short	  times	  of	  e.g.	  a	  few	  minutes	  while	  others	  can	  last	  much	  longer.	  This	  is	  often	  controlled	   by	   protein	   tags	   like	   ubiquitin,	   which	   is	   recognized	   by	   degradation	  mechanisms.	  	  	  These	   post-­‐translational	   regulatory	   events	   are	   essential	   mechanisms	   used	   by	  eukaryotic	   cells	   to	   diversify	   their	   protein	   functions.	   Imperfections	   in	   these	   post-­‐translational	   events	   can	   lead	   to	   numerous	   developmental	   disorders	   and	   human	  diseases	   [48].	   Recently,	   Wang	   et	   al.	   2014	   revealed	   the	   critical	   role	   of	   the	   post-­‐translational	   events	   (glycosylation,	   phosphorylation,	   acetylation	   and	   methylation)	   in	  the	  regulation	  of	  the	  pluripotency	  state	  of	  human	  cells	  [48].	  
1.5.4 Other	  factors	  affecting	  the	  regulation	  machinery	  	  In	   addition	   to	   the	   aforementioned	   cellular	   events	   and	   genetic	   factors	   affecting	   the	  regulatory	  machinery,	   there	   are	   other	   extrinsic	   factors	   which	   take	   part	   in	   regulating	  specific	  biological	  processes.	  For	  instance,	  hematopoiesis	  (the	  blood	  cell	  differentiation	  process)	   is	   regulated	   in	   part	   by	   extrinsic	   signaling	   molecules	   including	   colony-­‐stimulating	   factors	   (CSFs)	   and	   interleukins	   (ILs)	   that	   activate	   intracellular	   signaling	  molecules	   such	   as	   kinases	   and	   cytokines.	   These	   subsets	   of	   factors	   are	   known	   to	  influence	   Hematopoietic	   Stem	   Cell	   (HSC)	   pluripotency,	   proliferation,	   and	   lineage	  commitment	  (www.RnDSystems.com/HSC).	  	  Moreover,	   it	  has	  been	  shown	  that	  biophysical	  properties	   including	  wettability,	  surface	  topography,	   and	   surface	   chemistry,	   could	   also	   affect	   the	   biological	   performance	   of	  human	  embryonic	  stem	  and	  induced	  pluripotent	  stem	  cells	  [49]. 
1.6 Motivation	  and	  goal	  of	  the	  work	  	  
	  Given	   the	   highly	   complex	   functional	   interdependencies	   between	   the	   molecular	  components	   (such	   as	   genes,	   TFs,	   and	  miRNAs)	   and	  mutations	   thereof	   in	   a	   living	   cell,	  biological	   processes	   as	   well	   as	   disease	   pathogenesis	   are	   rarely	   a	   consequence	   of	   the	  activity	  of	  a	  single	  molecule,	  but	  typically	  reflect	  a	  combination	  of	  interactions	  between	  the	  associated	  regulators	  (TFs	  and	  miRNAs)	  and	  their	  target	  genes	  [8,	  50].	  Such	  cellular	  interactions	   occurring	   on	   multiple	   genomic	   levels	   compose	   a	   complex	   and	   densely	  connected	   regulatory	   machinery.	   Uncovering	   the	   architecture,	   dynamics,	   and	   the	  interwoven	   nature	   of	   the	   regulatory	   machinery	   on	   different	   levels	   of	   regulations	  remains	  a	  challenging	  task	  and	  a	  focal	  point	  of	  modern	  systems	  biology.	  	  	  	  Moreover,	   the	   correct	   identification	   of	   the	   combined	   regulatory	   interactions	   on	  different	   levels	   of	   regulation,	   will	   not	   only	   help	   in	   labeling	   hundreds	   of	   genetic	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molecules	   that	   are	   responsible	   for	   diseases,	   but	   also	   in	   identifying	   disease-­‐associated	  cooperative	  functional	  modules	  of	  different	  genetic	  molecules.	  This	  would	  improve	  our	  understanding	   of	   disease	   development,	   diagnosis,	   and	   in	   turn,	   would	   suggest	   novel	  therapeutic	   strategies	   in	   disease	   treatment.	   However,	   this	   depends	   largely	   on	  integrating	   information	   from	   biological	   knowledge	   bases	   and	   large-­‐scale	   omics	   data	  from	  different	  sources	  and	  experiments	  that	  capture	  the	  regulatory	  events	  occurring	  on	  the	  levels	  of	  regulations.	  	  	  To	  this	  end,	  we	  aim	  in	  this	  work	  at	  developing	  practical	  computational	  approaches	  that	  integrate	   heterogeneous	   genomic	   datasets	   to	   unravel	   the	   combined	   regulatory	  interactions	  between	  different	  molecular	  elements.	  Then,	  we	  applied	  these	  approaches	  to	   omics	   data	   for	   human	   breast	   cancer	   as	   well	   as	   for	   hematopoiesis	   as	   a	   well-­‐established	  model	  for	  stem	  cell	  differentiation.	  	  
1.7 Author	  contributions	  	  The	  contribution	  of	  this	  thesis	  is	  two-­‐fold.	  First,	  we	  present	  integrative	  systems	  biology	  approaches	   and	   bioinformatics	   frameworks	   that	   we	   have	   developed	   for	   reverse	  engineering	   the	   gene	   regulatory	   networks	   at	   transcriptional	   and	   post-­‐transcriptional	  levels	   from	  heterogeneous	  genomic	  data	  sources.	  Second,	  we	  apply	  our	  approaches	  to	  hematopoietic	  datasets	  as	  an	  example	  for	  cellular	  differentiation	  and	  to	  breast	  cancer	  as	  well	  as	  diabetes	  datasets	  as	  examples	  for	  complex	  diseases.	  Then,	  we	  discuss	  our	  results	  and	  the	  potential	  biological	  findings	  and	  conclusions.	  	  The	   work	   presented	   in	   this	   dissertation	   has	   led	   to	   the	   following	   publications	   and	  conference	   posters.	   At	   the	   beginning	   of	   each	   chapter,	   we	   list	   the	   corresponding	  publication(s)	  on	  which	  it	  is	  based.	  Furthermore,	  the	  contributions	  of	  the	  co-­‐authors	  are	  reported	  in	  the	  text	  as	  well.	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   International	   Journal	   of	   Pharma	   Medicine	   and	  Biological	  Sciences	  (IJPmbs)	  Vol.	  4,	  No.	  3,	  July	  2015.	  	  	  
! Christian	  Spaniol,	  Mohamed	  Hamed,	  Johannes	  Trumm	  and	  Volkhard	  Helms,	  Mebitoo:	  an	  Extensible	   Software	  Framework	   for	  Bioinformatics	  Analysis	  Workflow	  Automatization	  [BICoB-­‐2015,	   7th	   international	   conference	   on	   bioinformatics	   and	   computational	  biology].	  	  
! Alexander	   Zapp,	   Volkhard	   Helms,	   and	   Mohamed	   Hamed,	   SnvDMiR:	   Associating	   the	  genomic	   proximity	   of	   genetic	   variants	   with	   deregulated	   miRNAs	   and	   differentially	  methylated	   regions.	   [ICABEE	   -­‐2015,	  2nd	   international	   conference	  on	  Advances	   in	  Bio-­‐Informatics	  and	  Environmental	  Engineering].	  
 
! Irhimeh	  M.R,	  Barthelmes	  D,	  Mohamed	  Hamed,	  Zhu	  L,	  Helms	  V,	  Gillies	  M.C,	  Shen	  W,	  Novel	  Gene	  Regulatory	  Network	  in	  diabetic	  bone	  marrow-­‐derived	  endothelial	  progenitor	  cells.	  [In	  revision].	  	  
! Other	  four	  manuscripts	  are	  either	  submitted	  or	  in	  preparation.	  	  
1.8 Organization	  of	  the	  thesis	  	  This	   dissertation	   is	   organized	   in	   nine	   chapters,	   including	   this	   introduction	   chapter	  (Chapter	  1)	  and	  the	  conclusion	  (Chapter	  9).	  At	  the	  beginning	  of	  each	  chapter,	  we	  list	  the	  related	  scientific	  articles	  and	  a	  synopsis,	  which	  provides	  a	  general	  overview	  about	  the	  chapter	  contents	  in	  the	  context	  of	  the	  thesis.	  	  In	   chapter	   2,	   we	   will	   discuss	   the	   state–of-­‐the-­‐art	   of	   existing	   methods	   that	   touch	   the	  same	   research	   problem	   and	   we	   will	   briefly	   illustrate	   the	   used	   genomic	   data	  repositories,	   the	   applied	   statistical	  methods,	   and	   the	   involved	   biological	   resources	   in	  this	  work.	  	  Chapter	  3	  presents	   the	  main	  body	  of	   software	  development	  achieved	   in	   this	   research	  work.	   It	   focuses	   on	   the	   development	   of	   scalable	   computational	   approaches	   and	  automated	   systems	   biology	   tools	   and	   pipelines	   to	   integrate	   experimentally	   acquired	  and	   computationally	   derived	   omics	   data	   and	   unravel	   the	   combinatorial	   regulatory	  interactions	  between	  different	  molecular	  elements.	  	  	  First,	   we	   present	   an	   automated	   GRN	   pipeline	   that	   constructs	   the	   genomic	   regulatory	  machinery	  of	  a	  cell	  from	  expression,	  sequencing,	  and	  annotation	  datasets	  through	  three	  modules	  implemented	  as	  separated	  software	  components	  (plugins)	  that	  are	  hosted	  by	  our	  software	  framework	  Mebitoo	  for	  automation	  of	  bioinformatics	  workflows.	  Then,	  we	  further	  extended	  it	  to	  a	  general	  integrative	  network-­‐based	  approach	  that	  involves	  also	  post-­‐transcriptional	   interactions	   and	   reports	   the	   computational	   analysis	   of	   gene	   and	  miRNA	   transcriptomes,	   DNA	   methylome,	   and	   somatic	   mutations.	   This	   aimed	   at	  identifying	  putative	  disease	  drivers	   and	  novel	   targets	   for	   therapeutic	   treatment.	  With	  regard	  to	  the	  incorporation	  of	  somatic	  mutations	  with	  other	  genomic	  data	  sets,	  a	  stand-­‐alone	   pipeline	   named	   “SnvDMiR”	   was	   implemented	   to	   explore	   possible	   genomic	  proximity	   relationships	   between	   somatic	   variants	   and	   both	   differentially	   methylated	  CpG	   sites	   as	   well	   as	   differentially	   expressed	   miRNAs.	   With	   respect	   to	   genomic	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mutations,	   we	   also	   present	   an	   NGS	   pipeline	   and	   apply	   it	   to	   two	   groups	   of	   bacterial	  isolates	   (nasal	   and	   invasive)	   to	   investigate	   the	   phylogenetic	   positions	   of	   the	   recently	  emerged	  t504	  clone	  (Spa-­‐type	  t504)	  in	  the	  Saarland	  province	  of	  Germany	  and	  to	  better	  understand	  the	  infectivity	  mechanism	  of	  the	  invasive	  group.	  Motivated	  by	  all	  of	  this,	  we	  developed	  TFmiR	  as	  a	  freely	  available	  web	  server	  for	  deep	  and	  integrative	  downstream	  analysis	  of	  combinatorial	  regulatory	  interactions	  between	  TFs/genes	  and	  miRNAs	  that	  are	  involved	  in	  human	  disease	  pathogenesis.	  	  In	  the	  second	  part	  of	  this	  thesis	  (from	  chapter	  4	  to	  chapter	  8),	  we	  will	  demonstrate	  the	  usefulness	  and	  applicability	  of	  the	  developed	  approaches	  and	  frameworks	  by	  applying	  them	   to	   two	   different	   cellular	   activities:	   hematopoietic	   stem	   cell	   differentiation	   and	  disease	  pathways.	  	  In	   chapter	   4,	   we	   discuss	   genomic	   imprinting	   as	   an	   epigenetic	   phenomenon	   that	   is	  closely	   associated	  with	   cell	   development	   and	   cellular	   differentiation.	  We	   characterize	  the	   role	   of	   imprinted	   genes	   during	   differentiation	   processes	   and	   comprehensively	  investigate	   the	   cellular	   functions	   of	   the	   whole	   set	   of	   imprinted	   genes,	   paternally	  expressed	   genes,	   and	  maternally	   expressed	   genes	   as	  well	   as	   the	   transcription	   factors	  that	   are	   predicted	   to	   regulate	   the	   imprinted	   genes	   and	   their	   relatedness	   to	   cell	  differentiation	   in	   both	   human	   and	  mouse.	   The	   findings	   of	   this	   chapter	  motivated	   the	  study	  presented	   in	  chapter	  5	  regarding	  the	  nature	  and	  extent	  of	   the	  role	  of	   imprinted	  genes	  in	  hematopoietic	  stem	  cell	  differentiation.	  	  In	  chapter	  6,	  we	  demonstrate	  the	  effectiveness	  of	  one	  of	  our	  developed	  approaches	  (the	  integrative	   network-­‐based	   approach)	   to	   identify	   genetic	   key	   elements	   that	   could	  possibly	   drive	   the	   tumorigenesis	   in	   human	   breast	   cancer.	   Also	   in	   chapter	   7,	   we	   will	  consider	  the	  differential	  network	  analysis	  concept	  that	  makes	  use	  of	  our	  developed	  GRN	  pipeline	   to	   elucidate	   the	   molecular	   mechanisms	   by	   which	   diabetes	   impairs	   Bone	  marrow-­‐derived	  endothelia	  progenitor	  cells	  (EPC)	  in	  mouse.	  	  Chapter	   8	   concerns	   the	   role	   of	   genomic	  mutations.	   Here,	   we	   apply	   our	   implemented	  NGS	   pipeline	   to	   identify	   core-­‐genome	   SNPs	   and	   genetic	   variations	   between	   two	  phenotypic	  groups	  in	  a	  similar	  analogy	  to	  somatic	  mutations	  between	  the	  healthy	  and	  disease	  cohorts.	  This	  project	  involved	  two	  groups	  of	  MRSA	  bacterial	  isolates	  (nasal	  and	  invasive)	   to	   investigate	   the	  phylogenetic	  positions	  of	   the	  recently	  emerged	  t504	  clone	  (Spa-­‐type	   t504)	   in	   the	   Saarland	   province	   of	   Germany	   and	   to	   better	   understand	   the	  infectivity	  mechanism	  of	  the	  invasive	  group	  as	  a	  prototype	  example	  for	  “from	  genotype	  to	   phenotype”	   studies.	   In	   the	   last	   chapter	   (chapter	   9),	   we	   summarize	   the	   results	  achieved	  in	  this	  thesis	  and	  discuss	  the	  current	  limitations	  of	  the	  introduced	  approaches	  and	  directions	  for	  further	  improvements	  and	  outlook.	  Finally	  the	  appendices	  A,	  B,	  C,	  D,	  and	  E	  contain	  supplementary	  information	  for	  chapters	  4,	  5,	  6,	  7,	  and	  8,	  respectively.	  	  In	  summary,	  the	  work	  presented	  in	  this	  thesis	  has	  led	  to	  the	  development	  of	  interesting	  computational	   approaches	   that	   are	   introduced	   to	   the	   scientific	   community	   as	   non-­‐commercial	  software	  toolkits.	  The	  provided	  topological	  and	  functional	  analyses	  of	  our	  approaches	  as	  validated	  on	  cellular	  differentiation	  and	  complex	  diseases	  promote	  them	  as	  reliable	  systems	  biology	  tools	  for	  researchers	  across	  different	  life	  science	  disciplines.	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2. Theory	  and	  computational	  
biology	  tools	  	  	  	  	  	  
Synopsis	  	  
In	   this	   chapter,	  we	   discuss	   the	   state–of-­‐the-­‐art	   of	   existing	  methods	   that	   touch	   the	   same	  
research	  problem.	  A	  brief	  description	  of	  some	  of	  the	  data	  repositories,	  statistical	  tools,	  and	  
biological	  resources	  used	  in	  this	  work	  is	  also	  provided	  here.	  
	  	  
	  	  
2.1 GRN	  reconstructing	  methods	  	  A	  gene	  regulatory	  network	   is	   typically	  represented	  as	  a	  graph	   in	  which	   the	  nodes	  are	  target	  genes	  or	  regulators	  (TFs,	  miRNAs)	  and	  the	  edges	  between	  nodes	  represent	  gene	  interactions	   through	   which	   the	   products	   of	   one	   gene	   affect	   those	   of	   another.	   These	  regulatory	  links	  can	  be	  inducting	  or	  activating,	  where	  an	  increase	  in	  the	  expression	  of	  one	  leads	  to	  an	  increase	  in	  the	  other,	  or	  inhibitory/	  repressing,	  where	  an	  increase	  in	  one	  leading	   to	   a	   decrease	   in	   the	   other.	   A	   series	   of	   edges	   indicates	   a	   chain	   of	   such	  dependencies,	  with	  cycles	  corresponding	  to	  feedback	  loops.	  	  By	   reconstructing	   the	   gene	   regulatory	   network	   (GRN)	   of	   a	   single	   cell	   or	   of	   a	  multicellular	  system	  we	  mean	  here	  the	  process	  of	  unraveling	  the	  regulatory	  machinery	  of	   this	   biological	   system	   and	   then	   studying	   its	   structure,	   function,	   and	   mode	   of	  operation.	   Over	   the	   past	   years,	   several	  methods	   have	   been	   developed	   and	   applied	   to	  reconstruct	  GRN	  topologies	  from	  high-­‐	  throughput	  data	  sources.	  In	  the	  next	  section,	  we	  provide	  an	  overview	  of	  these	  methods	  that	  are	  categorized	  according	  to	  the	  underlying	  model	  of	  gene	  regulation.	  
2.1.1 Boolean	  Networks	  	  	  Boolean	  networks	  are	  one	  of	  the	  oldest	  dynamical	  methods	  that	  generate	  experimental	  time	  series	  for	  gene	  expression	  of	  gene	  circuits[51].	  The	  state	  of	  each	  variable	  (genes)	  at	  the	   next	   time	   step	   depends	   in	   a	   deterministic	   manner	   on	   the	   states	   of	   some	   other	  variables	   at	   the	   current	   time	   step.	   These	   dependencies	   are	   encoded	   in	   the	   form	   of	  matrix-­‐like	  condition	  tables.	  Boolean	  networks	  are	  based	  on	  the	  assumption	  that	  binary	  on/off	   switches	   in	   discrete	   time	   steps	   can	   describe	   important	   aspects	   of	   gene	  regulation.	  In	  a	  boolean	  network,	  the	  network	  state	  can	  be	  defined	  as	  n-­‐tuples	  of	  0s	  and	  1s	   describing	   which	   genes	   in	   the	   network	   are	   or	   are	   not	   expressed	   at	   a	   particular	  moment.	   For	   a	   network	   of	   n	   genes,	   there	   are	   2^n	   possible	   different	   states.	   As	   time	  progresses,	  the	  network	  states	  transition	  through	  this	  ’state	  space’,	  switching	  from	  one	  state	   to	  another.	  These	   states	   can	  be	  monitored	   to	  determine	  which	   states	  have	  been	  reached	  and	  which	  (cycles	  between)	  states	  the	  network	  prefers	  to	  stay	  in	  once	  they	  are	  reached	   (so-­‐called	   attractors).	   Stochastic	   and	   probabilistic	   extensions	   to	   Boolean	  networks	   were	   also	   proposed	   by	   Akutsu	   et	   al.	   [52]	   and	   Shmulevich	   et	   al.	   [53],	  respectively.	  
2.1.2 Dynamical	  models	  	  Dynamical	  models	  such	  as	  ordinary	  differential	  equations	  (ODE)	  are	  important	  classes	  of	  GRN	  inference	  methods	  and	  probably	  the	  most-­‐used	  formalism	  for	  modeling	  genetic	  networks.	   In	   these	   models,	   the	   concentrations	   of	   genes,	   mRNAs,	   or	   proteins	   are	  represented	  by	  continuous,	  time-­‐dependent	  variables	  as	  follows:	  
	  where	   xi is	   the	   expression	   level	   of	   gene	   i and	   x is	   the	   state	   vector	   containing	   the	  expression	   levels	   of	   all	   other	   genes.	  The	   so-­‐called	   input	   functions f can be linear (first 
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order) or non-linear ODE functions. The	   linear	   model	   is	   the	   most	   commonly	   used	  dynamical	  model	  for	  gene	  network	  inference	  due	  to	  its	  simplicity	  [54-­‐56].	  However,	   it	  turned	   out	   that	   linear	  models	   often	   don’t	   provide	   plausible	   results	  when	   only	  mRNA	  concentrations	   are	   modeled.	   Successful	   models	   often	   also	   requires	   considering	   the	  process	   of	   protein	   translation	   via	   introducing	   protein	   concentrations	   as	   further	  dynamical	   variables.	   On	   the	   other	   hand,	  methods	   of	   reconstructions	   using	   non-­‐linear	  models	  employ	  complicated	  numerical	  optimization	  techniques	  to	  fit	  experimental	  gene	  expression	  data	   [57,	   58].	   	   Yip	   et	   al.	   presented	   in	   2010	  ODE	  models	   for	   knockout	   and	  perturbation	   data	   sets	   to	   infer	   the	   topology	   of	   GRN	   networks	   and	   achieved	   the	   best	  score	  in	  the	  Dream	  3	  challenge	  [59].	  	  
2.1.3 Stochastic	  approaches	  	  	  Although	  differential	  equations	  allow	  predicting	  the	  exact	  concentrations	  of	  genes	  and	  proteins,	   they	   assume	   that	   these	   molecular	   concentrations	   vary	   continuously	   and	  deterministically.	  However,	  in	  real	  biological	  systems,	  cellular	  activities	  and	  regulatory	  processes	   are	   stochastic	   processes	   subject	   to	   considerable	   noise	   [60,	   61].	   	   Especially	  when	  the	  number	  of	  molecules	  in	  a	  certain	  cellular	  reaction	  is	  small,	  stochastic	  methods	  can	   be	   efficient	   in	   modeling	   the	   underlying	   networks	   [62].	   Due	   to	   the	   complexity	  involved	  in	  estimating,	  solving	  and	  analyzing	  stochastic	  models,	  these	  are	  rarely	  used	  to	  model	  real	  networks	  of	  more	  than	  two	  or	  three	  genes	  and	  therefore	  are	  not	  applicable	  to	  high-­‐throughput	  datasets	  of	  the	  sort	  considered	  in	  this	  thesis.	  
2.1.4 Bayesian	  Networks	  	  Among	   the	   various	   kinds	   of	   computational	   methods	   that	   have	   been	   presented	   for	  reconstructing	   gene	   networks,	   Bayesian	   network	   (BN)	   approaches	   have	   shown	   great	  promise	  to	  infer	  causal	  relationships	  between	  genes	  based	  on	  their	  expression	  profiles.	  BNs	  are	  in	  principal	  probabilistic	  graphical	  models	  that	  encode	  dependencies	  between	  genes	   and	   represent	   the	   state	   of	   each	   gene	   as	   a	   joint	   probability	   distribution	   via	   a	  product	  of	  terms	  [63].	  Theoretically,	  Bayesian	  networks	  are	  graphical	  notation	   for	   conditional	   independence	  assertions	  between	  random	  variables	  and	  hence	  for	  compact	  representation	  of	  full	  joint	  distributions.	   Consider	   a	   finite	   set	  X = (X1, X2.... Xn)	   of	   random	   variables	   (genes)	   and	  their	  values	  refer	  to	  their	  gene	  expression	  measurements.	  The	   joint	  distributions	  over	  the	   set X can be represented as	   a	   product	   of	   conditional	   probabilities,	   where	   each	  variable	  Xi	  is	  associated	  with	  a	  conditional	  probability	  P(Xi | Pai) and Pai ⊆ X	  is	  a	  set	  of	  variables	   that	   are	   the	   parents	   of	   Xi.	   Thus,	   the	   values	   the	   Xi	   are	   independent	   on	   the	  values	  of	   the	  other	  variables	  given	   the	  parents	  of	  Xi,	   in	  other	  words,	   the	  parents	  of	  Xi	  directly	  influence	  the	  values	  for	  Xi	  (an	  example	  is	  shown	  in	  Figure	  2-­‐1).	  	  
	  The	   theory	   of	   learning	   Bayesian	   network	   structure	   from	   data	   can	   be	   formulated	   as	  follows:	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Given	  a	  training	  set D = X1, X2... XN of	  independent	  instances	  of X, find	  a	  network B = 
(G, Θ)	   that	   best	   matches D, where G is	   the	   network	   structure	   and Θ describes	   the	  graph	  parameters	  of	  the	  conditional	  probability	  table	  for	  each	  random	  variable	  X.	  	  
	  
Figure	  2-­‐1	  Bayesian	  network	  representation.	  Left:	  acyclic	  directed	  graph	  showing	  a	  Bayesian	  network	  with	  five	  random	  variables,	  where	  nodes	  (A	  to	  E)	  represent	  genes	   and	   edges	   represent	   direct	   dependencies	   between	   them.	   Right:	   conditional	   probability	   distribution	   for	   the	  gene	  C,	  where	  the	  expression	  level	  of	  its	  parents	  is	  discretized	  to	  a	  Boolean	  value.	  The	  product	  form	  specified	  by	  this	  Bayesian	  network	  is	  P (A, B, C, D, E) = P(A) P(B) P(C | A, B) P(D | A) P(E | C).	  	  	  The	  common	  method	  of	  Bayesian	  structure	  learning	  is	  to	  start	  from	  an	  initial	  network	  model	   (usually	  known	  as	  prior	  knowledge)	  and	   then	  adding	  nodes/genes	  using	   some	  operators	   (add	   edge,	   reverse	   edge,	   and	   remove	   edge).	   At	   every	   iteration,	   cyclic	  structures	   are	   removed	  and	  only	   candidate	   structures	  or	  models	   are	   subjected	   to	   the	  next	  step.	  Then,	  a	  structure-­‐scoring	  function	  is	  applied	  to	  find	  which	  model	  best	  fits	  the	  data.	   Since	   the	   number	   of	   generated	   models	   is	   super-­‐exponential	   in	   the	   number	   of	  involved	  random	  variables	  (genes),	  an	  efficient	  search	  algorithm	  (e.g.	  greedy	  algorithm)	  has	  to	  be	  employed	  to	  search	  the	  model	  space	  and	  find	  the	  model	  with	  the	  highest	  score.	  The	  approach	  can	  be	  summarized	  in	  the	  following	  procedure:	  	  
 
I/P   
       -M measurements of a finite set of random variables D= X1, X2.... Xn. 
       -An initial network Ninit(V, E) where V ∈ D. 
 
O/P  
       -A directed Bayesian network B = (G, Θ)	  that best matches D, where G is the network   




For each variable Xi ∈ D and ∉ V: 
 
       Step 1:  Add Xi  to Ninit using the operators (add edge, reverse edge, and remove edge) and  
                   generate a structure space S={ S1, S2 , ……..Sh} that contains all possible candidate   
                   structures. 
       Step 2:  Remove cyclic structures. 
       Step 3:  Apply a scoring function (ex: BDe) to all candidate structures. 
       Step 4:  Search for the highest score structure Sbest using an effective search algorithm. 
       Step 5:  Update the initial network with the inferred best structure, Ninit = Sbest. 
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A	   commonly	   used	   scoring	   function	   for	   evaluating	   the	   candidate	   Bayesian	   models	   is	  called	  Bayesian	  Dirichlet	  method	   (BDe)	   scoring	  metric	  which	   calculates	   the	   posterior	  probability	  of	  a	  network	  G	  given	  data	  D [64].	  The	  posterior	  probability	  of	  a	  graph	  given	  the	  data	  is:	  	  
BDe(G : D) = log P(G|D) =log P(D|G) + log P(G) + C  where	  P(D|G) is	   the	  marginal	   likelihood	  which	  averages	   the	  probability	  of	   the	  data	  D	  over	  all	  possible	  parameter	  assignments	  to	  G, P(G) is the prior probability of network G, 
and C is a	  constant	  independent	  of	  G [64]. An	   advantage	   of	   using	   Bayesian	   networks	   to	  model	   gene	   regulatory	   networks	   is	   that	  they	   can	   readily	   handle	   the	   stochastic	   aspects	   of	   input	   data	   as	   well	   as	   noisy	   and	  incomplete	   datasets.	   These	   problems	   are	   typical	   for	   gene	   expression	   data.	  Moreover,	  Bayesian	  networks	  facilitate	  the	  combination	  of	  prior	  or	  domain	  knowledge	  and	  input	  data.	  This	  allows	  making	  use	  of	  what	  is	  already	  known	  from	  regulatory	  interactions	  and	  regulatory	   repositories	   to	   infer	   regulatory	   relationships	   between	   genes	   involved	   in	  specific	  input	  data.	  Also,	  Bayesian	  networks	  encode	  the	  strength	  of	  causal	  relationships	  with	   probabilities.	   Therefore,	   prior	   knowledge	   and	   data	   can	   be	   combined	   with	   well-­‐studied	  techniques	  from	  Bayesian	  statistics	  [65].	  In	  addition,	  Bayesian	  methods	  offer	  an	  efficient	  approach	  for	  avoiding	  the	  overfitting	  of	  data.	  There	  is	  no	  need	  to	  dedicate	  some	  of	  the	  available	  data	  for	  testing.	  Using	  the	  Bayesian	  approach,	  models	  can	  be	  evaluated	  or	   scored	   in	   such	  a	  way	   that	   all	   available	  data	   can	  be	  used	   for	   learning.	  On	   the	  other	  hand,	  Bayesian	  networks	  don’t	  model	   the	  dynamical	  aspects	  of	  gene	  expression.	  Since	  the	  Bayesian	  networks	  are	  directed	  acyclic	  graphs	  (DAGs),	   this	  doesn’t	  allow	  network	  structures	   such	   as	   feedback	   loops	   or	   self–regulation	   links	   to	   be	   modeled,	   which	   is	  actually	  the	  case	  for	  most	  human	  genes	  (that	  typically	  have	  a	  negative	  auto-­‐regulatory	  feedback	  resulting	  in	  a	  sigmoidal	  thresholding	  of	  their	  maximal	  expression	  levels).	  
2.2 Biological	  data	  repositories	  
2.2.1 The	  Cancer	  Genome	  Atlas	  (TCGA)	  	  The	   TCGA	   portal	   [66]	   (http://cancergenome.nih.gov/)	   is	   a	   cancer-­‐specific	   	   data	  warehouse	   	   to	   search,	   download,	   and	   analyze	   consistent	   genome-­‐scale	   datasets	  generated	   from	   cancer	   patient	   samples	   by	   the	   TCGA	   consortium.	   The	   TCGA	   initiative	  was	   established	   in	   2005	   in	   the	   context	   of	   the	   “war	   on	   cancer”	   initiative.	   Most	   data	  samples	  are	  freely	  available	  to	  allow	  researchers	  around	  the	  world	  to	  analyze	  and	  make	  predictions.	   In	   this	   thesis,	   TCGA	   healthy	   and	   tumor	   samples	   were	   analyzed	   using	  different	  techniques	  such	  as	  gene	  expression	  profiling,	  genome	  wide	  DNA	  methylation,	  miRNA	   profiling,	   and	   SNP	   genotyping.	   Every	   TCGA	   sample	   carries	   a	   unique	   barcode,	  which	  is	  composed	  of	  a	  set	  of	  data	  element	  identifiers	  such	  as	  tissue	  source	  site,	  patient	  name,	  and	  sample	  type	  (healthy	  or	  tumor).	  See	  Figure	  2-­‐2.	  In	  chapter	  6,	  we	  applied	  our	  computational	   pipeline	   to	   breast	   cancer	   data	   downloaded	   from	   the	   TCGA	   portal	   and	  revealed	  strong	  associations	  between	  regulatory	  elements	  from	  different	  genomic	  data	  sources.	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Figure	  2-­‐2	  Illustration	  of	  the	  TCGA	  barcode	  and	  its	  data	  element	  identifier.	  	  Source:	  National	  cancer	  institute	  (NCI),	  https://wiki.nci.nih.gov/display/TCGA/TCGA+barcode.	  
2.2.2 Gene	  Expression	  Omnibus	  (GEO)	  	  GEO	  (http://www.ncbi.nlm.nih.gov/geo/)	  is	  an	  international	  public	  genomic	  repository	  maintained	  by	  NCBI	  to	  collect	  and	  freely	  disseminate	  raw	  and	  preprocessed	  microarray	  and	  next	  generation	  sequencing	  datasets.	  GEO	  data	  are	  organized	  in	  three	  entities:	  	  1-­‐ Platform:	  a	  platform	  is	  a	  list	  of	  probes	  related	  to	  an	  array	  technology	  provider.	  2-­‐ Sample:	  a	  sample	  describes	  the	  set	  of	  molecules	  (here:	  genes)	  whose	  expression	  profiles	  are	  measured	  in	  certain	  condition/tissue.	  3-­‐ Series:	   a	   series	   groups	   samples	   into	   meaningful	   data	   sets,	   which	   make	   up	   an	  experiment.	  The	  hematopoiesis	  study	  presented	  in	  chapter	  5	  used	  expression	  profiles	  of	  blood	  cell	  lines	  downloaded	  from	  GEO.	  
2.3 Biological	  knowledge	  databases	  	  Biological	   databases	   are	   informative	   digital	   libraries	   collected	   from	   scientific	  experiments,	  published	  literature,	  and	  computational	  analyses	  of	  high-­‐throughput	  data.	  These	   biological	   data	   are	   often	   structured	   and	   represented	   in	   tabular	   data,	   XML	  formats,	   key-­‐delimited	   records,	   ontology	   classes,	   well-­‐established	   attributes,	   and	  relationships.	   Various	   biological	   databases	   were	   tightly	   integrated	   in	   the	   tools	   and	  approaches	   developed	   in	   this	   thesis.	   Below,	   we	   will	   briefly	   introduce	   some	   of	   them	  below.	  
2.3.1 Gene	  Ontology	  (GO)	  	  The	  Gene	  ontology	  [67]	  is	  a	  set	  of	  formal	  vocabularies	  and	  explicit	  specifications	  of	  gene	  annotation	  terms	  that	  are	  used	  to	  describe	  the	  attributes	  of	  genes	  in	  an	  organism.	  GO	  is	  composed	  of	  three	  sub	  ontologies	  on	  the	  biological	  processes	  (BP),	  molecular	  functions	  (MF),	  and	  cellular	  components	  (CC)	  annotated	  to	  genes.	  The	  building	  blocks	  of	  GO	  are	  the	   terms	  (also	  called	   functional	  classes	  or	   functional	  categories).	  Each	  GO	  term	  has	  a	  unique	  ID	  and	  a	  textual	  name,	  Ex,	  GO:	  0042660:	  positive regulation of cell 
fate specification.	  A	  gene	  can	  be	  associated	  with	  one	  or	  more	  GO	  terms	  and	  may	  belong	  to	  different	  GO	  sub	  ontologies.	  The	  terms	  of	  the	  GO	  database	  are	  organized	  in	  a	  hierarchical	   structure	   where	   a	   few	   general	   terms	   such	   as	   developmental	   process	   are	  linked	  to	  numerous	  more	  specific	  terms	  on	  the	  next	  hierarchical	  level.	  Note	  that	  cycles	  are	   allowed.	   Recently,	   the	   developers	   team	   behind	   the	   David	   resource	   [68]	   has	  established	   GO_FAT.	   This	   is	   a	   subset	   of	   the	   full	   set	   of	   GO	   terms	   so	   that	   the	   broadest	  terms	  should	  not	  overshadow	  more	  specific	  terms.	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2.3.2 KEGG	  	  The	   Kyoto	   Encyclopedia	   of	   Genes	   and	   Genomes	   (KEGG)	   is	   a	   group	   of	   linked	  comprehensive	   databases	   that	   store	   information	   about	   gene	   products,	   biological	  pathways,	  drugs,	  diseases,	  and	  chemical	  substances	  as	  a	  knowledge	  base	  for	  systematic	  analysis	  of	  genetic	  molecules	   [69].	  The	  core	  of	   the	  KEGG	  suite	   is	   the	  KEGG	  PATHWAY	  database	   that	   contains	  metabolic	   pathway	  maps	   integrating	   genes,	   proteins,	  miRNAs,	  and	  chemical	  compounds	  as	  well	  as	  disease	  genes	  and	  drug	  targets.	  	  	  Similar	   to	   the	  Gene	  Ontology,	  KEGG	  can	  be	  used	  to	  determine	  whether	  or	  not	  a	  set	  of	  genes	  is	  functionally	  enriched.	  However,	  the	  term	  (enrichment)	  here	  is	  more	  related	  to	  the	   biological	   pathways,	   in	   other	   words,	   the	   contributions	   of	   these	   genes	   in	   the	  background	   of	   all	   chemical	   reactions	   occurring	   within	   the	   cell	   such	   as	   metabolism,	  membrane	  transport,	  and	  signal	  transduction.	  
2.3.3 Molecular	  signature	  database	  (MSigDB	  )	  
	  MSigDB	  is	  a	  well-­‐annotated	  gene	  set	  representing	  the	  universe	  of	  biological	  processes	  and	  is	  used	  for	  interpretation	  of	  large-­‐scale	  genomic	  data	  [70].	  Genes	  are	  grouped	  into	  annotated	   sets	   based	   on	   specific	   genomic	   properties	   among	   them	   such	   as	   shared	  binding	   sites	   for	   transcription	   factor	   families	   (motif	   gene	   sets),	   associations	  with	   the	  same	   GO	   functional	   terms	   (GO	   gene	   sets),	   or	   being	   involved	   in	   the	   same	   diseases	  (oncogenic	   signature	   sets).	   Here,	   we	   incorporated	   the	   motif	   gene	   sets	   into	   our	  developed	  tools	  and	  used	  them	  also	  to	  investigate	  whether	  binding	  sites	  for	  distinct	  TFs	  are	  enriched	  in	  the	  promoter	  regions	  of	  imprinted	  genes	  (chapter	  4).	  
2.3.4 Regulatory	  interaction	  databases	  	  	  Several	  databases	  and	  online	  repositories	  have	  been	  developed	  in	  order	  to	  facilitate	  the	  research	   on	   predicted	   and	   experimentally	   verified	   genome-­‐wide	   transcriptional	   and	  post-­‐transcriptional	   regulatory	   interactions.	   For	   instance,	   TransFac	   [71]	   and	   MsigDB	  [70]	  maintain	  interactions	  of	  TFs	  regulating	  genes	  (TF"gene).	  TransmiR	  [30]	  provides	  information	   on	   which	   TFs	   regulate	   miRNAs	   (TF"miRNA).	   mirTarBase[72],	   TarBase	  [73]	  and	  miRecords	   [74]	  comprise	  miRNAs	  and	  their	   target	  genes	  (miRNA"genes)	   in	  different	   organisms.	   Although	   still	   little	   is	   known	   about	   miRNA-­‐mediated	   miRNA	  regulations,	   miRNA"miRNA	   interactions	   were	   computationally	   predicted	   and	  maintained	   in	   the	   PmmR	   database	   [75].	   An	   extensive	   study	   of	   the	   integration	  mechanisms	  of	  such	  databases	  and	  further	  downstream	  analysis	  of	  the	  involved	  genetic	  molecules	  and	  their	  pathways	  in	  cancer	  is	  described	  in	  Chapter	  3.	  	  
2.4 Statistical	  tools	  
2.4.1 Over	  representation	  analysis	  (ORA)	  	  The	   demand	   on	   computational	   biology	   for	   evaluating	   results	   of	   high-­‐throughput	   data	  analysis	  has	  led	  to	  the	  development	  of	  several	  popular	  tools	  and	  statistical	  approaches	  [76].	   ORA	   is	   a	   widely	   used	   statistical	   approach	   that	   increases	   the	   likelihood	   for	  researchers	  to	  identify	  biological	  terms	  most	  relevant	  to	  their	  study.	  More	  specifically,	  ORA	  compares	  a	  reference	  set	  of	  genes	  to	  a	  test	  set	  in	  terms	  of	  their	  associations	  with	  a	  certain	   biological	   term.	   For	   instance,	  when	   considering	   a	   certain	   GO	   functional	   term,	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this	  method	  assesses	  whether	  this	  GO	  term	  is	  over-­‐represented	  or	  under-­‐represented	  in	  the	   respective	   study	   set	   and	  estimates	  how	   likely	   this	   is	   to	  happen	  by	   chance.	  DAVID	  [68]	  and	  WebGestalt	  [77]	  are	  famous	  examples	  for	  tools	  that	  have	  been	  developed	  for	  the	   purpose	   of	   ORA	   analysis.	   ORA	   uses	   both	   parametric	   statistical	   tests	   (ex:	  hypergeometric	   test)	   and	   non-­‐parametric	   statistical	   tests	   (ex:	   Kolmogorov-­‐Smirnov	  test)	  to	  assess	  the	  significance	  of	  term	  enrichment.	  ORA	  was	  a	  central	  part	  in	  the	  study	  of	   chapter	   4	   where	   we	   examined	   the	   cellular	   functions	   and	   motif	   enrichment	   of	  imprinted	  genes	  and	  hence	   their	   regulatory	   roles	   in	   cellular	  differentiation	  and	  blood	  cell	  development	  (chapter	  5).	  
2.4.2 Hypergeometric	  test	  	  The	   hypergeometric-­‐based	   test	   estimates	   the	   discrete	   probability	   that	   describes	   the	  number	   of	   successes	   in	   a	   sequence	   of	   n	   draws	   from	   a	   finite	   population	   without	  replacement.	  	  	  Given	   a	   set	   of	   N	   study	   genes,	   of	   which	   x	   belong	   to	   a	   functional	   category	   C,	   and	   a	  population	   set	   of	   size	  M,	   of	  which	  k	   belong	   to	  C.	   Then,	   the	   probability	   of	   observing	   x	  genes	  out	  of	  N	   by	   chance	  belonging	   to	   the	  C	   category	   containing	  k	   genes	   from	  a	   total	  population	  of	  size	  M	  can	  be	  modeled	  as	  follows:	  	  	  
	  The	  closer	  the	  probability	  (p-­‐value)	  is	  to	  0,	  the	  more	  unlikely	  is	  the	  chance	  of	  error	  that	  the	  majority	  of	  genes	  belong	  to	  that	  category	  C	  (enriched).	  
2.4.3 Kolmogorov-­‐Smirnov	  test	  (KS	  test)	  	  KS	   test	   is	   a	   non-­‐parametric	   (distribution	   free)	   test	   for	   comparing	   a	   sample to	   a	  reference	   probability	   distribution	   (one-­‐sample	   KS	   test),	   or	   for	   comparing	   the	  distributions	  of	  two	  samples	  (two-­‐sample	  K–S	  test).	  The	  KS	  test	  computes	  the	  distance	  between	  the	  empirical	  distribution	  function	  of	  a	  sample	  and	  the	  cumulative	  distribution	  of	  the	  reference	  hypothesis	  (in	  case	  of	  the	  one-­‐sample	  KS	  test)	  or	  between	  the	  empirical	  distribution	  functions	  of	  two	  samples	  (in	  case	  of	  the	  two-­‐sample	  KS	  test).	  	  Due	   to	   its	   sensitivity	   to	   differences	   in	   both	   the	   location	   and	   shape	   of	   the	   empirical	  distribution	   functions,	   the	   two-­‐sample	  KS	   test	   is	  considered	  as	  one	  of	   the	  most	  useful	  and	  most	   general	   nonparametric	  methods	   for	   comparing	   two	   samples.	   Therefore,	  we	  incorporated	   the	  KS	   test	   in	  our	  developed	  TFmiR	  web	  server	   (Chapter	  3)	   to	   compare	  two	  distributions	  of	  gene	  pairwise	  functional	  similarity	  scores.	  	  
2.4.4 Multiple	  test	  correction	  	  Since	  we	  are	  testing	  the	  enrichment	  of	  a	  set	  of	  genes	  with	  multiple	  biological	  categories,	  several	   independent	   statistical	   tests	   are	   performed	   simultaneously.	   This	   leads	   to	  increasing	   the	  probability	   for	   false	  positive	  predictions	  or	  what	   is	  a	   so-­‐called	   “Type	  1	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error”.	   The	   multiple	   testing	   corrections	   adjust	   p-­‐values	   derived	   from	   multiple	  hypothesis	   testing	   to	   correct	   for	   the	   occurrence	   of	   false	   positives.	   In	   gene	   expression	  analysis,	   for	   example,	   false	   positives	   could	   be	   those	   genes	   that	   are	   found	   to	   be	  statistically	  differentially	  expressed	  between	  two	  conditions,	  but	  are	  not	  in	  reality.	  	  In	   our	   developed	   computational	   tools,	   we	   utilized	   the	   Benjamini	   and	   Hochberg	   (BH)	  [78]	   False	  Discovery	  Rate	   (FDR)	   as	   a	  multiple	   testing	   correction	   approach.	   Instead	  of	  controlling	  the	  probability	  of	  committing	  any	  type	  I	  error	  by	  setting	  a	  more	  severe	  cut	  off	  level	  as	  in	  the	  Bonferroni	  method,	  this	  BH	  method	  controls	  the	  expected	  proportion	  of	  errors	  among	  the	  rejected	  null	  hypotheses.	  	  
 Therefore,	  it	  is	  the	  least	  stringent	  of	  all	  corrections	  and	  keeps	  a	  good	  balance	  between	  the	  discovery	   of	   statistically	   significant	   genes	   and	   limitations	   of	   the	   predictive	   power	  due	  to	  the	  occurrence	  of	  false	  positives.	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In	   this	  chapter,	  we	  present	  scalable	  computational	  approaches	  and	  automated	  pipelines	   that	  we	  
implemented	  as	   freely	  available	   software	   tools	   to	   integrate	  heterogeneous	   sources	  of	   large-­‐scale	  
genomic	   data	   and	   to	   unravel	   the	   combinatorial	   regulatory	   interactions	   between	   different	  
molecular	   elements.	   We	   started	   with	   a	   GRN	   pipeline	   to	   reverse	   engineer	   the	   regulatory	  
interactions	   from	   gene	   expression	   and	   gene	   sequence	   data.	   Then,	   we	   expand	   it	   to	   a	   general	  
integrative	   network	   based	   approach	   involving	  miRNA	   expression,	  DNA	  methylation,	   and	   genetic	  
variants.	   An	   NGS	   pipeline	   was	   implemented	   to	   identify	   the	   core	   genome	   SNPs	   between	   two	  
different	  phenotype	  groups	  in	  analogy	  to	  the	  identification	  of	  somatic	  mutations	  between	  disease	  
and	  healthy	  samples.	  A	  standalone	  proximity	  pipeline	  was	  also	   implemented	  to	  study	  the	  vicinity	  
relationships	  between	  a	  significant	  set	  of	  gene	  promoters,	  miRNAs	  and	  genetic	  variations.	  Finally,	  
we	   developed	   TFmiR	   as	   a	   freely	   available	   comprehensive	   web	   server	   for	   deep	   and	   integrative	  
analysis	  of	  regulatory	   information	  between	  TFs/genes	  and	  miRNAs	  and	  their	   interwoven	  critical	  
roles	  in	  the	  pathology	  of	  human	  diseases.	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In	   this	   chapter,	   we	   present	   the	   bioinformatics	   tools	   and	   approaches	   that	   were	  implemented	  in	  the	  course	  of	  this	  thesis.	  The	  aim	  of	  these	  approaches	  is	  unraveling	  the	  interwoven	   gene	   regulatory	   network	   between	   genetic	  molecules	   that	   are	   involved	   in	  cellular	  functions	  and	  disease	  pathways.	  We	  applied	  these	  approaches	  to	  omics	  data	  of	  human	  breast	  cancer	  as	  well	  as	  hematopoiesis	  as	  a	  well-­‐established	  model	  for	  stem	  cell	  differentiation.	  	  
3.1 The	  model	  of	  gene	  regulation	  	  As	  shown	  in	  Chapter	  two,	  several	  complex	  approaches	  to	  reconstruct	  cellular	  networks	  from	  gene	  expression	  data	  have	  been	  published	  over	  the	   last	   few	  years.	  Among	  these,	  only	  Bayesian	  networks	   infer	  causal	  relationships	  between	  genes	  while	  making	  use	  of	  known	   regulatory	   information	   that	   is	   already	   stored	   in	   regulatory	   databases.	   This	  information	  is	  referred	  to	  here	  as	  a	  primary	  or	  prior	  knowledge.	  Hence,	  we	  adopted	  the	  Bayesian	   approach	   in	   our	   implemented	   pipeline	   to	   reconstruct	   the	   GRN	   from	  expression	  and	  gene	  sequence	  data.	  	  In	  this	  thesis,	  we	  formulate	  the	  architecture	  of	  GRNs	  as	  follows,	  both	  target	  genes	  and	  genes	   coding	   for	   transcription	   factors	   are	   represented	   as	   nodes	   in	   the	   network.	  Regulatory	  interactions	  are	  represented	  as	  directed	  edges	  from	  TF	  or	  miRNA	  to	  target	  genes.	  On	  the	  transcription	  level,	  if	  a	  gene	  is	  silenced	  while	  the	  methylation	  level	  of	  its	  promoter	   was	   high,	   we	   assume	   that	   gene	   silencing	   results	   from	   the	   increase	   in	  promoter	  methylation	  and	  is	  not	  due	  to	  TFs	  nor	  miRNA	  regulation	  [79].	  In	  addition,	  we	  assumed	   direct	   individual	   binding	   of	   transcription	   factors	   to	   the	   regulatory	   site	   of	   a	  gene:	   in	   other	   words,	   regulation	   role	   of	   transcription	   factors	   complexes	   are	   not	  considered	  here.	  On	  the	  post-­‐transcriptional	  level,	  we	  only	  considered	  the	  regulation	  of	  genes	  by	  miRNAs	  and	   ignored	  other	  degradation	   causes	  of	  mRNA	   transcripts.	   Finally,	  although	   post-­‐translational	   regulation	   is	   an	   important	   aspect	   in	   the	   regulatory	  machinery	   in	   complex	   cellular	   systems,	   there	   was	   no	   chance	   to	   model	   it	   within	   the	  scope	  of	  this	  work	  for	  lack	  of	  time.	  Nevertheless,	  it	  is	  discussed	  in	  the	  last	  chapter	  as	  a	  high	  potential	  follow-­‐up	  work	  to	  this	  dissertation.	  
3.2 GRN	  construction	  pipeline	  	  	  The	  reconstruction	  pipeline	  consists	  of	  three	  steps:	  	  	   1. Build	  a	  weighted	  co-­‐expression	  network	  from	  gene	  expression	  data.	  	  2. Query	  known	  regulatory	  interactions	  that	  are	  likely	  involved	  in	  the	  constructed	  co-­‐expression	   network	   and	   do	  motif	   search	   using	   sequencing	   data	   of	   network	  genes.	  	  3. Learn	   the	   network	   topology	   using	   Bayesian	   approach	   by	   utilizing	   information	  from	  step	  2	  as	  a	  prior	  knowledge.	  	  	  	  The	  first	  step	  outputs	  an	  undirected	  network G(V, E) with	  edge	  thickness	  representing	  the	  correlation	  strength	  between	  the	  expression	  profiles	  of	  the	  connected	  genes.	  In	  the	  second	  step,	  we	  examine	  the	  regulation	  directionality	  for	  each	  undirected	  edge	  e	  in	  the	  co-­‐expression	   network	   by	   connecting	   to	   transcriptional	   regulatory	   databases	   and	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performing	   motif	   discovery	   analysis.	   If	   a	   directed	   interaction	   between	   the	   two	  examined	  nodes	  is	  found	  in	  the	  regulatory	  databases	  or	  confirmed	  by	  motif	  search,	  the	  corresponding	  undirected	  edge	  e will	  be	  updated	  accordingly	  to	  a	  directed	  edge	  ed.	  The	  resulting	  network	  of	  this	  step	  would	  contain	  both	  directed	  and	  undirected	  edges.	  	  Next,	  the	   directed	   sub-­‐network	   Gd(Vd, Ed)	   representing	   the	   constructed	   directed	   edges	   is	  extracted	   and	  used	   as	   a	   prior	   knowledge	   to	   statistically	   learn	   the	   remaining	  network	  structure	  via	  Bayesian	  approach	   in	   the	   third	  step.	  This	   last	   step	   takes	   two	   inputs:	   the	  prior	   network	   constructed	   from	   step	  2	   as	  well	   as	   the	   expression	  dataset	   of	   genes	  Vud	  that	  are	  still	   involved	  in	  undirected	  edges.	  This	  outputs	  a	  directed	  causal	  probabilistic	  network	  that	  best	  fits	  the	  expression	  data	  of	  the	  involved	  genes.	  	  	  Then,	  the	  final	  network	  topology	  is	  composed	  of	  directed	  interactions	  identified	  in	  step	  2	  as	  well	  as	  interactions	  confirmed	  by	  both	  step	  1	  (co-­‐expression)	  and	  step	  3	  (Bayesian	  learning).	  Each	  of	  these	  steps	  is	  detailed	  below;	  see	  Figure	  3-­‐1	  for	  an	  overview	  for	  the	  entire	  pipeline.	  The	  last	  block	  refers	  to	  the	  integrative	  network-­‐based	  approach	  which	  was	   developed	   as	   an	   extension	   to	   the	   GRN	   pipeline	   to	   process	   information	   from	  epigenetic	   data	   and	   somatic	   mutations,	   see	   section	   3.4.	   The	   three	   steps	   of	   the	   GRN	  pipeline	   are	   implemented	   as	   separate	   software	  modules	   (plugins)	   and	   hosted	   by	   our	  software	   framework	   Mebitoo	   for	   workflow	   automation	   (section	   3.3).	   We	   note	   that	  coupling	  the	  third	  module	  is	  still	  in	  progress.	  	  
	  
	  
Figure	  3-­‐1	  GRN	  construction	  pipeline	  from	  heterogeneous	  sources	  of	  genomics	  data.	  The	  steps	  are	  as	  follows:	  (1)	  Build	  weighted	  co-­‐expression	  network	  from	  gene	  expression	  data.	  	  (2)	  Query	  regulatory	  interactions	   and	   do	   a	   search	   for	   binding	   motifs	   using	   sequencing	   data	   of	   network	   genes.	   (3)	   Learn	   the	   network	  topology	  using	  Bayesian	  approach	  and	  utilizing	  information	  from	  step	  2	  as	  a	  prior	  knowledge.	  The	  last	  block	  refers	  to	  the	   integrative	   network-­‐based	   approach,	   which	   was	   developed	   as	   an	   extension	   to	   the	   GRN	   pipeline	   to	   process	  information	  from	  epigenetic	  data	  and	  somatic	  mutations.	  	  
3.2.1 Plugin	  1:	  Weighted	  co-­‐expression	  network	  	  Co-­‐expression	   networks	   provide	   a	   widely	   applicable	   framework	   for	   assigning	   gene	  cellular	  functions	  and	  identifying	  functional	  network	  modules	  [80].	  Gene	  co-­‐expression	  concurs	   the	   functional	   similarity	   between	   genes	   based	   on	   gene	   ontology	   (GO)	  annotations	   [67].	   Co-­‐expression	   networks	   are	   defined	   as	   undirected	   gene	   networks	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Figure	  3-­‐3	  Preprocessing	  options	  of	  raw	  expression	  data.	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The	   plugin	   utilizes	   the	   WGCNA	   R	   package	   [81]	   to	   build	   a	   weighted	   co-­‐expression	  network	  from	  gene	  expression	  data.	  First,	  we	  measure	  the	  concordance	  between	  gene	  expression	  profiles	  using	  Pearson	  correlation.	  Then,	  the	  pairwise	  correlation	  matrix	   is	  subjected	   to	  power	   adjacency	   function	   to	  obtain	   a	  weighted	   correlation	  matrix	  which	  emphasizes	  high	  correlations	  at	  the	  expense	  of	  low	  correlations	  as	  follows.	  
	  	  	  where	   is	   the	   weighted	   correlation	   that	   refers	   to	   the	   connection	   strength	   between	  gene	  pairs	   ,	  while	  β	  is	  a	  coefficient	  that	  controls	  the	  soft	  threshold	  curvature	  and	  its	  value	  is	  recommended	  by	  the	  tool	  for	  each	  dataset.	  
	  Next,	  we	  use	  average	  linking	  hierarchical	  clustering	  to	  cluster	  genes	  into	  co-­‐expression	  network	  modules.	  Finally,	  for	  each	  module	  we	  display	  the	  corresponding	  weighted	  co-­‐expression	  network	  and	  the	  list	  of	  involved	  genes.	  Results	  can	  be	  exported	  to	  network	  files	  and	  used	  as	  input	  parameters	  for	  the	  next	  plugin	  (Figure	  3-­‐4).	  	  
	  
	  
Figure	  3-­‐4	  visualizing	  the	  network	  and	  gene	  lists	  for	  each	  co-­‐expression	  module.	  	  
3.2.2 Plugin	  2:	  Online	  query	  for	  regulating	  links	  and	  motif	  search	  	  This	  plugin	  was	  designed	  by	  the	  author	  of	  this	  thesis	  and	  implemented	  by	  Mr.	  Johannes	  Trumm	   during	   his	   M.Sc.	   thesis	   under	   the	   supervision	   of	   the	   PhD	   author.	   The	   co-­‐expression	  network	  constructed	  in	  the	  first	  plugin	  is	  subjected	  to	  plugin	  2	  as	  an	  input	  parameter.	   This	   plugin	   matches	   the	   co-­‐expression	   interactions	   with	   regulatory	  information	   retrieved	   from	   the	   Transcriptional	   Regulatory	   Element	   Database	   (TRED)	  [82],	  Molecular	  Signatures	  Database	  (MSigDB)	  [70],	  and	  JASPAR	  database	  [83].	  Also	  the	  tool	   utilizes	   the	   NCBI	   (http://www.ncbi.nlm.nih.gov/)	   and	   HGNC	  (http://www.genenames.org/)	  repositories	  to	  download	  gene	  promoter	  sequences	  and	  map	   the	   input	   gene	   names	   to	   unique	   identifiers,	   respectively.	   Figure	   3-­‐5	   shows	   the	  integrated	  genomic	  resources	  and	  software	  components	  in	  this	  plugin.	  Finally,	  the	  user	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has	   the	   option	   to	   set	   the	   parameters	   required	   for	  motif	   search	   and	   promoter	   region	  identification	   via	   a	   user	   control	   panel	   (Figure	   3-­‐6).	   The	   matching	   process	   can	   be	  summarized	  in	  the	  following	  steps:	  	   1. Assigning	  transcription	  factors.	  All	  genes	  involved	  in	  the	  co-­‐expression	  network	  and	  listed	  in	  at	  least	  one	  of	  the	  above	  databases	  to	  code	  for	  a	  transcription	  factor	  (TF)	  were	  marked	  as	  TFs.	  	  2. Adding	  known	  regulatory	  interactions.	  For	   each	  TF-­‐gene	   link	   in	   the	   co-­‐expression	  network,	  we	   searched	  whether	   the	  databases	   contain	   a	   known	   regulation	   for	   this	   TF-­‐target	   gene	   pair.	   In	   each	   of	  these	  cases,	  a	  directed	  edge	  was	  added	  between	  the	  transcription	  factor	  and	  the	  target	  gene.	  	  3. Searching	  for	  known	  binding	  motifs.	  Here,	   we	   used	   the	   Motif	   Statistics	   and	   Discovery	   (MoSDi)	   [84]	   software	   to	  conduct	  a	  motif	  search	  for	  all	  known	  binding	  motifs	  of	  the	  TFs	  represented	  in	  the	  co-­‐expression	  network	  against	  the	  promoter	  regions	  of	  all	  genes	  in	  the	  network.	  If	  a	  match	  was	   found,	  a	  new	  directed	  edge	   from	  the	  TF	  to	   the	  gene	  was	  added.	  Finally,	   the	   constructed	   directed	   interactions	   are	   visualized	   in	   an	   interactive	  display	   and	   can	   be	   exported	   to	   Cytoscape	   [85]	   or	   VisANT	   [86]	   network	   files	  	  (Figure	  3-­‐7).	  	  
	  
Figure	  3-­‐5	  The	  integrated	  genomic	  resources	  and	  SW	  components	  used	  in	  the	  GRN	  query	  plugin.	  Source:	  M.Sc.	  thesis	  by	  Johannes	  Trumm.	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Figure	  3-­‐6	  User	  control	  panel	  to	  set	  the	  parameters	  for	  the	  GRN	  query	  plugin.	  	  
	  
	  
Figure	  3-­‐7	  Results	  of	  the	  GRN	  query	  plugin-­‐	  Interactive	  network	  visualization	  and	  export	  options.	  Transcription	  factors	  involved	  in	  the	  input	  network	  are	  identified	  and	  marked	  in	  yellow	  while	  the	  remaining	  genes	  are	   colored	   blue.	   The	   tool	   can	   expand	   the	   input	   network	   by	   adding	   additional	   transcription	   factors	   (marked	   in	  orange)	   that	   are	   annotated	   as	   known	   regulators	   of	   the	   input	   genes	   and	   also	   by	   adding	   additional	   target	   genes	  (marked	  in	  green)	  that	  are	  annotated	  to	  be	  regulated	  by	  the	  TFs	  in	  the	  input	  network.	  
3.2.3 Plugin	  3:	  learning	  the	  network	  topology	  using	  Bayesian	  network	  	  This	  plugin	  is	  still	  running	  as	  a	  script	  and	  needs	  to	  be	  coupled	  and	  integrated	  to	  Mebitoo	  framework.	   In	   this	   step	   (plugin	   3),	   we	   constructed	   a	   causal	   probabilistic	   Bayesian	  
Chapter	  3	   	   	   Approaches	  and	  methods	  	  	  
	  	   34	  
network	   from	   the	  co-­‐expression	  modules	  where	  we	  used	   the	  directed	  edges	  obtained	  from	  plugin	  2	  as	  a	  start	  search	  point	  to	  infer	  directionality	  between	  nodes.	  	  	  As	  discussed	  in	  chapter	  two,	  learning	  of	  network	  structures	  using	  a	  Bayesian	  approach	  requires	  a	  scoring	  function	  to	  assess	  how	  well	  a	  certain	  structure	  fits	  the	  input	  data	  and	  a	  search	  algorithm	  to	   find	  structures	  with	  high	  scores.	  Here,	  we	  can	  adopt	   the	  greedy	  algorithm	   as	   a	   search	   algorithm	   and	   the	   likelihood-­‐equivalence	   Bayesian	   Dirichlet	  (BDe)	  [87]	  method	  as	  a	  scoring	  function	  for	  assessing	  network	  topology,	  see	  chapter	  2.	  	  	  Instead	   of	   taking	   the	   best	   network	   structure	   that	   has	   the	   best	   score,	  we	   perform	   the	  learning	  approach	  three	  times	  and	  select	  only	  edges	  that	  were	  inferred	  at	  least	  twice	  in	  the	  three	  runs	  (edge	  confidence	  level	  ≥	  66.6%).	  	  
3.3 Mebitoo:	  An	  extensible	  software	  framework	  hosting	  the	  pipeline	  plugins	  
3.3.1 Description	  	  
The Mebitoo framework has mainly been developed by Mr .Christian Spaniol who is 
another PhD student in the Helms group. During the time line of this PhD thesis, the 
author was involved in extending some functionalities of Mebitoo and in writing new 
add-on modules and plugins.  Mebitoo	   is	   a	   software	   application	   suite	  written	   in	   Java	   that	   is	   based	   on	   the	  Netbeans	  Rich-­‐Client	   platform	   (RCP)	   project	   that	   can	   easily	   be	   extended	   with	   additional	  functionality	  deployed	  as	  modules.	  Moreover, the software enables persistent storage 
with an incorporated database engine, which supports XML files for customized data 
structures. Since	   the	   Mebitoo	   framework	   implements	   a	   uniform	   plugin	   interface,	  automated	  data	  processing	  can	  be	  invoked	  using	  a	  task	  execution	  interface	  in	  order	  to	  queue	  multiple	  operations	  of	  different	  modules	  and	  process	  datasets	  in	  parallel. Mebitoo	   is	   appropriate	   for	   inexperienced	   users,	   researchers	   without	   programming	  knowledge	  as	  well	  as	  scientific	  programmers,	  and	  developers.	  Aiming	  at	  the	  first	  group,	  an	  easy	  and	  friendly	  GUI	  is	  provided	  that	  guides	  the	  user	  to	  sequentially	  define	  his	  tasks	  (every	   task	   represents	   a	   one-­‐time	   running	  module)	   and	   gets	   the	   final	   results	   in	   one–click	  press	  button.	  For	  advanced	  users	  with	  knowledge	   in	   Java	  programming,	  Mebitoo	  can	  be	  used	  as	  a	  ready	  hosting	  workflow	  automation	  framework	  for	  coupling	  more	  new	  bioinformatics	  add-­‐on	  plugins	  or	  modules.	  	  
3.3.2 Software	  design	  consideration	  	  As	   shown	   above,	   the	   three	   GRN	   steps	   were	   implemented	   as	   independent	   Java	  modules/plugins	   of	   the	   Mebitoo	   framework.	   Figure	   3-­‐8	   illustrates	   the	   system	  architecture	  of	  the	  GRN	  plugins	  hosted	  by	  Mebitoo	  and	  the	  followed	  design	  paradigms.	  The	  GRN	  pipeline	  is	  designed	  to	  support	  both	  thin	  and	  fat	  client	  paradigms.	  Currently,	  it	  works	  on	  the	  fat	  client	  paradigm	  where	  all	  business	  logic	  and	  data	  processing	  occur	  in	  the	   desktop	   version	   installed	   on	   the	   user	   machine.	   However,	   to	   achieve	   better	  performance	  in	  data	  processing,	  these	  plugins	  could	  be	  easily	  switched	  to	  the	  thin	  client	  paradigm	  once	  the	  fat	  server	  configuration	  (application	  server)	  is	  available.	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Figure	  3-­‐8	  SW	  architecture	  and	  design	  paradigms	  of	  the	  GRN	  pipeline	  modules	  hosted	  by	  Mebitoo.	  Business	   logic	  and	  data	  processing	   functions	  are	   implemented	   in	  R	  and	   located	  on	   the	  client	  version	   in	   case	  of	   fat	  client	  model	  or	  located	  on	  application	  server	  in	  case	  of	  thin	  client	  model.	  	  The	  business	  logic	  functions	  are	  invoked	  by	  plugins	  GUI	  through	  the	  Java–R	  interfaces	  JRI.	  
3.4 Integrative	  network-­‐based	  approach	  	  	  To	   date,	   a	   large	   number	   of	   various	  methods	   have	   been	   developed	   to	   investigate	   the	  molecular	   basis	   of	   complex	  diseases	   and	   integrate	  heterogeneous	   sources	   of	   genomic	  data.	  Due	  to	  the	  complexity	  of	  the	  disease	  pathways	  and	  the	  underlying	  biology,	  it	  is	  still	  challenging	   to	   integrate	   and	   extract	   meaningful	   information	   from	   large	   genomic	  datasets	  (See	  literature	  of	  chapter	  6	  for	  detailed	  examples).	  In	  this	  regard,	  we	  presented	  a	  network-­‐based	  approach	   [7]	  utilizing	   the	  GRN	  pipeline	  explained	  above	   to	  elucidate	  the	  regulatory	  mechanisms	  of	  several	  disease	  pathways	  at	  the	  molecular	  transcriptional	  and	  post-­‐transcriptional	   level.	   Sofar,	  our	  approach	  reports	   the	  computational	  analysis	  of	   gene	   and	   miRNA	   transcriptomes,	   DNA	   methylome,	   and	   somatic	   mutations	   to	  highlight	  putative	  disease	  drivers	  and	  novel	  targets	  for	  treatment.	  	  This	  approach	  was	  applied	  to	  breast	  cancer	  data	  downloaded	  from	  the	  TCGA	  portal	  [66]	  and	  was	  able	  to	  reveal	  strong	  associations	  between	  regulatory	  elements	  from	  different	  genomic	  data	  sources	  (see	  chapter	  6).	  The	  integrated	  molecular	  analysis	  enabled	  by	  this	  approach	  substantially	  expands	  our	  knowledge	  base	  of	  prospective	  genomic	  drivers	  of	  genes,	  miRNAs,	   and	  mutations	   and	  highlighted	   candidates	   for	   further	   investigation	   in	  the	   wet	   lab	   as	   novel	   targets	   for	   breast	   cancer	   treatment	   (chapter	   6).	   The	   provided	  network-­‐based	   approach	   can	   be	   applied	   in	   a	   similar	   fashion	   to	   other	   cancer	   types,	  complex	  diseases,	  or	   for	   studying	   cellular	  differentiation	  processes	  where	   such	  multi-­‐dimensional	  datasets	  are	  available.	  The	  integrative	  network-­‐based	  approach	  illustrated	  in	   Figure	   3-­‐9	   currently	   is	   able	   to	   process	   four	   different	   genomic	   datasets:	   gene	  expression,	  DNA	  methylation,	  miRNA	  expression,	  and	  somatic	  mutations	   from	  normal	  and	  diseased	  cohorts.	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3.4.1 Data	  consistency	  and	  preprocessing	  	  For	   consistency,	   we	   considered	   only	   samples	   that	   were	   common	   between	   all	   four	  datasets.	  For	  both	  gene	  expression	  and	  methylation	  datasets,	  all	  probes	  containing	  NA	  values	   or	   that	   were	   annotated	   to	   unknown	   or	   multiple	   genes	   were	   removed.	   Also,	  probes	  values	  were	  merged	  by	  computing	  the	  mean	  of	  all	  probes	  related	  to	  single	  genes	  within	  a	  single	  sample	  as	  previously	  described	  in	  [88].	  	  	  From	  the	  DNA	  methylation	  data,	  we	  kept	  only	   those	  probes	  representing	  CpG	  sites	   in	  the	  promoter	  regions	  of	  genes.	  For	  this,	  we	  used	  the	  transcription	  start	  sites	  (TSS)	  for	  all	  human	  genes	  as	  annotated	  in	  the	  Eukaryotic	  Promoter	  Database	  EPD	  [89].	  Promoter	  regions	  were	  defined	  as	  an	  interval	  of	  ±2kb	  around	  the	  TSS	  as	  described	  in	  [70].	  Then	  we	   selected	   only	   those	   CpG	   sites	   whose	   genomic	   coordinates	   are	   contained	   in	   that	  interval.	  
3.4.2 Differential	  analysis	  	  The	  differential	  expression/methylation	  analysis	  was	  performed	  using	  three	  methods:	  1)	  Significance	  Analysis	  of	  Microarray	  (SAM)	  [90],	  2)	  moderated	  t-­‐test	  [91],	  	  and	  3)	  area	  under	   the	   curve	   of	   the	   receiver	   operator	   characteristics	   (AUC	   ROC)	   [91].	   Genes	   that	  were	   classified	   as	   differentially	   expressed/methylated	   genes	   by	   at	   least	   two	   of	   those	  three	  methods	  were	   included	   in	   the	   list	   of	   differentially	   expressed/methylated	  genes.	  The	  same	  procedure	  was	  applied	  to	  determine	  differentially	  expressed	  miRNAs	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3.4.3 Network	  construction	  using	  the	  GRN	  pipeline	  	  The	   GRN	   construction	   pipeline	   that	   consists	   of	   plugins	   1	   to	   3	   was	   applied	   to	   the	  differentially	   expressed	   genes	   to	   obtain	   the	   GRN	   network	   involving	   DNA	   binding	  proteins	   (TF)	   and	   target	   genes.	   Using	   plugin	   1,	   we	   constructed	   from	   the	   identified	  differentially	   expressed	   genes	   the	   co-­‐expression	   network	   based	   on	   the	   pairwise	  correlation	  as	  a	  distance	  measure.	  	  	  The	  resultant	  co-­‐expression	  networks	  were	  subjected	  to	  plugin	  2	  as	  input	  parameters.	  Gene	   interactions	   suggested	   from	   the	   co-­‐expression	   networks	   were	   connected	   to	  regulatory	   information	   retrieved	   from	   the	   Transcriptional	   Regulatory	   Element	  Database	   (TRED)	   [82],	   Molecular	   Signatures	   Database	   (MSigDB)	   [70],	   and	   JASPAR	  database	  [83].	  All	  genes	  involved	  in	  the	  co-­‐expression	  network	  and	  listed	  in	  at	  least	  one	  of	  the	  databases	  to	  code	  for	  a	  transcription	  factor	  (TF)	  were	  marked	  as	  TFs.	  Then,	   for	  each	   TF-­‐gene	   link	   in	   the	   co-­‐expression	   network,	  we	   searched	  whether	   the	   databases	  contain	   a	   known	   regulation	   for	   this	   TF-­‐target	   gene	   pair.	   In	   each	   of	   these	   cases,	   a	  directed	  edge	  was	  added	  between	  the	  transcription	  factor	  and	  the	  target	  gene.	  Also,	  we	  used	  the	  Motif	  Statistics	  and	  Discovery	  (MoSDi)	  [84]	  software	  to	  conduct	  a	  motif	  search	  for	   all	   known	   binding	   motifs	   of	   the	   TFs	   represented	   in	   the	   co-­‐expression	   network	  against	  the	  promoter	  regions	  of	  all	  genes	  in	  the	  network.	   If	  a	  match	  was	  found,	  a	  new	  directed	   edge	   from	   the	   TF	   to	   the	   gene	   was	   added.	   In	   the	   last	   step	   (plugin	   3),	   we	  constructed	   a	   causal	   probabilistic	   Bayesian	   network	   from	   the	   co-­‐expression	  modules	  where	  we	  used	  the	  directed	  edges	  obtained	  from	  plugin	  2	  as	  a	  start	  search	  point	  to	  infer	  directionality	  between	  nodes,	  see	  chapter	  2	  for	  more	  details.	  	  As	  candidate	  set	  of	   the	   final	  directed	   interactions,	  we	  considered	  directed	  edges	   from	  plugin	   2	   as	   well	   as	   directed	   edges	   confirmed	   by	   both	   plugin	   1	   and	   plugin	   3.	  Subsequently,	  the	  entire	  network	  containing	  both	  directed	  and	  undirected	  interactions	  was	   exposed	   to	   the	   pruning	   step	   explained	   below.	   The	   GRN	   network	   was	   visualized	  using	  the	  igraph	  [92]	  package	  in	  R	  as	  will	  be	  illustrated	  in	  chapter	  6.	  
3.4.4 Pruning	  the	  GRN	  using	  methylation	  and	  expression	  profiles	  	  GRN	  pruning	  was	  carried	  out	  based	  on	  the	  observation	  that	  some	  genes	  show	  increased	  promoter	  DNA	  methylation	   levels	  coupled	  to	  a	  remarkable	  decline	  of	   their	  expression	  [79].	   In	   such	   cases,	   we	   assumed	   that	   the	   downregulation	   of	   gene	   expression	   results	  from	  the	   increase	   in	  promoter	  methylation	  and	  not	  due	   to	  TFs	  or	  miRNAs	  regulation.	  	  Thus,	   we	   removed	   regulatory	   interactions	   whose	   target	   genes	   had	   absolute	   anti-­‐correlation	   between	   their	   expression	   and	   methylation	   profiles	   above	   a	   selected	  threshold	  of	  0.65.	  
3.4.5 Constructing	  miRNA-­‐mRNA	  interactions	  	  The	  integrated	  association	  of	  the	  differentially	  expressed	  miRNAs	  and	  the	  differentially	  expressed	   genes	   (mRNAs)	   involved	   three	   steps.	   First,	   for	   the	   set	   of	   differentially	  expressed	  miRNAs,	  which	  were	  either	  up-­‐	  or	  down-­‐regulated	  between	   the	   tumor	  and	  normal	   samples,	   we	   used	   miRTrail	   [93]	   via	   MicroCosm	   Targets	   V5	  (http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/)	   to	   extract	   their	   target	  mRNAs	   (regulated	   genes)	   and	   overlapped	   them	   with	   the	   identified	   differentially	  expressed	  mRNAs.	   Second,	   we	   used	   the	   experimentally	   validated	   database	   TransmiR	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[30]	   to	   retrieve	   the	   regulatory	   genes	   (TFs)	   that	   potentially	   regulate	   the	   differentially	  expressed	  miRNAs.	   In	  both	  steps,	   the	  hypergeometric	   test	  with	  a	  p-­‐value	   threshold	  of	  0.05	   was	   applied	   to	   test	   the	   regulation	   dependencies	   between	   the	   differentially	  expressed	  miRNAs	  and	  their	  target	  genes	  /their	  regulatory	  TFs.	  Finally,	  both	  miRNA→	  mRNA	  (including	  TF	  genes)	  interaction	  pairs	  from	  step	  one	  and	  TF→	  miRNA	  interaction	  pairs	  from	  step	  two	  were	  joined	  and	  merged	  to	  a	  final	  network.	  
3.4.6 Identifying	  the	  genetic	  key	  drivers/determinants	  	  Key	  regulators	  in	  the	  constructed	  networks	  were	  identified	  by	  determining	  the	  minimal	  set	   of	   nodes	   that	   regulate	   (i.e	   dominate)	   the	   entire	   network.	   This	   problem	   can	   be	  modeled	  as	  the	  following	  optimization	  problem:	  	  Let	   graph	  G(V,E) be	   a	   connected	   graph,	  n = |V|, adj is	   the	   adjacency	  matrix	   of G, and 
adj(i, i) = 0, X is	  a	  binary	  array	  of	  size	  n, such	  that	  X(i) = 1 if	  node i was	  marked	  as	  a	  key	  node,	  and 0 otherwise.	  Then	  the	  objective	  function	  is: 
	  The	   last	  constraint	  guarantees	   that	  every	  node	   in	   the	  network	  must	  have	  at	   least	  one	  key	   node	   in	   its	   neighborhood.	   To	   solve	   such	   an	   optimization	   problem,	   we	   used	   the	  linear	  programming	  gplk	  solver	  [94]	  via	   the	  numerical	  optimization	  package	  OpenOpt	  [95].	  
3.4.7 Enrichment	  and	  druggability	  analysis	  	  For	   gene	   set	   enrichment	   analysis,	   KEGG	  pathways	   and	  GO	   functional	   categories	  were	  identified	  using	  the	  DAVID	  [68]	  tool.	  Briefly,	  we	  determined	  which	  pathways/functional	  terms	  were	  annotated	   to	   at	   least	   two	  genes	  and	  were	   statistically	  overrepresented	   in	  the	  study	  gene	  set.	  Enrichment	  was	  evaluated	  through	  the	  hyper-­‐geometric	  test	  using	  a	  p-­‐value	   threshold	   of	   0.05	   as	   explained	   in	   details	   in	   chapter	   2.	   For	   the	   enrichment	  analysis	   of	   the	   miRNAs	   set,	   we	   used	   the	   TAM	   tool	   [96]	   which	   also	   uses	   the	   hyper-­‐geometric	  test	  .	  Druggability	  analysis	  of	  the	  identified	  driver	  genes	  was	  performed	  using	  the	  PharmGKB	  [97],	  CTD	  [98],	  and	  CancerResource	  [99]	  databases.	  
3.5 SnvDMiR:	   Associating	   the	   genomic	   proximity	   of	   genetic	   variants	   with	  
deregulated	  miRNAs	  and	  differentially	  methylated	  regions	  	  Although	  next	  generation	  sequencing	  of	  diseased	  traits	  has	  unraveled	  thousands	  of	  DNA	  alterations,	  the	  functional	  relevance	  of	  most	  of	  these	  mutations	  and	  how	  they	  relate	  to	  other	  epigenetic	  mechanisms	  are	  still	  poorly	  understood.	  Alexander	  Zapp	  developed	  in	  his	  M.Sc.	  thesis	  under	  the	  direction	  of	  the	  author	  of	  this	  PhD	  thesis	  a	  small	  tool	  SnvDMiR	  as	  a	  freely–available	  R	  pipeline	  that	  conducts	  combinatorial	  proximity	  analysis	  between	  disease–associated	   SNVs,	   deregulated	   miRNAs,	   and	   differentially	   methylated	   regions	  (DMRs)	   to	   identify	   genomically	   adjacent	   SNV-­‐miRNA	  pairs	   as	  well	   as	   SNV-­‐DMR	  pairs.	  These	   variants	   could	   be	   further	   investigated	   as	   putative	   candidates	   for	   driving	  pathogenic	   processes	   in	   diseases.	   We	   demonstrated	   the	   usefulness	   of	   the	   SnvDMiR	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pipeline	   by	   applying	   it	   on	   a	   published	   set	   of	   breast	   cancer-­‐related	   mutations,	  deregulated	  miRNAs,	  and	  DMRs.	  Our	  pipeline	  characterized	  potential	  driver	  mutations	  that	   are	  predicted	   to	  have	  damaging	   effects	   on	   related	  protein	   functions.	  Availability:	  http://gepard.bioinformatik.uni-­‐saarland.de/software.	  	  Background	  	  	  To	   further	   our	   understanding	   of	   human	   oncogenesis,	   high-­‐throughput	   sequencing	   of	  tumor	  genomes	  has	  uncovered	  thousands	  of	  DNA	  alterations	  such	  as	  somatic	  mutations	  of	   single	   nucleotide	   variants	   (SNVs)	   that	   may	   be	   important	   for	   tumor	   initiation	   or	  progression	   [100-­‐106].	   Nevertheless,	   it	   remains	   a	   pressing	   challenge	   to	   determine	  which	   mutations	   are	   key	   drivers	   for	   tumor	   pathophysiology	   and	   which	   ones	   are	  passengers	  with	   no	   functional	   effects.	   To	   address	   this	   need,	   several	   approaches	   have	  been	   presented	   to	   characterize	   driver	   missense	   mutations	   [103,	   107-­‐109].	   Most	  straightforward	  is	  the	  annotation	  of	  non-­‐synonymous	  mutations	  in	  oncogenes	  or	  tumor	  suppressors.	  In	  contrast,	  relatively	  little	  attention	  has	  been	  paid	  to	  cases	  where	  driver	  mutations	   could	   be	   in	   close	   genomic	   proximity	   to	   disease-­‐related	   genes,	   miRNAs,	   or	  methylated	  CpG	  sites.	  Chapter	   1	   explained	   the	   importance	   of	   DNA	   methylation	   and	   the	   phenomenon	   of	  differential	  methylation	  as	  well	  as	  miRNAs	  and	  their	  correlations	  to	  genetic	  mutations.	  In	   this	   regard,	   the	   recent	   availability	  of	  disease-­‐related	  genomic	  data	   such	  as	   somatic	  mutations,	   associated	   DMRs	   and	   miRNAs	   calls	   for	   the	   development	   of	   integrative	  genomic	  proximity-­‐based	  approaches	  to	  better	  understand	  the	   functional	  relevance	  of	  most	   of	   these	   mutations	   and	   how	   they	   relate	   to	   epigenetic	   marks.	   To	   this	   end,	   we	  developed	   SnvDMiR	   as	   a	   freely–available	   R	   pipeline	   that	   is	   able	   to	   conduct	  combinatorial	   proximity	   analysis	   between	   disease–associated	   SNVs,	   deregulated	  miRNAs,	  and	  DMRs	  to	   identify	  genomically	  adjacent	  SNV-­‐miRNA	  pairs	  as	  well	  as	  SNV-­‐DMR	  pairs.	  We	  demonstrated	  these	  features	  on	  breast	  cancer-­‐related	  datasets	  and	  the	  matched	   SNVs	   suggested	   putative	   driver	   mutations	   that	   could	   play	   a	   critical	   role	   in	  breast	  cancerogenesis	  (chapter	  6).	  
3.5.1 Implementation	  	  SnvDMiR	  is	  a	  computational	  pipeline	  implemented	  in	  R	  (Figure	  3-­‐10).	  Based	  on	  lists	  of	  genomic	  variants,	  deregulated	  miRNAs,	  differentially	  methylated	  sites,	  and	  user	  defined	  parameters	   (configurations),	   SnvDMiR	   investigates	   whether	   the	   significantly	  deregulated	  miRNAs	  and	  differentially	  methylated	  sites	  are	  in	  close	  genomic	  vicinity	  to	  the	  provided	  genomic	  variants	  and	  outputs	  matching	  entries	  in	  tabular	  and	  ideograms	  plots.	   The	  user	  needs	  only	   to	   run	   the	  main	   script	   SnvDMiR.R	  which	   in	   turn	   loads	   the	  required	   libraries/packages,	   carries	   out	   the	   analysis	   on	   the	   input	  data,	   and	  visualizes	  the	  matched	  entries	  in	  	  genomic	  ideograms	  with	  circular	  layouts.	  For	  matching	  miRNAs	  and	  somatic	  variants,	  the	  genomic	  coordinates	  of	  the	  significantly	  deregulated	  miRNAs	  were	  downloaded	   from	  miRBase	   [110].	  Then,	   SnvDMiR	  searches	  for	   the	   miRNA	   sequences	   in	   a	   predefined	   genomic	   window	   (default	   is	   250kb	   [111])	  around	   each	   somatic	   variant.	   The	   window	   size	   can	   be	   set	   in	   the	   configuration	   file	  attached	  with	   the	  SnvDMiR	  script.	  The	  matched	  miRNA-­‐SNV	  pairs,	  where	   the	  miRNAs	  occur	  within	  the	  window	  around	  the	  SNV	  location,	  are	  extracted	  into	  the	  som-­‐miRNA-­‐matches.txt	  file	  in	  the	  output	  folder.	  	  The	   second	   part	   of	   the	   SnvDMiR	   functionality	   is	   to	   explore	   whether	   differentially	  methylated	   regions	   (usually	   CpG	   islands)	   are	   in	   the	   vicinity	   of	   somatic	  mutations.	   To	  this	   end,	   our	   tool	   tests	   the	   occurrence	   of	   the	   SNV	  within	   a	   certain	   genomic	   distance	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(default	  is	  3kb)	  from	  the	  genomic	  coordinates	  of	  the	  differentially	  methylated	  sites.	  The	  default	  setting	  of	   the	  predefined	  distance	   in	   the	  configuration	   file	  (3kb)	  was	  based	  on	  the	  maximum	  considered	  length	  of	  typical	  CpG	  islands,	  that	  is,	  500bp	  [21]	  ≤	  CpG	  islands	  ≤	  3kb	  [112].	  Moreover,	  the	  user	  has	  the	  option	  to	  investigate	  only	  the	  C-­‐>A,	  C-­‐>G,	  and	  C-­‐>T	   SNVs	   instead	   of	   all	   mutations	   via	   setting	   the	   parameter	   filter_Cytosine	   in	   the	  configuration	  file.	  The	  matched	  entries	  are	  also	  exported	  to	  som-­‐DMR-­‐matches.txt	  file	  in	  the	  output	  folder.	  	  
	  
	  
Figure	  3-­‐10	  The	  data	  model	  for	  the	  SnvDmiR	  proximity	  pipeline.	  	  The	   pipeline	   is	   used	   to	   investigate	   the	   vicinity	   of	   genetic	   variants	   to	   the	   deregulated	   miRNAs	   and	   differentially	  methylated	  regions.	  Source:	  modified	  from	  @	  Alexander	  zapp	  M.Sc.	  thesis.	  	  Finally,	  the	  SnvDmiR	  utilizes	  the	  circlize	  R	  package	  [113]	  to	  efficiently	  plot	  the	  related	  ideogram	  and	   flexibly	  visualize	   the	  matched	  entries	   in	  a	  circular	   layout	  as	  well	  as	   the	  entire	  input	  data	  (all	  SNVs	  and	  either	  all	  miRNAs	  or	  all	  DMRs)	  as	  genomic	  background.	  This	  helps	  to	  better	  understand	  the	  genomic	  patterns	  behind	  the	  matched	  entries.	  	  
3.6 TFmiR	  web	  server	  	  	  	  The	  TFmiR	  web	   server	  was	  developed	   in	   a	   collaborative	   fashion	  of	   the	   author	  of	   this	  thesis	   together	   with	   Christian	   Spaniol	   and	   Maryam	   Nazarieh.	   The	   contribution	   of	  Maryam	  was	  the	  design	  and	  computation	  of	  minimum	  connected	  dominating	  sets	  (see	  below).	   The	   contribution	   of	   Christian	   was	   the	   design	   and	   implementation	   of	   the	  presentation	   layer	   of	   the	   web	   server.	   The	   author	   of	   this	   thesis	   designed	   and	  implemented	   the	   methodology	   of	   setting	   up	   integrated	   regulatory	   databases,	  constructing	  all	   relative	  networks,	  performing	   statistical	   analysis	   as	  well	   as	   the	  down	  stream	  network	  analysis	  	  (as	  explained	  below	  for	  the	  breast	  cancer	  case	  study).	  
SNP_ID Chrom SNP_Pos Gene Ref Alt
10-52595937-A1CF 10 52595937 A1CF G A
2-215815648-ABCA12 2 215815648 ABCA12 C G
19-1041509-ABCA7 19 1041509ABCA7 G A
X-74296386-ABCB7 X 74296386 ABCB7 G A
X-74296386-ABCB7 X 74296386 ABCB7 G A
16-48173212-ABCC12 16 48173212 ABCC12 C T
12-39947821-ABCD2 12 39947821 ABCD2 G A
1-179095776-ABL2 1 179095776 ABL2 C T
18-47329199-ACAA2 18 47329199 ACAA2 C A
18-47329199-ACAA2 18 47329199 ACAA2 C A
12-109617839-ACACB 12 109617839 ACACBC A
11-108002665-ACAT1 11 108002665 ACAT1 C T
11-76572075-ACER3 11 76572075 ACER3 G T
14-74010102-ACOT1 14 74010102 ACOT1 G A
2-111875316-ACOXL 2 111875316 ACOXLT A
12-6753326-ACRBP 12 6753326ACRBP G T
12-6753326-ACRBP 12 6753326ACRBP G T
12-7475135-ACSM4 12 7475135ACSM4 G T
2-148657335-ACVR2A 2 148657335 ACVR2A T G
14-75520314-ACYP1 14 75520314 ACYP1 G A
14-70924304-ADAM21 14 70924304 ADAM21 C G
14-70924844-ADAM21 14 70924844 ADAM21 C T
1-120438621-ADAM30 1 120438621 ADAM30 C A
19-8651269-ADAMTS10 19 8651269ADAMTS10 T G
16-50341017-ADCY7 16 50341017 ADCY7 C G
8-131826458-ADCY8 8 131826458 ADCY8 G A
8-131826458-ADCY8 8 131826458 ADCY8 G A
6-147123111-ADGB 6 147123111 ADGB A C
4-100340221-ADH7 4 100340221 ADH7 G A
15-87531306-AGBL1 15 87531306 AGBL1 C T
7-134800290-AGBL3 7 134800290 AGBL3 A G
7-134800290-AGBL3 7 134800290 AGBL3 A G
7-141296374-AGK 7 141296374 AGK C G
7-141296374-AGK 7 141296374 AGK C G
8-6590094-AGPAT5 8 6590094AGPAT5 TATG -
1-27876098-AHDC1 1 27876098 AHDC1 C A
1-222876531-AIDA 1 222876531 AIDA G A








































Methyl_ID Gene Chrom Methyl_Pos
cg00019495 HOPX 4 57547525
cg00029931 RPL36A X 100645741
cg00037940 PIK3CB3 138479285
cg00072216 MXD4 4 2263638
cg00078867 WAS X 48542398
cg00091693 KRT20 17 39041602
cg00094851 KIF3C 2 26205706
cg00105253 NUDT14 14 105647194
cg00123035 RFX5 1 151319538
cg00126657 SSX6 X 47967250
cg00133909 CD276 15 73977201
cg00136477 C1QC 1 22970339
cg00138126 PMEPA1 20 56286697
cg00152644 SPRR2E 1 153068236
cg00184893 ALOXE3 17 8021705
cg00187686 TCN1 11 59634218
cg00208830 LAMC2 1 183154778
cg00221494 FARP1 13 98794593
cg00308133 GAMT 19 1401118
cg00311768 TSTA3 8 144698857
cg00321478 CRB1 1 197238398
cg00334507 PRRT2 16 29824599
cg00347729 MMP10 11 102651753
cg00376639 ZNF581 19 56155151
cg00392257 ISG20L2 1 156696747
cg00411097 TMEM184A 7 1596050
cg00446235 TSTD1 1 161008644
cg00453258 CALHM1 10 105219172
cg00466249 SLC38A10 17 79269884
cg00480115 FXYD3 19 35606877
cg00488364 IL13RA2 X 114253315
cg00491839 PPP1R15A 19 49375640
cg00497251 RNPEPL1 2 241508725
cg00519627 CORO7 16 4466650
cg00536175 GATA1 X 48645024
cg00616129 STYK1 12 10827014
cg00619207 DENND2D 1 111743368
DMRs
Input
miRNA miRNA_Start miRNA_End Chrom SNP SNP_Pos
hsa-mir-9-1 156390133 156390221 1 1-156498803-IQGAP3 156498803
hsa-mir-205 209605478 209605587 1 1-209605636-MIR205HG 209605636
hsa-mir-181b-1 198828002 198828111 1 1-198711494-PTPRC 198711494
hsa-mir-181a-1 198828173 198828282 1 1-198711494-PTPRC 198711494
hsa-miR-1290 19223572 19223590 1 1-19186120-TAS1R2 19186120
hsa-mir-152 46114527 46114613 17 17-46136186-NFE2L1 46136186
hsa-mir-199a-1 10928102 10928172 19 19-10870471-DNM2 10870471
hsa-mir-520d 54223350 54223436 19 19-54254529-MIR522 54254529
hsa-miR-1323 54175232 54175253 19 19-54254529-MIR522 54254529
hsa-mir-519e 54183194 54183277 19 19-54254529-MIR522 54254529
hsa-mir-3129 189997762 189997837 2 2-189928732-COL5A2 189928732
hsa-mir-145 148810209 148810296 5 5-148730786-GRPEL2 148730786
hsa-mir-143 148808481 148808586 5 5-148730786-GRPEL2 148730786
hsa-mir-106b 99691616 99691697 7 7-99662436-ZNF3 99662436
hsa-mir-93 99691391 99691470 7 7-99662436-ZNF3 99662436
hsa-mir-25 99691183 99691266 7 7-99662436-ZNF3 99662436
hsa-miR-320a 22102488 22102509 8 8-22136963-PIWIL2 22136963
hsa-mir-199b 131007000 131007109 9 9-131048299-SWI5 131048299
hsa-mir-199b 131007000 131007109 9 9-131023779-GOLGA2 131023779
hsa-miR-718 153285379 153285399 X X-153278098-IRAK1 153278098
hsa-let-7f-2 53584153 53584235 X X-53644041-HUWE1 53644041
SnvDMiR.R
miRNA-SNV.R DMR-SNV.Rplot-miRNA.R plot-DMR.R
DMR_ID DMR_Pos Chrom SNP_ID SNP_Pos Ref Alt
cg14387505 31538946 16 16-31539850-AHSP 31539850 C G
cg02989940 31539234 16 16-31539850-AHSP 31539850 C G
cg10392768 802182817 17-8022084-ALOXE3 8022084C A
cg00184893 802170517 17-8022084-ALOXE3 8022084C A
cg13003163 48866481 12 12-48866491-ANP32D 48866491 C T
cg14203758 14247374 19 19-14247177-ASF1B 14247177 C G
cg01545242 14248090 19 19-14247177-ASF1B 14247177 C G
cg26248486 76742361 12 12-76741035-BBS10 76741035 C T
cg10027114 76742097 12 12-76741035-BBS10 76741035 C T
cg10027114 76742097 12 12-76740626-BBS10 76740626 C -
cg01254505 17516470 19 19-17516273-BST2 17516273 C G
cg16363586 17516329 19 19-17516273-BST2 17516273 C G
cg07790638 113508575 4 4-113508772-C4orf21 113508772 C T
cg10409560 76481299 4 4-76481299-C4orf26 76481299 C G
cg22960952 76481169 4 4-76481299-C4orf26 76481299 C G
cg22805517 42951105 7 7-42949923-C7orf25 42949923 C T
cg06766367 67062687 16 16-67063684-CBFB 67063684 C T
cg06766367 67062687 16 16-67063371-CBFB 67063371 C G
cg06766367 67062687 16 16-67063695-CBFB 67063695 C -
cg14623805 70481056 10 10-70482304-CCAR1 70482304 C T





# miRNA matching #
# #
#############################




# DMR matching #
# #
#############################
# Only considers mutations with reference allele = C
# The DMR plot will display amount of C->A, C->G and C->T mutations
filter.mutations = TRUE







# specifies height and width of plots
# both given in inches
height = 15
width = 15
# Sets the size and color of text in the plots
text.size = 1
text.col = black
# If set to True, positions of the matched somatic mutations will be drawn
draw.som.pos = TRUE
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We	  developed	  TFmiR	   [114]	   as	   a	   freely	   available	  web	   server	   for	   deep	   and	   integrative	  analysis	  of	  combinatorial	  regulatory	  interactions	  between	  TFs/genes	  and	  miRNAs	  that	  are	   involved	   in	   disease	   pathogenesis.	   Since	   the	   biological	   function	   of	   molecular	  components	  are	  highly	  connected	  with	  the	  underlying	  cellular	  malfunctions	  and	  disease	  pathways,	   TFmiR	  helps	   to	   elucidate	   their	   cellular	  mechanisms	   on	   the	  molecular	   level	  from	  a	  network	  perspective.	  The	  provided	  topological	  and	  functional	  analyses	  promote	  TFmiR	   as	   a	   reliable	   systems	   biology	   tool	   for	   researchers	   across	   the	   life	   science	  communities.	   TFmiR	   web	   server	   is	   accessible	   through	   the	   following	   URL:	  http://service.bioinformatik.uni-­‐saarland.de/tfmir.	  
3.6.1 Background	  
 TFs	  and	  miRNAs	  frequently	  form	  Feed	  Forward	  Loops	  (FFLs)	  and	  other	  network	  motifs	  to	  regulate	  gene	  transcription	  in	  a	  collaborative	  manner	  [115-­‐118].	  Therefore,	  utilizing	  the	   combinatorial	   regulatory	   information	   on	   TFs	   and	  miRNAs	   and	   their	   target	   genes	  could	   shed	   light	   on	   key	   driver	   genes	   and	   miRNAs	   in	   human	   diseases	   and,	   in	   turn,	  suggests	  novel	  therapeutic	  strategies	  in	  disease	  treatment	  [7,	  115].	  	  	  Several	   databases	   have	   been	   developed	   in	   order	   to	   facilitate	   the	   research	   on	  transcriptional	   and	   posttranscriptional	   interaction	   types	   between	   TFs/genes	   and	  miRNAs.	   For	   instance,	   TransFac	   [71],	   OregAnno	   [119],	   and	   MsigDB	   [70]	   maintain	  interactions	   of	   TFs	   regulating	   genes	   (TF"gene).	   TransmiR	   [30]	   provides	   information	  on	   which	   TFs	   regulate	   miRNAs	   (TF"miRNA).	   mirTarBase[72],	   TarBase	   [73]	   and	  miRecords	  [74]	  collect	  target	  genes	  of	  miRNAs	  (miRNA"genes)	  in	  different	  organisms.	  Although	  still	  little	  is	  known	  about	  miRNA-­‐mediated	  miRNA	  regulations,	  recent	  studies	  have	   reported	  plausible	   evidences	   that	  miRNAs	  may	   regulate	   the	   expression	   of	   other	  miRNAs	   as	   well	   as	   their	   target	   genes	   [120-­‐124].	   Thus,	   miRNA"miRNA	   interactions	  were	  computationally	  predicted	  and	  maintained	  in	  the	  PmmR	  database	  [75].	  	  Despite	   the	  general	  availability	  of	  such	  databases,	  generalized	  repositories	   integrating	  different	  kinds	  of	  molecular	   interactions	  and	   intensively	  analyzing	   their	   contributions	  to	  diseases	  are	  still	  missing.	  To	  this	  end,	  we	  developed	  TFmiR,	  a	  web	  server	  that	  allows	  for	  integrative	  and	  comprehensive	  analysis	  of	  interactions	  between	  a	  set	  of	  deregulated	  TFs/genes	  and	  a	  set	  of	  deregulated	  miRNAs	  within	  the	  relevant	  pathways	  of	  a	  certain	  disease.	   It	   unravels	   the	   disease-­‐specific	   co-­‐regulatory	   network	   between	   TFs	   and	  miRNAs	  and	  performs	  over	  representation	  analysis	   (ORA)	   for	   the	   involved	  TFs/genes	  and	   miRNAs.	   Our	   web	   server	   also	   detects	   feed	   forward	   loops	   (FFLs)	   consisting	   of	  miRNAs,	  TFs,	  and	  co-­‐targeted	  genes	  (TF-­‐miRNA	  co-­‐regulatory	  motifs)	  and	  assesses	  the	  functional	   homogeneity	   between	   the	   co-­‐regulated	   targets	   in	   terms	   of	   their	   statistical	  significance.	  	  	  Furthermore,	   TFmiR	   utilizes	   7	   different	  methods	   for	   identifying	   key	   network	   players	  that	  could	  possibly	  drive	  oncogenic	  processes	  of	  diseases	  and	  thus	  act	  as	  potential	  drug	  targets.	   Especially	   when	   combined	   with	   experimental	   validation,	   these	   putative	   key	  players	   as	   well	   as	   the	   novel	   TF-­‐miRNA	   co-­‐regulatory	   motifs	   could	   promote	   novel	  insights	   to	   develop	   new	   therapeutic	   approaches	   for	   human	   diseases.	   Overall,	   TFmiR	  presents	  a	  comprehensive	  analysis	  suite	  for	  studying	  the	  architecture	  and	  feature	  of	  the	  TF-­‐miRNA	  co-­‐regulatory	  network.	  	  	  
Chapter	  3	   	   	   Approaches	  and	  methods	  	  	  
	  	   42	  
3.6.2 Description	  
 TFmiR	  is	  a	  freely	  available	  web	  server	  that	  integrates	  genome-­‐wide	  transcriptional	  and	  post-­‐transcriptional	   regulatory	   interactions	   to	   elucidate	   human	   diseases.	   Based	   on	   a	  selected	  disease	  and	  user-­‐supplied	  lists	  of	  deregulated	  genes/TFs	  and	  miRNAs,	  TFmiR	  investigates	   four	   different	   types	   of	   interactions,	   TF"gene,	   TF"miRNA,	  miRNA"miRNA,	   miRNA"gene.	   It	   also	   unravels	   the	   interplay	   circuitry	   between	  miRNAs,	   TFs	   and	   target	   genes	   within	   the	   pathogenicity	   of	   the	   specified	   disease	   in	   a	  systems	   biology	   approach.	   For	   each	   interaction	   type,	   TFmiR	   utilizes	   information	  provided	  by	  well	  -­‐established	  and	  finely-­‐curated	  regulatory	  databases	  of	  both	  predicted	  and	   experimentally	   validated	   interactions	   (Figure	   3-­‐11)	   whereby	   all	   repeated	  interactions	  were	  removed.	  	  	  For	  TF"miRNA	  interactions,	  we	  also	  integrated	  manually	  curated	   regulatory	   relationships	   from	   large	   numbers	   (~5000)	   of	   published	   papers	  (PMID:	   20584335)	   [125].	   From	   the	   predicted	   miRNA"miRNA	   interactions	   in	   the	  PmmR	   database	   [75],	   we	   considered	   only	   the	   best	   hits	   having	   score	   <	   0.2	   which	   is	  computed	   as	   the	   normalized	   path	   length	   between	   the	   two	   involved	   miRNAs.	   The	  incorporated	  predicted	  miRNA"gene	  interactions	  were	  retrieved	  from	  starBase	  [126]	  by	  selecting	  only	  those	  predictions	  confirmed	  by	  three	  out	  of	  five	  prediction	  algorithms	  (targetScan	   [127],	   picTar	   [128],RNA22	   [129],	   PITA	   [130],	   and	  miRanda	   [131]).	   Table	  3-­‐1	   lists	   the	   included	   databases	   and	   the	   number	   of	   regulations	   available	   for	   each	  interaction	   type.	   In	   total,	  TFmiR	   integrates	   information	  on	  almost	  10.000	  genes,	  1856	  miRNAs,	  ~	  3000	  diseases	  including	  subtypes,	  and	  more	  than	  111.000	  interactions.	  	  
	  	  
Figure	  3-­‐11	  A	  system	  level	  overview	  of	  the	  TFmiR	  architecture.	  This	  schematic	  diagram	  describes	  the	  incorporated	  databases,	  data	  flows	  and	  output	  downstream	  analysis.	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3.6.3 TFmiR	  user	  input	  scenarios	  	  TFmiR	  can	  be	  called	   through	   two	  scenarios.	   	   If	   a	  user	   submits	   two	  RNA	  sets	   (a	   set	  of	  deregulated	  mRNAs/genes	   and	   a	   set	   of	   deregulated	  miRNAs),	   the	   TFmiR	  web	   server	  will	   return	   regulatory	   interactions	   based	   on	   the	   provided	   deregulated	   genes	   and	  deregulated	  miRNAs.	   In	   the	  second	  scenario,	  a	  user	  submits	  only	  a	   set	  of	  deregulated	  genes.	  In	  such	  a	  case,	  TFmiR	  identifies	  the	  set	  of	  miRNAs	  whose	  target	  genes	  as	  well	  as	  regulator	  TFs	   are	   significantly	   enriched	  within	   the	   input	   deregulated	   genes	   using	   the	  hypergeometric	   distribution	   function	   followed	   by	   the	   Benjamini-­‐Hochberg	   (BH)	  adjustment	  with	  a	  cutoff	  value	  of	  0.001.	  Sample	  input	  files	  of	  the	  deregulated	  genes	  and	  miRNAs	  are	  provided	   in	   the	  TFmiR	  web	  page.	  The	  user	  can	  optionally	   set	   the	  p-­‐value	  cutoff	   (default	   is	   0.05)	   required	   later	   for	   over	   representation	   analysis	   (ORA)	   on	   the	  resulting	  network	  nodes	  (genes	  /	  miRNAs),	  see	  chapter	  2.	  Finally,	  the	  user	  can	  control	  the	   evidence	   level	   (experimentally	   validated,	   predicted,	   or	   both)	   for	   the	   constructed	  regulatory	   interaction	   that	   will	   be	   subjected	   later	   to	   further	   network	   analysis.	   See	  	  Figure	  3-­‐12.	  
	  
	  
Table	  3-­‐1	  The	  integrated	  databases	  and	  interaction	  types	  in	  TFmiR.	  (P)	  means	  predicted	  interactions	  and	  (E)	  means	  experimentally	  validated	  interactions.	  All	  databases	  were	  downloaded	  before	  August	  2014.	  
Interaction Databases (P/E) * Genes miRNAs Edges Version /frozen date 
TF"gene TRANSFAC  (E) [71]  1279  -- 2943  V11.4 
OregAnno (E)[119] 1132 -- 1083 Nov 2010 
TRED (P) [82] 3038 -- 6462 2007 
TF"miRNA TransmiR (E) [30]  158 175 567 V1.2, Jan 2013 
PMID20584335 (E) [125]  58 56 102 Apr 2009 
ChipBase (P) [132] 119 1380 33087 V1.1, Nov 2012 
miRNA "  gene miRTarBase (E)[72] 2244 551 5640 V4.5, Nov 2013 
TarBase (E) [73] 422 79 492 V7.0 
miRecords (E)[74] 543 157 780 Mar 2009 
starBase (P)[126] 5720 249 56051 V2.0, Sept 2013 
miRNA"miRNA PmmR (P) [75] -- 312 3846 Mar 2011 
3.6.4 Functionality	  of	  TFmiR	  	  	  The	   TFmiR	   web	   server	   pools	   all	   the	   four	   interactions	   types	   based	   on	   the	   significant	  TF(gene)-­‐miRNA	  pairs	   from	  the	   input	  deregulated	  genes	  and	  miRNAs	  and	  accordingly	  generates	  an	  entire	  combinatorial	  regulatory	  network,	  see	  Figure	  3-­‐13.	  If	  a	  disease	  was	  selected,	  TFmiR	  integrates	  the	  human	  miRNA	  disease	  database	  (HMDD)	  [133]	  as	  well	  as	  DisGeNET	   (a	   database	   for	   gene-­‐disease	   association)	   [134]	   as	   reliable	   sources	   for	  disease-­‐associated	  miRNAs	  and	  genes,	  respectively.	  Interactions	  whose	  target	  nodes	  or	  regulator	  nodes	  are	  known	  to	  be	  associated	  with	  the	  disease	  are	  composing	  the	  putative	  disease-­‐specific	  network.	  As	  the	  next	  step,	  TFmiR	  offers	  a	  downstream	  analysis	  on	  three	  different	  levels:	  (1)	  the	  regulatory	  subnetwork	  of	  each	  of	  the	  four	  interaction	  types,	  (2)	  the	  combined	  network	  of	  all	   interaction	  types,	  and	  (3)	  the	  disease-­‐specific	  network	  (if	  disease	   was	   selected).	   	   For	   each	   interaction	   type	   subnetwork	   representing	   a	   set	   of	  regulator	  "	   target	   links,	  we	  display	   the	   total	  number	  of	   targets	  and	  regulators	   in	   the	  corresponding	  interaction	  databases,	  a	  Venn	  diagram	  depicting	  the	  overlap	  between	  the	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input	   deregulated	   targets	   (miRNAs/genes)	   and	   the	   targets	   of	   the	   input	   deregulated	  regulators	  (genes/miRNAs)	  available	   from	  the	  database.	  The	  significance	  of	  overlap	   is	  computed	   using	   the	   hypergeometric	   distribution	   test.	   To	   avoid	   the	   effect	   of	   false-­‐positives	  in	  the	  regulator	  "	  target	  databases	  and	  to	  account	  for	  a	  different	  number	  of	  targets	   for	   the	   input	   deregulated	   regulators,	   a	   randomization	   test	   is	   conducted	  (n=1000).	   Furthermore,	   the	   TFmiR	   web	   server	   carries	   out	   statistical	   over	  representation	  analysis	  (ORA)	  for	  both	  gene	  and	  miRNA	  sets	  comprising	  the	  interaction	  subnetwork.	  	  	  
	  
	  	  Figure	  3-­‐12	  TFmiR	  homepage	  showing	  user	  input	  parameters.	  
	  For	  gene	  set	  analysis,	  TFmiR	  employs	  DAVID	  [135]	  to	  check	  for	  enrichment	  of	  GO	  terms	  (BP	  subcategory),	  KEGG	  pathways,	  and	  OMIM	  diseases	  as	  well	  as	  a	  clustering	  of	  genes	  based	   on	   their	   functional	   similarities.	   For	   miRNA	   set	   analysis,	   we	   used	   the	   miRNA-­‐functional	   association	   data	   and	   miRNA-­‐disease	   association	   data	   from	   HMDD	   to	  statistically	  relate	  the	  functional	  and	  disease	  terms	  to	  the	  miRNA	  set.	  	  For	  levels	  2	  and	  3,	  the	   TFmiR	   web	   server	   calculates	   for	   each	   network	   the	   basic	   topological	   features,	  relevance	   to	   the	  disease-­‐associated	   genes/miRNAs	  by	   testing	   the	   overlap	   significance	  with	   the	   network	   nodes,	   degree	   distribution	   plot,	   ORA	   analyses	   for	   both	   gene	   and	  miRNA	  nodes,	  network	  key	  players	  (hot	  spots),	  and	  detects	  3-­‐node	  motifs.	  To	  measure	  the	   strength	   of	   correlation	   between	   the	   potential	   disease-­‐specific	   network,	   the	   input	  disease,	   and	   the	   input	   deregulated	   genes	   and	  miRNAs,	   we	   compute	   a	   coverage	   ratio	  (CR)	   between	   the	   nodes	   of	   the	   disease-­‐specific	   network	   and	   the	   nodes	   of	   the	   entire	  combined	  network.	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Here	  Nd	  represents	  the	  number	  of	  disease-­‐specific	  network	  nodes,	  and	  Nt	  represents	  the	  total	  number	  of	  nodes	  in	  the	  entire	  network.	  We	  also	  calculate	  the	  CR	  ratio	  between	  the	  edges	   of	   the	   two	   networks.	   Along	   with	   the	   aforementioned	   analysis,	   all	   resulting	  networks	  are	  visualized	  using	  the	  interactive	  Cytoscape-­‐web	  viewer	  [136].	  	  
	  
	  
Figure	  3-­‐13	  Reconstructed	  networks	  from	  the	  input	  deregulated	  genes	  and	  miRNAs.	  Four	  interaction	  networks	  corresponding	  to	  the	  four	  interactions	  types	  as	  well	  as	  the	  entire	  interaction	  network	  and	  disease–specific	  network.	  	  
3.6.5 Identification	  of	  network	  key	  players	  (hot	  spots)	  	  To	   identify	   crucial	   network	   players	   that	   could	   possibly	   be	   critical	   drivers	   of	   disease	  pathogenesis,	  TFmiR	  utilizes	  7	  different	  methods	   (Figure	  3-­‐14).	  The	   first	   six	  methods	  use	   the	   well	   known	   topological	   centrality	   measures:	   degree	   centrality,	   closeness	  centrality,	   betweenness	   centrality,	   eigenvector	   centrality	   as	   well	   as	   the	   common	   and	  union	  sets	  of	  the	  key	  nodes	  identified	  by	  these	  four	  measures.	  	  	  We	  defined	  the	  key	  nodes	  as	  the	  top	  10%	  highest	  centrality	  nodes	  of	  the	  TFs,	  miRNAs,	  and	   genes	   in	   the	   disease-­‐specific	   and	   whole	   network.	   The	   last	   method	   is	   based	   on	  determining	  the	  minimal	  set	  of	  nodes	  that	  regulate	  the	  entire	  network.	  We	  mapped	  this	  problem	   into	   the	   Minimum	   Connected	   Dominating	   Set	   (MCDS)	   and	   employed	   the	  algorithm	   presented	   by	   Rai	   et	   al.	   2009	   [137]	   to	   search	   for	   the	   minimum	   connected	  dominating	   node	   set.	   This	   feature	   was	   the	   contribution	   of	   Maryam	   Nazarieh	   to	   the	  TFmiR	  publication.	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Figure	  3-­‐14	  Network	  visualization	  and	  key	  players	  identification	  in	  the	  TFmiR	  webserver.	  
3.6.6 Identification	  of	  TF-­‐miRNA	  co-­‐regulatory	  motifs	  	  Feed	  Forward	  Loops	   (FFLs)	  are	   interconnection	  patterns	   that	   recur	   in	  many	  different	  parts	   of	   a	   network	   and	   form	   key	   functional	   modules	   [115,	   138].	   They	   have	   been	  demonstrated	  as	  one	  of	  the	  most	  important	  motif	  patterns	  in	  transcriptional	  regulation	  networks	   [138]	   that	  govern	  many	  aspects	  of	  normal	  cell	   functions	  and	  diseases	   [139-­‐146].	   	   Here,	   TFmiR	   identifies	   4	   types	   of	   3-­‐node	   motifs	   (3	   FFLs	   and	   1	   co-­‐regulation	  motif)	   consisting	  of	   a	  TF,	   a	  miRNA,	   and	   their	   co-­‐targeted	  gene	   that	   are	   considered	  as	  	  TF-­‐miRNA	  co-­‐regulatory	  motifs	  (Figure	  3-­‐15).	  	  (1)	  The	  so-­‐called	  Composite-­‐FFL,	  which	  includes	  TF	  regulation	  of	  both	  a	  miRNA	  and	  a	  target	  gene	  as	  well	  as	  miRNA	  suppression	  of	  that	  TF	  and	  that	  target	  gene.	  (2)	  The	  so-­‐called	  TF-­‐FFL	  includes	  TF	  regulation	  of	  the	  expression	  of	  both	  a	  miRNA	  and	  a	  target	  gene	  and	  it	  also	  includes	  miRNA	  repression	  of	  that	  target	  gene.	  (3)	  The	  so-­‐called	  miRNA-­‐FFL	  includes	  miRNA	  repression	  of	  both	  a	  TF	  and	   a	   target	   gene,	   as	   well	   as	   TF	   regulation	   of	   this	   target	   gene.	   (4)	   The	   so-­‐called	  Coregulation-­‐FFL	   includes	   only	   TF	   regulation	   of	   a	   target	   gene	   as	   well	   as	   miRNA	  repression	   of	   that	   target	   gene.	   TFmiR	   utilizes	   the	   following	   procedure	   in	   order	   to	  identify	  the	  aforementioned	  motif	  types.	  	  	  1-­‐Identifying	  significant	  TF-­‐miRNA	  co-­‐occuring	  pairs	  	  We	   identified	   statistically	   significant	   TF	   and	  miRNA	   pairs	   that	   cooperatively	   regulate	  the	  same	  target	  gene	  using	  the	  hypergeometric	  distribution	  and	  calculated	  the	  p-­‐values	  as	  given	  in	  the	  following	  function:	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  where	  k	  is	  the	  number	  of	  target	  genes	  regulated	  by	  a	  certain	  miRNA,	  N	  is	  the	  number	  of	  genes	  regulated	  by	  a	  certain	  TF,	  x	  is	  the	  number	  of	  common	  target	  genes	  between	  this	  TF	   and	   the	   miRNA,	   and	  M	   is	   the	   number	   of	   genes	   in	   the	   union	   of	   all	   human	   genes	  targeted	  by	  human	  miRNAs	  combined	  with	  all	  human	  genes	  regulated	  by	  all	  human	  TFs	  in	   our	  databases.	   Then,	   a	  multiple	   test	   correction	   	  was	  done	  by	  determining	   the	   FDR	  	  according	  to	  the	  Benjamini	  and	  Hochberg	  (BH)	  [78]	  method	  and	  only	  those	  pairs	  with	  a	  adjusted	  P-­‐value	  less	  than	  0.05	  were	  selected	  as	  significant	  TF-­‐miRNA	  pairs.	  	  2-­‐	  Construction	  of	  candidate	  TF-­‐miRNA-­‐gene	  FFLs	  	  All	   interactions	   associated	   with	   the	   significant	   TF-­‐miRNA	   pairs	   were	   represented	   as	  connectivity	  matrix,	  M,	   such	   that	  Mij	  =1	   if	   regulator	   i	   regulates	   target	   j	  where	   i	  ∈	   (TF,	  miRNA),	   and	   j	  ∈	   (TF,	  miRNA,	   gene).	   Then,	  we	   scan	   all	   the	   3*3	   submatrices	   of	  M	   that	  represent	  each	  type	  of	  the	  four	  considered	  FFL	  topologies	  (Figure	  3-­‐15).	  	   	  
	  
Figure	  3-­‐15	  Schematic	  illustration	  of	  the	  four	  motif	  types	  detected	  in	  TFmiR.	  	  All	  motifs	  contain	  a	  TF,	  a	  miRNA,	  and	  a	  common	  target	  gene.	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3-­‐Significance	  of	  the	  FFL	  motifs	  	  To	  evaluate	  the	  significance	  of	  each	  FFL	  motif	  type,	  we	  compared	  the	  number	  of	  times	  they	   appear	   in	   the	   real	   network	   to	   the	   number	   of	   times	   they	   appear	   in	   randomized	  ensembles	  preserving	  the	  same	  node	  degrees.	  The	  random	  networks	  were	  constructed	  100	  times	  and	  compared	  to	  the	  real	  network.	  	  A	  p-­‐value	  is	  calculated	  as	  :	  
	  where	  Nh is	  the	  number	  of	  random	  times	  that	  a	  certain	  motif	  type	  is	  acquired	  more	  than	  or	  equal	  to	  its	  number	  in	  the	  real	  network,	  and	  Nr is	  100.	  We	  also	  calculate	  the	  Z	  score	  for	   each	  motif	   type	   to	   examine	   by	   how	  many	   standard	   deviations	   the	   observed	   real	  motif	  occurred	  more	  often	  or	  less	  often	  than	  the	  mean	  of	  the	  random	  ones. 
	  Here	  No  is	  the	  number	  of	  motifs	  observed	  in	  the	  real	  network,	  while	  Nm,	  and	  σ	  are	  the	  mean	   and	   standard	   deviation	   of	   the	   motif	   occurrence	   in	   100	   random	   networks,	  respectively.	   
3.6.7 Functional	  homogeneity	  	  	  In	   order	   to	   evaluate	   the	  biological	   evidence	   of	   the	   identified	  TF-­‐miRNA	   co-­‐regulatory	  motifs	   and	   better	   understand	   their	   functional	   roles,	   TFmiR	   allows	   the	   user	   to	  investigate	  the	  GO	  semantic	  similarity	  for	  all	  pairs	  of	  co-­‐targeted	  genes	  (genes	  targeted	  by	   the	   same	   TF	   and	   miRNA	   pair)	   or	   for	   all	   pairs	   of	   co-­‐regulated	   genes	   (all	   genes	  regulated	   by	   the	   TF	   or	   the	   miRNAs	   of	   that	   TF-­‐miRNA	   pair)	   (Figure	   3-­‐16).	   The	  GoSemSim	  R	  package	  [147]	  is	  used	  to	  compute	  the	  semantic	  similarity	  scores	  according	  to	  the	  GO	  annotations.	  	  GoSemSim	  package	  computes	  the	  similarity	  scores	  based	  on	  the	  shared	  GO	  terms	  between	  each	  pair	  of	  genes.	  	  Statistical	  significance	  is	  determined	  by	  a	  permutation	  test.	  For	  this,	  we	  randomly	  select	  the	   same	   number	   of	   genes	   (co-­‐targeted	   genes	   or	   co-­‐regulated	   genes)	   from	   all	   Entrez	  genes	   with	   Go	   annotations,	   and	   compute	   their	   similarity	   scores.	   The	   permutation	  procedure	  is	  repeated	  1000	  times.	  Then,	  we	  run	  a	  Kolmogorov-­‐Smirnov	  test	  (KS	  test)	  to	  check	  whether	  the	  functional	  similarity	  scores	  of	  all	  gene	  pairs	  from	  the	  FFL	  motif	  are	  significantly	  larger	  than	  that	  of	  randomly	  selected	  pairs	  of	  genes,	  see	  chapter	  2	  for	  more	  details.	  	  
3.6.8 Case	  study	  	  We	  applied	  TFmiR	  to	  datasets	  associated	  with	  several	  complex	  diseases	  such	  as	  cancer,	  alzheimer	   and	   diabetes.	   In	   a	   study	   on	   breast	   cancer	   (chapter	   6),	   we	   identified	   1262	  deregulated	  genes	  and	  121	  deregulated	  miRNAs	  using	  gene	  and	  miRNA	  expression	  data	  from	   the	   TCGA	   portal	   (https://tcga-data.nci.nih.gov/tcga/).	   These	   two	   sets	   of	   deregulated	  genes	   and	   miRNAs	   are	   in	   fact	   the	   default	   sample	   input	   files	   now	   provided	   with	   the	  TFmiR	  web	  server.	  Next,	  TFmiR	  was	  used	  to	  reveal	  the	  co-­‐regulation	  network	  between	  the	   deregulated	   genes/TFs	   and	   deregulated	   miRNAs	   and	   to	   better	   understand	   the	  pathogenic	   mechanisms	   associated	   with	   breast	   tumorigenesis.	   The	   user	   input	  parameters	  were	  set	  as	  following:	  p-­‐value	  cut	  off	  =	  0.05,	  disease	  was	  selected	  to	  breast	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neoplasms,	   and	   the	   evidence	   level	   was	   set	   to	   both	   experimentally	   validated	   and	  predicted	  interactions.	  	  	  	  TFmiR	   constructed	   a	   total	   of	   294	   regulatory	   interactions	   comprising	   172	   nodes	   of	  deregulated	   miRNAs	   and	   deregulated	   TFs/genes.	   The	   breast	   cancer-­‐specific	   network	  involves	  216	   interactions	  and	  120	  nodes	  of	  deregulated	  miRNAs	  and	  genes	  with	  node	  and	   edge	   coverage	   ratios	   (CR)	   of	   80.6%,	   and	   80.8%	   respectively.	   This	   supports	   the	  strong	  relation	  between	  the	  input	  deregulated	  genes	  and	  the	  input	  deregulated	  miRNAs	  in	   the	   activity	   of	   the	   oncogenic	   processes	   of	   breast	   carcinoma.	   The	   provided	   ORA	  analysis	  of	  the	  disease	  network	  nodes	  reveals	  their	  implications	  in	  many	  cancer	  types	  as	  well	  as	  cancer-­‐related	  KEGG	  pathways.	  For	   instance,	   the	  network	  gene	  nodes	  are	  also	  significantly	   involved	   in	  pancreatic	   cancer,	   colorectal	   cancer,	   prostate	   cancer,	   and	   the	  p53	   signaling	  pathway,	  which	   is	   a	   tumor	   suppressor	   gene	   showing	  one	  of	   the	   largest	  frequencies	   of	   SNPs	   among	   all	   human	   genes	   that	   have	   been	   related	   	  to	   cancer	   [148].	  Moreover,	   ORA	   analysis	   of	   the	   network	   miRNAs	   shows	   their	   involvement	   in	  cancerogenesis	   of	   multiple	   organs	   such	   as	   lung	   neoplasms,	   ovarian	   cancer,	   and	  adenocarcinoma.	  Additionally,	  TFmiR	  identified	  22	  key	  network	  players	  (10	  genes	  and	  12	  miRNAs)	  based	  on	  the	  union	  set	  of	  four	  centrality	  measures	  described	  above.	  These	  key	  genes	  are	  E2F6,	  TP53,	  SPI1,	  TGFB1,	  SMAD4,	  ESR1,	  TERT,	  E2F3,	  BRCA2,	  AKT1,	  and	  the	  key	  miRNAs	   are	  hsa-­‐mir-­‐148a,	  hsa-­‐mir-­‐21,	  hsa-­‐mir-­‐93,	  hsa-­‐mir-­‐152,	  hsa-­‐mir-­‐106b,	  hsa-­‐
mir-­‐143,	  hsa-­‐mir-­‐200c,	  hsa-­‐mir-­‐27a,	  hsa-­‐mir-­‐23a,	  hsa-­‐mir-­‐22,	  hsa-­‐mir-­‐146a,	  hsa-­‐mir-­‐335.	  Interestingly,	   some	   of	   the	   identified	   key	   genes	   such	   as	  BRCA2,	  ESR1,	  AKT1,	  and	   TP53	  	  were	  previously	   implicated	  and	  significantly	  mutated	   in	  breast	  cancer	  samples	   [148].	  More	   importantly,	   the	   protein	   products	   of	   the	   genes	   ESR1,	   TP53,	   TGFB1,	   AKT1,	   and	  
BRCA2	  are	  binding	  targets	  for	  anti-­‐breast	  cancer	  drugs	  [7].	  	  
	  
Figure	  3-­‐16	  Co-­‐targeted	  and	  co-­‐regulated	  genes.	  (a)	   Co-­‐targeted	   genes	   defined	   as	   genes	   that	   are	   targeted	   by	   the	   same	  TF	   and	  miRNA	  pair.	   (b)	   Co-­‐regulated	   genes	  defined	  as	  all	  genes	  regulated	  by	  the	  TF	  and	  the	  miRNA	  of	  this	  TF-­‐miRNA	  pair.	  	  It	  has	  been	  demonstrated	  that	  the	  E2F3	  gene	  plays	  a	  critical	  role	  in	  the	  transcriptional	  activation	   of	   genes	   that	   control	   the	   rate	   of	   proliferation	   of	   tumor	   cells	   [149-­‐151].	  Furthermore,	   Vimala	   et	   al.	   [152]	   recently	   showed	   that	   E2F3	   is	   overexpressed	   in	   11	  breast	  cancer	  cell	  lines	  and	  siRNA-­‐E2F3	  based	  gene	  silencing	  facilitates	  the	  silencing	  of	  
E2F3	  overexpression	  and	  limits	  the	  progression	  of	  breast	  tumors.	  This	  strongly	  matches	  our	   findings	   using	  TFmiR	   that	  E2F3	  may	   be	   a	   potential	   therapeutic	   target	   for	   human	  breast	  cancer.	  The	  two	  identified	  key	  regulator	  miRNAs	  hsa-­‐mir-­‐143,	  and	  hsa-­‐mir-­‐200c	  
(b) (a) 
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are	   deregulated	   tumor	   suppressor	   miRNAs	   in	   many	   cancer	   types	   [153-­‐155]	   and	   are	  involved	   in	   chemotherapy	   resistance	   and	   showed	   promising	   insights	   in	   the	  development	  and	  delivery	  of	  miRNA-­‐based	  cancer	  therapeutics	  [156].	  	  Next,	  we	  examined	  the	  TF-­‐miRNA	  co-­‐regulatory	  motifs	  that	  are	  significantly	  enriched	  in	  the	   entire	   interaction	  network.	  We	   identified	  53	  FFL	  motifs	   (3	   composite-­‐FFLs,	   2	  TF-­‐FFLs,	  6	  miRNA-­‐FFLs,	  and	  42	  coreg-­‐FFLs).	  An	  interesting	  motif	  involves	  the	  TF	  SPI1,	  the	  miRNA	  hsa-­‐mir-­‐155,	   and	   the	   target	   gene	  FLI1.	  This	   is	   an	   example	   for	   how	  FFL	  motifs	  hint	   at	   better	   understanding	   the	  pathogenicity	   of	   breast	   cancer	   (Figure	  3-­‐17).	   Recent	  studies	   reported	   that	   the	   oncogene	   SPI1	   is	   involved	   in	   tumor	   progression	   and	  metastasis	   [157-­‐159].	   However,	   the	   co-­‐regulation	   of	   the	   oncogene	  FLI1	   [160-­‐162]	   by	  both	  SPI1	   and	   the	   oncomiR	  hsa-­‐mir-­‐155	  was	   not	   reported	   before.	  However,	  we	   show	  here	  that	  the	  co-­‐regulated	  target	  genes	  of	  SPI1	  and	  hsa-­‐mir-­‐155	  have	  significantly	  more	  cellular	   functions	   in	  common	  than	  randomly	  selected	  genes	  (Figure	  3-­‐18).	  Hence,	   this	  FFL	  motif	  provides	  novel	  insights	  on	  how	  SPI1-­‐and	  miRNA	  affect	  the	  cellular	  network	  in	  breast	   cancer	   and	   suggests	   a	   cooperative	   functional	   role	   between	   SPI1	   and	   potential	  miRNA	  partners.	  	  	  In	  conclusion,	  unlike	  the	  traditional	  separate	  analysis	  of	  gene	  expression	  profiles	  [163-­‐167]	  or	  the	  aberration	  of	  miRNA	  expression	  in	  cancer	  tissues	  [168-­‐170],	  this	  integrated	  molecular	  analysis	  of	  deregulated	  miRNAs	  and	  genes	  using	  TFmiR	  was	  able	  to	  uncover	  important	   aspects	   of	   the	   TF/gene-­‐miRNA	   interactomes,	   their	   co-­‐regulation	  mechanisms,	  and	  the	  underlying	  pathogenesis	  of	  human	  breast	  cancer	  	  
	  
Figure	  3-­‐17	  A	  composite	  FFL	  motif	  involves	  the	  TF	  SPI1,	  the	  miRNA	  has-­‐mir-­‐155,	  and	  the	  target	  gene	  FLI1.	  The	  co-­‐regulated	  nodes	  are	  also	  visualized	  and	  to	  be	  further	  tested	  for	  composing	  a	  cooperative	  functional	  module	  in	  breast	  cancerogenesis.	  
3.6.9 Comparison	  with	  other	  tools	  	  In	   comparison	   with	   the	   web	   interfaces	   of	   related	   databases	   such	   as	   Transmir	   [30],	  ChIPBase	   [132],	   CircuitsDB	   [146],	   starBase	   [126],	   and	  miR2Disease	   [171],	   our	  TFmiR	  web	  server	  has	  several	  distinctive	   features:	  1-­‐	  TFmiR	  performs	   integrative	  analysis	  of	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molecular	   interactions	   between	   a	   set	   of	   deregulated	   genes	   and	   a	   set	   of	   deregulated	  miRNAs	  within	  or	  without	  the	  pathogenic	  pathways	  of	  a	  certain	  disease.	  In	  contrast,	  the	  abovementioned	  web	  tools	  can	  only	  search	  the	  regulatory	  interactions	  of	  a	  single	  gene	  or	  a	  single	  miRNA.	  2-­‐	  TFmiR	  performs	  a	  rich	  network	  analysis	  involving	  TF-­‐miRNA	  co-­‐regulatory	  motif	  detection,	  plausible	  network	  visualization,	  statistical	  significance	  of	  the	  extracted	   interactions,	   and	   ORA	   analysis	   for	   each	   interaction	   type,	   the	   combined	  interaction	   network,	   and	   the	   disease	   network.	   Such	   an	   integrated	   analysis	   is	   not	  provided	  by	  other	  web	  tools.	  3-­‐	  TFmiR	  allows	  the	  user	  to	  retrieve	  either	  experimentally	  validated	   or	   predicted	   interactions	   or	   both.	   Such	   an	   option	   is	   not	   available	   using	   the	  other	   tools.	   In	   a	   relatively	   similar	   fashion,	   DisTMGneT	   [172]	   was	   developed	   for	  obtaining	  cancer-­‐specific	  network	  based	  on	  user-­‐selected	  sets	  of	  deregulated	  genes	  and	  miRNAs.	   However,	   it	   lacks	   the	   downstream	   analysis,	   the	   varieties	   of	   user	   input	  parameters,	  and	  it	  is	  limited	  to	  a	  predefined	  set	  of	  miRNAs	  and	  genes	  as	  well	  as	  cancer	  disease.	  Also	  miRTrail	  [93]	  performs	  ORA	  and	  Gene	  Set	  Enrichment	  (GSEA)	  analyses	  of	  interactions	   of	   genes	   and	  miRNAs	   based	   on	   expression	   profiles.	   However,	   it	   explores	  only	  miRNA"gene	  interactions.	  	  
	  
Figure	  3-­‐18	  	  Cumulative	  distributions	  of	  GO	  functional	  semantic	  scores	  of	  gene	  pairs	  of	  co-­‐regulated	  genes	  in	  
the	   examined	   motif	   (red)	   versus	   randomly	   selected	   genes	   (black).	  The	   p-­‐value	   was	   calculated	   using	   the	  Kolmogorov-­‐Smirnov	  test.	  	  
3.6.10 Conclusion	  	  We	   developed	   TFmiR	   as	   a	   comprehensive	   web	   server	   for	   integrative	   analysis	   of	   the	  molecular	   interactions	   between	   TFs/genes	   and	  miRNAs	   and	   their	   interwoven	   critical	  roles	   in	   the	   pathology	   of	   human	   diseases.	   TFmiR	   shows	   advances	   over	   other	   related	  web	   tools	   in	   terms	   of	   the	   extended	   downstream	   analysis,	   the	   varieties	   of	   user	  parameters,	   use	   case	   scenarios,	   and	   in	   incorporating	   information	   from	   various	   well-­‐
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established	  regulatory	  databases.	  TFmiR	  is	  based	  on	  user-­‐provided	  sets	  of	  deregulated	  genes	   and/or	   miRNAs	   regardless	   of	   the	   data	   producing	   technologies	   of	   either	  microarray	   experiments,	   NGS,	   or	   PCR.	   The	   application	   of	   TFmiR	   on	   breast	   cancer–related	   deregulated	   genes	   and	   mirNAs	   demonstrated	   the	   usefulness	   of	   TFmiR	   in	  constructing	   the	   breast	   cancer–specific	   network	   and	   identifying	   literature-­‐confirmed	  core	   regulators	   as	   well	   as	   novel	   hub	   nodes	   of	   TFs/miRNAs	   that	   could	   be	   further	  experimentally	   investigated	   as	   new	   potential	   drug	   targets.	   TFmiR	   was	   also	   able	   to	  characterize	  important	  TF–miRNA	  co-­‐regulatory	  motifs	  whose	  co-­‐regulated	  genes	  form	  cooperative	  functional	  modules	  in	  breast	  cancerogenesis.	  
3.6.11 Outlook	  	  Besides	   the	   involved	   transcriptional	   and	   posttranscriptional	   regulatory	   interactions,	  possible	   extensions	   are	   to	   integrate	   data	   for	   posttranslational	   events	   such	   as	   protein	  phosphorylation	   and	   localization.	   Also	   enriching	   TFmiR	   with	   additional	   well-­‐established	   databases	   and	   extending	   the	   downstream	   analysis	   of	   the	   interaction	  networks	  would	  be	  a	  valuable	  asset.	  Furthermore,	  an	  extra	  analysis	  module	  of	  detecting	  4-­‐nodes	  FFL	  motifs	  between	  TFs,	  miRNAs,	  and	  target	  genes	  can	  be	  coupled	  into	  TFmiR.	  Finally,	   expanding	   the	   TFmiR	   to	   elucidate	   the	   regulatory	   mechanisms	   of	   cellular	  processes	   (ex.	   stem	  cell	  differentiation)	   in	  addition	   to	  diseases	  would	  make	  TFmiR	  of	  great	  interest	  to	  a	  wide	  range	  of	  researchers	  in	  the	  life	  science	  community.	  	  
3.7 NGS	  pipeline	  	  
3.7.1 Background	  	  In	   collaboration	   with	   Dr.	   Ulrich	   Nübel	   at	   the	   Robert-­‐Koch-­‐Institute	   institute,	   we	  developed	  a	  Whole	  Genome	  Sequencing	  (WGS)	  pipeline	   to	   identify	  core-­‐genome	  SNPs	  that	  can	  be	  effectively	  used	  to	  study	  the	  phylogenetic	  arrangements	  between	  bacterial	  isolates	  as	  well	  as	  an	  additional	  module	  to	  elucidate	  phenotypic	  characteristics	  such	  as	  virulence	  (Figure	  3-­‐19).	  The	  pipeline	  was	  written	  in	  a	  combination	  of	  shell	  scripting	  and	  R	  language[173].	  	  In	  a	  collaboration	  with	  Prof.	  Dr.	  Lutz	  von	  Müller	  and	  Prof.	  Dr.	  Mathias	  Herrmann	  (both	  medical	   faculty,	  Saarland	  University)	  and	  Dr.	  Patrick	  Nitsche	  (HZI	  Braunschweig),	   this	  pipeline	  was	  applied	   to	  Methicillin-­‐Resistant	  Staphylococcus	  Aureus	   (MRSA)	  genomes	  to	  investigate	  the	  phylogenetic	  positions	  of	  the	  recently	  emerged	  t504	  clone	  (Spa-­‐type	  t504)	  in	  the	  Saarland	  province	  of	  Germany	  in	  relation	  to	  the	  currently	  dominant	  clone	  t003	   in	   the	   surrounding	   areas	   of	   south	   Germany	   and	   Luxemburg.	   Following	   this,	   we	  analyzed	  the	  differentially	  occurring	  genetic	  mutations	  between	  nasal	  and	  blood	  stream	  (invasive)	   samples	   of	   the	   predominant	   CC5	  with	   the	   aim	  of	   better	   understanding	   the	  infectivity	  mechanism	  of	  the	  invasive	  group.	  The	  whole	  study	  is	  introduced	  in	  full	  detail	  in	  Chapter	  8.	  
3.7.2 Pipeline	  description	  	  	  Whole	   genome	   sequencing	   of	   MRSA	   DNA	   was	   performed	   using	   an	   Illumina	   MiSeq	  sequencer	   at	   the	   HZI	   in	   Braunschweig,	   Germany,	   producing	   paired-­‐end	   reads	   of	   251	  basepair	  lengths	  with	  an	  average	  coverage	  of	  110-­‐fold.	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The	  first	  step	  in	  the	  pipeline	  is	  quality	  control	  of	  the	  input	  sequencing	  data.	  For	  this,	  the	  pipeline	  utilizes	  the	  FastQC	  [174]	  tool	  to	  evaluate	  the	  efficacy	  of	  the	  short	  read	  data	  to	  be	  involved	  in	  the	  analysis.	  Secondly	  reads	  are	  mapped	  against	  the	  complete	  reference	  genome	   of	   interest	   using	   the	   short	   read	   alignment	   version	   of	   the	   Burrows-­‐wheeler	  Aligner	   (BWA)	   algorithm	   [175].	   In	   our	   case	   study	   presented	   in	   chapter	   8,	  we	   used	  S.	  
aureus	  CC5	  strain	  NC_017340.1	  (http://www.ncbi.nlm.nih.gov/nuccore/NC_017340)	  as	  a	   reference	   genome.	   Once	   the	   short	   reads	   are	   mapped	   to	   the	   reference	   genome,	   we	  reprocess	  the	  mapped	  reads	  and	  investigate	  the	  mapping	  quality	  distribution	  (Figure	  3-­‐20)	   such	   that	   both	   duplicate	   reads	   and	   reads	   with	   low	   mapping	   quality	   (<	   30)	   are	  filtered	  out	  and	  the	  final	  alignments	  are	  sorted	  via	  samtools	  [176].	  	  	  
	  
Figure	  3-­‐19	  NGS	  pipeline	  for	  identifying	  core-­‐genome	  SNPs.	  And	  detecting	  genetic	  differences	  between	  two	  sets	  of	  isolates,	  such	  as	  groups	  of	  invasive	  and	  nasal	  MRSA	  isolates.	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As	  a	  next	  step,	  genetic	  mutations	  of	   the	  consensus	  genotypes	   (SNPs,	  and	   INDELS)	  are	  called	  using	  the	  VarScan2	  [177]	  tool	  based	  on	  the	  number	  of	  aligned	  reads	  supporting	  each	  allele.	  	  
	  	  
Figure	  3-­‐20	  An	  example	  for	  mapping	  quality	  distribution	  after	  the	  alignment	  step.	  	  To	  avoid	  false	  positives	  (phylogenetic	  mispositioning),	  the	  analysis	  was	  restricted	  to	  the	  consensus	   sequence	   of	   the	   highly	   conserved	   core-­‐genome.	   Therefore,	   variants	   that	  occurred	  in	  mobile	  genetic	  islands	  as	  well	  as	  repetitive	  sequence	  regions	  were	  masked	  by	  the	  same	  reference	  nucleotide	  (Figure	  3-­‐21).	  	  This	  step	  was	  performed	  using	  a	  list	  of	  fast	  evolving	  regions	  assembled	  in	  the	  group	  of	  Dr.	  Ulrich	  Nübel.	  The	  reason	  for	  this	  is	  that	  these	  specific	  genomic	  regions	  do	  evolve	  randomly	  in	  various	  rates	  within	  different	  strains.	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Figure	  3-­‐22	  Padding	  the	  unmapped	  regions	  with	  an	  N	  nucleotide	  to	  construct	  the	  consensus	  sequence.	  	  In	   order	   to	   obtain	   a	   phylogenetic	   representative	   core-­‐genome	   SNP	   matrix,	   we	  considered	   the	   genomic	  positions	  where	   at	   least	   one	   variant	  was	   found	   in	   any	  of	   the	  bacterial	  isolates	  (Figure	  3-­‐23).	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4. Imprinted	  genes	  and	  cell	  
differentiation	  	  	  	  This	  chapter	  is	  a	  shortened	  version	  of	  the	  following	  publication:	  	  
• Mohamed	  Hamed,	  Siba	  Ismael,	  Martina	  Paulsen,	  and	  Volkhard	  Helms,	  Cellular	  functions	  of	  genetically	  imprinted	  genes	  in	  human	  and	  mouse	  as	  annotated	  in	  the	  Gene	  Ontology.	  PLoS	  One,	  2012.	  7(11):	  p.	  e50285.	  	  	  	  	  
Synopsis	  
	  
Genomic	   imprinting	   is	   an	   epigenetic	   phenomenon	   that	   is	   closely	   associated	   with	   cell	  
development	   and	   cellular	   differentiation.	   In	   order	   to	   characterize	   the	   role	   of	   imprinted	  
genes	  during	  differentiation	  processes,	  the	  study	  presented	  in	  this	  chapter	  was	  set	  out	  to	  
comprehensively	   investigate	   the	   cellular	   functions	   of	   the	   whole	   set	   of	   imprinted	   genes,	  
paternally	   expressed	   genes,	   and	  maternally	   expressed	   genes	   in	   both	   human	   and	  mouse.	  
Additionally,	   we	   examined	   the	   transcription	   factors	   that	   are	   predicted	   to	   regulate	   the	  
imprinted	  genes	  and	  their	  relatedness	  to	  cell	  differentiation.	  The	   findings	  of	   this	  chapter	  
raised	  intriguing	  questions	  regarding	  the	  nature	  and	  extent	  of	  the	  role	  of	  imprinted	  genes	  
in	   hematopoietic	   stem	   cell	   differentiation,	   which	   will	   be	   covered	   in	   chapter	   5.	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Abstract	  	  By	  analyzing	   the	   cellular	   functions	  of	   genetically	   imprinted	  genes	  as	   annotated	   in	   the	  Gene	  Ontology	  for	  human	  and	  mouse,	  we	  found	  that	  imprinted	  genes	  are	  often	  involved	  in	  developmental,	   transport	  and	  regulatory	  processes.	   In	  human,	  paternally	  expressed	  genes	  are	  enriched	  in	  GO	  terms	  related	  to	  the	  development	  of	  organs	  and	  of	  anatomical	  structures.	  In	  mouse,	  maternally	  expressed	  genes	  regulate	  cation	  transport	  as	  well	  as	  G-­‐protein	  signaling	  processes.	  We	  noticed	  that	  the	  Gene	  Ontology	  currently	  only	  provides	  a	  partial	   compilation	  of	  which	  genes	  are	  known	   to	  be	  genetically	   imprinted	  and	  what	  their	   functions	   are.	   Furthermore,	  we	   investigated	   if	   imprinted	  genes	   are	   regulated	  by	  common	  transcription	  factors.	  We	  identified	  25	  TF	  families	  that	  showed	  an	  enrichment	  of	  binding	  sites	  in	  the	  set	  of	  imprinted	  genes	  in	  human	  and	  40	  TF	  families	  in	  mouse.	  In	  general,	   maternally	   and	   paternally	   expressed	   genes	   are	   not	   regulated	   by	   different	  transcription	  factors.	  The	  genes	  Nnat,	  Klf14,	  Blcap,	  Gnas	  and	  Ube3a	  contribute	  most	  to	  the	   enrichment	   of	   TF	   families.	   In	   mouse,	   genes	   that	   are	   maternally	   expressed	   in	  placenta	   are	   enriched	   for	   AP1	   binding	   sites.	   In	   human,	   we	   found	   that	   these	   genes	  possessed	  binding	  sites	  for	  both,	  AP1	  and	  SP1.	  
4.1 Background	  	  Genomic	  imprinting	  is	  an	  epigenetic	  phenomenon	  observed	  in	  eutherian	  mammals.	  For	  the	   large	   majority	   of	   autosomal	   genes,	   the	   two	   parental	   copies	   are	   both	   either	  transcribed	   or	   silent.	   However,	   in	   a	   small	   group	   of	   genes	   one	   copy	   is	   turned	   off	   in	   a	  parent-­‐of-­‐origin	   specific	   manner	   thereby	   resulting	   in	   monoallelic	   expression.	   These	  genes	   are	   called	   'imprinted'	   because	   the	   silenced	   copy	   of	   the	   gene	   is	   epigenetically	  marked	  or	  imprinted	  in	  either	  the	  egg	  or	  the	  sperm	  [179].	  	  Imprinted	   genes	   play	   important	   roles	   in	   development	   and	   growth	   both	   pre-­‐	   and	  postnatally	  by	  acting	  in	  fetal	  and	  placental	  tissues	  [180].	  Interestingly,	  there	  appears	  to	  exist	   a	   general	   pattern	  whereby	  maternally	   expressed	   genes	   tend	   to	   limit	   embryonic	  growth	  and	  paternally	  expressed	  genes	  tend	  to	  promote	  growth.	  A	  model	  case	  for	  this	  striking	   scenario	   is	   the	   antagonistic	   action	  of	   Igf2	   and	   Igf2r	   in	  mouse.	  Deletion	  of	   the	  paternally	  expressed	   Igf2	  gene	  results	   in	   intrauterine	  growth	  restriction.	  On	  the	  other	  hand,	  deletion	  of	  the	  maternally	  expressed	  gene	  Igf2r,	  results	  in	  overgrowth	  [181].	  	  The	   observation	   that	   maternally	   and	   paternally	   expressed	   genes	   apparently	   act	   as	  antagonists	  has	  inspired	  several	  evolutionary	  theories	  that	  aim	  to	  explain	  the	  origin	  of	  genetic	  imprinting	  under	  the	  process	  of	  ‘natural	  selection’	  [180].	  The	  most	  scientifically	  accepted	   theory	   is	   currently	   the	   kinship	   theory	   [182]	   and	   [183].	   Briefly,	   this	   theory	  suggests	   that	   in	   polygamous	   mammalian	   species,	   silencing	   of	   maternally	   derived	  growth	   inhibiting	  genes	   results	   in	   increased	  growth	  of	   the	  embryo.	  This	   is	   associated	  with	   an	   increased	   nutritional	   demand	   and	   thereby	   with	   an	   exploitation	   of	   maternal	  resources	  at	  the	  cost	  of	  future	  off-­‐spring	  that	  might	  be	  fathered	  by	  a	  different	  male.	  	  	  The	  evolution	  of	  a	  gene	  regulatory	  mechanism	  that	  silences	  preferentially	  one	  parental	  allele	   of	   a	   gene	   implies	   that	   paternally	   and	   maternally	   expressed	   genes	   experience	  different	   selective	   pressures	   during	   evolution.	   This	   assumption	   is	   supported	   by	   the	  finding	  that	  the	  two	  groups	  reveal	  different	  patterns	  of	  sequence	  conservation.	  Whereas	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the	  protein-­‐encoding	  DNA	  sequences	  of	  paternally	  expressed	  genes	  are	  well	  conserved	  among	   different	   mammalian	   species,	   maternally	   expressed	   genes	   are	   much	   more	  divergent	   [184].	   Whether	   paternally	   and	   maternally	   expressed	   genes	   differ	   also	   in	  molecular	  functions	  and	  gene	  regulation	  is	  a	  question	  that	  has	  not	  yet	  been	  investigated	  in	  detail.	  	  	  As	   the	   phenomenon	   of	   genomic	   imprinting	   is	   an	   important	   evolutionary	   facet	   of	  mammals	  with	  placentas,	   it	   is	   of	   great	   interest	   to	   identify	  which	   sorts	   of	   cellular	   and	  developmental	  processes	  of	  developing	  and/or	  mature	  organisms	  are	  subject	  to	  control	  by	   imprinted	   genes.	   We	   aimed	   in	   this	   study	   at	   characterizing	   the	   cellular	   roles	   of	  imprinted	   genes	   in	   an	   unbiased,	   data-­‐driven	   approach.	   For	   this,	   we	   used	   the	   gene	  annotations	  of	  the	  Gene	  Ontology	  (GO)	  that	  consists	  of	  three	  structured	  and	  controlled	  vocabularies	  for	  the	  biological	  processes,	  cellular	  components,	  and	  molecular	  functions	  associated	  with	  particular	  genes.	  As	  it	  is	  of	  particular	  interest	  to	  analyze	  which	  of	  these	  functions	  are	  controlled	  by	   the	  sets	  of	  maternally	  and	  paternally	  expressed	  genes,	  we	  have	  also	  separately	  analyzed	  the	  enrichment	  of	  GO	  terms	  in	  these	  two	  groups. 
4.2 Methods	  
4.2.1 Gene	  Selection	  	  Imprinted	   genes	   of	   human	   and	   mouse	   were	   downloaded	   from	   the	   Catalogue	   of	  Imprinted	  Genes	  and	  Parent-­‐of-­‐origin	  Effects	  in	  Humans	  and	  Animals	  (IGC)	  [180,	  185].	  The	  catalogue	  encompasses	  genes	  that	  were	  described	  as	  being	  imprinted	  in	  literature.	  As	   the	   related	   experiments	   were	   done	   in	   many	   different	   labs,	   the	   experimental	  procedures	  differed	  considerably.	  After	  reading	  the	  original	  publications,	  we	  manually	  selected	  64	  imprinted	  genes	  that	  are	  imprinted	  without	  doubt	  in	  at	  least	  one	  of	  the	  two	  species,	   see	   table	   A-­‐1.	   This	   list	   was	   provided	   to	   us	   by	   our	   collaborator	   Dr.Martina	  Paulsen.	   For	   the	   gene	   C15orf2,	   the	   expressed	   allele	   is	   unknown	   since	   there	   is	   no	  information	   on	   the	   parental	   origin	   of	   the	   alleles.	   Copg2,	   and	   Zim2	   are	   paternally	  expressed	   in	   the	   human,	   but	   maternally	   expressed	   in	   the	   mouse.	   Grb10	   exhibits	  isoform-­‐specific	   imprinting	   effects,	   i.e.	   there	   are	   paternally	   expressed	   and	  maternally	  expressed	   isoforms.	   The	   other	   60	   genes	   have	   been	   experimentally	   classified	   into	  paternally	  and	  maternally	  expressed	  alleles	  in	  two	  equal	  halves.	  25	  genes	  are	  imprinted	  in	  both	  species,	  for	  the	  remaining	  imprinted	  expression	  was	  proven	  only	  for	  one	  of	  the	  two	   species.	   As	   control	   group	   for	   the	   human	   (mouse)	   imprinted	   genes	   we	   used	   all	  human	  (mouse)	  genes	  that	  are	  annotated	  in	  the	  Gene	  Ontology.	  
4.2.2 Functional	  Enrichment	  Analysis	  	  For	   analyzing	   significantly	   enriched	   functional	   categories,	   we	   used	   the	   functional	  annotation	   tool	   available	   in	   the	  Database	   for	  Annotation,	  Visualization	  and	   Integrated	  Discovery	   (DAVID)	   [135].	   We	   determined	   which	   GO	   categories	   are	   statistically	  overrepresented	   in	   different	   sets	   of	   genes.	   Enrichment	   was	   evaluated	   through	   the	  Fisher	  Exact	   test	  using	  a	  significance	   level	  or	  p-­‐value	   threshold	  of	  0.05.	  We	  suspected	  that	   some	   functional	   categories	   with	   a	   high	   statistical	   significance	   may	   show	   over-­‐representation	  even	  when	  annotated	  only	  to	  a	  single	  gene.	  In	  that	  case,	  it	  would	  not	  be	  clear	  if	  this	  function	  is	  related	  to	  monoallelic	  expression	  of	  the	  gene	  in	  certain	  tissues,	  or	  when	   it	   is	  biallelically	  expressed	   in	  other	  tissues.	  Therefore	  we	  required	  that	  each	  GO	  term	  considered	  here	  is	  annotated	  to	  at	  least	  two	  human	  (mouse)	  genes.	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For	   the	  most	   specific	   GO	   terms,	  we	   ran	   the	   same	   enrichment	   analysis	   procedures	   by	  using	   the	   biological	   process	   GO_FAT	   database	   instead	   of	   using	   the	   general	   GO	  knowledgebase.	  The	  map	  enrichment	  plugin	  in	  Cytoscape	  [85]	  was	  used	  to	  visualize	  the	  overrepresented	  functional	  terms	  and	  display	  the	  overlapping	  functional	  sets.	  
4.2.3 Gene	  Functional	  clustering	  	  	  Clustering	  and	  grouping	  of	  the	  imprinted	  genes	  were	  performed	  using	  the	  DAVID	  gene	  functional	   classification	   tool.	  This	   tool	  employs	  a	   set	  of	   fuzzy	  clustering	   techniques	   to	  classify	   input	  genes	   into	   functionally	  related	  gene	  groups	  (or	  classes).	  This	   is	  done	  on	  the	   basis	   of	   the	   co-­‐occurrence	   of	   annotation	   terms	   by	   generating	   a	   gene-­‐to-­‐gene	  similarity	  matrix	   based	   on	   shared	   functional	   annotation.	   This	   switches	   the	   functional	  annotation	  analysis	  from	  a	  gene-­‐centric	  analysis	  to	  a	  biological	  module-­‐centric	  analysis	  [135].	   The	   similarity	   threshold	   was	   set	   to	   the	   minimum	   similarity	   threshold	   of	   0.3	  suggested	  by	  the	  DAVID	  consortium.	  This	  is	  then	  the	  minimum	  value	  to	  be	  considered	  by	   the	   similarity-­‐matching	   algorithm	   as	   biologically	   significant.	   Also,	   we	   set	   the	  minimum	  gene	  number	  in	  a	  seeding	  group	  to	  2.	  This	  would	  be	  the	  minimum	  size	  of	  each	  cluster	  in	  the	  final	  results.	  All	  remaining	  parameters	  were	  kept	  to	  their	  default	  values.	  The	  results	  of	  the	  functional	  classification	  tool	  are	  visualized	  as	  heat	  maps	  to	  show	  the	  corresponding	  gene-­‐annotation	  association	  across	  the	  clustered	  genes.	  
4.2.4 Transcription	  Factor	  Target	  Enrichment	  	  The	   web-­‐based	   gene	   set	   analysis	   toolkit	   WebGestalt	   [77]	   was	   used	   to	   analyze	   the	  targets	  of	  transcription	  factors	  (TFs).	  This	  tool	  incorporates	  information	  from	  different	  public	   resources	   such	   as	   NCBI	   Gene,	   GO,	   KEGG	   and	   MsigDB	  (http://bioinfo.vanderbilt.edu/webgestalt/).	  Using	  the	  TF	  target	  analysis	   tool	   implemented	  in	  WebGestalt,	   we	   analyzed	   whether	   a	   set	   of	   genes	   is	   significantly	   enriched	   with	   TF	  targets	   (TFT).	   TFT's	   are	   specific	   sets	   of	   genes	   that	   share	   a	   common	   TF-­‐binding	   site	  defined	  in	  the	  TRANSFAC	  database	  [186].	  TFT's	  are	  collected	  in	  the	  Molecular	  signature	  Database	  (MsigDB)	  [187]	  and	  are	  retrieved	  by	  WebGestalt	  upon	  analysis	  request.	  The	  examined	  promoter	  region	  has	  the	  size	  of	  -­‐2kb,	  +2kb	  around	  the	  transcription	  start	  site.	  Then	   enrichment	   was	   evaluated	   through	   the	   hypergeometric	   test	   using	   the	   10	   most	  enriched	   terms	  with	  maximum	  significance	   level	  or	  p-­‐value	  of	  0.05.	  As	  we	  are	   testing	  multiple	  TFT	  families	  at	  the	  same	  time,	  the	  p	  values	  need	  to	  be	  adjusted	  for	  the	  effects	  of	   multiple	   testing,	   therefore	   we	   applied	   the	   sequential	   Bonferroni	   type	   procedure	  method	   proposed	   by	   [78].	  We	   only	   considered	   enrichment	   of	   TFT	   families	   that	  were	  annotated	   for	   at	   least	   two	   genes.	   Finally,	   the	   results	   of	   the	   TFT	   enrichment	   analysis	  were	  visualized	  as	  heat	  maps	  to	  identify	  the	  common	  principles	  and	  differences	  of	  the	  enriched	  TF	  targets	  across	  the	  corresponding	  imprinted	  genes.	  This	  was	  done	  using	  the	  statistical	  language	  R	  [188].	  
4.3 Results	  	  In	   this	   study	   we	   addressed	   the	   question	   whether	   imprinted	   genes	   as	   a	   group	   fulfill	  specific	  functions	  in	  mammalian	  organisms.	  For	  this,	  we	  tested	  if	  specific	  GO	  terms	  are	  overrepresented	   in	   the	   group	   of	   imprinted	   genes	   in	   comparison	   to	   all	   genes	   in	   the	  human	  or	  mouse	  genome.	  Of	  the	  41	  selected	  human	  imprinted	  genes,	  38	  are	  annotated	  in	  the	  GO	  database	  that	  contains	  in	  total	  14116	  human	  genes.	  In	  contrast,	  all	  48	  mouse	  imprinted	   genes	   are	   among	   the	   14219	   annotated	   mouse	   genes.	   One	   should	   note,	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though,	   that	   many	   genes	   are	   represented	   by	   more	   than	   one	   transcript	   in	   the	   GO	  database.	  	  
4.3.1 Imprinted	  genes	  are	  involved	  in	  developmental,	  transport	  and	  regulatory	  functions	  	  	  First,	  we	  analyzed	  which	  terms	  of	   the	  Gene	  Ontology	  are	  enriched	   in	  the	   full	  set	  of	  all	  imprinted	  genes	  when	  compared	  to	  the	  set	  of	  all	  human	  genes	  or	  all	  mouse	  genes.	  We	  concentrate	   in	   this	   analysis	   on	   GO	   terms	   that	   are	   shared	   by	   at	   least	   2	   different	  imprinted	   genes.	   In	   this	   way,	   we	   assume	   to	   emphasize	   those	   cellular	   functions	   that	  relate	  to	  the	  controlled	  mono-­‐allelic	  expression	  of	  the	  set	  of	  genes	  studied	  here.	  
	  In	  the	  human,	  the	  term	  system	  development	  is	  the	  term	  with	  the	  lowest	  p-­‐value.	  This	  term	  is	  associated	  with	  15	  out	  of	  the	  38	  human	  imprinted	  genes.	  This	  corresponds	  to	  2.6	  fold	  enrichment	  in	  comparison	  to	  the	  annotation	  frequency	  in	  the	  group	  of	  all	  genes.	  
Cellular	  processes	  is	  the	  term	  which	  is	  associated	  with	  the	  largest	  number	  of	  imprinted	  genes	  in	  the	  human:	  32	  imprinted	  genes	  (84.2%	  of	  all	  imprinted	  genes)	  are	  associated	  with	  this	  term,	  whereas	  this	  is	  only	  the	  case	  for	  74.6%	  of	  all	  genes.	  For	  comparison,	  the	  imprinted	  genes	  in	  mouse	  showed	  a	  narrower	  range	  of	  1.8	  and	  2	  fold	  enrichment	  for	  these	  two	  broad	  terms,	  and	  only	  for	  system	  development	  the	  p-­‐value	  is	  below	  0.05.	  As	  shown	  in	  Table	  4-­‐1	  
Table	   4-­‐1,	   only	   the	   five	   generic	   GO	   terms,	   multicellular	   organismal	   development,	  
developmental	   process,	   neuron	   development,	   system	   development,	   and	   anatomical	  
structure	  development	  appear	   in	  both	  species	  with	  close	  to	  2-­‐fold	  enrichment	  (p<0.05,	  Fisher	  exact	  test).	  Only	  neuron	  development	  is	  5-­‐fold	  enriched.	  	  	  As	  terms	  such	  as	  system	  development	  and	  cellular	  processes	  are	  rather	  general	  terms,	  we	  subsequently	   analyzed	   the	   enrichment	   of	   terms	   in	   the	   GO_FAT	   section	   of	   the	   DAVID	  database.	   As	   shown	   in	   Figure	   4-­‐1,	   among	   the	   enriched	   specific	   terms	   in	   human	   and	  mouse,	  some	  are	   linked	  to	  neuron	  development	  and	  differentiation	  and	  are	   intimately	  related	   with	   the	   CDKN1C	   and	   NDN	   genes.	   Interestingly,	   the	   terms	   regulation	   of	   RNA	  
metabolic	   process,	   regulation	   of	   transcription,	   DNA-­‐dependent,	   and	   regulation	   of	  
transcription	   are	   the	   terms	   that	   are	   associated	   with	   the	   largest	   numbers	   of	   human	  imprinted	   genes	   (28.9,	   28.9	   and	   34.2	   %,	   respectively).	   Moreover,	   around	   8.5%	   and	  10.5%	  of	  the	  examined	  mouse	  imprinted	  genes	  are	  involved	  in	  the	  regulation	  process	  of	  phosphorylation	  and	  positive	  regulation	  of	  molecular	  function,	  respectively.	  This	  group	  includes	  the	  imprinted	  genes	  Igf2,	  Ins2,	  Kcnq1,	  Htr2a,	  Grb10,	  Ndn,	  Tp73,	  Impact,	  Cdkn1c,	  
Zim2,	  and	  Plagl1.	  	  The	   two	   GO	   terms	   Regulation	   of	   RNA	   metabolic	   process	   and	   the	   daughter	   node	  
Regulation	   of	   transcription,	  DNA-­‐dependent	   are	   associated	   with	   processes	   involved	   in	  the	  role	  of	  RNA	  synthesis	  regulation.	  Some	  of	  the	  encoded	  proteins	  are	  tumor	  proteins;	  others	   are	   inhibitors	   of	   the	   cell	   cycle,	   thus	   inhibiting	   division.	   It	   is	   also	   worth	  mentioning	  that	  the	  functional	  term	  regulation	  of	  gene	  expression	  by	  genetic	  imprinting	  (this	   is	  abbreviated	  to	   ‘genetic	  imprinting’	   in	   the	  DAVID	  database)	   is	  over-­‐represented	  as	  well	  although	  it	  is	  associated	  in	  the	  Gene	  Ontology	  only	  with	  the	  genes	  INS,	  IGF2,	  and	  
KCNQ1	   (Note:	   INS	   and	   IGF2	   are	   being	   interpreted	   by	   DAVID	   as	   a	   single	   locus	   which	  includes	  two	  alternatively	  spliced	  read-­‐through	  transcript	  variants	  and	  align	  to	  the	  INS	  gene	  in	  the	  5'	  region	  and	  to	  the	  IGF2	  gene	  in	  the	  3'	  region).	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Table	  4-­‐1	  Conserved	  functional	  classes	  in	  imprinted	  genes	  in	  human	  (green)	  and	  mouse	  (brown)	  at	  adjusted	  
p-­‐value	  of	  0.05.	  	  
Term	   Species	   Count	   Percentage	   Fold	  Enrichment	   -­‐Log	  (p-­‐value)	  
GO:0007275	  
~multicellular	   organismal	  
development	  
Human	   16	   42.1	   IIIIIIIIIIIIIIIIIIIIII	  2.3	   IIIIIIIIIIIIIIIIIIIIIIIIIIII	  2.8	  
Mouse	   14	   29.2	   IIIIIIIIIIIIIIIIIII	  	  	  	  	  1.9	   IIIIIIIIIIIIIIIII	  1.8	  
GO:0032502	  
~developmental	  process	  
Human	   17	   44.7	   IIIIIIIIIIIIIIIIIIIII	  	  	  2.2	   IIIIIIIIIIIIIIIIIIIIIIIIIIIII	  2.9	  
Mouse	   15	   31.3	   IIIIIIIIIIIIIIIIIII	  1.9	   IIIIIIIIIIIIIIIIII	  1.8	  	  
GO:0048666~neuron	  
development	  
Human	   4	   10.5	   IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	  4.8	   IIIIIIIIIIIII	  1.3	  
Mouse	   4	   8.3	   IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	  4.8	   IIIIIIIIIIIII	  1.3	  
GO:0048731	   ~system	  
development	  
Human	   15	   39.5	   IIIIIIIIIIIIIIIIIIIIIIIIII	  2.6	   IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII	  3.3	  
Mouse	   12	   25.0	   IIIIIIIIIIIIIIIIIIII	  2.1	   IIIIIIIIIIIIIIII	  1.7	  
GO:0048856	   ~anatomical	  
structure	  development	  
Human	   15	   39.5	   IIIIIIIIIIIIIIIIIIIIIII	  2.4	   IIIIIIIIIIIIIIIIIIIIIIIIIIII	  2.9	  
Mouse	   12	   25.0	   IIIIIIIIIIIIIIIIIII	  1.9	   IIIIIIIIIIIIII	  1.5	  	  	  These	  functional	  associations	  rely	  on	  publications	  about	  prominent	  imprinting	  control	  elements	  in	  the	  vicinity	  of	  these	  genes	  [189]	  and	  about	  epigenetic	  abnormalities	  in	  the	  
IGF2/H19	   region	   of	  Beckwith-­‐Wiedemann	   syndrome	  patients	   [190].	   Furthermore,	   the	  GO	  term	  genetic	  imprinting	  that	  is	  a	  parent	  of	  the	  term	  regulation	  of	  gene	  expression	  by	  
genetic	  imprinting	  is	  also	  annotated	  to	  the	  well-­‐known	  imprinted	  genes	  Gnas,	  NDN/Ndn	  and	  Peg3.	  All	   in	  all,	   it	   is	  certainly	  fair	  to	  say	  that	  the	  coverage	  of	  genetically	  imprinted	  genes	  in	  the	  Gene	  Ontology	  is	  currently	  quite	  low.	  	  Some	  functions	  related	  to	  transport	  are	  enriched	  and	  associated	  with	  both	  human	  and	  mouse	   imprinted	   genes.	   For	   instance,	   the	   Growth	   factor	   receptor-­‐bound	   protein	   10	  (GRB10)	   is	   involved	   in	   the	  Negative	   regulation	   of	   transport.	   This	   gene	   interacts	   with	  insulin	   receptors	   and	   insulin-­‐like	   growth-­‐factor	   receptors	   [191].	   Overexpression	   of	  some	   isoforms	   of	   GRB10	   inhibits	   tyrosine	   kinase	   activity	   and	   results	   in	   growth	  suppression,	  e.g.	  by	  suppressing	  glucose	  import	  [192].	  	  	  The	   two	   enriched	   GO	   terms	   Organic	   cation	   transport	   and	   Ion	   transport	   describe	   the	  regulation	  of	   the	  directed	  movement	  of	  organic	  cations	   into,	  out	  of	  or	  within	  a	  cell,	  or	  between	   cells,	   by	  means	  of	   some	  agent	   such	   as	   a	   transporter	   or	  pore.	  The	   associated	  mouse	   imprinted	   genes	   Slc22a2	   and	   Slc22a3	   are	   polyspecific	   organic	   cation	  transporters	  in	  the	  liver,	  kidney,	  intestine,	  and	  other	  organs.	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Figure	  4-­‐1	  The	  most	  specific	  enriched	  GO	  terms	  of	  biological	  functions	  for	  the	  full	  set	  of	  imprinted	  genes	  in	  
human	   (green)	   and	   mouse	   (brown).	   Nodes	   represent	   the	   enriched	   Go	   terms	   and	   the	   thickness	   of	   the	  interconnected	  links	  corresponds	  to	  the	  number	  of	  shared	  genes.	  	  Grouping	   genes	   based	   on	   shared	   GO	   terms	   can	   highlight	   functional	   similarities	   of	  different	  genes.	  For	  this,	  clustering	  algorithms	  were	  applied	  to	  a	  gene-­‐to-­‐gene	  similarity	  matrix	   and	   imprinted	  genes	  were	   classified	   into	  highly	   related	  groups	   (see	  methods).	  We	   identified	  one	  gene	  cluster	   in	   the	  human	  and	   two	  clusters	   in	   the	  mouse.	  The	  only	  discovered	  cluster	   in	  human	  resembles	  the	  second	  cluster	   in	  mouse	  and	  encompasses	  zinc	  finger	  protein	  genes	  such	  as	  PEG3,	  ZNF597	  and	  ZNF331.	  Its	  members	  have	  a	  strong	  association	  with	  regulatory	  and	  transcriptional	  tasks	  (Figure	  4-­‐2).	  For	  mouse,	  the	  first	  cluster	   contains	   mostly	   genes	   that	   encode	   proteins	   that	   are	   involved	   in	   transport	  processes	  (Figure	  4-­‐3a).	  As	  mentioned,	  the	  second	  group	  consists	  mostly	  of	  zinc	  finger	  protein	  genes	  similar	  to	  the	  human	  one	  (Figure	  4-­‐3b).	  	  
4.3.2 Maternally	  expressed	  genes	  dominate	  the	  role	  of	  imprinted	  genes	  in	  transport	  and	  
gene	  regulation	  	  In	   previous	   studies	   [184],	   Hutter	   et	   al.	   2010	   showed	   that	   maternally	   and	   paternally	  expressed	   genes	   differ	   in	   the	   level	   of	   conservation	   of	   their	   DNA	   sequences.	   For	   this	  reason,	  we	  analyzed	  whether	  maternally	  and	  paternally	  expressed	  genes	  differ	  also	   in	  their	  biological	  and	  molecular	  functions.	  	  	  For	   the	  19	  maternally	  expressed	  genes	   in	  human,	  only	  3	  broad	   functional	   terms	  were	  found	   to	   be	   enriched,	   nervous	   system	  development,	   organ	  morphogenesis,	   and	   positive	  
regulation	  of	  osteoblast	  differentiation.	   For	   the	   last	  GO	   term,	   the	  maternally	  expressed	  genes	   even	   showed	  a	  59.4-­‐fold	   enrichment	   although	  only	   two	   imprinted	  genes	   (DLX5	  and	  GNAS)	  are	  associated	  with	  this	  term.	  Thus,	  the	  enormous	  enrichment	  likely	  reflects	  that	  positive	  regulation	  of	  osteoblast	   is	  so	  far	  associated	  with	  very	  few	  genes	  in	  the	  full	  genome.	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Figure	  4-­‐2	  Functionally	  related	  imprinted	  genes	  in	  human.	  	  The	  heat	  map	  view	  shows	  the	  gene-­‐term	  association	  for	  those	  genes	  that	  share	  a	  high	  number	  of	  associated	  GO	  terms.	  Marked	  in	  red	  on	  the	  left	  side	  are	  maternally	  expressed	  genes;	  marked	  in	  blue	  are	  paternally	  expressed	  genes.	  
 In	  mouse,	  24	  genes	  are	  classified	  as	  maternally	  expressed.	  We	  found	  that	  14	  biological	  functions	  are	  significantly	  associated	  with	  these	  genes.	  These	  14	  terms	  are	  dominated	  by	  a	  group	  of	  relatively	  unspecific	  terms	  related	  to	  transport	  processes	  such	  as	  organic	  
cation	   transport,	   transmembrane	   transport,	   ion	   transport	   and	  organic	  cation	   transport.	  Therefore,	  not	  surprisingly,	  the	  five	  maternally	  expressed	  genes	  Kcnk9,	  Kcnq1,	  Slca22a2,	  
Slca22a3	  and	  Slca22a18	  form	  a	  gene	  cluster	  that	  is	  associated	  with	  the	  same	  transport-­‐related	   GO	   terms.	   The	   second	   gene	   cluster	   is	   formed	   by	   TF	   genes	   including	   the	  maternally	  expressed	  genes	  Klf4	  and	  Zim1	  (Figure	  4-­‐4).	  	  
4.3.3 Only	  few	  paternally	  expressed	  genes	  in	  human	  possess	  similar	  functions	  	  The	   17	   paternally	   expressed	   genes	   in	   human	   are	   associated	   with	   fewer	   over-­‐represented	   GO	   terms	   (p<0.05)	   than	   the	   maternally	   expressed	   genes.	   Most	   of	   them	  were	   already	   present	   in	   the	   over-­‐represented	   terms	   for	   all	   imprinted	   genes	   (Figure	  4-­‐5).	  Thus	  we	  examined	   these	  genes	  on	   the	  basis	  of	   the	  GO_FAT	  knowledge	  base	   that	  contains	   more	   specific	   terms.	   Only	   two	   terms,	   i.e.	   regulation	   of	   transcription,	   DNA-­‐
dependent	   and	   regulation	   of	   RNA	   metabolic	   process	   are	   enriched	   for	   paternally	  expressed	  genes.	  Both	  terms	  are	  associated	  with	  the	  genes	  PLAGL1,	  L3MBTL,	  IGF2,	  WT1,	  
ZIM2,	   and	   PEG3.	   Hence,	   both	   maternally	   and	   paternally	   expressed	   genes	   contain	  prominent	   groups	   of	   genes	   that	   have	   regulatory	   roles.	   Paternally	   expressed	   genes	   in	  mouse	  did	  not	  show	  any	  significant	  enrichment.	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Figure	  4-­‐3	  Functionally	  related	  imprinted	  genes	  in	  mouse.	  	  Heat	  maps	  showing	  the	  gene-­‐term	  association	  for	  the	  first	  and	  second	  gene	  clusters	  in	  Mouse.	  Marked	  in	  red	  on	  the	  left	  side	  are	  maternally	  expressed	  genes;	  marked	  in	  blue	  are	  paternally	  expressed	  genes.	  	  	  
Chapter	  4	   	   Imprinted	  genes	  and	  cell	  differentiation	  	  	  




Figure	   4-­‐4	   The	   enriched	   GO	   terms	   of	   biological	   functions	   for	   the	   maternally	   expressed	   genes	   in	   human	  
(green)	  and	  mouse	  (brown).	  Nodes	  represent	  the	  enriched	  Go	  terms	  and	  the	  thickness	  of	  the	  interconnected	  links	  corresponds	  to	  the	  number	  of	  shared	  genes.	  	  
4.3.4 Enrichment	  analysis	  for	  the	  transcription	  factor	  targets	  	  Mammalian	  genes	  are	  usually	  controlled	  by	  combinations	  of	  different	  TFs	  that	  bind	  to	  distinct	   binding	   sites	   in	   regulatory	   regions	   such	   as	   the	   promoters	   of	   genes.	  We	  were	  interested	   in	   the	  questions	  which	  TFs	   regulate	   imprinted	   genes	   and	   if	   paternally	   and	  maternally	  expressed	  genes	  can	  be	  distinguished	  by	  their	  TFs.	  	  	  In	  total,	  we	  identified	  25	  TF	  families	  that	  showed	  an	  enrichment	  of	  binding	  sites	  in	  the	  set	   of	   imprinted	   genes	   in	   human	   (p<0.01,	   hyper-­‐geometric	   test,	   see	   Methods).	   The	  associations	  between	  these	   families	  and	  the	  corresponding	  genes	  are	  shown	  in	  Figure	  A-­‐1	   (a)	   together	   with	   the	   expressed	   allele	   type.	   For	   mouse,	   binding	   sites	   for	   40	   TF	  families	   are	   enriched	   in	   imprinted	   genes	   at	   the	   same	   significance	   level	   of	   0.01,	   see	  Figure	  A-­‐1	  (b).	  19	  transcription	  factor	  families	  possess	  binding	  sites	  that	  are	  enriched	  in	  the	  imprinted	  genes	  in	  both	  species	  (Figure	  4-­‐6).	  In	  species,	  Nnat,	  Klf14,	  Blcap,	  Gnas,	  and	  
Ube3a	   are	   the	   genes	   that	   contribute	   most	   to	   the	   enrichment	   of	   transcription	   factor	  binding	  sites.	  	  	  Figure	   4-­‐6	   shows	   that	   in	   mouse	   and	   human,	   imprinted	   genes	   form	   similar,	   but	   not	  identical,	  clusters	  of	  genes	  that	  are	  regulated	  by	  the	  same	  transcription	  factor	  families.	  For	  example,	  the	  potassium	  channel	  genes	  Kcnq1	  and	  Kcnk9	  show	  an	  enrichment	  of	  heat	  shock	   factor	   2	   (HSF2)	   binding	   sites	   in	   human	   and	   mouse.	   Similarly,	   genes	   that	   are	  maternally	  expressed	  in	  placenta,	  such	  as	  Slc22a18,	  Tfip2,	  and	  Phlda2,	  cluster	  together	  in	   both	   species.	   In	   the	  mouse,	   this	   cluster	   is	   characterized	   by	   an	   enrichment	   of	   AP1	  binding	   sites,	   whereas	   the	   prominent	   feature	   of	   the	   human	   gene	   cluster	   is	   a	  combination	  of	  AP1	  and	  SP1	  sites.	  Finally,	  Figure	  6	  illustrates	  clearly	  that	  paternally	  and	  maternally	   expressed	   genes	   do	   not	   cluster	   apart.	   This	   is	   also	   not	   the	   case	   if	   species-­‐specifically	   enriched	   transcription	   factor	  binding	   sites	   are	   included	   (data	  not	   shown).	  Hence,	   paternally	   and	   maternally	   expressed	   genes	   are	   apparently	   not	   regulated	   by	  distinct	  combinations	  of	  TFs.	  and	  cannot	  be	  distinguished	  on	  a	  general	  level.	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Figure	  4-­‐5	  The	  enriched	  GO	  terms	  of	  biological	  functions	  for	  the	  paternally	  expressed	  genes	  in	  human.	  	  Nodes	  represent	  the	  enriched	  Go	  terms	  and	  the	  thickness	  of	  the	  interconnected	  links	  corresponds	  to	  the	  number	  of	  shared	  genes.	  	  
4.4 Discussion	  	  This	   study	   analyzed	   enriched	   functional	   annotations	   of	   genetically	   imprinted	   genes	  based	   on	   the	   "biological	   process"	   tree	   of	   the	   Gene	   Ontology.	   In	   their	   seminal	   review	  [193],	   Tycko	   and	   Morrison	   concluded	   that	   the	   group	   of	   imprinted	   genes	   is	  predominantly	   involved	   in	   controlling	   growth	   and	   neurobehavioral	   traits.	   Tycko	   and	  Morrison	  pointed	  out	   that	   the	  numbers	  of	  paternally	  and	  maternally	  expressed	  genes	  related	   to	   growth	   are	   almost	   identical.	   On	   the	   other	   hand,	   only	   one	   maternally	  expressed	   gene	   (UBE3A)	   was	   linked	   to	   behavioral	   functions,	   in	   contrast	   to	   three	  paternally	   expressed	   genes	   (SGCE,	  NDN,	  PWCR1),	   as	  well	   as	   the	   paternally	   expressed	  genes	   PEG1	   (MEST)	   and	   PEG3	   that	   were	   related	   both	   to	   growth	   and	   behavior.	   Thus,	  Tycko	   and	   Morrison	   argued	   that	   imprinting	   effects	   due	   to	   either	   maternally	   or	  paternally	   expressed	   genes	   are	   related	   to	   growth	   whereas	   behavioral	   functions	   are	  mostly	   controlled	   by	   paternally	   expressed	   genes.	   However,	   at	   the	   present	   stage,	   it	   is	  unclear	   if	   imprinted	   genes	   act	   indeed	   in	   the	   control	   of	   behavior,	   or	   if	   the	   observed	  behavioral	   abnormalities	   in	   mutant	   mice	   are	   caused	   by	   an	   impaired	   development	   of	  neurons	  and	  brain	  structures.	  	  	  Our	  study	  did	  reveal	  an	  association	  of	   imprinted	  genes	  with	  developmental	  processes	  such	   as	   organ	   development	   in	   human	   and	   mouse.	   This	   indicates	   that	   these	   genes	  function	  indeed	  during	  embryogenesis,	  but	  they	  are	  not	  necessarily	  growth-­‐regulating	  genes.	   The	   terms	   that	   are	   related	   to	   development	   in	   human	   as	  well	   as	   in	  mouse	   are	  associated	  with	  25%	  to	  44.7%	  of	  all	  imprinted	  genes	  in	  the	  respective	  species.	  Hence,	  a	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large	  proportion	  of	  imprinted	  genes	  contribute	  to	  developmental	  processes.	  Imprinted	  genes	   are	   also	   associated	   with	   GO	   terms	   that	   are	   related	   to	   neuronal	   development.	  Interestingly,	   neuronal	   development	   is	   apparently	   not	   a	   function	   that	   is	   restricted	   to	  paternally	   expressed	   genes.	   Furthermore,	   in	   comparison	   to	   developmental	   functions	  only	  a	  rather	  small	  number	  of	  imprinted	  genes	  (7	  genes)	  show	  a	  functional	  association	  to	  the	  nervous	  system	  [194].	  	  	  When	  paternally	  and	  maternally	  expressed	  genes	  are	  analyzed	  separately,	  mouse	  and	  human	  show	  clearly	  different	  associations.	  In	  the	  human,	  several	  maternally	  expressed	  genes	   (DLX5,	   GNAS,	   TP73,	   PHLDA2,	   CDKN1C,	   PPP1R9A,	   UBE3A)	   are	   associated	   with	  
organ	   morphogenesis,	   and	   more	   particularly	   with	   nervous	   system	   development	   and	  
oesteoblast	   differentiation.	   In	   the	   mouse,	   maternally	   expressed	   genes	   form	   two	  functional	   networks	   that	   are	   clearly	   separated.	   One	   is	   related	   to	   transport	   processes,	  and	  includes	  carrier	  proteins	  and	  channel	  proteins.	  Especially	  transport	  processes	  that	  are	   a	   key	   feature	   of	   placenta	   function	   are	   specifically	   associated	   with	   maternally	  expressed	   genes	   in	   the	   mouse.	   The	   second	   network	   consists	   of	   terms	   related	   to	   G	  protein	  signaling.	  This	  network	  is	  clearly	  dominated	  by	  CALCR	  and	  SLC22A18.	  	  	  For	   the	  paternally	   expressed	  genes,	   a	   functional	  network	   is	  only	   found	   in	   the	  human.	  This	  network	  consists	  mostly	  of	   terms	  associated	  with	  development,	   and	  a	   few	   terms	  that	  are	  related	   to	  gene	  regulation.	   Interestingly,	   several	   imprinted	  genes	   that	  encode	  transcription	  factors	  (PLAGL1,	  L3MBTL,	  WT1,	  ZIM2,	  PEG3)	  seem	  to	  be	  key	  players	  in	  this	  network.	   Nevertheless,	   also	   among	   the	   maternally	   expressed	   genes	   are	   genes	   that	  regulate	   transcription.	   Thus,	   regulatory	   functions	   are	   not	   an	   exclusive	   feature	   of	  paternally	  expressed	  genes.	  	  In	  this	  context	  we	  will	  briefly	  consider	  possible	  biases	  and	  shortcomings	  in	  the	  results	  obtained.	  While	   it	   is	   of	   course	   impossible	   to	   estimate	   how	  much	  we	   still	   don't	   know,	  even	  the	  annotations	  stored	  in	  the	  Gene	  Ontology	  clearly	  only	  represent	  a	  fraction	  of	  all	  knowledge	  in	  the	  original	  scientific	   literature.	   It	   is	  actually	  very	  difficult	  to	  provide	  an	  estimate	   how	   large	   this	   fraction	   is.	   As	   an	   example	   for	   this,	   only	   three	   out	   of	   41	  imprinted	  genes	  studied	  here	  are	  actually	  annotated	   in	   the	  GO	  as	  being	  "regulated	  by	  genetic	  imprinting"	  plus	  three	  that	  are	  related	  to	  "genetic	  imprinting".	  It	  is	  quite	  likely	  that	   the	   GO	   gives	   a	  more	   complete	   picture	   about	   the	   cellular	   functions	   of	   genes	   that	  have	  been	  studied	   intensely	  compared	   to	   the	  average	  gene.	   It	   is	   furthermore	  possible	  that	  some	  of	  the	  known	  imprinted	  genes	  such	  as	  IGF2	  belong	  to	  the	  group	  of	  intensely	  studied	  genes	  so	  that	  their	  cellular	  functions	  are	  known	  to	  a	  larger	  extent	  than	  those	  of	  less	  well	  studied	  genes	  and	  when	  compared	  to	  the	  average	  bi-­‐allelically	  expressed	  gene.	  In	  agreement	  with	  this	   idea,	  we	   found	  that	   the	  three	  well-­‐known	  genes	   IGF2,	  INS,	  and	  
GRB10	   (out	   of	   30)	   tended	   to	   dominate	   the	   functional	   enrichments	   in	   the	   group	   of	  paternally	  expressed	  genes.	   In	  contrast,	   the	  enrichments	   in	   the	  group	  of	  all	   imprinted	  genes	  were	  stable	  even	  when	  we	  removed	  the	  well-­‐known	  genes	  IGF2,	  INS,	  and	  GRB10.	  	  	  When	  grouping	  the	  imprinted	  genes	  by	  enriched	  GO	  annotations	  found	  for	  at	  least	  two	  genes,	  we	  applied	  the	  lowest	  recommended	  threshold	  value	  of	  0.3.	  In	  future,	  when	  more	  complete	   functional	   associations	   will	   be	   available,	   it	   remains	   to	   be	   tested	   whether	   a	  higher,	  more	  cautious	  threshold	  would	  be	  advantageous.	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Figure	  4-­‐6	  Conserved	  transcription	  factors	  in	  the	  full	  set	  of	  imprinted	  genes	  in	  human	  (a)	  and	  mouse	  (b)	  at	  
adjusted	   p-­‐value	   of	   0.01.	  Marked	   in	   red	  and	  blue	   in	   the	   top	   line	   are	   the	  maternally,	   paternally	   expressed	  genes,	  respectively.	  Genes	  that	  are	  imprinted	  in	  both	  species	  are	  marked	  in	  green.	  Pink	  are	  the	  genes	  shown	  to	  be	  imprinted	  only	  in	  human,	  and	  brown	  are	  the	  genes	  shown	  to	  be	  imprinted	  only	  in	  mouse.	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We	  found	  that	  when	  applied	  to	  the	  currently	  available	  data,	  this	  threshold	  gave	  a	  good	  compromise	  between	  coverage	  and	  specificity	  of	  the	  obtained	  results.	  	  In	   the	   second	   part	   of	   the	   study,	   we	   were	   interested	   in	   the	   question	   if	   functionally	  related	   gene	   groups	   such	   as	   the	   prominent	   groups	   of	   transcription	   factors,	   and	  transport	   related	   proteins,	   are	   co-­‐regulated	   by	   similar	   sets	   of	   transcription	   factor	  families.	   This	   is	   obviously	   not	   the	   case.	   Interestingly,	   also	   maternally	   and	   paternally	  expressed	   genes	   are	   not	   regulated	   by	   distinct	   sets	   of	   transcription	   factor	   families.	   In	  general,	  a	  few	  genes,	  i.e.	  UBE3A,	  KLF14,	  BLCAP,	  NAP1L5,	  NNAT,	  and	  GNAS,	  show	  an	  over-­‐proportional	   enrichment	   of	   distinct	   transcription	   factor	   binding	   sites.	   Interestingly,	  these	   genes	   possess	   rather	   diverse	   functions.	   For	   example,	   UBE3A	   seems	   to	   act	   in	  neuronal	  development,	  whereas	  GNAS	  acts	  mostly	  in	  endocrinal	  pathways.	  	  	  Although	  imprinted	  genes	  appear	  to	  be	  regulated	  by	  similar	  sets	  of	  transcription	  factors	  in	  mouse	  and	  human,	  it	  is	  difficult	  to	  identify	  a	  typical	  transcription	  factor	  that	  regulates	  imprinted	  genes.	  The	  most	  prominent	  factor	  appears	  to	  be	  SP1.	  This	  rather	  ubiquitous	  factor	  might	  be	  responsible	  for	  the	  broad	  tissue	  spectrum	  of	  imprinted	  genes	  [195].	  On	  the	  other	  hand	  SP1	  deficiency	   is	   to	  some	  extent	  associated	  with	  placental	  defects	  and	  impaired	  ossification,	  that	  are	  typical	  features	  of	  defects	  in	  imprinting	  [196].	  	  Varrault	  and	  co-­‐workers	  have	  recently	   identified	  a	  network	  of	  co-­‐regulated	   imprinted	  genes	   involving	   the	   genes	   Plagl1,	   Gtl2,	   H19,	   Mest,	   Dlk1,	   Peg3,	   Grb10,	   Igf2,	   Igf2r,	   Dcn,	  
Gnas,	  Gatm,	  Ndn,	  Cdkn1c	   and	  Slc33a4	   [197].	  According	   to	  Fig.	  6(b),	  E12	  regulates	   four	  genes	  from	  this	  list	  (Dlk1,	  Cdkn1c,	  Igf2	  and	  Gnas);	  SP1	  regulates	  three	  genes	  (Peg3,	  Ndn	  and	  Igf2)	  as	  well	  as	  AACTTT_UNKNOWN	  (Igf2r,	  Dlk1	  and	  Gnas).	  We	  suggest	  these	  three	  transcription	  factors	  as	  candidates	  that	  may	  be	  responsible	  for	  the	  coregulation	  of	  this	  imprinting	  network.	  	  Berg	  and	  colleagues	  [198]	  recently	  analyzed	  the	  expression	  levels	  of	  ten	  of	  these	  genes	  (Cdkn1c,	  Dlk1,	  Grb10,	  Gtl2,	  H19,	   Igf2,	  Mest,	  Ndn,	  Peg3,	   and	  Plagl1)	   in	  mouse	   long-­‐term	  repopulating	   hematopoietic	   stem	   cells	   and	   in	   representative	   differentiated	   lineages.	  Intriguingly,	   they	   found	   that	   most	   of	   the	   genes	   were	   severely	   down	   regulated	   in	  differentiated	   cells.	   They	   noticed	   that	   their	   study	   is	   the	   first	   one	   that	   connected	  imprinted	  genes	   that	   are	  known	   to	  be	  associated	  with	  embryonic	   and	  early	  postnatal	  growth	   to	   the	   regulation	  of	   somatic	   stem	  cells.	   Consequently,	   they	   suggested	   that	   the	  balancing	   forces	   of	   growth-­‐promoting	   paternally	   expressed	   genes	   and	   of	   growth-­‐limiting	  maternally	  expressed	  genes	  may	  as	  well	  play	  a	  role	  in	  keeping	  stem	  cells	  in	  the	  delicate	   balance	   of	   pluripotency.	   Along	   these	   lines,	   but	   in	   the	   opposite	   direction,	   our	  above	   finding	   that	   the	   global	   transcription	   factors	   E12	   and	   SP1	   play	   key	   roles	   in	   the	  regulation	   of	   imprinted	   genes	   fits	   to	   their	   well-­‐known	   role	   in	   cell	   differentiation	  processes	  [199,	  200].	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5. Regulatory	  role	  of	  
imprinted	  and	  pluripotency	  
genes	  in	  hematopoiesis	  	  	  	  This	  chapter	  is	  a	  shortened	  version	  of	  the	  following	  manuscript:	  	  
• Mohamed	   Hamed,	   Johannes	   Trum,	   Christian	   Spaniol,	   Mohammad	   R.	   Irhimeh,	   Martina	  Paulsen,	   and	   Volkhard	   Helms,	   Expression	   of	   pluripotency	   genes	   and	   imprinted	   genes	  during	  the	  onset	  of	  differentiation	  and	  during	  hematopoiesis	  [SUBMITTED]. 	  	  	  	  
Synopsis	  	  
The	   previous	   chapter	   discussed	   the	   functional	   roles	   of	   the	   imprinted	   genes	   and	  
interestingly	   reported	   that	   many	   imprinted	   genes	   are	   transcriptionally	   regulated	   by	  
hematopoiesis-­‐related	  transcription	  factors	  such	  as	  NFAT,	  FOXO4,	  E2A,	  and	  TCF3.	  This	  has	  
motivated	   the	  work	  presented	   in	   this	   chapter	  where	  we	  aimed	  at	   identifying	   regulatory	  
elements	   from	   imprinted,	   pluripotency,	   and	   hematopoiesis	   associated	   genes	   that	   are	  
putatively	   related	   to	   the	   transition	  of	   cells	   from	   the	  pluripotent	   stem-­‐cell	   stage	   into	   the	  
onset	  of	  development	  and	  into	  hematopoietic	  lineage	  commitment.	  To	  this	  end,	  we	  applied	  
the	  GRN	  pipeline	  to	  gene	  expression	  data	  from	  three	  hematopoiesis–related	  datasets	  and	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Abstract	  	  Maintenance	  of	  cell	  pluripotency,	  differentiation,	  and	  reprogramming	  are	  regulated	  by	  complex	   gene	   regulatory	   networks	   including	   monoallelically	   expressed,	   imprinted	  genes.	   Besides	   transcriptional	   control,	   epigenetic	   modifications	   such	   as	   DNA	  methylation	   and	   histone	   marks	   are	   increasingly	   gaining	   attention	   with	   respect	   to	  cellular	  differentiation.	  As	  a	  model	  system	  to	  study	  the	  onset	  of	  cell	  differentiation	  and	  subsequent	  cellular	  specialization,	  we	  have	  selected	  hematopoiesis	  and	  supplemented	  this	  with	  data	  from	  embryonic	  stem	  cell	  (ESC)	  lines.	  Using	  high	  throughput	  analysis	  of	  gene	   expression	   in	   mouse,	   the	   expression	   profiles	   of	   pluripotency-­‐associated	   and	  imprinted	   genes	   were	   evaluated	   against	   known	   hematopoiesis-­‐associated	   genes.	   We	  found	   that	   more	   than	   half	   of	   the	   pluripotency	   and	   imprinted	   genes	   are	   clearly	  upregulated	   in	   ESC	   and	   subsequently	   repressed.	   The	   remaining	   genes	   were	   either	  upregulated	   in	   progenitor	   or	   in	   differentiated	   cells.	   Thus,	   the	   three	   gene	   sets	   each	  consist	   of	   three	   similarly	   behaving	   gene	   groups	   with	   similar	   expression	   profiles	   in	  various	   lineages	   of	   the	   hematopoietic	   system	   as	  well	   as	   in	   ESCs.	   Co-­‐expressed	   genes	  derived	   from	   the	   three	   gene	   sets	   were	   found	   to	   share	   gene	   ontology	   terms,	   which	  suggests	  a	  functional	  connection	  of	  the	  three	  sets	  during	  differentiation.	  To	  explain	  this	  coordinated	   behavior,	   we	   constructed	   a	   novel	   regulatory	   network	   of	   32	   imprinting-­‐related	  genes	  that	  are	  shared	  with	  pluripotency	  or	  hematopoiesis	  genes.	  This	  network	  includes,	  among	  others,	  the	  genes	  Myc,	  Nfkb1,	  Sp1,	  Sp3,	  and	  Tgfb1,	   the	  regulatory	  gene	  
Oct4,	   and	   Wt1	   and	   Sp2	   that	   regulate	   other	   genes	   that	   control	   pluripotency	   and	  hematopoiesis.	   This	   association	   suggests	  new	  aspects	   of	   the	   cellular	   regulation	  of	   the	  onset	  of	   cellular	  differentiation	  and	  during	  hematopoiesis	   involving,	   on	   the	  one	  hand,	  pluripotency-­‐associated	   genes	   that	   were	   previously	   not	   discussed	   in	   the	   context	   of	  hematopoiesis	   and,	   on	   the	   other	   hand,	   involve	   genes	   that	   are	   related	   to	   genomic	  imprinting.	  These	  are	  new	  links	  between	  hematopoiesis	  and	  cellular	  differentiation	  and	  the	  important	  field	  of	  epigenetic	  modifications.	  	  
5.1 Introduction	  	  The	  maintenance	  of	  cellular	  pluripotency,	  the	  onset	  of	  differentiation	  as	  well	  as	  cellular	  differentiation	  into	  particular	  lineages	  appear	  to	  be	  controlled	  by	  tightly	  regulated	  gene	  regulatory	   networks	   (GRNs)	   that	   describe	   the	   interactions	   between	   transcription	  factors	  (TCFs)	  and	  microRNAs	  and	  their	  target	  genes	  [201].	  For	  mouse,	  Füllen,	  Schöler	  and	  co-­‐workers	  have	  manually	  compiled	  from	  the	  original	  literature	  a	  dataset	  of	  genes	  termed	   the	   PluriNetwork	   that	   are	   involved	   in	   the	   regulation	   of	   the	   pluripotent	   state	  [202].	   Besides	   transcriptional	   control,	   epigenetic	   modifications	   such	   as	   DNA	  methylation	   and	   histone	   marks	   are	   increasingly	   gaining	   attention	   with	   respect	   to	  cellular	  differentiation.	  	  	  One	  of	   the	  hallmarks	  of	   epigenetics	   is	   the	  phenomenon	  of	   genomic	   imprinting,	  which	  describes	   parent-­‐of-­‐origin	   mono-­‐allelic	   expression	   [179].	   As	   the	   importance	   of	  epigenetic	  modes	  of	  gene	  regulation	   is	  particularly	  evident	   for	   imprinted	  genes,	   these	  genes	   serve	   as	   common	   model	   systems.	   Therefore,	   we	   are	   focusing	   here	   on	   the	  expression	  patterns	  and	  modes	  of	  regulation	  of	  the	  genes	  that	  have	  been	  shown	  to	  be	  mono-­‐allelically	  expressed	  in	  the	  mouse.	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Hematopoiesis	   describes	   the	   differentiation	   of	   hematopoietic	   stem	   cells	   (HSCs)	   into	  lineage-­‐committed	   progenitor	   cells.	   Recent	   transcriptomics	   studies	   have	   identified	  important	  parts	  of	  the	  regulatory	  networks	  that	  control	  maintenance	  of	  HSCs	  [203]	  and	  progenitors	  [201,	  204,	  205].	  Despite	  the	  fact	  that	  HSCs	  share	  the	  hallmark	  properties	  of	  long-­‐term	   self-­‐renewal	   and	   multi-­‐lineage	   differentiation	   capacity,	   it	   has	   been	   shown	  that	   their	   chromatin	   state	   and	   the	   expression	   patterns	   of	   TCFs	   do	   vary	   substantially	  based	  on	   the	   location	  of	  HSCs	   in	  bone	  marrow,	   the	  origin	   (i.e	  embryo,	  adult,	  or	  aged)	  and	   time	   of	   study	   [206].	   Still,	   some	  parts	   of	   the	  GRN	   architecture	   are	   expected	   to	   be	  conserved	  in	  the	  different	  hematopoietic	  lineages	  [206].	  	  Not	  much	   is	   known	   about	   the	   imprinting	   status	   of	   imprinted	   genes	   during	   blood	   cell	  differentiation.	  As	  an	  exception	  to	   this,	  maternal	   imprinting	  at	   the	  H19-­‐Igf2	   locus	  was	  shown	   to	  maintain	   adult	   haemotopoietic	   stem	   cell	   quiescence	   [207].	   Besides,	   several	  lines	  of	  evidence	  do	  exist	   for	   the	   importance	  of	   imprinted	  genes	  during	   the	   transition	  from	   the	   stem	   cell	   stage	   to	   differential	   commitment	   as	   well	   as	   during	   particular	   cell	  lineages,	  namely	  hematopoiesis.	  For	  example,	  a	  network	  of	  15	  co-­‐regulated	   imprinted	  genes	  involved	  in	  embryonic	  growth	  has	  been	  identified	  [197].	  10	  of	  these	  genes	  were	  down	   regulated	   in	   terminally	   differentiated	   mouse	   cells	   compared	   to	   long-­‐term	  repopulating	  HSCs	  [198].	  In	  multipotent	  progenitor	  cells,	  13	  out	  of	  15	  imprinted	  genes	  were	  clearly	  downregulated	  compared	   to	  HSC	  whereas	   the	   two	   imprinted	  genes	  Gnas	  and	   Gatm	   were	   upregulated	   in	   MPP3	   and	   MPP4	   relative	   to	   MPP1	   and	   HSC	   [204].	  Recently,	  we	  have	  identified	  10	  imprinted	  genes	  that	  are	  transcriptionally	  regulated	  by	  the	  hematopoiesis	  related	  TCF	  NFAT.	  We	  also	  found	  9	  imprinted	  genes	  that	  are	  targets	  of	   FOXO4	   TCF.[208]	   In	   CD34+	   cells,	   the	   imprinted	   maternally	   expressed	   gene	   p57	  (Cdkn1c)	  was	  the	  only	  cyclin-­‐dependent	  kinase	  inhibitor	  to	  be	  rapidly	  up-­‐regulated	  by	  TGFβ,	   a	   negative	   regulator	   of	   hematopoiesis	   [209].	   Additionally,	   we	   found	   that	  promoter	   regions	   around	   the	   transcription	   start	   sites	   of	  Mkrn3,	   Igf2,	   and	  Gnas	   genes	  contain	  DNA	  motifs	   that	  match	   to	  annotated	  binding	  site	  motifs	   for	   the	  TCFs	  E2A	   and	  
TCF3.	   The	   latter	   plays	   major	   roles	   in	   determining	   tissue-­‐specific	   cell	   fate	   during	  embryogenesis	  such	  as	  early	  B	  lymphopoiesis	  and	  germinal	  center	  B-­‐cell	  development	  [210].	   Several	   studies	   from	   the	   Li	   group	   indicated	   that	   the	   expression	   of	   certain	  imprinted	  genes	  changes	  in	  HSCs	  during	  differentiation	  from	  quiescent	  to	  multi-­‐lineage	  progenitors	   [211].	   However,	   the	   transcriptional	   activity	   of	   imprinted	   genes	   and	  imprinting-­‐related	  genes	  that	  are	  regulators	  of	  imprinted	  genes	  in	  the	  onset	  and	  further	  progression	  of	  cell	  differentiation	  (on	  the	  example	  of	  hematopoiesis)	  and	  the	  aspects	  of	  their	  involvement	  have	  not	  been	  addressed	  in	  detail	  before.	  	  	  In	  this	  study,	  we	  aim	  at	  identifying	  regulatory	  elements	  that	  are	  putatively	  related	  to	  the	  transition	   of	   cells	   from	   the	   pluripotent	   stem-­‐cell	   stage	   into	   the	   onset	   of	   development	  and	   into	   lineage	   commitment.	   In	   order	   to	   characterize	   the	   involvement	   of	   imprinted	  genes	  and	  pluripotency-­‐associated	  genes	  during	  murine	  hematopoiesis	  in	  a	  systematic	  way	   we	   have	   re-­‐analyzed	   previously	   deposited	   microarray	   datasets	   from	   different	  stages	  of	  hematopoiesis	  and	  from	  embryonic	  stem	  cells	  (ESC).	  The	  expression	  patterns	  of	   imprinted	   genes	   and	   pluripotency-­‐associated	   genes	   during	   these	   stages	   were	  compared	  to	  the	  global	  expression	  patterns	  of	  hematopoiesis-­‐associated	  genes	  and	  we	  set	  out	  to	  explain	  how	  the	  similarity	  of	  the	  gene	  expression	  arises.	  Our	  results	  suggest	  that	   imprinted	   genes,	   that	   are	   known	   to	   be	   associated	   with	   embryonic	   and	   early	  postnatal	  growth,	  may	  as	  well	  play	  a	  collaborative	  role	  (i)	   in	  keeping	  stem	  cells	   in	  the	  
Chapter	  5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Regulatory	  role	  of	  imprinted	  and	  pluripotency	  genes	  in	  hematopoiesis	  	  	  
	  	   76	  
delicate	  balance	  of	  pluripotency	  and	  (ii)	  during	  the	  onset	  of	  cell	  differentiation	  towards	  hematopoiesis.	  	  
5.2 Methods	  
5.2.1 Genes	  selection	  	  Three	  mouse	   gene	   lists	  were	   prepared	   (imprinted,	   pluripotency,	   and	   hematopoiesis).	  Our	   selection	   of	   imprinted	   genes	   was	   not	   done	  manually	   as	   in	   chapter	   4	   and	   in	   the	  thesis	  work	  of	  Barbara	  hutter	  [208,	  212,	  213]	  as	  the	  manually	  curated	  lists	  contained	  a	  rather	  restricted	  number	  of	  genes.	  In	  this	  study,	  our	  selection	  was	  based	  on	  the	  overlap	  of	   several	   well-­‐known	   online	   catalogs	   of	   imprinted	   genes.	   Imprinted	   genes	   were	  downloaded	   in	   July	   2012	   from	   four	   well-­‐known	   catalogs	   [IGC	   database	  (http://www.otago.ac.nz/IGC)	   [185],	   Geneimprint	  (http://www.geneimprint.com/site/genes-by-species.Musmusculus),	   WAMIDEX	  (https://atlas.genetics.kcl.ac.uk),[214]	   and	   MouseBookTM	  (http://www.mousebook.org/catalog.php?catalog=imprinting)].	   Then	   a	   single	   list	   of	   120	  genes	  (called	  henceforth	  candidate	  imprinted	  genes)	  was	  created	  from	  the	  four	  catalogs	  by	  including	  only	  genes	  that	  appeared	  in	  at	  least	  two	  catalogs	  and	  by	  filtering	  out	  genes	  that	  have	  conflicting	  or	  unknown	  imprinting	  status	  in	  the	  various	  catalogs	  (i.e	  whether	  they	  are	  maternally	  or	  paternally	  expressed).	  86	  imprinted	  genes	  were	  present	  on	  the	  microarray	   chip.	   As	   this	   is	   a	   computational	   study,	   we	   did	   not	   verify	   experimentally	  whether	  these	  genes	  are	  actually	  mono-­‐allelically	  expressed.	  	  The	  pluripotency	  list	  including	  274	  genes	  was	  obtained	  from	  the	  PluriNetWork	  [202],	  	  a	  hand	   curated	   pluripotency-­‐controlling	   gene	   network	   in	   mouse	   with	   574	   regulatory	  interactions.	   To	   the	   best	   of	   our	   knowledge,	   no	   generally	   accepted	  GRN	   for	   the	   global	  hematopoiesis	   system	   has	   been	   established.	   In	   the	   absence	   of	   such	   a	   model,	   we	  considered	   as	   hematopoiesis	   genes	   the	   615	   genes	   that	   are	   annotated	   in	   the	   Gene	  Ontology	   [67]	   for	   the	   GO	   term	   hematopoietic	   or	   lymphoid	   organ	   development	  (GO:0048534).	  Not	   all	   genes	   in	   the	   three	   gene	   lists	  were	   annotated	   in	   the	  Affymetrix	  array.	  Of	  the	  120	  imprinted	  genes	  only	  86	  were	  annotated	  (the	  rest	  were	  mostly	  non-­‐coding	  RNAs,	  which	  are	  thus	  not	  considered),	  whereas	  only	  2	  out	  of	  274	  pluripotency	  genes	   and	   53	   out	   of	   the	   615	   hematopoietic	   genes	  were	   not	   annotated.	   The	   counts	   of	  overlapping	  genes	  are	  shown	  in	  Figure	  5-­‐1.	  	  
5.2.2 Microarray	  analysis	  	  	  Gene	  expression	  microarray	  data	  [three	  hematopoietic	  datasets	  (accession	  IDs	  GSE6506	  [215],	  GSE14833	  [216],	  GSE34723	  [217])	  	  and	  one	  non-­‐hematopoietic	  specific	  (control)	  (GSE10246	  [218])	  that	  also	  contains	  ESC	  samples]	  generated	  with	  Affymetrix	  GeneChip	  Mouse	   Genome	   430	   2.0	   Array	  were	   downloaded	   from	   the	   Gene	   Expression	   Omnibus	  (http://www.ncbi.nlm.nih.gov/geo/)	  [219].	  	  Data	   normalization,	   model-­‐based	   expression	   measurements,	   and	   annotation	   of	   the	  imprinted	   and	   pluripotency	   genes	   to	   their	   corresponding	   probes	   in	   the	   four	   datasets	  were	   done	   using	   the	   GC-­‐RMA	  method	   and	  mouse	   4302.db	   packages,	   respectively,	   by	  using	  the	  Bio-­‐conductor	  software	  [220]	  within	  the	  statistical	  programming	  language	  R	  [188].	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Figure	  5-­‐1	  Venn diagram of the 3 gene sets involved in the analysis. Imprinted, pluripotency, and 
hematopoietic genes.	   	  A	   gene	   expression	   similarity	   score	  was	   calculated	   to	   test	   how	   similar	   the	   normalized	  expression	   of	   an	   individual	   gene	   (in	   the	   chip	   including	   imprinted	   genes)	   is	   to	   the	  distribution	   of	   normalized	   expression	   values	   for	   the	   sets	   of	   pluripotency	   and	  hematopoiesis	  genes	  separately	  across	  the	  four	  datasets,	  see	  supplementary	  material.	  	  When	   considering	   the	   similarity	   to	   pluripotency	   genes,	   for	   example,	   the	   expression	  value	  of	  a	  gene	  gi	  in	  a	  cell	  sample	  sj	  was	  weighted	  by	  the	  number	  of	  pluripotency	  genes	  having	  the	  same	  expression	  value	   in	   the	  same	  sample	  PDsj.	  This	  product	  was	  summed	  over	  all	  samples	  to	  give	  a	  representative	  score	  for	  each	  gene.	  	  	  𝑆𝑖𝑚𝑆𝑐𝑜𝑟𝑒   𝑔𝑖 = 𝑃𝐷!" 𝑔𝑖!"!"##  !"#$%&!!!!                         𝑤ℎ𝑒𝑟𝑒  𝑖   ∈ 1, 𝑖𝑚𝑝𝑟𝑖𝑛𝑡𝑒𝑑  𝑔𝑒𝑛𝑒𝑠  𝑐𝑜𝑢𝑛𝑡 	  	           𝑎𝑛𝑑  𝑗   ∈ [1, 𝑎𝑙𝑙  𝑐𝑒𝑙𝑙  𝑠𝑎𝑚𝑝𝑙𝑒𝑠  𝑝𝑒𝑟  𝑑𝑎𝑡𝑎𝑠𝑒𝑡]    	  	  Next,	  we	   separated	   the	   similarity	   scores	  of	   imprinted	  genes	  and	  non-­‐imprinted	  genes	  and	   examined	  with	   the	  Mann-­‐Whitney	  U-­‐test	  whether	   imprinted	   genes	  have	   a	   higher	  gene	   expression	   similarity	   to	   pluripotency	   and	   hematopoiesis	   genes	   than	   the	  background	  of	  all	  other	  genes.	  Additionally,	  we	  defined	  top	  scored	  genes	  as	  the	  highest	  10%	  of	  the	  ranked	  genes	  and	  then	  applied	  the	  hyper-­‐geometric	  test	   to	   investigate	  the	  significance	  of	  having	  imprinted	  genes	  among	  the	  defined	  top	  scored	  genes.	  	  	  For	  lineage	  specificity,	  six	  isometric	  lineages	  (three	  lymphoid	  and	  three	  myeloid)	  were	  constructed	   from	   the	   four	   expression	   datasets	   by	   following	   the	   hematopoietic	  differentiation	  model	  in	  [217]	  (	  We	  looked	  at	  three	  main	  hematopoiesis	  developmental	  stages:	   early	   progenitors	   (LTHSC	   and	   STHSC),	   intermediate	   progenitors	   (LMPP	   and	  CLP),	   and	   terminally	   differentiated	   blood	   cells	   (MKE	   and	   GM).	   Then	   we	   used	   a	  conservative	  differential	  expression	  approach	  based	  on	  moderated	  t-­‐test	  to	  encode	  the	  differences	  between	  the	  three	  stages.	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Table	   5-­‐1).	   We	   looked	   at	   three	   main	   hematopoiesis	   developmental	   stages:	   early	  progenitors	   (LTHSC	   and	   STHSC),	   intermediate	   progenitors	   (LMPP	   and	   CLP),	   and	  terminally	   differentiated	   blood	   cells	   (MKE	   and	   GM).	   Then	   we	   used	   a	   conservative	  differential	   expression	   approach	  based	  on	  moderated	   t-­‐test	   to	   encode	   the	  differences	  between	  the	  three	  stages.	  	  
	  
	  
Table	  5-­‐1	  Selected	  hematopoietic	  lineages	  and	  their	  stages	  of	  sequential	  cell	  development.	  	  
HSC,	  Hematopoietic	  Stem	  Cells;	  MPPa,	  Multipotent	  Progenitor	  state	  A;	  MPPb,	  Multipotent	  Progenitor	  state	  B;	  GMLPa,	  Granulocyte	  Macrophage	  Lymphoid	  Progenitor	  state	  A;	  GMLPb,	  Granulocyte-­‐Macrophage-­‐Lymphoid	  Progenitor	  state	  B;	   CLP,	   Common	   Lymphoid	   Progenitor;	   BLP,	   Earliest	   B	   Lymphoid	   Progenitor;	   PREPROB,	   Precursor	   of	   B-­‐cells	  Progenitor;	   FrB,	   Fraction	   B	   B-­‐cell;	   FrC,	   Fraction	   C	   B-­‐cell;	   FrD,	   Fraction	   D	   B-­‐cell;	   FrE,	   Fraction	   E	   B-­‐cell;	   iNK,	  intermediate	   Natural	   Killer	   Cell;	   mNK,	   mature	   Natural	   Killer	   Cell;	   DN1,	   Double	   Negative	   T-­‐cell	   1;	   DN2,	   Double	  Negative	  T-­‐cell	  2;	  DN3a,	  Double	  Negative	  T-­‐cell	  3a;	  DN3b,	  Double	  Negative	  T-­‐cell	  3b;	  DN4,	  Double	  Negative	  T-­‐cell	  4;	  DPCD69-­‐,	  Double	   Positive	   CD69-­‐	  T-­‐cell;	   DPCD69+,	  Double	   Positive	   CD69+	  T-­‐cell;	   CD4+CD69+,	   CD4+	  CD69+	  T-­‐cell;	  CD4+CD69-­‐,	  CD4+	  CD69-­‐	  T-­‐cell;	  MEP,	  Megakaryocyte/	  Erythrocyte	  Progenitor;	   	  pMEP,	  pre	  of	  MEP;	  pCFU-­‐E,	   	  pre	  of	  CFU-­‐E;	   sCMP,	   Strict	   Common	   Myeloid	   Progenitor;	   GMP,	   Granulocyte-­‐Macrophage-­‐Progenitor;	   pGMPa,	   pre	   of	   GMP	  state	  A;	  pGMPb,	  pre	  of	  GMP	  state	  B;	  Mono,	  Monocytes;	  Gra,	  Granulocytes.	  
	  P-­‐values	   were	   adjusted	   using	   Benjamin-­‐	   Hochberg	   procedure	   [78]	   to	   limit	   the	   false	  discovery	  rate	  to	  5%.	  In	  order	  to	  alleviate	  the	  typical	  loss	  of	  statistical	  power	  resulting	  from	  performing	  multiple	   testing	  on	  a	  gene-­‐by-­‐gene	  basis,	  we	  performed	  non-­‐specific	  pre-­‐filtering	  by	  selecting	  genes	  on	  the	  basis	  of	  variability	  before	  the	  differential	  analysis.	  We	   removed	   20%	   of	   all	   genes	   showing	   the	   least	   variability	   across	   lineages	   in	   the	  datasets	  and	  kept	  only	  genes	   that	   showed	  higher	  variation	  across	   the	   lineage	  and	  are	  thus	  potentially	  good	  candidates	  for	  differentially	  expressed	  genes	  [221].	  	  Lineages	  that	  are	  constructed	  from	  GSE6506	  dataset	  and	  contain	  only	  two	  stages	  (early	  progenitors	   and	   terminally	   differentiated	   cells)	   were	   analyzed	   by	   setting	   on/off	  expression	   threshold	   (similar	   to	   [215])	   to	   identify	   uniquely	   expressed	   genes	   in	   each	  stage	   of	   the	   cell	   development	   of	   each	   lineage.	   Finally,	   a	   gene	   was	   confirmed	   as	  differentially	  expressed	  gene	  if	  it	  appeared	  in	  the	  same	  lineage	  in	  at	  least	  two	  different	  datasets.	  
5.2.3 Reconstruction	  of	  an	  imprinted	  gene	  network	  (IGN)	  	  Gene	   expression	   data	   of	   the	   four	   accession	   IDs	  were	   subjected	   to	  weighted	   gene	   co-­‐expression	  network	  analysis	  for	  describing	  the	  correlation	  patterns	  among	  genes	  across	  the	   67	   considered	  microarray	   biological	   samples.	   The	   popular	   hierarchical	   clustering	  (HCL)	  method	  was	  used	  for	  clustering	  taking	  Pearson	  correlation	  as	  a	  distance	  metric.	  
Lineage	   Sequential	  Cell	  Development	  	  
B-­‐cell	   HSC!	  MPPa	  !	  MPPb!	  GMLPa	  !	  GMLPb	  !	  CLP!	  BLP!	  PREPROB	  !	  FrB!	  FrC	  !	  FrD	  !	  FrE	  
NK-­‐cell	   HSC!	  MPPa!	  MPPb!	  GMLPa!	  GMLPb!	  CLP!	  iNK!	  mNK	  
T-­‐cell	   HSC!	  MPPa!	  MPPb!	  GMLPa!	  GMLPb!	  CLP!	  DN1!	  DN2!	  DN3a!	  DN3b!	  DN4!	  
DPCD69-­‐	  !	  DPCD69+!	  CD4+CD69+	  !	  CD4+CD69-­‐	  	  
Erythrocytes	   HSC!	  MPPa	  !	  pMEP	  !	  MEP	  !	  pCFU–E	  
Monocytes	   HSC	  !	  MPPa	  !	  sCMP!	  pGMPa!	  pGMPb	  !	  GMP	  !	  Mono	  
Granulocytes	   HSC!	  MPPa	  !	  sCMP	  !	  pGMPa	  !	  pGMPb	  !	  GMP	  !	  Gra	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The	   WGCNA	   package	   [81]	   was	   employed	   to	   map	   the	   strength	   of	   gene	   pair	  interconnections	   to	   proportional	   edge	   weights	   and	   to	   produce	   a	   module	   centric	   co-­‐expression	  network.	  This	  co-­‐expression	  network	  of	  imprinted	  genes	  was	  subsequently	  expanded	   by	   (a)	   including	   additional	   genes	   coding	   for	   TCFs	   that	   regulate	   any	   of	   the	  considered	  imprinted	  genes,	  and	  (b)	  by	  including	  target	  genes	  that	  are	  regulated	  by	  any	  of	   the	   imprinted	   genes	   acting	   as	   TCFs	   themselves	   and	   then	   called	   "imprinted	   gene	  network"	  (IGN).	  
5.2.4 Functional	  enrichment	  and	  similarity	  	  The	   functional	   annotation	   tool	   in	   DAVID	   was	   used	   to	   identify	   significantly	   enriched	  functional	  categories	  in	  gene	  sets	  [135].	  We	  determined	  which	  GO	  categories	  that	  were	  annotated	  to	  at	  least	  2	  genes	  and	  are	  statistically	  overrepresented	  in	  the	  co-­‐expressed	  genes	  against	  the	  full	  mouse	  genome	  (control).	  Enrichment	  was	  evaluated	  through	  the	  Fisher	   Exact	   test	   using	  p-­‐value	   threshold	   of	   0.05.	   Functional	   similarity	   between	   each	  pair	   of	   genes	   was	   measured	   by	   FunSimMat	   [222]	   (http://funsimmat.bioinf.mpi-
inf.mpg.de/help8.php)	  and	  GO	  terms	  were	  visualized	  as	  a	  scatter	  plot	  by	  REVIGO	  [223].	  
5.3 Results	  	  In	   this	  study,	  we	  re-­‐analyzed	  published	  gene	  expression	  microarray	  data	  deposited	   in	  GEO	   [219]	   [three	   hematopoietic	   datasets	   (accession	   IDs	   GSE6506	   [215],	   GSE14833	  [216],	   GSE34723	   [217])	   and	   one	   non-­‐hematopoietic	   specific	   (control)	   (GSE10246	  [218])].	   As	   explained	   in	   the	   methods	   section,	   we	   established	   three	   gene	   lists	   of	  imprinted,	   pluripotency-­‐associated,	   and	   hematopoiesis-­‐associated	   genes.	   In	   the	  remainder	   of	   this	   chapter,	   we	   will	   use	   the	   short	   names	   "pluripotency	   genes"	   and	  "hematopoiesis	  genes"	  while	  noting	  that,	  e.g.	  some	  genes	  in	  the	  pluripotency	  list	  might	  be	   directly	   involved	   in	   maintaining	   the	   pluripotency	   of	   ES/iPS	   cells,	   whereas	   some	  genes	  might	  have	  indirect	  and	  more	  general	  functionalities,	  such	  as	  cell	  cycle	  regulators	  etc.	  From	  these	  lists,	  86	  imprinted,	  272	  pluripotency	  and	  562	  hematopoietic	  genes	  are	  annotated	  on	  the	  microarray.	  	  
5.3.1 Imprinted	   genes	   show	   similar	   expression	   patterns	   to	   pluripotency	   and	  
hematopoiesis	  genes	  	  To	  get	  an	  overview,	  Figure	  5-­‐2	  shows	  clustered	  normalized	  expression	  profiles	  for	  two	  ESC	   lines,	   three	   progenitor	   cell	   lines	   (Long	   Term	   HSC:	   LTHSC,	   Common	   Myeloid	  Progenitor:	  CMP,	  and	  Granulocyte-­‐Macrophage-­‐Progenitor:	  GMP),	  and	  three	  terminally	  differentiated	  cell	  lines	  (Nk-­‐cells,	  B-­‐cells,	  T-­‐cells).	  Clustering	  as	  well	  as	  visual	  inspection	  revealed	   three	   main	   classes	   of	   expression	   patterns,	   which	   are	   shared	   by	   most	  imprinted,	   pluripotency	   and	   hematopoietic	   genes.	   The	   first	   class	   contains	   genes	   that	  have	   high	   expression	   levels	   in	   ESC	   and	   have	   gradually	   decreasing	   expression	   levels	  during	   the	   two	   stages	   of	   hematopoiesis	   (early	   and	   intermediate	   progenitors	   and	  terminally	   differentiated	   blood	   cells).	   As	   expected,	   more	   than	   half	   of	   the	   imprinted	  genes	  (left	  panel,	  green)	  and	  of	   the	  pluripotency	  genes	  (middle	  panel,	  blue)	  belong	   to	  this	  class.	  Also,	  about	  one	  third	  of	  the	  hematopoiesis	  genes	  (right	  panel,	  orange)	  belong	  to	  this	  class.	  Genes	  of	  the	  second	  class	  are	  characterized	  by	  over-­‐expression	  in	  the	  early	  and	  intermediate	  progenitors	  (more	  specifically	  in	  Common	  Lymphoid	  Progenitor:	  CLP)	  and	   relatively	   lower	   levels	   in	   both	   ESC	   and	   terminally	   differentiated	   cells.	   The	   third	  class	   includes	   genes	   that	   are	   predominantly	   upregulated	   in	   matured	   blood	   cells.	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Interestingly,	  the	  second	  and	  third	  classes	  contain	  genes	  from	  all	  three-­‐gene	  sets.	  On	  the	  basis	  of	  gene	  ontology	  (GO)	  annotation,	  we	  investigated	  the	  functional	  similarity	  of	  the	  three	  genes	  sets	  among	  each	  other	  and	  with	  respect	   to	  randomly	  selected	  genes.	  This	  analysis	   revealed	   that	   pluripotency	   genes	   and	   hematopoiesis	   genes	   share	   the	   highest	  similarity	  of	  GO	  annotation.	  This	   is	  quite	  expected	   since	   the	  genes	   from	  both	   sets	  are	  involved	  in	  regulating	  cell	  fate.	  No	  difference	  was	  found	  when	  the	  functional	  similarity	  of	  pluripotency	  genes	  belonging	  to	  class	  1	  was	  compared	  to	  hematopoiesis	  genes	  also	  belonging	   to	   class	   1,	   or	   when	   comparing	   the	   similarity	   between	   mixed	   classes.	   In	  comparison,	   the	   average	   functional	   similarity	   of	   imprinted	   genes	   with	   pluripotency	  genes	  or	  with	  hematopoiesis	  genes	  was	  lower	  (about	  0.6),	  but	  still	  clearly	  higher	  than	  that	  with	  randomly	  selected	  genes.	  	  To	   put	   this	   visual	   impression	   onto	   a	   quantitative	   basis,	   we	   then	   ranked	   all	   genes	  according	  to	  their	  gene	  expression	  similarity	  score	  across	  all	  considered	  hematopoietic	  samples.	   Notably,	   all	   p-­‐values	   for	   the	   three	   hematopoietic	   datasets	   (that	   encompass	  differentiation	   and	   cell	   development	   data	   only)	   were	   significant	   (between	   0.001	   and	  0.01).	  Moreover,	  a	   large	  portion	  of	   imprinted	  genes	  belongs	  to	  the	  highest	  10%	  of	  the	  ranked	   genes	   in	   GSE6506	   and	   GSE34723	   datasets	   (66	  %	   and	   59	  %	   respectively).	   In	  contrast,	   no	   significant	  difference	  was	   found	  between	   the	   ranking	  of	   imprinted	   genes	  and	  the	  background	  of	  all	  genes	  of	  the	  control	  (GSE10246;	  largely	  non-­‐hematopoietic)	  and	  the	  number	  of	  top	  ranked	  imprinted	  genes	  was	  lowest	  here.	  	  	  
Table	  5-­‐2	  Genes’	  similarity	  scores	  statistical	  comparison.	  	  Mann-­‐Whitney	  U-­‐test	  was	  used	   to	   test	   if	   imprinted	  genes	  have	  a	  higher	  gene	  expression	  similarity	   to	  pluripotency	  and	  hematopoiesis	  genes	  than	  the	  background	  of	  all	  other	  genes	  (non-­‐imprinted	  genes).	  Then	  genes	  the	  ranked	  top	  10%	   scoring	   genes	  were	   tested	   using	   hyper-­‐geometric	   test	   to	   find	   out	   the	   significance	   of	   having	   imprinted	   genes	  among	   the	  defined	   top	  scored	  genes.	   (*)	  Among	   the	   three	  consistent	  datasets,	  only	   the	  p-­‐value	  of	  hyper-­‐geometric	  test	  for	  GSE14833	  does	  not	  meet	  the	  significance	  threshold	  of	  0.05.	  	  
Dataset	  









Pluripotency	   0.006	   55	   0.006	  
Hematopoietic	   0.044	   57	   0.010	  
GSE34723[217]	  
Pluripotency	   0.004	   50	   0.004	  
Hematopoietic	   0.003	   51	   0.009	  
GSE14833[216]	  
Pluripotency	   0.003	   18	   0.195	  *	  
Hematopoietic	   0.006	   24	   0.214	  *	  
GSE10246[218]	  
(Control)	  
Pluripotency	   0.106	   11	   0.784	  
Hematopoietic	   0.101	   14	   0.700	  
5.3.2 All	  three	  gene	  sets	  contribute	  to	  hematopoietic	  lineage	  specificity	  	  To	   discover	   if	   there	   are	   proteins	   encoded	   by	   imprinted,	   pluripotency,	   and	  hematopoietic	  genes	  that	  act	  during	  differentiation	  of	  particular	  lineages,	  we	  subjected	  the	  selected	  microarray	  datasets	  to	  differential	  analysis.	  We	  studied	  genes	  that	  change	  their	   expression	   patterns	   during	   the	   sequential	   stages	   of	   cell	   development	   of	   specific	  lineages	  (Table	  5-­‐1)	  	  
Chapter	  5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Regulatory	  role	  of	  imprinted	  and	  pluripotency	  genes	  in	  hematopoiesis	  	  	  
	  	  81	  
	  
Figure	  5-­‐2	  Heatmaps showing transient changes in expression profiles.  
Different groups of ESC and hematopoietic cells (e.g stem cells, intermediate progenitors, and terminally differentiated 
blood cells) from the GSE10246 dataset for (left panel) imprinted genes, (middle panel) pluripotency genes and (right panel) 
hematopoietic genes were compared. Green spots represent down-regulated genes, and red spots represent up-regulated 
genes. The order of genes is obtained by hierarchical clustering, which shows three similar pattern classes between 
imprinted, pluripotency and hematopoietic genes.	   	  
Chapter	  5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Regulatory	  role	  of	  imprinted	  and	  pluripotency	  genes	  in	  hematopoiesis	  	  	  
	  	   82	  
For	   the	  purpose	  of	  differential	  expression	  analysis,	  we	  divided	  cell	  samples	   into	   three	  classes	  [early	  progenitors	  (e.g	  HSC	  and	  MPP),	   intermediate	  progenitors	  (e.g	  GMLP	  and	  
CLP),	   and	   terminally	   differentiated	   blood	   cells	   (e.g	   Monocytes	   and	   Nk-­‐cells)].	   This	  analysis	  was	  now	  based	  on	  far	  more	  cell	  types	  than	  the	  global	  analysis	  of	  Figure	  5-­‐2.	  	  	  Lineage-­‐specific	  differentially	  expressed	  genes	  (here	  termed	  marker	  genes)	  found	  in	  the	  three	   gene	   sets	   and	   the	   related	   expression	   heatmaps	   for	   NK-­‐cells,	   monocytes,	   and	  erythrocytes	  are	  shown	  in	  Figure	  5-­‐3	   (heatmaps	  for	  the	  other	  3	  lineages	  are	  shown	  in	  supplementary	  Figure	  B-­‐1).	  The	  number	  of	  significant	  lineage	  markers	  varies	  between	  23	  genes	   (in	  granulocytes)	  and	  193	  genes	   (in	  B-­‐cells).	  Only	   the	   three	  genes	  Rbp1	   and	  the	   two	   imprinted	   genes	   Sgce	   and	   Mkrn3	   are	   shared	   by	   all	   myeloid	   branches	  (erythrocytes,	  monocytes,	   and	  granulocytes)	   (Supplementary	  Table	  B-­‐1).	  Additionally,	  we	  identified	  16	  marker	  genes	  (e.g	  Lgals1,	  Gimap5,	  Pml,	  and	  Hoxa5)	  that	  are	  exclusively	  differentially	   expressed	   in	   myeloid	   lineages	   (not	   in	   lymphoid).	   These	   16	   genes	   are	  annotated	   for	   terms	   like	   GO:0002317	   "plasma	   cell	   differentiation",	   GO:0043011"	  
myeloid	   dendritic	   cell	   differentiation”,	   GO:0030099	   “	  myeloid	   cell	   differentiation”,	   and	  GO:0045639	  “positive	  regulation	  of	  myeloid	  cell	  differentiation”,	   respectively.	  Along	   the	  same	   lines,	   the	   lymphoid	  markers	   contain	  30	  genes	   shared	  by	   all	   lymphoid	  peers	   (B-­‐cell,	  T-­‐cell,	  and	  NK-­‐cell)	  and	  226	  genes	  that	  were	  only	  detected	  for	  individual	  lymphoid	  lineages	  (not	  myeloid)	  such	  as	  Tcf7,	  Lef1,	  and	  Rel,	  which	  plays	  a	  role	  in	  differentiation	  and	   lymphopoiesis	   [224].	   Remarkably,	   most	   differentially	   expressed	   genes	   in	   B-­‐cells	  (102	  genes)	  and	  in	  T-­‐cells	  (70	  genes)	  belong	  to	  the	  pluripotency	  genes	  (Supplementary	  Table	   B-­‐1)	   and	   a	   large	   portion	   of	   them	   was	   imprinted	   (27,	   and	   30,	   respectively),	  whereas	   the	   large	   hematopoiesis	   set	   (516	   genes)	   contributes	   only	   64	   and	   53	  differentially	  expressed	  genes,	  respectively.	  	  Separate	   labeling	  of	  maternally	  and	  paternally	  expressed	  genes	  did	  not	  reveal	  a	  clear-­‐cut	   separation,	   which	   is	   consistent	   with	   previous	   findings	   [208].	   Nevertheless,	   only	  paternally	   expressed	   genes	   were	   differentially	   expressed	   in	   the	   erythrocyte	   lineage	  (Figure	  5-­‐3).	  In	  contrast,	  the	  imprinted	  genes	  that	  are	  overexpressed	  during	  late	  stages	  of	  hematopoiesis	   tend	   to	  be	  maternally	   expressed	   (e.g	  Cmah	   and	  Nap1l4	   in	  B-­‐	   and	  T-­‐cells,	  Klrb1f	   in	  monocytes	  and	  NK-­‐cells,	  Th	  and	   Igf2r	   in	  T-­‐cells)	  rather	   than	  paternally	  expressed	  (Sp2,	  Mcts2,	  and	  Ddc	  only	  in	  B-­‐cells	  and	  T-­‐cells).	  Three	  imprinted	  genes	  (Ndn,	  Peg3,	   and	   Peg12)	   that	   were	   annotated	   by	   Chambers	   and	   colleagues	   [215]	   as	   HSC	  specific	   genes	   were	   identified	   here	   as	   marker	   genes	   for	   differentiated	   lineages.	  Consistent	  with	  the	  findings	  of	  Chambers	  et	  al.,	   they	  are	  highly	  expressed	  in	  HSCs	  and	  downregulated	  in	  differentiated	  states.	  	  	  The	  postulated	   functional	   role	  of	   the	   identified	   lineage	  markers	  during	  hematopoiesis	  was	   backed	   up	   by	   inspecting	   the	   mammalian	   phenotypes	   associated	   with	  hematopoiesis	  abnormalities	  using	   the	  MGI	  database	   [225],	  Supplementary	  Table	  B-­‐1.	  Apparently,	   lineage-­‐specific	   genes	   show	   deficiencies	   in	   either	   functionalities	   or	  differentiation	   of	   a	   specific	   lineage,	   validating	   the	   used	   approach	   in	   identifying	   the	  lineage	  markers.	  An	  example	   from	   the	  B-­‐cell	   lineage	   is	   the	  knockout	  of	   the	   imprinted	  gene	  CD81.	  This	  is	  reported	  to	  cause	  abnormal	  B	  cell	  morphology	  (MGI	  ID:	  MP:0004939),	  
decreased	   B-­‐1	   B	   cell	   number	   (MP:0004978),	   and	   instability	   in	   B	   cell	   proliferation	  (MP:0005154,	   MP:0005093).	   More	   generally,	   the	   knockout	   of	   the	   imprinted	   gene	  
Cdkn1c	  leads	  to	  decreasing	  hematopoietic	  stem	  cell	  number	  (MP:0004810)	  and	  abnormal	  
hematopoietic	  stem	  cell	  physiology	   (MP:0010763).	   From	   the	   set	  of	  pluripotency	  genes,	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gene	   knockout	   of	   Relb	   exhibits	   also	   several	   abnormalities	   such	   as	   decreased	   B	   cell	  
number	  (MP:0005017),	  decreased	  B	  cell	  proliferation	  (MP:0005093),	  absent	  lymph	  nodes	  (MP:0008024),	   decreased	   pre-­‐B	   cell	   number	   (MP:0008209),	   and	   extra-­‐medullary	  
hematopoiesis	  (MP:0000240).	  	  
	  
Figure	  5-­‐3	  Heatmaps of differentially expressed imprinted genes.  
The order of genes is obtained by hierarchical clustering of three blood lineages (NK-cells, Monocytes, and Erythrocytes) 
based on the GSE34723 dataset. Gene clustering color coding is (blue) for paternally expressed genes, (red) for maternally 
expressed, (cyan) for pluripotency genes, and (orange) for hematopoietic genes.  The other three lineages (B-cells, T-cells, 
and granulocytes) are shown in the supplementary Figure B-1. Shared genes between the pluripotency and hematopoietic 
gene sets are marked in black. Green spots represent down-regulated genes, and red spots represent up-regulated genes. The 
clustering reveals that for every lineage, there exist imprinted as well pluripotency and hematopoietic genes showing similar 
expression changes during cell development.	  	  	  Finally,	  we	  analyzed	  the	  functional	  similarity	  of	  the	  identified	  imprinted	  genes	  either	  to	  pluripotency	   or	   hematopoietic	   genes	   using	   the	   tool	   FunSimMat	   [222].	   This	  was	   done	  separately	   for	   each	   lineage	   in	   comparison	   to	   the	   similarity	   values	   of	   the	   background	  genes	   that	  are	  not	  differentially	  expressed	   in	   the	  corresponding	   lineage.	   Interestingly,	  we	   found	   that	   lineage	   specific	   genes	   from	   the	   gene	   set	   pairs	   (imprinted-­‐pluripotency	  and	   imprinted-­‐hematopoietic)	  have	  an	  elevated	   functional	   similarity	  between	  0.4	   and	  0.6	  to	  each	  other	  for	  the	  biological	  process	  (BP)	  category	  in	  comparison	  to	  that	  between	  the	  other	  genes	  in	  the	  two	  gene	  set	  pairs	  (Supplementary	  Figure	  B-­‐2a).	  The	  functional	  similarity	  scores	  between	  imprinted	  and	  hematopoietic	  genes	  were	  ~0.35	  to	  0.75	   	  (p-­‐values	  0.178	   to	  6.0E-­‐237)	   (only	   in	  erythrocytes	   lineage,	  marker	  genes	  did	  not	  show	  a	  significantly	  different	   functional	   similarity	   than	   the	  background	  genes).	  For	   imprinted	  and	  pluripotency	  gene	  markers	  the	  scores	  were	  between	  0.38	  and	  0.64	  (P-­‐values	  0.006	  to	   4.5E-­‐24)	   (Supplementary	   Figure	   B-­‐2b).	   This	   strengthens	   our	   hypothesis	   that	   the	  identified	  imprinted	  lineage-­‐specific	  genes	  play	  a	  role	  in	  the	  development	  of	  lineage	  cell	  states.	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5.3.3 Large	  co-­‐expressed	  module	  of	  imprinted,	  pluripotency,	  and	  hematopoietic	  genes	  	  To	   characterize	   the	   relationship	   between	   imprinted,	   pluripotency	   and	   hematopoietic	  genes	   in	  diverging	  hematopoietic	   lineages	  and	  to	  gain	   insight	   into	  the	  structure	  of	   the	  underlying	   gene	   interaction	   network,	   we	   performed	   a	   combined	   (clustering)	   co-­‐expression	   and	   functional	   analysis	   of	   the	   three	   gene	   lists.	   Interestingly,	   hierarchical	  clustering	  (HCL)	  analysis	  of	  the	  expression	  patterns	  of	  the	  868	  genes	  yielded	  one	  large	  core	  cluster	  (turquois)	  composed	  of	  635	  genes	  as	  well	  as	  four	  small	  clusters	  that	  occur	  along	  the	  diagonal	  of	  the	  heatmap	  (Figure	  5-­‐4a).	  We	  found	  that	  the	  core	  cluster	  contains	  79%	  of	  all	  pluripotency	  genes	  (215	  genes),	  84%	  of	  the	  imprinted	  genes	  (73	  genes),	  and	  69%	   of	   the	   hematopoietic	   genes	   (319).	   This	   again	   supports	   an	   important	   role	   of	  imprinted	  genes	  in	  hematopoietic	  development	  and	  differentiation.	  	  Next,	   we	   related	   the	   grouped	   genes	   of	   this	   core	   cluster	   to	   functional	   GO	   terms.	   The	  color-­‐coded	  scatter	  plot	   in	  Figure	  5-­‐4b	  shows	  the	  ten	  most	  significant	  GO	  terms	  (after	  removing	  the	  child	  terms)	  that	  are	  enriched	  in	  this	  list	  of	  clustered	  genes.	  Some	  of	  the	  most	   significant	   terms	   are	   cell	   differentiation,	   cellular	   developmental	   process,	   immune	  
system	   development	   and	   hematopoiesis.	   All	   biological	   processes	   listed	   in	   Figure	   5-­‐4b	  involve	  considerable	  numbers	  of	  imprinted,	  pluripotency,	  and	  hematopoietic	  genes.	  For	  instance,	   around	   20%	   and	   24%	   of	   the	   imprinted	   genes	   are	   involved	   in	   cell	  
differentiation	  and	  organ	  development,	  respectively.	  	  
5.3.4 Putative	  transcriptional	  network	  involving	  imprinted	  genes	  	  After	   finding	   such	   similarities	   in	   gene	   expression	   and	   functional	   association	   between	  major	  parts	  of	  the	  imprinted	  genes	  and	  pluripotency	  and	  hematopoiesis	  genes	  we	  asked	  how	  this	  interconnectivity	  may	  be	  established	  in	  the	  cell.	  In	  the	  simplest	  scenario,	  many	  imprinted	   genes	  would	   actually	   be	   part	   of	   the	   PluriNetWork	   or	  would	   belong	   to	   the	  hematopoietic	   genes,	  what	   is	   not	   the	   case.	   In	   our	   analysis,	   only	   five	   imprinted	   genes	  (Gab1,	   Ins1,	   Phf17,	   Tsix,	   and	   Xist)	   are	   present	   in	   the	   pluripotency	   list	   and	   three	  imprinted	   genes	   (Axl,	   Calcr,	  and	  Gnas)	   belong	   to	   the	   hematopoietic	   list.	   However	   the	  observed	   co-­‐expression	   profiles	   might	   also	   be	   due	   to	   shared	   regulatory	   genes	   that	  control	  imprinted	  genes	  as	  well	  as	  pluripotency	  and	  hematopoiesis	  genes.	  Alternatively,	  imprinted	  genes	  might	  act	  as	  regulators	  of	  pluripotency	  and	  hematopoiesis	  genes.	  For	  these	  reasons,	  we	  generated	  an	  expanded	  imprinted	  gene	  network	  (IGN)	  that	  includes	  the	  annotated	  regulators	  of	  imprinted	  genes	  and	  genes	  that	  are	  regulated	  by	  imprinted	  genes	  (see	  methods).	  The	  IGN	  consists	  of	  169	  nodes	  and	  1818	  edges,	  each	  representing	  a	   direct	   interaction	   or	   regulation	   between	   two	   nodes.	   Hence,	   the	   IGN	   is	   highly	  interconnected,	  and	  this	  seems	  to	  be	  due	  to	  a	  specific	  functional	  module	  within	  the	  IGN	  (see	  next	  section)	  showing	  particularly	  high	  connectivity.	  Out	  of	  the	  169	  IGN	  genes,	  only	  14	   genes	  were	  not	   annotated	   on	   the	  microarray	   chip.	   Intriguingly,	   the	   IGN	   shares	   32	  genes	   (called	   IGN-­‐shared	  genes)	  with	  either	   the	  pluripotency	  or	  hematopoietic	  genes;	  most	   of	   them	   are	   highly	   interconnected	   in	   the	   IGN	   network.	   20	   genes	   (Ccnd1,	   Cdh1,	  
Cdkn1a,	  Creb1,	  Gab1,	  Ins1,	  Myc,	  Mycn,	  Nfkb1,	  Phf17,	  Pou2f1,	  Oct4	  (Pou5f1),	  Rela,	  Sp1,	  Sp3,	  
Tert,	  Tgfb1,	  Tsix,	  Ube2i,	  and	  Xist)	  are	  shared	  with	  the	  pluripotency	  genes	  and	  17	  genes	  	  (Axl,	   Bcl2,	   Calcr,	   Cebpa,	   Egr1,	   Ets1,	   Gnas,	  Hoxa5,	   Jun,	   Junb,	  Myb,	  Myc,	  Nfkb1,	   Rara,	   Sp1,	  
Sp3,	  Tgfb1)	  are	  shared	  with	  the	  hematopoietic	  genes.	  Markedly,	  five	  genes	  (Myc,	  Nfkb1,	  
Sp1,	  Sp3,	  and	  Tgfb1)	  appeared	   in	  both	  sets.	   Supplementary	  Table	  B-­‐2	  summarizes	   the	  complete	  gene	  sets	  considered	  in	  the	  analysis.	  
Chapter	  5	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Regulatory	  role	  of	  imprinted	  and	  pluripotency	  genes	  in	  hematopoiesis	  	  	  
	  	  85	  
	  
	  
Figure	  5-­‐4	  Co-expression and functional analysis of imprinted, pluripotency and hematopoietic genes.  
A) On the left, heatmap depicting a gene interaction network based on the topological overlap matrix (TOM) [226] among 
the three gene lists. The TOM describes the distance between two genes in the co-expression network and reflects their 
similarity in terms of the commonality of the nodes they are connected to. A topological overlap of 1 between genes i and j 
implies that they are connected to the same genes, whereas a 0 value indicates that i and j do not share co-expression links to 
common genes. Each row and column of the heatmap corresponds to a single gene. Spots with light colors denote weak 
interaction and darker colors strong adjacency interaction. The dendrograms on the upper and left sides show the hierarchical 
clustering of genes. The turquoise, yellow, brown, blue, and grey colors represent the identified clusters and the black frame 
highlights the main gene cluster in turquois.  B) Right, A scatterplot visualizing the top 10 enriched GO terms in the main 
(turquois) gene cluster in a two dimensional space of GO term semantic similarities. Node colors indicate the p-values for 
the enrichment of terms.  The scatter plot was generated using the web tool REVIGO similarity [223]. This tool uses multi 
dimensional scaling to reduce the dimensionality of a matrix of the GO terms pairwise semantic similarity and projects the 
GO terms on the two axes. The axes thus visualize the semantic similarity of GO terms, but have no intrinsic meaning.  	  We	   then	   explored	   the	   network	   modularity	   according	   to	   the	   topological	   feature	   edge	  betweenness	   of	   the	   IGN	   network	   (Figure	   5-­‐5).	   Apparently,	   IGN-­‐shared	   genes	   show	   a	  high	  modularity	  in	  IGN	  as	  they	  are	  grouped	  in	  only	  four	  modules.	  Importantly,	  75%	  (24	  genes)	  belong	  to	  a	  single	  module	  (Figure	  5-­‐5,	  green).	  By	  extracting	  the	  BP	  terms	  that	  are	  enriched	   in	   this	   gene	   module	   (excluding	   the	   24	   IGN-­‐shared	   genes)	   we	   found	   many	  statistically	  significant	  functional	  terms	  related	  to	  differentiation	  and	  cell	  development	  such	   as	   GO:0008283	   “cell	   proliferation”,	   GO:0009887	   “organ	   morphogenesis”,	  GO:0030154	  “cell	  differentiation”,	  and	  GO:0048863	  “stem	  cell	  differentiation”.	  
5.4 Discussion	  	  In	  this	  study	  we	  compared	  the	  expression	  patterns	  of	  86	  candidate	  imprinted	  genes	  and	  272	  pluripotency	  genes	  taken	  from	  the	  PluriNetWork	  [202]	  in	  ESC	  and	  during	  different	  stages	   of	   hematopoiesis	   to	   the	   global	   expression	   pattern	   of	   hematopoietic	   genes.	  We	  discovered	   that	   the	   three	   gene	   sets	   showed	   similar	   changes	   between	   pluripotent,	  intermediate,	   and	   differentiated	   stages	   suggesting	   that	   these	   gene	   sets	   have	   partially	  overlapping	  functions.	  Furthermore,	  we	  identified	  lineage	  markers	  from	  the	  three	  gene	  sets	   for	   three	   lymphoid	   and	   three	   myeloid	   branches	   that	   were	   found	   to	   exhibit	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significant	  functional	  similarities.	  In	  a	  collaborative	  fashion,	  they	  seem	  to	  participate	  in	  cellular	  differentiation	  and	  development	  in	  the	  corresponding	  lineages.	  	  Interestingly,	  many	   imprinted	  genes	  shared	  very	  similar	  expression	  patterns	  with	   the	  pluripotency	   and	   hematopoiesis	   sets	   (Figure	   5-­‐2)	   similar	   to	   observations	  made	   for	   a	  smaller	   set	   of	   imprinted	   genes	   in	   murine	   HSCs	   [198].	   This	   similarity	   was	   most	  pronounced	   for	   genes	   belonging	   to	   expression	   class	   1	   that	   are	   overexpressed	   in	   ESC.	  However,	   the	   functional	   similarity	   of	   imprinted	   genes	   and	   pluripotency	   and	  hematopoiesis	   genes,	   respectively,	   does	   not	   quite	   reach	   the	   level	   that	   is	   seen	   for	   the	  similarity	   between	   PluriNetWork	   and	   hematopoiesis	   genes.	   We	   attribute	   the	  observation	   that	   particular	   imprinted	   genes	   show	   a	   high	   variability	   of	   expression	  among	  the	  various	  stages	  of	  differentiation	  to	  the	  different	  roles	  played	  by	  these	  genes	  in	  the	  cell.	  	  	  
	  
Figure	   5-­‐5	  The expanded imprinted gene network (IGN) including all considered imprinted genes, transcriptions 
factors that regulate imprinted genes, as well as target genes regulated by imprinted genes. The edges of this graph 
may either indicate a significant degree of co-expression of two genes or a regulatory interaction. The IGN was clustered 
based on edge-betweenness. The full network is decomposed into only 4 topological modules. Large nodes represent the 32 
genes that are shared with the PluriNetWork or with the set of hematopoietic genes. 24 of them belong to the main module 
(green).  	  Comparing	   the	   expression	   levels	   of	   known	   pluripotency	   with	   hematopoiesis	   genes	  showed	   that	   the	   compiled	   PluriNetWork	   [202]	   contains	   not	   only	   the	   GRN	   that	   keeps	  cells	  in	  the	  pluripotent	  state	  but	  appears	  also	  to	  be	  related	  to	  the	  regulation	  of	  the	  onset	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of	  cellular	  differentiation	  such	  as	  hematopoiesis.	  In	  fact,	  the	  GO	  terms	  hematopoietic	  or	  
lymphoid	   organ	   development,	   haemopoiesis,	   myeloid	   cell	   differentiation,	   leukocyte	  
differentiation	   are	   annotated	   to	   44,	   39,	   27,	   and	   23	   pluripotency	   genes,	   respectively,	  suggesting	   that	   a	   significant	   portion	   of	   the	   pluripotency	   genes	   is	   indeed	   involved	   in	  hematopoiesis	  regulation.	  Moreover,	  Figures	  1	  and	  2	  demonstrate	  convincingly	  that	  the	  full	  set	  of	  pluripotency	  genes	  displayed	  pronounced	  variations	  during	  different	  stages	  of	  hematopoiesis	  and	  in	  individual	  cell	  lineages	  as	  well.	  These	  findings	  agree	  with	  previous	  studies	   that	   discussed	   the	   role	   of	   pluripotency	   genes	   in	   determining	   cell	   fate	   and	  controlling	  differentiation	  [227].	  	  Different	   cell	   types	   showed	  pronounced	  differences	   in	   their	   gene	   expression	   profiles:	  most	  prominent	  was	  the	  high	  number	  of	  differentially	  expressed	  genes	  in	  B-­‐cells	  and	  T-­‐cells	  with	  a	  major	  contribution	  of	  pluripotency	  genes	  and	  to	  some	  extent	  also	  imprinted	  genes.	   This	   expression	   profile	   is	   interesting	   as	   a	   substantial	   portion	   of	   B-­‐cells	   and	  T-­‐cells	   serve	   as	   memory	   cells	   that	   can	   be	   induced	   by	   secondary	   infections	   to	   undergo	  further	  cell	  divisions.	  NK-­‐cells	  that	  have	  recently	  been	  shown	  to	  have	  some	  potential	  for	  further	  cell	  divisions	  [228]	  tend	  also	  to	  have	  higher	  numbers	  of	  differentially	  expressed	  genes	  compared	  to	  the	  differentiated	  myeloids.	  Most	  of	  the	  lineage	  markers	  identified	  in	  this	  work	  were	   concordant	  with	   the	   findings	  of	   recently	  published	   studies.	  Generally,	  the	  ten	  lineage	  markers	  (Cdkn1c,	  Ndn,	  Gatm,	  Phlda2,	  Air,	  Igf2r,	  Slc22a3,	  H13,	  Sfmbt2,	  and	  
Peg12)	   that	   participate	   in	   most	   lineages	   were	   demonstrated	   to	   be	   differentially	  expressed	  in	  the	  early	  onset	  of	  the	  hematopoietic	  process.[207,	  229]	  More	  specifically,	  the	  identified	  erythrocytes	  lineage	  markers	  Fli1,	  Mpl,	  and	  Gata2	  were	  previously	  found	  to	  determine	  the	  erythrocytes	  signature	  [204,	  230-­‐232].	  	  In	  order	  to	  validate	  that	  the	  identified	  lineage	  markers	  indeed	  have	  functional	  roles	  in	  the	   respective	   lineages,	   we	   have	   referred	   to	   their	   phenotypic	   gene	   knock-­‐out	  characteristics	   documented	   in	   the	   MGI	   repository	   [225]	   (Supplementary	   Table	   B-­‐1).	  Interestingly,	   knock-­‐out	   of	   B-­‐cell	  markers	   lead	   to	   abnormal	   B-­‐cell	   differentiation	   and	  abnormal	  B-­‐cell	  morphology	  etc.	  	  	  In	  order	  to	  get	  more	  insight	  into	  the	  putative	  association	  between	  imprinted	  genes	  and	  their	   regulatory	   partners,	   we	   constructed	   an	   expanded	   IGN	   that	   is	   associated	   with	  genomic	   imprinting	   effects	   although	   only	   half	   of	   its	   genes	   are	   actually	   imprinted.	  Particularly,	   32	   IGN	   genes	   appeared	   in	   the	   pluripotency	   or	   hematopoietic	   sets.	   24	   of	  them	  (75%)	  belong	  to	  one	  topological	  module	  (Figure	  5-­‐5)	  suggesting	  that	  this	  module	  of	   77	   genes	   that	   are	   related	   to	   genomic	   imprinting	   due	   to	   their	   membership	   in	   IGN	  affects	  maintenance	  of	  pluripotency	  and	  hematopoietic	  differentiation	  in	  a	  cooperative	  manner.	  This	  module	  is	  also	  enriched	  in	  GO	  functional	  terms	  related	  to	  differentiation,	  development	   and	   hematopoiesis.	   Of	   the	   32	   IGN-­‐shared	   genes	   Oct4	   and	   Myc	   are	  considered	   strategic	   players	   in	   maintaining	   the	   induced	   pluripotent	   state.	   Five	   IGN-­‐shared	   genes	   (Myc,	   Nfkb1,	   Sp1,	   Sp3,	   and	   Tgfb1)	   were	   shared	   among	   the	   three	   sets	  indicating	   a	   regulatory	   role	   in	   cell	   differentiation	   and	   hematopoiesis.	   The	   TCF	   Myc	  belongs	   to	   the	   four	   known	   Yamanaka	   factors	   that	   play	   a	   significant	   role	   in	   cell	  reprogramming	   [233]	   and	   were	   shown	   to	   be	   sufficient	   for	   reprogramming	  differentiated	  cells	  into	  induced	  pluripotent	  stem	  cells	  [234].	  Myc	  is	  believed	  to	  regulate	  expression	   of	   15%	   of	   all	   human	   genes	   [235]	   and	   plays	   an	   important	   role	   in	   B-­‐cell	  proliferation	   [236].	   Recently,	  Myc	   and	   the	   changes	   in	   its	   expression	   level	   have	   been	  reported	   as	   a	   key	   player	   in	   embryonic	   stem	   cell	   development	   into	   megakarcocytes	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[237],	   and	   in	   erythropoiesis	   [238].	   Tgfb1	   is	   known	   to	   be	   involved	   in	   differentiation	  processes	   and	   was	   identified	   as	   a	   key	   regulator	   for	   HSCs	   homeostasis	   [239].	  Nfkb1,	  when	  knocked	  out	  in	  mice,	  caused	  significant	  reduction	  in	  granulocytic	  progenitors	  and	  CFU-­‐granulocytes	   [240]	   and	   it	   modulates	   proliferation	   and	   survival	   of	   erythroid	  progenitors	   derived	   from	   CD34+	  HSCs	   [241].	   Sp1	   and	   Sp3	   control	   gene	   expression	   in	  myeloid	  cells	  [242]	  and	  during	  erythrocyte	  maturation	  [243].	  Therefore,	  these	  5	  genes	  might	   be	   the	   major	   connectors	   between	   the	   IGN,	   pluripotency	   and	   hematopoiesis	  networks.	  	  	  In	  summary,	  the	  present	  analysis	  suggested	  new	  aspects	  of	  the	  cellular	  regulation	  of	  the	  onset	   of	   cellular	   differentiation	   and	   during	   hematopoiesis.	   These	   involve,	   on	   the	   one	  hand,	  genes	  that	  were	  previously	  not	  discussed	  in	  the	  context	  of	  hematopoiesis	  and,	  on	  the	  other	  hand,	  involve	  genes	  that	  are	  related	  to	  genomic	  imprinting.	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6. Application	  to	  breast	  
invasive	  carcinoma	  	  	  	  This	  chapter	  is	  a	  shortened	  version	  of	  the	  following	  publication:	  	  
• Mohamed	  Hamed,	  Christian	  Spaniol,	  Alexander	  Zapp,	   and	  Volkhard	  Helms,	   Integrative	  network	  based	  approach	   identifies	  key	  genetic	   elements	   in	  breast	   invasive	   carcinoma.	  BMC	  Genomics,	  2015.	  16	  (Suppl	  5):	  p.	  S2.	  	  	  	  	  
Synopsis	  	  
In	  this	  chapter,	  we	  demonstrate	  the	  usefulness	  of	  the	  integrative	  network-­‐based	  approach	  
to	   identify	   genetic	   key	   elements	   that	   could	   possibly	   drive	   the	   tumorogenesis	   in	   human	  
breast	   cancer.	  The	   introduced	  approach	  was	  able	   to	   reveal	   strong	  associations	  between	  
regulatory	   elements	   from	   four	   consistent	   genomic	   data	   sources:	   gene	   expression,	   DNA	  
methylation,	  miRNA	  expression,	  and	  somatic	  mutations.	  Integrative	  screening	  of	  miRNAs,	  
mRNAs,	   and	   genetic	   variations	   can	   contribute	   to	   an	   improved	   understanding	   of	   human	  
diseases	   and	   hence	   to	   a	   better	   prognosis	   and	   treatment.	   Taken	   together,	   these	   findings	  
endorse	   the	   reliability	   of	   the	   proposed	   approach	   so	   that	   it	   can	   be	   applied	   in	   a	   similar	  
fashion	   to	  other	  cancer	   types,	   complex	  diseases,	  or	   for	   studying	  cellular	   functions	  where	  
such	  multi-­‐dimensional	  genomic	  datasets	  are	  available.	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Abstract	  	  Breast	   cancer	   is	   a	   genetically	   heterogeneous	   type	   of	   cancer	   that	   belongs	   to	   the	  most	  prevalent	   types	  with	   a	  high	  mortality	   rate.	   Treatment	   and	  prognosis	   of	   breast	   cancer	  would	   profit	   largely	   from	   a	   correct	   classification	   and	   identification	   of	   genetic	   key	  drivers	   and	  major	  determinants	  driving	   the	   tumorigenesis	  process.	   In	   the	   light	  of	   the	  availability	   of	   tumor	   genomic	   and	   epigenomic	   data	   from	   different	   sources	   and	  experiments,	   new	   integrative	   approaches	   are	   needed	   to	   boost	   the	   probability	   of	  identifying	   such	   genetic	   key	   drivers.	   We	   present	   here	   an	   integrative	   network-­‐based	  approach	   that	   is	   able	   to	   associate	   regulatory	   network	   interactions	   with	   the	  development	   of	   breast	   carcinoma	   by	   integrating	   information	   from	   gene	   expression,	  DNA	  methylation,	  miRNA	  expression,	  and	  somatic	  mutation	  datasets.	  	  Our	  results	  showed	  strong	  association	  between	  regulatory	  elements	  from	  different	  data	  sources	   in	   terms	   of	   the	   mutual	   regulatory	   influence	   and	   genomic	   proximity.	   By	  analyzing	   different	   types	   of	   regulatory	   interactions,	   TF-­‐gene,	   miRNA-­‐mRNA,	   and	  proximity	   analysis	   of	   somatic	   variants,	   we	   identified	   106	   genes,	   68	   miRNAs,	   and	   9	  mutations	  that	  are	  candidate	  drivers	  of	  oncogenic	  processes	  in	  breast	  cancer.	  Moreover,	  we	  unraveled	  regulatory	  interactions	  among	  these	  key	  drivers	  and	  the	  other	  elements	  in	  the	  breast	  cancer	  network.	  Intriguingly,	  about	  one	  third	  of	  the	  identified	  driver	  genes	  are	  targeted	  by	  known	  anti-­‐cancer	  drugs	  and	  the	  majority	  of	  the	  identified	  key	  miRNAs	  are	   implicated	   in	   cancerogenesis	   of	   multiple	   organs.	   	   Also,	   the	   identified	   driver	  mutations	   likely	   cause	   damaging	   effects	   on	   protein	   functions.	   The	   constructed	   gene	  network	   and	   the	   identified	   key	   drivers	   were	   compared	   to	   well-­‐established	   network-­‐based	  methods.	  	  	  The	   integrated	  molecular	   analysis	   enabled	  by	   the	  presented	  network-­‐based	   approach	  substantially	   expands	   our	   knowledge	   base	   of	   prospective	   genomic	   drivers	   of	   genes,	  miRNAs,	  and	  mutations.	  For	  a	  good	  part	  of	  the	  identified	  key	  drivers	  there	  exists	  solid	  evidence	  for	  involvement	  in	  the	  development	  of	  breast	  carcinomas.	  Our	  approach	  also	  unraveled	   the	   complex	   regulatory	   interactions	   comprising	   the	   identified	   key	   drivers.	  These	   genomic	   drivers	   could	   be	   further	   investigated	   in	   the	   wet	   lab	   as	   potential	  candidates	   for	  new	  drug	  targets.	  This	   integrative	  approach	  can	  be	  applied	   in	  a	  similar	  fashion	  to	  other	  cancer	  types,	  complex	  diseases,	  or	  for	  studying	  cellular	  differentiation	  processes.	  
6.1 Background	  	  Breast	   cancer	   is	   one	   of	   the	  most	   common	   and	   predominant	   cancer	   types	   that	   affects	  millions	   of	   cases	   and	   causes	   thousands	   of	   deaths	   every	   year	   [148,	   244].	   With	   an	  individual	   probability	   of	   12%	   to	   develop	   breast	   cancer,	   it	   is	   the	   most	   frequently	  diagnosed	  cancer	   type	  among	  women	  and	  accounts	   for	   the	   second-­‐highest	  number	  of	  fatalities	   (15%)	   of	   female	   cancer	   patients	   besides	   lung	   cancer	   [245].	   Due	   to	   its	  complexity	  and	  heterogeneity	  [246],	  the	  molecular	  mechanism	  and	  regulatory	  patterns	  underlying	  breast	  carcinoma	  have	  not	  been	  completely	  unraveled	  so	  far.	  	  Treatment	  and	  prognosis	  of	  cancer	  development	  relies	  largely	  on	  a	  correct	  classification	  of	   the	   histological	   grade	   and	   identification	   of	   the	   major	   determinants	   driving	   the	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tumorigenesis	   process.	   To	   better	   address	   this,	  many	   studies	   have	   attempted	   to	   build	  predictive	   models	   by	   analyzing	   and	   integrating	   heterogeneous	   data	   sources.	   For	  example,	  Cava	  et	  al.	  presented	  an	  effective	  discrimination	  of	  breast	  cancer	  types	  based	  on	   a	   support	   vector	  machine	   classifier	   combining	   copy	   number	   variations,	   SNP	   data,	  and	   the	   expression	   values	   of	   miRNAs,	   and	   mRNAs	   [247].	   Also,	   miRNA-­‐mRNA	  interactions	  were	  combined	  with	  transcription	  factor	  (TF)-­‐gene	  interactions	  to	  unravel	  the	   combinatorial	   molecular	   regulations	   that	   facilitate	   progression	   of	   colorectal	   and	  breast	  cancer	  [118,	  172].	  Along	  the	  same	  lines,	  the	  integration	  of	  gene	  expression	  data	  with	   protein	   interaction	   networks	   into	   integrated	   weighted	   networks	   has	   already	  proven	   fruitful	   in	   a	   variety	   of	   applications	   within	   cancer	   genomics	   [248-­‐263].	   In	  general,	   the	   combination	   of	   microarray	   studies	   with	   mathematical	   models	   such	   as	  network	   theory	   allows	   to	   define	   relationships	   between	   genes	   and	   to	   discover	  interacting	  networks	  and	  pathways,	   improving	  the	  understanding	  of	  complex	  diseases	  [264].	  
 In	  recent	  years,	  novel	  network-­‐based	  approaches	  have	  been	  introduced	  to	  improve	  the	  understanding	   of	   complex	   human	   diseases	   from	   multiple	   perspectives.	   For	   instance,	  differential	  network	  analysis	  attempts	  to	  better	  characterize	  disease	  phenotypes	  under	  two	   different	   conditions	   by	   studying	   the	   changes	   in	   the	   related	   network	   interaction	  patterns	   [248,	   249,	   257,	   258,	   265-­‐269].	   In	   cancer	   genomics,	   the	   differential	   network	  approach	   was	   able	   to	   identify	   essential	   gene	   modules	   that	   lead	   to	   crucial	   novel	  biological	   insights	   and	   significant	   implications	   for	   understanding	   tumorigenesis	   [249,	  257,	  258].	  	  In	   the	   light	  of	   the	  recent	  availability	  of	   tumor	  genomic	  data	  and	  the	  complexity	  of	   the	  related	  high	  throughput	  analysis,	  new	  integrative	  approaches	  are	  needed	  to	  boost	   the	  probability	   of	   successfully	   identifying	   the	   associated	   genetic	   key	   drivers,	   the	   causal	  regulators,	   the	   related	   mutations,	   biomarkers,	   and	   their	   molecular	   interactions	   that	  potentially	  drive	  tumorigenesis.	  To	  this	  end,	  this	  study	  presents	  an	  integrative	  network-­‐based	   approach	   based	   on	   whole-­‐genome	   gene	   expression	   profiling,	   DNA	  methylome,	  miRNA	   expression,	   and	   genomic	   mutations	   of	   breast	   cancer	   samples	   from	   the	   TCGA	  portal	  [66].	  Based	  on	  this,	  we	  constructed	  a	  gene	  regulatory	  network	  that	  conforms	  to	  the	   conditions	   of	   such	   biological	   data	   and	   we	   identified	   network	   modules	   of	  dysregulated	   genes.	   Each	   module	   turned	   out	   to	   have	   distinct	   functional	   categories,	  cellular	   pathways,	   as	   well	   as	   oncogene	   and	   tumor	   suppressor	   specificity.	   We	   also	  extracted	   breast	   cancer	   specific	   subnetworks	   from	   the	   human	   genome	   regulatory	  interactome	   induced	   by	   the	   dysregulated	   miRNAs	   and	   the	   dysregulated	   mRNAs.	  Furthermore,	   we	   demonstrated	   a	   strong	   association	   between	   the	   different	   genetic	  molecules	   in	   terms	   of	   the	   interchangeable	   regulatory	   effect	   and	   genomic	   proximity.	  Then,	  we	  identified	  putative	  genetic	  key	  drivers/determinants	  from	  genes,	  miRNAs,	  and	  somatic	  mutations	  that	  could	  possibly	  drive	  the	  oncogenic	  processes	  in	  breast	  cancer.	  	  	  Our	  findings	  are	  strongly	  supported	  by	  independent	  evidences.	  For	  instance,	  the	  protein	  products	  of	  about	  one	  third	  of	  the	  identified	  driver	  genes	  are	  known	  binding	  targets	  of	  anti-­‐breast	   cancer	   drugs,	   and	   most	   of	   the	   identified	   key	   miRNAs	   are	   implicated	   in	  cancerogenesis	   of	   multiple	   organs.	   Moreover,	   all	   the	   identified	   driver	   mutations	   are	  predicted	  to	  cause	  damaging	  effects	  on	  structures	  and	  functions	  of	  the	  related	  proteins.	  The	  rest	  of	  the	  identified	  driver	  molecules	  represent	  novel	  potential	  candidates	  for	  new	  drug	  targets	  and	  further	  experimental	  research	  is	  warranted	  to	  confirm	  these	  findings.	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6.2 Methods	  	  See	  the	  integrative	  network-­‐based	  approach	  presented	  in	  section	  3.4. 
6.3 Results	  and	  discussion	  
6.3.1 Differential	  analysis	  	  We	   developed	   and	   applied	   an	   integrative	   network-­‐based	   approach	   to	   conduct	  combinatorial	  regulatory	  network	  analysis	   in	  the	  context	  of	  breast	   invasive	  carcinoma	  with	  the	  aim	  of	  identifying	  the	  major	  genetic	  drivers	  that	  lead	  to	  tumorigenesis	  (Figure	  3-­‐9).	   We	   processed	   mRNA	   expression,	   DNA	   methylation,	   miRNA	   expression,	   and	  somatic	  mutation	   datasets	   for	   131	   tumor	   samples	   and	   20	   control	   samples	   of	   healthy	  tissues.	  The	  differential	  analysis	  of	   the	  mRNA	  expression,	  DNA	  promoter	  methylation,	  and	   miRNA	   expression	   data	   gave	   1317	   differentially	   expressed	   genes,	   2623	  differentially	  methylated	  genes,	  and	  121	  differentially	  expressed	  miRNAs,	  respectively.	  
6.3.2 TF-­‐gene	  interactions	  	  The	  expression	  profiles	  of	  the	  1317	  identified	  differentially	  expressed	  genes	  were	  used	  to	   compute	   the	   co-­‐regulation	   strength	   between	   genes	   using	   the	   topological	   overlap	  (TOM)	   measure.	   Then,	   we	   performed	   hierarchical	   clustering	   (HCL)	   to	   construct	   the	  undirected	   co-­‐expression	   network.	   HCL	   yielded	   10	   segregated	   network	  modules	   that	  contain	   between	   26	   and	   295	   gene	   members	   (Table	   6-­‐1).	   For	   the	   seven	   smallest	  modules,	   we	   collected	   the	   related	   directed	   regulatory	   interactions	   available	   in	   three	  online	  regulatory	  databases	  (JASPAR	  [83],	  TRED	  [82],	  and	  MSigDB	  [70])	  and	  used	  them	  as	  a	  prior	  for	  a	  Bayesian	  learner	  to	  learn	  the	  causal	  probabilistic	  regulatory	  interactions	  and	   to	   generate	   a	   directed	   network	   topology,	   (see	   methods	   for	   details).	   The	   three	  largest	  modules	  (blue,	  brown,	  and	  turquoise)	  comprised	  too	  many	  nodes	  that	  exceeded	  the	   complexity	   that	   can	   be	   handled	   by	   the	   Bayesian	   learning	   approach.	   Hence,	   we	  deliberated	  the	  co-­‐expression	  networks	  for	  these	  three	  modules	  by	  requiring	  a	  tighter	  co-­‐expression	  threshold	  and	  used	  the	  obtained	  network	  modules	  for	  further	  analysis.	  It	  should	  be	  mentioned	  that	  the	  Bayesian	  approach	  prevents	  cyclic	  topology	  such	  as	  self-­‐regulation,	  which	   is	   the	   case	   for	  many	   genes.	   Therefore,	  we	   note	   that	   self-­‐regulatory	  interactions	   are	   not	   considered	   in	   this	   study.	   Next,	   the	   GRN	   network	   modules	   were	  pruned	  in	  order	  to	  maximize	  consistency	  between	  gene	  expression	  profiles,	  methylation	  fingerprints	  of	  gene	  promoters,	  and	  the	   inferred	  regulatory	   interactions.	  This	  helps	   to	  contextualize	   the	   network	   to	   the	   biological	   experiments	   from	   which	   it	   was	   reverse	  engineered.	   We	   removed	   89	   inferred	   interactions	   whose	   target	   genes	   are	  downregulated	  and	  their	  expression	  profiles	  showed	  absolute	  anti-­‐correlation	  measure	  >	  0.65	  with	  their	  methylation	  profiles.	  In	  those	  cases	  we	  reasoned	  that	  downregulation	  of	  these	  target	  genes	  was	  most	  likely	  due	  to	  their	  promoter	  methylation	  and	  not	  due	  to	  TF	  binding	  [79].	  	  By	   linking	   the	   network	   modules	   genes	   to	   GO	   and	   KEGG	   annotations	   via	   over	  representation	   analysis	   (ORA),	  we	   identified	   the	  most	   significant	  metabolic	   processes	  and	   functional	   categories	   that	   were	   enriched	   in	   each	   network	   module	   and	   showed	  relevance	  to	  breast	  cancer,	  see	  Table	  6-­‐1.	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Table	  6-­‐1	  The	  key	  driver	  elements	  identified	  from	  TF-­‐gene	  interactions	  and	  miRNA-­‐mRNA	  interactions.	  For	  the	  10	  gene	  modules	  identified	  in	  TF-­‐mRNA	  interactions,	  we	  list	  counts	  of	  the	  involved	  genes,	  the	  most	  significant	  GO	   and	   KEGG	   terms,	   and	   the	   identified	   key	   driver	   genes	   from	   each	   module.	   	   Similarly	   for	   the	   miRNA-­‐mRNA	  interactions,	  we	  list	  the	  key	  driver	  molecules	  of	  both	  genes	  and	  miRNAs.	  The	  driver	  genes,	  whose	  protein	  products	  are	  known	  to	  be	  targeted	  by	  drugs,	  are	  underlined	  and	  marked	  in	  red.	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mir-133a-1, let-7i, mir-93, mir-23a, mir-
148a, mir-196a-2, mir-487b, mir-149 	  For	   instance,	   the	   red	   and	   green	   modules	   are	   enriched	   with	   the	   endometrial	   cancer	  pathway,	   which	   is	   tightly	   associated	   with	   breast	   cancer	   and	   subsequent	   treatment	  [270].	  Also,	  the	  magenta	  and	  turquoise	  modules	  were	  significantly	  involved	  in	  the	  p53	  signaling	  pathway,	  a	  tumor	  suppressor	  gene	  showing	  one	  of	  the	  largest	  frequencies	  of	  SNPs	   among	   all	   human	   genes	   that	   have	   been	   related	   to	   cancer	   [148].	   It	   has	   also	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important	  roles	  in	  diagnosis,	   in	  prognostic	  assessment	  and,	  ultimately,	   in	  treatment	  of	  breast	   cancer	   [271-­‐275].	   The	   inferred	   network	   topologies	   for	   the	   first	   three	  modules	  (red,	   green,	   and	  magenta)	   highlighting	   their	   identified	   driver	   genes	   are	   presented	   in	  Figure	  6-­‐1.	  Other	  network	  modules	  are	  shown	  in	  Figure	  C-­‐1.	  Then	  we	  utilized	  the	  gplk	  solver	  [94]	  via	  OpenOpt	  [95]	  on	  the	  10	   inferred	  network	  modules	  to	   find	  the	  minimal	  set	  of	  nodes	  that	  dominate	  and	  regulate	  all	  nodes	  in	  each	  network.	  In	  total,	  we	  identified	  94	   key	   dominating/driver	   genes	   in	   all	   network	   modules	   (Table	   6-­‐1).	   The	   follow-­‐up	  analysis	  of	  these	  driver	  genes	  is	  discussed	  below.	  
6.3.3 miRNA-­‐mRNA	  interactions	  	  To	   extract	   the	   breast	   cancer	   specific	   subnetworks	   from	   the	   human	   genome	   wide	  regulatory	   interactome	   induced	   by	   miRNAs	   and	   mRNAs,	   we	   examined	   two	   possible	  regulation	   types	   between	   the	   differentially	   expressed	  miRNAs	   and	  mRNAs:	   	   miRNAs	  regulating	   target	   mRNAs	   and	   mRNA	   products	   (TFs)	   regulating	   expression	   of	   the	  miRNAs.	   We	   relied	   on	   the	   experimentally	   validated	   interactions	   of	   both	   types	   in	  building	   the	   two	   networks,	   (see	   methods	   for	   details).	   The	   identified	   miRNA→mRNA	  interactions	  consist	  of	  65	  unique	  miRNAs	  and	  770	  unique	  genes	  involved	  in	  1949	  links.	  The	   TF→miRNA	   interactions	   include	   112	   unique	   TFs	   and	   100	   unique	   miRNAs	  composing	   336	   links.	   	   A	   total	   of	   869	   genes	   (including	   TFs)	   and	   120	   miRNAs	   were	  present	   in	   the	   combined	   miRNA→mRNA	   and	   TF→miRNA	   interaction	   network.	   13	  mRNAs	  and	  45	  miRNAs	  were	  common	   in	  both	   interaction	   types.	  The	  869	  genes	  were	  mostly	   involved	   in	   regulation	   of	   macromolecular	   metabolic	   processes	   and	   cancer	  pathways	  of	  multiple	  organs	  (Table	  6-­‐1).	  Moreover,	  the	  HMDD	  (Human	  miRNA	  Diseases	  Database)	   [133]	   analysis	   of	   the	   120	   miRNAs	   revealed	   their	   implication	   in	  cancerogenesis	   of	   various	  organs	   (Table	  6-­‐1).	  Next,	   the	   two	  networks	   comprising	   the	  dysregulated	   miRNAs	   and	   mRNAs	   as	   well	   as	   the	   interactions	   among	   them	   were	  combined	   and	   further	   analyzed	   using	   OpenOpt	   [95]	   and	   gplk	   solver[94]	   to	   identify	  genetic	  drivers	  and	  major	  regulators.	  This	  yielded	  in	  total	  85	  key	  dominating	  molecules	  (68	   miRNAs	   and	   17	   genes)	   that	   regulate	   the	   entire	   network	   nodes	   (Table	   6-­‐1).	   The	  network	  topologies	  highlighting	  the	  dominating	  genes	  are	  shown	  in	  Figure	  6-­‐2.	  	  	  Interestingly,	  some	  of	  the	  identified	  key	  driver	  genes	  such	  as	  MYC,	  AKT1,	  and	  TP53	  were	  previously	  implicated	  and	  significantly	  mutated	  in	  breast	  cancer	  samples	  [148].	  Also	  the	  
TCF3	  gene,	   a	  well-­‐known	   TF	   controlling	   stem	   cell	   identity	   and	   self-­‐renewal,	   is	   highly	  expressed	   in	   tumor	   samples	   and	   has	   a	   central	   regulatory	   role	   in	   the	   onset	   of	   breast	  cancer	   cell	   differentiation	   and	   tumor	   growth	   [276].	   Additionally,	   many	   studies	   have	  reported	   the	   aberrant	   expression	   patterns	   of	   the	   CREB1	   gene	   and	   its	   role	   in	   breast	  tumor	  cell	  growth	  [277-­‐280]	  suggesting	  its	  protein	  product	  as	  a	  worthwhile	  target	  for	  anti-­‐cancer	  drugs	  [281,	  282].	  	  It	  has	  been	  demonstrated	  that	  the	  E2F3	  gene	  plays	  a	  critical	  role	  in	  the	  transcriptional	  activation	   of	   genes	   that	   control	   the	   rate	   of	   proliferation	   of	   tumor	   cells	   [149-­‐151].	  Furthermore,	  Vimala	  et	  al.	  [152]	  recently	  showed	  that	  the	  E2F3	  gene	  is	  overexpressed	  in	   11	   breast	   cancer	   cell	   lines	   and	   siRNA-­‐E2F3	   based	   gene	   silencing	   facilitates	   the	  silencing	   of	   E2F3	   overexpression	   and	   limits	   the	   progression	   of	   breast	   tumors.	   This	  strongly	  conforms	  to	  our	  findings	  and	  implies	  that	  E2F3	  may	  be	  a	  potential	  therapeutic	  target	  for	  human	  breast	  cancer.	  HMDD	  analysis	  of	  the	  68	  driver	  miRNAs	  revealed	  that	  36	  miRNAs	  are	  involved	  in	  breast	  neoplasms,	  and	  the	  rest	  are	  associated	  with	  various	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cancer	   types	   such	   as	   hepatocellular	   carcinoma,	   adenocarcinoma,	   and	  prostate	   cancer.	  Also	   the	   identified	  key	  miRNA	  mir-­‐29c	  as	  well	  as	   the	  key	  gene	  POU2F1	  have	  recently	  been	  characterized	  as	  common	  hub	  nodes	  for	  three	  types	  of	  breast	  cancer	  [118].	  Thus,	  unlike	   the	   traditional	   separate	   analysis	   of	   gene	   expression	   profiles	   [163-­‐167]	   or	   the	  aberration	  of	  miRNA	  expression	  in	  cancer	  tissues	  [168-­‐170],	  this	  integrated	  molecular	  analysis	  of	  the	  dysregulated	  miRNAs	  and	  mRNAs	  was	  able	  to	  uncover	  important	  aspects	  of	   the	   miRNA-­‐mRNA	   interactome,	   the	   co-­‐regulation	  mechanisms,	   and	   the	   underlying	  pathogenesis	  of	  human	  cancer.	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Figure	  6-­‐2	  Regulatory	  interactions	  of	  the	  17	  key	  driver	  genes	  identified	  from	  miRNA-­‐mRNA	  interactions. Large	  nodes	  represent	  key	  driver	  genes	  and	  small	  nodes	  represent	  miRNAs,	  which	  regulate	  or	  are	  regulated	  by	  these	  driver	  genes.	  Square	  nodes	  are	   the	   identified	  driver	  genes	   that	  are	   targeted	  by	  drugs.	  The	  network	  was	  visualized	  using	  the	  Igraph	  package	  in	  R. 	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Table	  6-­‐2	  The	  deregulated	  miRNAs	  in	  proximity	  to	  somatic	  mutations.	  21	  cases	  of	  miRNA-­‐SNV	  pairs	  were	  identified.	  The	  genomic	  distance	  between	  miRNAs	  and	  SNVs	  is	  reported	  in	  base	  pairs.	  SNVs	  marked	  with	  (*)	  are	  the	  exclusive	  ones	  associated	  only	  with	  the	  dysregulated	  miRNAs	  and	  not	  with	  any	  of	  the	  non-­‐dysregulated	  miRNAs.	  	  
miRNA Chrom SNP Position SNP occurring gene Genomic distance (in bp) 
hsa-mir-181b-1 1 198711494    * PTPRC 116508 
hsa-mir-181a-1 1 198711494    * PTPRC 116679 
hsa-mir-1290 1 19186120      * TAS1R2 37445 
hsa-mir-9-1 1 156498803    * IQGAP3 -108670 
hsa-mir-205 1 209605636    * MIR205HG -158 
hsa-mir-3129 2 189928732 COL5A2 69030 
hsa-mir-145 5 148730786    * GRPEL2 79423 
hsa-mir-143 5 148730786    * GRPEL2 77695 
hsa-mir-106b 7 99662436      * ZNF3 29180 
hsa-mir-93 7 99662436      * ZNF3 28955 
hsa-mir-25 7 99662436      * ZNF3 28747 
hsa-mir-320a 8 22136963      * PIWIL2 -34488 
hsa-mir-199b 9 131048299 SWI5 -41299 
hsa-mir-199b 9 131023779 GOLGA2 -16779 
hsa-mir-152 17 46136186 NFE2L1 -21659 
hsa-mir-520d 19 54254529 MIR522 -31179 
hsa-mir-519e 19 54254529 MIR522 -71335 
hsa-mir-1323 19 54254529 MIR522 -79307 
hsa-mir-199a-1 19 10870471 DNM2 57631 
hsa-let-7f-2 X 53644041 HUWE1 -59888 
hsa-mir-718 X 153278098 IRAK1 7273 	   	  	  The	   deregulated	  miRNAs	   identified	   in	   the	   21	   cases	   were	   significantly	   closer	   to	   their	  somatic	  SNVs	  pairs	   in	  comparison	  to	  random	  SNV	  positions	  (p-­‐value	  equals	  to	  0.001).	  We	  also	  checked	  whether	  the	  non-­‐dysregulated	  miRNAs	  (925	  miRNAs)	  are	  in	  genomic	  proximity	  to	  the	  15	  somatic	  mutations	  involved	  in	  the	  21	  cases	  as	  well.	  We	  found	  that	  52	  non-­‐dysregulated	  miRNAs	   (5.6%)	  were	   in	   vicinity	   to	   only	   8	  mutations	   so	   that	   the	  other	  7	  mutations	  are	  exclusively	  associated	  with	  the	  dysregulated	  miRNAs	  (Table	  6-­‐2).	  	  Similarly,	   we	   analyzed	   the	   somatic	   mutations	   that	   mainly	   occur	   at	   differentially	  methylated	   CpG	   sites	   in	   promoter	   regions.	   Overall	   we	   identified	   347	   cases	   of	   SNV-­‐	  differentially	  methylated	   gene	   pairs.	   These	   are	  mostly	   located	   on	   chromosomes	   1,	   5,	  and	   X	   (Figure	   6-­‐3-­‐b).	   To	   address	   how	   changes	   in	   methylation	   levels	   caused	   by	  tumorigenesis	   correlate	   with	   mutation	   rates	   of	   different	   mutation	   genotypes,	   we	  separately	   analyzed	   the	   cases	   of	   up-­‐	   and	  down-­‐methylated	   genes.	   234	   cases	   involved	  up-­‐methylated	  genes,	  whereas	  only	  113	  were	  associated	  with	  down-­‐methylated	  genes.	  Generally,	   mutations	   in	   the	   promoter	   areas	   of	   up-­‐methylated	   genes	   occur	   at	   a	  remarkably	   higher	   rate	   than	   its	   peers	   in	   down-­‐methylated	   genes	   especially	   the	   C-­‐>T	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genotypes	  (Figure	  C-­‐2)	  since	  methylated	  cytosines	  are	  prone	  to	  thymine	  transitions	  by	  via	  deamination.	  This	  result	  is	  in	  line	  with	  the	  findings	  of	  Xia	  et	  al.	  [21]	  who	  examined	  the	   relationship	   between	   DNA	  methylation	   and	  mutation	   rate.	   Further,	   we	   examined	  which	   of	   the	   above	   somatic	   mutations,	   which	   were	   identified	   on	   the	   basis	   of	   their	  vicinity	   to	   either	   dysregulated	   miRNAs	   or	   differentially	   methylated	   genes,	   could	  potentially	   drive	   tumor	   cell	   proliferation	   in	   breast	   cancer.	   For	   this,	   we	   applied	   the	  random	  forest	  as	  a	  machine	  learning	  method	  implemented	  in	  the	  CHASM	  tool	  [100]	  to	  distinguish	  between	  driver	  and	  passenger	  somatic	  mutations.	  As	  training	  set,	  we	  used	  the	   breast	   cancer	   labeled	   data	   (BRCA)	   curated	   from	   the	   COSMIC	   database	   [283]	   and	  provided	  by	  CHASM.	  We	  identified	  nine	  driver	  mutations	  (three	  from	  miRNA	  cases	  and	  six	  from	  differentially	  methylated	  gene	  cases)	  suggesting	  their	  causative	  role	  in	  breast	  tumorigenesis	  (Table	  6-­‐3).	  All	  these	  nine	  mutations	  are	  missense	  and	  lead	  to	  an	  amino	  acid	   substitution.	   Next,	   we	   analyzed	   the	   possible	   impact	   of	   the	   resulting	   amino	   acid	  substitution	   on	   structure	   and	   function	   of	   the	   respective	   protein	   using	   the	   PolyPhen	  [284]	   and	   SIFT	   [285]	   prediction	   tools.	   Interestingly,	   both	  methods	   predict	   damaging	  effects	  of	   these	  mutations	  on	  protein	   function	  conforming	   their	   role	   in	  driving	  cancer	  (Table	  6-­‐3).	  	  	  
	  
	  
Figure	   6-­‐3	   Proximity	   analysis	   of	   the	   somatic	   mutations	   with	   the	   dysregulated	   miRNAs	   and	   differentially	  
methylated	   genes. Ideogram	  plots	   showing	   the	  genomic	  distribution	   for	   (a)	   the	  21	  cases	  of	  deregulated	  miRNAs	  adjacent	   to	   somatic	   mutations.	   The	   outer	   green	   circle	   shows	   the	   entire	   dataset	   of	   miRNAs	   ,	   whereas	   the	   next	  highlighted	  	  red	  lines	  refer	  to	  the	  adjacent	  deregulated	  miRNAs	  (20	  miRNAs	  where	  one	  miRNA	  is	  matched	  to	  2	  SNVs).	  The	   inner	   blue	   circle	   represent	   the	   entire	   set	   of	   somatic	   SNVs	   and	   the	   next	   highlighted	   red	   lines	   depict	   the	   SNVs	  matched	  to	  the	  21	  cases.	  (b)	  The	  347	  cases	  of	  somatic	  mutations	  occurring	  in	  the	  promoter	  regions	  of	  differentially	  methylated	  genes.	  The	  outer	  green	  circle	  shows	   the	  entire	  set	  of	  differentially	  methylated	  genes,	  whereas	   the	  next	  highlighted	  red	  lines	  refer	  to	  the	  identified	  cases	  adjacent	  to	  the	  somatic	  mutations.	  The	  inner	  blue	  circle	  represents	  the	  entire	  set	  of	  somatic	  SNVs	  and	  the	  next	  highlighted	  red	  lines	  depict	  the	  SNVs	  matched	  to	  the	  identified	  cases.	  The	  plot	   illustrates	   also	   the	   fractions	   of	   the	   three	   considered	   types	   of	   mutations	   (C-­‐>T,	   C-­‐>G	   and	   C-­‐>A)	   showing	   the	  occurrence	  frequency	  for	  each	  one. 	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6.3.5 Druggability	  analysis	  of	  protein	  products	  of	  the	  identified	  driver	  genes	  	  As	  mentioned	  above,	  we	  identified	  94	  driver	  genes	  from	  the	  TF-­‐mRNA	  interactions	  and	  17	  driver	  genes	  from	  the	  miRNA–mRNA	  interactions.	  The	  five	  well-­‐known	  breast	  cancer	  associated	  genes	  CREB1,	  MYC,	  TGFB1,	  TP53,	  and	  SPI1	  were	  common	  in	  both	  sets.	  Hence,	  in	  total	  106	  driver	  genes	  were	  identified.	  Also,	  we	  characterized	  68	  dominating	  miRNAs	  from	   the	   miRNA-­‐mRNA	   interactions,	   and	   nine	   driver	   mutations	   from	   the	   proximity	  analysis.	  	  To	   identify	  driver	  genes	  marked	  as	   anti-­‐breast	   cancer	  drug-­‐targets,	  we	   looked	  up	   the	  drugs	  and	  the	  anti-­‐neoplastic	  agents	  that	  target	  the	  proteins	  corresponding	  to	  the	  106	  driver	  genes	  based	  on	  the	  experimentally	  validated	  drug-­‐targets	  reports	  (see	  methods).	  	  We	   found	   that	   31%	   (33	   proteins)	   of	   the	   proteins	   belonging	   to	   the	   identified	   driver	  genes	  are	  binding	  targets	  of	  at	  least	  one	  anti-­‐breast	  cancer	  drug	  (Table	  C-­‐2).	  These	  33	  genes	   are	   highlighted	   as	   square	   nodes	   in	   the	   network	   visualizations	   of	   TF-­‐mRNA	  interactions	  (Figure	  6-­‐1,	  and	  Figure	  C-­‐1)	  and	  miRNA-­‐mRNA	  interactions	  (Figure	  6-­‐2).	  The	  remaining	   73	   driver	   genes	  were	   involved	   in	   the	   regulation	   of	   biological	   processes	   as	  well	  as	  metabolic	  processes	  of	  cancerogenesis	  in	  multiple	  organs	  such	  as	  lung,	  prostate,	  and	  bladder	  (Table	  C-­‐1).	  This	  supports	  the	  hypothesis	  that	  products	  of	  the	  remaining	  73	  identified	   driver	   genes	   as	   well	   as	   the	   identified	   68	   driver	   miRNAs	   and	   the	   9	   driver	  mutations	  may	  open	  up	  new	  avenues	  for	  novel	  therapeutic	  drugs.	  	  
Table	  6-­‐3	  List	  of	  the	  identified	  driver	  mutations	  ordered	  by	  CHASM	  score. The	  CHASM	  score	  is	  defined	  as	  the	  fraction	  of	  trees	  in	  the	  Random	  Forest	  that	  voted	  for	  the	  mutation	  being	  classified	  as	  a	  passenger.	  Lower	  scores	  increase	  the	  confidence	  of	  driver	  mutations.	  P-­‐values	  are	  calculated	  based	  on	  the	  null	  score	  distribution.	  The	  table	  reports	  also	  the	  changes	  in	  the	  related	  codons	  and	  amino	  acids.	  The	  SIFT	  and	  PolyPhen	  scores	  refer	  to	  the	  prediction	  of	  whether	  an	  amino	  acid	  substitution	  affects	  the	  function	  and	  structure	  of	  the	  human	  proteins.	  The	  SIFT	  prediction	  is	  based	  on	  the	  degree	  of	  conservation	  of	  amino	  acid	  residues	  in	  sequence	  alignments	  derived	  from	  closely	  related	  sequences	  (lower	  scores	  represent	  high	  impacts),	  whereas	  the	  PolyPhen	  prediction	  uses	  physical	  and	  evolutionary	  comparative	  considerations	  (higher	  scores	  represent	  high	  impact	  and	  severe	  influence	  on	  the	  protein	  function	  and	  structure).	  
	  
	  







score P-value Ref Alt 
Amino 
acids Codons SIFT score PolyPhen score 
1 PTPRC 198711494 0.158 6.00E-04 G A E/K Gag/Aag Deleterious (0) probably_damaging (0.999) 
8 TNKS 9413850 0.162 6.00E-04 C T S/F tCc/tTc Deleterious (0.01) Unknown (0) 
X GRIA3 122319694 0.298 0.0119 C A F/L ttC/ttA Deleterious (0) probably_damaging (0.996) 
5 PCDHB14 140604126 0.308 0.0134 C T S/L tCg/tTg Deleterious (0.02) Benign (0.368) 
X HUWE1 53644041 0.31 0.0136 C A R/L cGa/cTa Deleterious (0) probably_damaging (1) 
17 NFE2L1 46136186 0.326 0.0175 C T S/F tCc/tTc Deleterious (0.01) probably_damaging (0.994) 
9 NAIF1 130829249 0.336 0.0204 C G K/N aaG/aaC Deleterious (0) probably_damaging (0.995) 
2 KLHL23 170592167 0.354 0.0251 C G R/G Cga/Gga Deleterious (0) probably_damaging (0.999) 
12 KCNA1 5021107 0.384 0.0406 C T T/M aCg/aTg Deleterious (0) probably_damaging (0.997) 
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approach	  showed	  61%	  edges	  overlap	  with	  the	   inferred	  differential	  KDDN	  interactions	  due	  to	  tumorigenesis.	  	  	  To	  assess	  the	  reliability	  of	  our	  predictions	  of	  key	  drivers,	  we	  further	  included	  another	  differential	  network	  method,	  DiffCoEx	   (Differential	  Co-­‐expression	  Modules)	   [268]	   	   for	  identifying	   differential	   co-­‐expression	   modules	   between	   two	   biological	   cohorts.	   As	  mentioned	  above,	  33	  genes	  (31%)	  out	  of	  the	  total	  106	  driver	  genes	  suggested	  here	  are	  known	  key	   drivers	   and	   are	   targeted	   by	   currently	   known	  drugs.	   In	   contrast,	   only	   114	  KDDN	   genes	   (~20%)	   out	   of	   584	   hot	   spot	   genes	   involved	   in	   the	   KDDN	   network,	   are	  binding	  targets	  for	  anti-­‐cancer	  drugs	  (Figure	  6-­‐4).	  	  	  We	  detected	  an	  overlap	  of	  44%,	  and	  16%	  of	  the	  key	  genes	  identified	  by	  our	  approach	  and	  those	  obtained	  by	  KDDN	  and	  DiffCoEx,	  respectively.	  DiffCoEx	  yielded	  five	  different	  modules	   of	   genes	   in	   which	   the	   correlation	   of	   gene	   pairs	   within	   the	   module	   was	  significantly	  different	  between	  normal	  and	  tumor	  samples	  (Figure	  6-­‐5).	  Only	  151	  genes	  (17%)	   out	   of	   total	   886	   genes	   involved	   in	   these	  modules	  were	  marked	   as	   anti-­‐cancer	  drug	  targets.	  These	  percentages	  strongly	  support	   the	  reliability	  and	  robustness	  of	  our	  strategy	  in	   identifying	  genomic	  drivers	  that	  could	  be	  further	  experimentally	  examined	  as	  drug	  targets.	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6.4 Conclusions	  	  The	   enormously	   increasing	   availability	   of	   transcriptomic	   and	   epigenomic	   data	   from	  different	  biological	  experiments	  allow	  for	  deep	  and	  comprehensive	  integrative	  analysis.	  To	  this	  end,	  this	  study	  provides	  new	  insights	  into	  the	  complex	  regulatory	  mechanisms	  between	  gene	  expression,	  miRNA	  biomarkers,	  epigenetic	  modifications	  (represented	  at	  the	  level	  of	  DNA	  methylation)	  and	  genetic	  variants	  that	  are	  associated	  with	  the	  human	  breast	  cancer	  network.	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miRNAs	   are	   involved	   in	   cancerogenesis	   of	  multiple	   organs.	   Also,	   the	   identified	   driver	  mutations	  are	  predicted	  to	  cause	  damaging	  effects	  on	  protein	  functions	  and	  structures.	  	  These	  results	  expand	  our	  knowledge	  base	  of	  prospective	  genomic	  drivers	  and	  provide	  encouraging	   support	   that	  many	   of	   the	   novel	   identified	   genetic	   elements	   are	   potential	  targets	   for	   new	   drugs.	   We	   note	   that	   these	   key	   drivers	   were	   identified	   based	   on	   the	  presented	  computational	  framework	  and	  further	  wet	  lab	  work	  is	  warranted	  to	  confirm	  their	   efficacy	   as	   putative	   anti-­‐cancer	   drug	   targets.	   Especially	   when	   combined	   with	  experimental	  validation,	  this	  network-­‐based	  approach	  could	  promote	  novel	  insights	  on	  cancer	  genomic	  data	  to	  develop	  new	  therapeutic	  strategies	  and	  thus	  better	  treatment.	  Finally,	   this	   approach	   can	   be	   applied	   to	   other	   cancer	   types	   or	   complex	   diseases	   and	  could	  be	  extended	  for	  studying	  cellular	  development	  as	  well.	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7. Application	  to	  diabetes	  in	  
mouse	  	  	  	  This	  chapter	  is	  a	  shortened	  version	  of	  the	  following	  publication:	  	  




Differential	   network	   analysis	   concept	   has	   been	   recently	   introduced	   to	   improve	  
understanding	   of	   cellular	   interactions	   of	   specific	   tissues	   and	   complex	   diseases.	   This	  
chapter	   discusses	   the	   molecular	   mechanisms	   by	   which	   diabetes	   impairs	   Bone	   marrow-­‐
derived	  endothelia	  progenitor	  cells	  (EPC)	  in	  mouse	  using	  the	  differential	  network	  analysis	  
approach	   that	   makes	   use	   of	   the	   implemented	   GRN	   pipeline.	   We	   note	   that	   all	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Abstract	  	  Endothelial	   progenitor	   cells	   (EPCs)	   are	   a	   group	  of	   rare	   cells	   that	   originate	   from	  bone	  marrow	  (BM)	  or	  the	  wall	  of	  blood	  vessels.	  They	  are	  believed	  to	  play	  an	  important	  role	  in	  the	  repair	  of	  injured	  vascular	  endothelial	  cells	  and	  assisting	  in	  reperfusion	  of	  ischemic	  tissue.	   Decreased	   production	   and/or	   loss	   of	   function	   of	   EPCs	   are	   associated	   with	  diabetic	   vascular	   complications	   such	   as	   diabetic	   retinopathy,	   nephropathy	   and	  cardiovascular	  disease.	  However,	  the	  molecular	  mechanisms	  by	  which	  diabetes	  impairs	  EPCs	  remain	  unclear.	  In	  this	  study	  we	  conducted	  microarray	  analysis	  of	  the	  differential	  gene	  expression	  between	  Akita	  diabetic	  mice	  and	  age-­‐matched	  non-­‐diabetic	  controls	  in	  BM-­‐derived	   Lin+	   cells	   and	   Lin-­‐/VEGF-­‐R2+	   EPCs	   isolated	   from	   animals	   18	  weeks	   after	  diabetes.	   EPCs	  were	   isolated	   using	  MACS	   technology	   based	   on	   hematopoietic	   lineage	  depletion	   followed	  by	  enrichment	   for	  VEGF-­‐R2+	   cells	   to	  produce	  Lin-­‐/VEGF-­‐R2+	  EPCs.	  Lin+	   fractions	   were	   kept	   and	   used	   as	   non-­‐hematopoietic	   cells	   for	   analysis.	   RNA	   was	  extracted,	   processed	   and	   then	   hybridized	   to	  mouse	  WG-­‐6	   V2	   beadchips,	   followed	   by	  data	  analysis.	  In	  total,	  11	  differentially	  expressed	  genes	  were	  identified	  as	  specific	  to	  BM	  EPCs	   including	   3	   genes	   (CLCNKA,	   PIK3C2A,	   PTF1A)	   with	   known	   association	   with	  diabetic	   complications	   and	   8	   genes	   classified	   as	   transcription	   factors	   (PPARG,	  PPARA,	  
VDR,	  FOXO1,	  AR,	  NFKB1,	  HNF4A,	  SREBF1).	   Further	   analysis	   led	   to	   establishing	   a	   novel	  gene	   regulatory	   network	   specific	   to	   diabetic	   EPCs,	   which	   includes	   11	   main	   well	  documented	  diabetic	  genes	  and	  47	  genes	  and	  transcription	  factors	  regulating/regulated	  directly	   by	   those	   genes.	   Our	   results	   suggest	   that	   diabetes	   may	   influence	   specific	  signature	  genes	  in	  BM	  EPCs	  altering	  their	  capacity	  to	  proliferate	  and	  differentiate.	  
7.1 Introduction	  	  Chronic	  diabetes	  is	  associated	  with	  endothelial	  cells	  (ECs)	  injury,	  cells	  forming	  the	  inner	  lining	   of	   blood	   vessels	   [287].	   Such	   injury	   is	   believed	   to	   be	   repaired	   by	   resident	  endothelial	   cells,	   which	   have	   limited	   regenerative	   capacity	   [288,	   289],	   resident	  endothelial	  progenitor	  cells	  (EPCs)	  [290,	  291],	  and	  BM	  derived	  EPCs	  [292-­‐294].	   It	  has	  been	  reported	  that	  diabetes	   is	  associated	  with	   impairment	  of	  EPC	   function	  [295-­‐297].	  Diabetic	   patients	  were	   shown	   to	   have	   reduced	   EPC	   numbers	   in	   the	   peripheral	   blood	  (PB)	   [298,	   299]	   and	   the	   ability	   of	   EPCs	   isolated	   from	   PB	   of	   people	   with	   diabetes	   to	  proliferate,	   form	   tubes	   and	   adhere	   in	   vitro	   is	   impaired	   [300,	   301].	  Most	   importantly,	  EPCs	  from	  diabetic	  individuals	  are	  less	  effective	  in	  repairing	  vascular	  injuries	  [300,	  302,	  303].	  Several	   studies	  suggest	   that	   reduced	  number	  and/or	  dysfunction	  of	  EPCs	   in	  cell	  mobilization,	   proliferation,	   adhesion	   and	   incorporation	   into	   the	   vasculature	   may	  contribute	  to	  diabetic	  vascular	  complications	  [298,	  300,	  304].	  	  Recently,	   our	   collaborators	   reported	   an	   impaired	  mobilization	   capacity	   of	  mouse	   BM	  Lin-­‐/VEGF-­‐R2+	   EPCs	   in	   diabetic	   mice	   [305].	   EPCs	   are	   usually	   defined	   based	   on	   their	  surface	  markers	  and	  proliferative	  and	  clonogenic	  potential	  and	  they	  are	  believed	  to	  be	  lineage	  and	  functionally	  heterogeneous	  [290],[293].	  It	  has	  been	  suggested	  that	  an	  insult	  to	   the	   stem	   cell	   niche	   might	   initiate	   or	   contribute	   to	   reduction	   in	   the	   numbers	   and	  impairment	  of	  EPC	   function	   [306].	  These	  EPCs	  play	  an	   important	  role	   in	  regenerating	  the	  endothelium	  through	  migration,	  proliferation,	  differentiation	  and	  by	  secreting	  pro-­‐angiogenic	   cytokines	   [307].	   BM	   Lin-­‐/VEGF-­‐R2+	   EPCs	   express	   VEGF-­‐R2	   and	   CD34	   and	  they	  do	  not	  express	  CD31,	  CD45,	  CD14	  and	  CD115.	  They	  have	  typical	  EPCs	  properties	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such	   as	   formation	   of	   cobblestone	   colonies,	   Dil-­‐acLDL	   uptake,	   lectin	   binding	   and	   can	  incorporate	  into	  damaged	  blood	  vessels	  in	  vivo	  after	  intravitreal	  transplantation	  in	  eyes	  subjected	   to	   the	   laser-­‐induced	   retinal	   vascular	   injury[293,	   308]	   in	   association	   with	  differential	   expression	   of	   only	   two	   genes	   (SDF-­‐1	   (CXCL12)	   and	   SELE)	   in	   diabetic	  Lin−/VEGF-­‐R2+	  EPCs	  [305].	  	  The	  majority	   of	  molecular	   studies	   on	   the	   impairment	   of	   diabetic	   EPCs	   function	   have	  been	  conducted	  on	  human	  EPCs	   isolated	   from	  the	  PB	  of	  people	  with	  a	   long	  history	  of	  diabetes.	  Thus,	   little	   is	  known	  about	  the	  changes	  occurring	   in	  EPCs	   located	  within	  the	  BM	  in	  the	  early	  stages	  of	  diabetes.	   In	   this	  study	  we	   isolated	  Lin+	  cells	  and	  Lin−/VEGF-­‐R2+	  EPCs	  from	  Akita	  diabetic	  mice	  and	  age-­‐matched	  non-­‐diabetic	  controls.	   In	  order	  to	  explore	  the	  molecular	  mechanisms	  by	  which	  early	  diabetes	  impairs	  the	  function	  of	  BM-­‐EPCs,	  we	  conducted	  microarray	  analysis	  to	  profile	  differential	  gene	  expression	  and	  their	  regulatory	   interactions	   between	   diabetic	   and	   non-­‐diabetic	   animals	   using	   well-­‐established	  data	  analysis	  methods	  [208,	  309].	  
7.2 Methods	  
7.2.1 Animals	  The	   Akita	   mouse	   carries	   a	   dominant	   point	   mutation	   in	   the	   Insulin	   2	   gene	   on	  chromosome	  7	  resulting	  in	  the	  development	  of	  diabetes	  at	  approximately	  4	  weeks	  after	  birth	  with	  almost	  100%	  penetrance.	  As	  female	  mice	  develop	  diabetes	  more	  slowly	  and	  less	   stably	   compared	  with	  males,	   only	  male	  mice	   heterozygous	   for	   the	   Ins2Akita	   allele	  (diabetic	   group)	  as	  well	   as	  male	  mice	  homozygous	   for	   the	  wild	   type	   Ins2	  allele	   (non-­‐diabetic	  mice)	  were	  used	   in	   this	   study.	  Once	  diabetes	  was	   established	   (blood	   glucose	  level>13.3mmol/L),	  mice	  were	  monitored	  weekly	  for	  changes	  in	  bodyweight	  and	  blood	  glucose	   levels	   for	   18	  weeks.	   The	   blood	   glucose	   level	   was	  measured	   using	   Accu-­‐Chek	  Performa	  (Roche,	  Germany).	  No	  supplemental	  insulin	  was	  given.	  Only	  mice	  with	  blood	  glucose	   levels	  consistently	  ≥	  13.3	  mmol/L	  were	  used	   in	   this	  study.	  Nine	  diabetic	  mice	  and	  age-­‐matched	  non-­‐diabetic	  controls	  were	  used	  in	  this	  study.	  
7.2.2 Group	  design	  and	  comparisons	  	  Four	   experimental	   groups	   were	   established:	   1)	   Lin+	   cells	   from	   non-­‐diabetic	   mice,	   2)	  Lin+	  cells	  from	  diabetic	  mice,	  3)	  Lin-­‐/VEGF-­‐R2+	  EPCs	  from	  non-­‐diabetic	  mice	  and	  4)	  Lin-­‐/VEGF-­‐R2+	  EPCs	  from	  diabetic	  mice.	  The	  Lin+	  cells	  were	  used	  as	  an	  internal	  reference	  to	  identify	   differential	   gene	   expression	   occurring	   not	   exclusively	   in	   Lin-­‐/VEGF-­‐R2+	   cells.	  Six	   different	   comparisons	  were	   conducted	   between	   the	   four	   groups	   (Table	   7-­‐1).	   This	  setup	  allowed	  us	  to	  distinguish	  differential	  gene	  expression	  which	  specifically	  occurred	  in	  diabetic	  BM	  derived	  Lin-­‐/VEGF-­‐R2+	  EPCs	  from	  that	  occurring	  in	  other	  phenotypes	  of	  hematopoietic	   lineage	   committed	   BM	   cells.	   Hence,	   only	   significant	   changes	   in	   gene	  expression	  observed	  in	  diabetic	  versus	  non-­‐diabetic	  Lin-­‐/VEGF-­‐R2+	  progenitor	  cells	  that	  did	  not	  occur	  in	  the	  Lin+	  population	  were	  considered	  in	  the	  final	  analysis.	  
7.2.3 Data	  processing	  	  Raw	   expression	   values	   were	   background	   corrected,	   log2	   transformed	   and	   quantile	  normalized	  using	  the	  lumiR	  package	  [310]	  of	  the	  Bioconductor	  suite	  [220].	  Expression	  profiles	   of	   redundant	   probe	   sets	   were	  merged	   by	   computing	   the	  mean	   of	   all	   probes	  related	  to	  single	  genes	  as	  reported	  before	  in	  [309].	  Before	  the	  differential	  analysis,	  we	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removed	   the	   25%	   of	   the	   genes	   that	   showed	   the	   least	   variability	   across	   the	   sample	  groups.	  Genes	  with	  higher	  variation	  were	  considered	  as	  potentially	  good	  candidates	  to	  be	  differentially	  expressed	  [221].	  	  
Table	  7-­‐1	  The	  six	  possible	  comparisons	  (1-­‐6)	  between	  the	  4	  groups	  of	  samples	  and	  the	  significance	  of	  each	  
comparison	  to	  the	  study	  analysis.	  	  
Comparison	   Compared	  groups	   Significance/meaning	  1	   Non-­‐diabetic	   Lin+	   vs	   diabetic	  Lin+	   Effect	  of	  diabetes	  on	  Lin+	  2	   Non-­‐diabetic	   Lin+	   vs	   Non-­‐diabetic	  EPC	   Difference	   between	   Lin+	   and	   EPC	  genes	  in	  healthy	  conditions	  3	   Diabetic	  Lin+	  vs	  diabetic	  EPC	   Difference	   between	   Lin+	   and	   EPC	  genes	  in	  diabetic	  conditions	  4	   Non-­‐diabetic	   EPC	   vs	   diabetic	  EPC	   Effect	  of	  diabetes	  on	  EPC	  5	   Lin+	  vs	  EPC	  	   Difference	   between	   Lin+	   and	   EPC	  combined	  6	   Non-­‐diabetic	  vs	  diabetic	   Difference	  between	  non-­‐diabetic	   and	  diabetic	  cells	  	  
7.2.4 Differential	  expression	  analysis	  	  The	   six	   comparisons	   of	   samples	   were	   compared	   by	   differential	   expression	   analysis	  using	  three	  methods:	  1)	  Significance	  Analysis	  of	  Microarray	  (SAM)	  [90],	  2)	  moderated	  t-­‐test,[221]	   3)	   the	   area	   under	   the	   curve	   of	   the	   receiver	   operator	   characteristics	   (AUC	  ROC)	  [221].	  Genes	  that	  were	  classified	  as	  differentially	  expressed	  genes	  by	  at	  least	  two	  of	   those	   three	  methods	  were	   included	   in	   the	   list	  of	  differentially	  expressed	  genes.	  We	  focused	  on	  genes	  that	  are	  exclusively	   involved	   in	  the	   fourth	  comparison	  (non-­‐diabetic	  Lin-­‐/VEGF-­‐R2+	   EPCs	   vs	   diabetes	   Lin-­‐/VEGF-­‐R2+	   EPCs)	   and	   not	   in	   any	   of	   the	   other	  comparisons.	  	  
7.2.5 Gene	  regulatory	  network	  (GRN)	  	  We	   applied	   the	   GRN	   pipeline	   presented	   in	   section	   3.2	   on	   the	   expression	   data	   of	   the	  differentially	  expressed	  genes	  for	  the	  healthy	  and	  diseases	  samples	  separately.	  Then	  we	  used	  the	  concept	  of	  the	  differential	  network	  analysis	  to	  infer	  the	  statistically	  significant	  topological	   changes	   in	   transcriptional	   networks	   representing	   the	   two	   biological	  samples	  (non-­‐diabetic	  Lin-­‐/VEGF-­‐R2+	  EPCs	  vs	  diabetes	  Lin-­‐/VEGF-­‐R2+	  EPCs).	  This	  gave	  a	  differential	  network	  of	  109	  genes	  (including	  25	  differentially	  expressed	  genes	  and	  84	  TCFs)	   and	   347	   edges.	   Figure	   7-­‐1	   depicts	   the	   differential	   network	   analysis	   approach	  employing	  the	  GRN	  pipeline	  for	  data	  processing	  and	  constructing	  the	  diabetes-­‐specific	  grn	  for	  BM	  derived	  EPC	  cells.	  	  	  We	  downloaded	  a	  list	  of	  266	  diabetic-­‐associated	  genes	  from	  Mouse	  Genome	  Informatics	  (MGI)	  database	  [225].	  Out	  of	  these	  109	  genes,	  only	  11	  genes	  (3	  differentially	  expressed	  genes	  and	  8	  TCFs)	  belong	  to	  the	  diabetic	  associated	  gene	  list.	  The	  full	  list	  of	  genes	  in	  the	  GRN	   is	   provided	   in	   supplementary	   Table	   D-­‐1.	   To	   extract	   only	   the	   network	   module	  related	   to	   the	  onset	  of	  diabetes,	  we	  removed	  unconnected	  nodes	  and	  considered	  only	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regulation	  links	  where	  either	  the	  “FROM”	  or	  “TO”	  nodes	  belong	  to	  the	  11	  diabetic	  genes	  identified	  above.	  Expression	  heat	  maps	  and	  PCA	  plots	  were	  generated	  by	  R	  [188].	  The	  GRN	  network	  was	  visualized	  using	  the	  igraph	  package	  in	  R.	  
7.2.6 Functional	  enrichment	  	  The	  functional	  enrichment	  and	  annotation	  analysis	  was	  conducted	  as	  reported	  before	  in	  [208].	   	  Briefly,	   enriched	  KEGG	  Pathways	  and	  GO	   functional	   categories	  were	   identified	  using	   the	  DAVID	   tool	   [135].	  We	  determined	  which	  pathways	   /	   functional	   terms	  were	  annotated	  to	  at	   least	  2	  genes	  and	  were	  statistically	  overrepresented	  in	  the	  study	  gene	  set	   against	   the	   full	   mouse	   genome	   (control).	   Enrichment	   was	   evaluated	   through	   the	  hyper-­‐geometric	  test	  using	  a	  p-­‐value	  threshold	  of	  0.05.	  	  
	  
	  
Figure	  7-­‐1	  The	  differential	  network	  approach	  utilizing	  the	  GRN	  pipeline.	  	  	  
7.3 Results	  
7.3.1 Probes	  summarization	  and	  filtration	  	  	  One	   of	   the	   aims	   of	   this	   study	   was	   to	   identify	   genes	   that	   are	   differentially	   expressed	  between	  2	  sample	  groups	  (diabetic	  and	  non-­‐diabetic	  Lin−/VEGF-­‐R2+	  EPCs).	  Microarray	  probes	  of	  mouse	  WG-­‐6V2	  beadchip	  (45,281	  probes)	  were	  summarized	  by	  considering	  the	  mean	  of	  the	  expression	  values	  of	  all	  probes	  related	  to	  each	  gene	  in	  each	  sample.	  This	  yielded	  at	  the	  end	  30,869	  mouse	  genes	  instead	  of	  45,281	  probes.	  Then,	  non-­‐specific	  pre-­‐filtering	   was	   performed	   removing	   the	   25%	   of	   all	   genes	   showing	   the	   least	   variability	  across	  the	  two	  sample	  groups	  before	  the	  differential	  analysis.	  	  
7.3.2 Differential	  expression	  analysis	  	  To	   identify	  differentially	  expressed	  genes	  between	  non-­‐diabetic	  and	  diabetic	   samples,	  only	  the	  summarized	  30,869	  genes	  were	  used	  for	  comparisons.	  After	  applying	  the	  three	  differential	  expression	  methods	  (SAM,	  moderated	  t-­‐test,	  and	  AUC	  ROC)	  on	  each	  of	   the	  six	  comparisons,	  genes	   that	  were	   identified	  as	  differentially	  expressed	  by	  at	   least	   two	  out	  of	  the	  three	  methods	  were	  chosen	  for	  further	  analysis.	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Then,	  using	  Venn	  diagrams	  we	  identified	  those	  genes	  which	  were	  exclusively	  included	  in	  the	  fourth	  comparison	  (between	  non-­‐diabetic	  EPCs	  and	  diabetic	  EPCs)	  and	  not	  in	  any	  of	  the	  other	  comparisons)	  as	  shown	  in	  Figure	  7-­‐2.	  This	  process	  identified	  80	  genes	  that	  are	  specific	  to	  comparison	  4	  only.	  	  	  
	  
	  
Figure	  7-­‐2	  Venn	  diagrams	  showing	  overlapping	  differentially	  expressed	  genes	  among	  the	  6	  comparisons.	  	  See	  Table	  1.	  (A)	  Comparisons	  1-­‐5,	  (B)	  comparisons	  1-­‐4	  and	  6.	  In	  both	  Venn	  diagrams	  the	  same	  80	  genes	  were	  found	  specific	  to	  comparison	  4	  (non-­‐diabetic	  EPCs	  versus	  diabetic	  EPCs).	  	  	  This	  approach	  allowed	  us	   to	   identify	   those	  genes	  which	  might	   influence	  BM	  EPCs	  but	  not	  hematopoietic	  lineage	  committed	  cells	  by	  targeting	  certain	  regulatory	  elements.	  To	  further	   investigate	   changes	   in	   diabetic	   associated	   genes	   in	   BM	   EPCs,	   266	   diabetic	  associated	  genes	  were	  downloaded	  from	  MGI[225]	  and	  then	  cross	  matched	  with	  the	  80	  identified	   genes.	   We	   found	   that	   the	   identified	   differentially	   expressed	   genes	   were	  significantly	  associated	  with	  the	  list	  of	  diabetic	  associated	  genes	  (p-­‐value	  0.0319	  using	  hyper-­‐geometric	   test)	   because	   the	   three	   genes	   CLCNKA	   (down-­‐regulated)	   and	  PTF1A	  and	  PIK3C2A	  (both	  up-­‐regulated)	  were	  common	  between	  the	  two	  lists.	  A	  heat	  map	  was	  generated	  to	  show	  the	  relative	  gene	  expression	  among	  the	  four	  sample	  groups	  (Figure	  2A).	   	  Then	  we	  selected	  non-­‐diabetic	  and	  diabetic	  EPCs	  groups	  to	  generate	  a	  heat	  map	  for	   the	   relative	   expression	   of	   the	   80	   identified	   genes	   (Figure	   7-­‐3).	   To	   show	   how	   the	  differentially	  expressed	  80	  genes	  are	  separated	  between	  non-­‐diabetic	  EPCs	  and	  diabetic	  EPCs,	   principle	   component	   (PCA)	   analysis	   was	   conducted.	   The	   PCA	   clustered	   the	  differentially	   expressed	   genes	   into	   down-­‐regulated	   and	   up-­‐regulated	   genes	   based	   on	  their	  relative	  expression	  levels.	  
7.3.3 Gene	  Regulatory	  Network	  	  Compiling	   the	  GRN	   for	   the	   identified	   differentially	   expressed	   genes	   revealed	   84	  TCFs	  that	  were	  regulating	  25	  out	  of	  the	  80	  differentially	  expressed	  genes.	  Figure	  7-­‐4	  shows	  an	  expanded	  GRN	  with	  25	  +	  84	  =	  109	  genes	  including	  the	  identified	  TCFs.	  Only	  8	  out	  of	  the	  84	  TCFs	  (PPARG,	  PPARA,	  VDR,	  FOXO1,	  AR,	  NFKB1,	  HNF4A,	  SREBF1)	  were	  classified	  as	  diabetes	  related	  genes.	  Thus,	  a	  total	  of	  11	  (3	  differentially	  expressed	  genes	  and	  8	  TCFs)	  diabetic	   related	   genes	   were	   present	   in	   the	   expanded	   GRN	   network	   of	   109	   genes.	  Interestingly,	   the	  hyper-­‐geometric	   test	  conducted	  on	   the	   list	  of	  all	   the	  109	  GRN	  genes	  showed	  a	  highly	  significant	  association	  with	  the	  diabetes	  related	  genes	  (P-­‐value	  1.138	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e-­‐09).	   When	   considering	   only	   genes	   and	   TCFs	   that	   are	   connected	   to	   the	   11	   diabetic	  related	  genes,	  a	  final	  GRN	  module,	  which	  includes	  58	  nodes	  that	  could	  potentially	  drive	  and	  dissect	  the	  early	  diabetes	  and	  related	  dysfunctions	  in	  BM	  EPC	  cells,	  was	  compiled	  and	  visualized	  in	  Figure	  7-­‐5.	  The	  details	  of	  the	  final	  58	  GRN	  genes	  and	  TCFs	  are	  listed	  in	  supplementary	  Table	  D-­‐1.	  	  	  
	  
Figure	  7-­‐3	  Heat	  maps	  of	  the	  microarray	  analysis	  results.	  Differentially	  expressed	  80	  core	  enrichment	  genes	  in	  comparison	  4	  (non-­‐diabetic	  EPCs	  versus	  diabetic	  EPCs).	  Green	  spots	  represent	  down-­‐regulated	  genes,	  and	  red	  spots	  represent	  up-­‐regulated	  genes.	  The	  order	  of	  genes	  is	  obtained	  by	  hierarchical	   clustering.	   The	   orange	   color	   represents	   the	   non-­‐diabetic	   EPCs	   while	   the	   blue	   color	   represents	   the	  diabetic	  EPCs.	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including	  increased	  oxidative	  stress,	  NADPH	  oxidase	  activation,	  an	  altered	  nitric	  oxide	  pathway	  and	  increases	  in	  inflammatory	  cytokines	  [311].	  However,	  it	  is	  unlikely	  that	  the	  dysfunction	   of	   diabetic	   EPCs	   could	   be	   explained	   by	   a	   single	   independent	  mechanism	  when	   diabetes	   is	   known	   to	   be	   a	   complex	   patho-­‐physiological	   syndrome	   that	   leads	   to	  EPCs	  dysfunction	  and	  subsequently	  vascular	  damage	  at	  several	   levels.	  Thus	  we	  used	  a	  microarray	   analysis	   approach	   and	   complemented	   that	   with	   powerful	   and	   well-­‐established	   data	   analysis	  methods	   [208,	   309]	   to	   investigate	   genes	   and	   TCFs	   that	   are	  potentially	  affected	  in	  diabetic	  EPCs	  and	  could	  be	  responsible	  for	  their	  dysfunction.	  We	  were	  able	  to	  construct	  a	  novel	  gene	  regulatory	  network	  specific	  to	  BM	  EPCs	  that	  have	  been	  exposed	  to	  short	  period	  of	  diabetes.	  	  
	  
Figure	  7-­‐4	  Gene	  regulatory	  network	  common	  to	  EPCs.	  	  The	  expanded	  diabetes	  gene	  regulatory	  network	  in	  EPCs	  including	  109	  genes	  (25	  differentially	  expressed	  genes	  and	  84	  transcription	  factors	  that	  regulate	  them).	  	  We	  previously	  demonstrated	  that	  BM	  Lin−/VEGF-­‐R2+	  EPCs	  form	  cobblestone	  colonies	  in	  culture,	   express	   surface	  markers	   such	   as	  VEGF-­‐R2	   and	  CD34,	   and	   are	  more	  primitive	  than	  other	  described	  EPCs	  with	   a	   limited	   capacity	   to	  participate	   in	   vascular	   repair.	   It	  appears	   that	   EPC	   function	   in	   the	   early	   stages	   of	   diabetes	   (18	   weeks)	   is	   impaired,	   in	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particular	   their	   ability	   to	   mobilize,	   rather	   than	   their	   ability	   to	   proliferate,	   leading	   to	  trapping	   of	   EPCs	   in	   BM	   [293,	   305,	   312].	   Since	   the	   exact	   mechanism	   underlying	   this	  impaired	  mobilization	   is	   still	   unknown,	   identifying	   the	   responsible	   genes	   through	   the	  use	  of	  high	  throughput	  methods	  such	  as	  microarray	  may	  lead	  to	  valuable	  insights	  into	  the	   pathogenesis	   of	   diabetic	   vascular	   disease.	   Most	   microarrays	   contain	   probes	   for	  many	  more	  genes	  than	  are	  differentially	  expressed.	  	  	  
	  
Figure	  7-­‐5	  A	  final	  gene	  regulatory	  network	  (GRN)	  module	  of	  the	  identified	  11	  diabetes-­‐related	  genes	  and	  the	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filter	   based	   on	   the	   variance	   itself	   and	   removed	   the	   25%	   genes	   showing	   the	   lowest	  variability	  across	  the	  samples,	  as	  previously	  described	  [208,	  309].	  	  Following	   the	   analysis	   of	   the	   differentially	   expressed	   genes,	   KEGG	   analysis	   of	   the	   58	  genes	  of	  the	  final	  GRN	  module	  revealed	  highly	  significant	  pathways	  (Table	  7-­‐2	  A)	  such	  as	   ‘maturity	   onset	   diabetes	   of	   the	   young’	   and	   ‘peroxisome	   proliferator-­‐activated	  receptor	   (PPAR)’	   signaling	   pathways.	   The	   PPAR	   pathway	   plays	   a	   critical	   role	   in	   the	  regulation	  of	  diverse	  biologic	  processes.	  There	  are	  3	  main	   isotypes	  of	  PPAR	  gene	  (α,	  β	  and	  γ).	   In	  our	  GRN	  two	  TCFs/genes	  (PPARα	  and	  PPARγ)	  are	  found	  as	  major	  players	  in	  the	   diabetic	   EPCs	   network.	   Previously,	   PPARα	   has	   been	   implicated	   in	   the	   hepatic	  metabolic	   response	   to	   diabetes	  mellitus.	  PPARγ	   is	   expressed	   in	   all	   major	   cells	   of	   the	  vasculature	   (e.g.,	   endothelial	   and	   smooth	   muscles	   cells)	   and	   there	   mutations	   lead	   to	  severe	  insulin	  resistant	  and	  type-­‐2	  diabetes	  [314].	  More	  recently,	  PPARα	  was	  found	  to	  play	   an	   important	   role	   in	   the	   regulation	   of	   EPC	   trafficking.	   Activation	   and	   over-­‐expression	   of	   PPARα	   both	   suppressed	   EPCs	   mobilization	   and	   homing	   induced	   by	  hypoxia,	  which	  was	   shown	   to	  be	   through	   the	   inhibition	  of	   the	  HIF-­‐1α/SDF-­‐1	   pathway	  [315].	  This	  supports	  our	  finding	  where	  PPARα	  was	  found	  to	  be	  up	  regulated	  in	  diabetic	  EPCs,	  consistent	  with	  an	  anti-­‐angiogenic	  role.	  	  Another	  TCF	  that	  is	  part	  of	  the	  diabetic	  EPC	  network	  is	  FOXO1	  which	  plays	  a	  crucial	  role	  in	   regulating	   gluconeogenesis	   and	   glycogenolysis	   by	   insulin	   signaling	   [316].	   FOXO1	  regulates	  PIK3C2A,	  one	  of	   the	  major	  diabetic	  genes	   in	   the	  GRN,	  which	  encodes	   for	   the	  PIK3C2A	  enzyme	  (PI3K	  family)	  that	  is	  activated	  by	  insulin.	  Thus,	  in	  diabetic	  conditions	  the	   activity	   of	   PIK3C2A	   enzyme	   is	   expected	   to	   be	   suppressed,	   which	   may	   result	   in	  upregulation	  of	  FOXO1.	  Both	  PIK3C2A	  and	  PTF1A,	  which	  are	  the	  only	  two	  differentially	  upregulated	   diabetic	   genes	   in	   the	   GRN,	   are	   found	   to	   be	   regulated	   by	   other	   identified	  genes	   and	  TCF	   in	   the	  GRN.	   In	   other	  words,	   they	  do	  not	   regulate	   any	  of	   the	   identified	  GRN	   genes	   and	   TCF	   leading	   to	   the	   assumption	   of	   them	  being	   the	  main	   and	   the	  most	  important	  genes	  of	  the	  diabetic	  GRN	  and	  perhaps	  they	  interact	  directly	  with	  the	  system	  (Figure	  7-­‐5).	  	  The	  other	  mechanism	  by	  which	  FOXO	  regulates	  diabetic	  EPCs	  is	  via	  the	  oxidative	  stress	  activated	  P66SHC-­‐AKT-­‐FOXO	  pathway	  [317].	  P66SHC	  was	  reported	  to	  be	  involved	  in	  EPC	  dysfunction	  due	  to	  hyperglycemia.	  When	  P66SHC	  was	  deleted	  in	  mice,	  the	  BM-­‐derived	  EPCs	  showed	  increased	  survival	  and	  more	  resistance	  to	  oxidative	  stress	  [318].	  Based	  on	  Figure	  5	  FOXO1	  is	  linked	  directly	  with	  PIK3C2A.	  This	  may	  contribute	  to	  the	  dysfunction	  of	   EPCs	   observed	   in	   diabetes	   through	   a	   negative	   effect	   of	   hyperglycemia-­‐induced	  oxidative	   stress	   on	   the	   PIK3C2A/FOXO1	   axis	   and	   the	   activation	   of	   P66SHC-­‐AKT-­‐FOXO	  pathway.	  Another	  list	  of	  26	  highly	  significant	  functional	  terms	  that	  are	  relevant	  to	  our	  cell	  type	  and	  injury	  were	  identified	  through	  GO	  analysis	  of	  the	  58	  genes	  of	  the	  final	  GRN	  module	  (Table	  7-­‐2	  B).	  	  	  There	   is	  strong	  evidence	  that	  supports	   the	  concept	  of	  diabetes	  altering	  the	  number	  of	  circulating	   EPCs	   [319,	   320],	   which	   are	   likely	   trapped	   in	   the	   BM,	   and	   impairing	   their	  vasoreparative	   potential	   resulting	   in	   premature	   senescence	   [298,	   321].	   In	   this	   study	  there	   was	   an	   obvious	   dominance	   of	   pathways	   that	   involve	   insulin	   and	   glucose	  metabolism,	  secretion,	  response	  and	  regulation	  (13	  pathways)	  and	  progenitor	  cells	  and	  epithelial	  cells	  differentiation,	  proliferation	  and	  development	  (13	  pathways).	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Table	  7-­‐2	  Selected	  highly	  significant	  (A)	  KEGG	  and	  (B)	  GO	  terms	  and	  the	  GRN	  genes	  that	  are	  involved	  in	  each	  
category.	  
A)	  	  
KEGG	  Subcategory	  name	   p-­‐value	   Number	   of	  
genes	  
Gene	  IDs	  of	  test	  set	  in	  subcategory	  Pathways	  in	  cancer	   8.82E-­‐07	   9	   AR	  FOXO1	  RUNX1	  PPARG	  TCF7	  CEBPA	  NFKB1	  
MAX	  CASP3	  Acute	  myeloid	  leukemia	   4.76E-­‐05	   4	   RUNX1	  TCF7	  CEBPA	  NFKB1	  Maturity	   onset	   diabetes	   of	   the	  young	   8.65E-­‐05	   3	   HNF4A	  HNF4G	  FOXA2	  MAPK	  signaling	  pathway	   2.18E-­‐03	   5	   NFATC2	  MEF2C	  NFKB1	  MAX	  CASP3	  Adipocytokine	   signaling	  pathway	   2.35E-­‐02	   2	   PPARA	  NFKB1	  Phosphatidylinositol	   signaling	  system	   3.09E-­‐02	   2	   CDS1	  PIK3C2A	  PPAR	  signaling	  pathway	   3.38E-­‐02	   2	   PPARA	  PPARG	  Apoptosis	   4.14E-­‐02	   2	   NFKB1	  CASP3	  
	  
B)	  
GO	  Subcategory	  name	   p-­‐value	   Number	   of	  
genes	  
GeneIDs	  of	  test	  set	  in	  subcategory	  Cell	  differentiation	   3.19E-­‐12	   21	   TCF3	   HNF4A	   MEF2C	   IKZF1	   AR	   VDR	  
RUNX1	   FOXJ1	   PPARG	   FOXA1	   FOXO4	  
CEBPA	  FOXD3	  FOXA2	  SRY	  ALX1	  NKX6-­‐2	  
ZEB1	  NR2F2	  CASP3	  PTF1A	  Regulation	  of	  cell	  proliferation	   3.52E-­‐07	   10	   HNF4A	   AR	   FOXO1	   FOXJ1	   PPARG	   TCF7	  
FOXO4	  CEBPA	  ZEB1	  CASP3	  Regulation	  of	  cell	  differentiation	   5.93E-­‐08	   10	   IKZF1	   AR	   VDR	   FOXJ1	   PPARG	   FOXA1	  
CEBPA	  FOXA2	  NKX6-­‐2	  ZEB1	  Cell	  fate	  commitment	   1.61E-­‐11	   9	   TCF3	   MEF2C	   AR	   PPARG	   FOXA1	   FOXA2	  
NKX6-­‐2	  CASP3	  PTF1A	  Negative	  regulation	  of	  cell	  Proliferation	   2.46E-­‐08	   8	   HNF4A	   AR	   FOXJ1	   PPARG	   FOXO4	   CEBPA	  
ZEB1	  CASP3	  Epithelium	  development	   4.48E-­‐07	   8	   AR	   VDR	   PPARG	   FOXA1	   FOXA2	   ALX1	  
ZEB1	  CASP3	  Positive	  regulation	  of	  cell	  differentiation	   8.51E-­‐06	   6	   IKZF1	   PPARG	   FOXA1	   CEBPA	   FOXA2	  
NKX6-­‐2	  Hemopoiesis	   3.23E-­‐05	   6	   TCF3	  IKZF1	  RUNX1	  FOXJ1	  CEBPA	  ZEB1	  Epithelial	  cell	  differentiation	   4.39E-­‐07	   6	   AR	  PPARG	  FOXA1	  FOXA2	  ZEB1	  CASP3	  Negative	  regulation	  of	  cell	  Differentiation	   8.33E-­‐04	   4	   FOXJ1	  FOXA2	  NKX6-­‐2	  ZEB1	  Blood	  vessel	  development	   2.61E-­‐03	   4	   MEF2C	  FOXO1	  RUNX1	  NR2F2	  Response	  to	  insulin	  stimulus	   5.18E-­‐04	   3	   PPARA	  FOXO1	  SREBF1	  Response	  to	  glucose	  stimulus	   5.92E-­‐05	   3	   HNF4A	  SREBF1	  CASP3	  Regulation	  of	  cell	  cycle	   9.67E-­‐03	   3	   HNF4A	  FOXO4	  CASP3	  Glucose	  metabolic	  process	   3.31E-­‐03	   3	   PPARA	  HNF4A	  FOXO1	  Glucose	  homeostasis	   9.52E-­‐05	   3	   HNF4A	  FOXA1	  ASPSCR1	  Cellular	  carbohydrate	  metabolic	  process	   2.67E-­‐02	   3	   PPARA	  HNF4A	  FOXO1	  Wnt	  receptor	  signaling	  pathway	   4.15E-­‐02	   2	   TCF7	  FOXL1	  Regulation	  of	  insulin	  secretion	   6.19E-­‐03	   2	   HNF4A	  SREBF1	  Regulation	  of	  glucose	  metabolic	  process	   1.58E-­‐03	   2	   HNF4A	  FOXO1	  Positive	   regulation	   of	   glucose	   metabolic	  process	   2.15E-­‐04	   2	   HNF4A	  FOXO1	  Positive	  regulation	  of	  Gluconeogenesis	   9.90E-­‐06	   2	   HNF4A	  FOXO1	  Monosaccharide	  biosynthetic	  process	   2.84E-­‐03	   2	   HNF4A	  FOXO1	  Insulin	  secretion	   1.19E-­‐02	   2	   HNF4A	  SREBF1	  Insulin	  receptor	  signaling	  pathway	   2.97E-­‐03	   2	   FOXO1	  SREBF1	  Cellular	  response	  to	  insulin	  stimulus	   6.19E-­‐03	   2	   FOXO1	  SREBF1	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Thus,	  it	  is	  likely	  that	  diabetes	  influences	  the	  expression	  of	  EPC	  genes	  that	  are	  specific	  to	  those	  pathways	  causing	  impairment	  in	  their	  vasoreparative	  potential.	  Based	  on	  the	  MGI	  database	  [225]	  eNOS	  (NOS3),	  SDF-­‐1,	  CXCR4,	  and	  SELE	  are	  all	  specific	  EPC	  genes	  yet	  they	  were	  not	  differentially	  expressed	  in	  any	  of	  the	  six	  comparisons	  in	  this	  study.	  However,	  we	   found	   that	   all	   of	   them	  were	   regulated	   by	   two	  TCFs	   that	   are	   identified	   in	   diabetic	  EPCs	   GRN	   (USF1	   and	   NFKB1).	   SELE	   appeared	   to	   be	   directly	   regulated	   by	   NFKB1	  while	  CXCR4	   is	   directly	   regulated	   by	  USF1,	   whereas	   SDF-­‐1	   and	   eNOS	   were	   indirectly	  regulated	  by	  USF1.	  Thus,	  USF1,	  and	  NFKB1	  might	  be	  driving	  the	  expression	  changes	  of	  those	  genes	  during	  diabetes	  (Figure	  7-­‐6).	  	  Dysfunction	  of	  eNOS	  signaling	  has	  also	  been	  implicated	  in	  EPC	  dysfunction	  in	  diabetes.	  The	  dysfunction	  has	  been	  linked	  with	  decreased	  eNOS	  activity	  [322,	  323]	  and	  the	  eNOS	  deficient	   (NOS3-­‐/-­‐)	  mouse	  had	   impaired	  EPC	  mobilization	  and	  angiogenesis	   [322].	  The	  expression	   and	  phosphorylation	   of	  eNOS	   are	   essential	   for	   the	   survival,	  migration	   and	  angiogenesis	   facilitated	   by	   EPCs	   and	   ECs	   [324,	   325].	   Human	   EPCs	   that	   overexpress	  
eNOS	  have	  increased	  migratory	  potential,	  increased	  ability	  to	  incorporate	  into	  tube-­‐like	  structures	  and	  to	  differentiate	  into	  endothelial	  spindle-­‐like	  structures	  [326].	  We	  did	  not	  observe	  a	  significant	  change	  in	  eNOS	  expression	  in	  diabetic	  EPCs.	  Nevertheless,	  two	  of	  the	  genes	   that	  were	   found	   to	  be	  differentially	  expressed	   in	  diabetic	  EPCs	   (NFKB1	   and	  
USF1)	   regulate	   eNOS	   indirectly,	   which	   could	   explain	   previous	   reports.	   We	   have	  previously	   reported	   that	   	   eNOS	   expression	   in	  BM	  Lin-­‐/VEGF-­‐R2+	  progenitor	   cells	  was	  very	   low	   indicating	   that	   they	   are	   early	   progenitor	   cells	   [312] since	   late	   EPCs	   have	  higher	  expression	  	  levels	  of	  eNOS	  [327].	  	  Although	   there	   are	   many	   reports	   that	   diabetes	   causes	   reduction	   in	   PB	   EPC	   number	  [300,	  328],	  others	  have	  reported	  an	  increase	  in	  EPC	  number	  in	  the	  circulation	  in	  specific	  animal	  models	   [329]	  while	   we	   did	   not	   find	   any	   significant	   effect	   of	   diabetes	   in	  mice	  [308].	  We	   previously	   reported	   down	   regulation	   of	   SDF-­‐1	  and	   SELE	   genes	   in	   diabetic	  EPCs.[312]	  Since	  EPCs	  have	   the	  ability	   to	  produce	  SDF-­‐1	   [330]	  and	  SDF-­‐1/CXCR4	   is	  a	  known	  EPC	  mobilization	  and	  maturation	  axis	  [331],	  this	  down	  regulation	  of	  SDF-­‐1	  may	  contribute	  to	  the	  impaired	  mobilization	  of	  diabetic	  EPCs.	  Thus	  the	  observed	  decrease	  of	  diabetic	  EPCs	  in	  PB	  could	  be	  attributed	  to	  the	  impaired	  mobilization	  ability	  from	  BM	  to	  PB	   leading	   to	   EPC	   BM-­‐trapping	   and	   not	   to	   the	   impaired	   proliferation.	   In	   this	   study	  neither	   SDF-­‐1	   nor	   SELE	   were	   found	   differentially	   expressed	   but	   were	   found	   to	   be	  closely	   regulated	   by	   two	   important	   diabetic	   genes	  NFKB1	   and	  USF1.	   Circulating	   EPCs	  have	   the	   ability	   to	   express	   SELE	   [332],	   a	   sign	   of	   EPC	   activation	   [333].	   We	   observed	  previously	   a	   2.5	   fold	   increase	   in	   the	   expression	   of	   SELE	   in	   diabetic	   EPCs.	   The	   up-­‐regulation	   of	   SELE	   in	   diabetic	   EPCs	   may	   be	   attributed	   to	   increased	   production	   of	  interleukin	  1	  and	  tumor	  necrosis	  factors	  caused	  by	  the	  diabetic	  condition	  [334]. 	  EPCs	  have	  a	  direct	  role	  in	  angiogenesis	  [288,	  335].	  We	  found	  that	  the	  same	  gene	  (USF1)	  that	  regulates	  eNOS	  indirectly	  through	  ETV4	  and	  ESR1,	  regulates	  SDF-­‐1	  via	  ESR1	  as	  well,	  which	   is	   implicated	   in	   diabetes	   [336].	   Thus	  ESR1	  may	   have	   a	   direct	   role	   in	   impaired	  diabetic	  EPCs.	  We	  also	   found	   that	  USF1	   regulates	  CXCR4	  directly,	  which	   indicates	   that	  
eNOS,	   SDF-­‐1	   and	   CXCR4	   are	   all	   closely	   related	   and	   regulated	   by	   the	   same	   key	  gene(USF1).	  Since	  ETV4	   is	  a	  downstream	  target	  gene	  of	  FGF	   signalling	  pathway	  which	  promotes	   tumour	   growth	   and	   angiogenesis	   [337],	   then	   such	   involvement	   in	  angiogenesis	   could	   explain	   its	   role	   in	   EPC,	   which	   under	   diabetic	   conditions	   have	  reduced	   potential	   to	   migrate,	   proliferate	   and	   form	   tubes	   [338].	   Leading	   to	   the	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conclusion	  that	  USF1	   is	  affected	  by	  diabetic	  environment	  and	  could	  be	  responsible	  for	  EPC	  angiogenic	  activity.	  	  
	  
Figure	  7-­‐6	  A	  gene	  network	  showing	  four	  EPC	  specific	  genes	  and	  their	  relationship	  to	  our	  constructed	  diabetic	  
EPC	  GRN.	  	  The	  four	  genes:	  eNOS	  (NOS3),	  SDF-­‐1	  (CXCL12),	  CXCR4,	  and	  SELE	  are	  marked	  in	  green.	  The	  two	  TCFs	  from	  the	  diabetic	  EPCs	  GRN	  regulating	  them	  are	  marked	  in	  yellow.	  Other	  TCFs	  regulated	  by	  the	  two	  TCFs	  (yellow)	  and	  also	  regulating	  those	  4	  genes	  are	  marked	  in	  grey.	  	  	  In	  conclusion	  we	  were	  able	  to	  detect	  specific	  genes	  that	  are	  affected	  by	  early	  stages	  of	  diabetes	   in	  BM	   in-­‐/VEGF-­‐R2+	  progenitor	   cells.	  Microarray	   experiments	   complemented	  by	   analysis	  methods	  were	  used	   in	   this	   study	  but	   no	   verification	  was	  performed,	   thus	  further	  research	  is	  warranted	  to	  confirm	  the	  results.	  To	  our	  knowledge,	  this	  is	  the	  first	  report	  that	  predicts	  and	  unravels	  a	  gene	  regulatory	  network	  that	  is	  specific	  to	  diabetic	  endothelial	  progenitor	  cells	  in	  BM.	  This	  novel	  GRN	  consists	  of	  11	  main	  well	  documented	  diabetic	  genes	  and	  47	  TCFs/genes	  that	  are	  regulating/regulated	  by	  those	  genes	  directly.	  It	   appears	   that	   PIK3C2	   and	   PTF1A	   are	   up	   regulated	   under	   diabetic	   conditions	   while	  
CLCNKA	  is	  down	  regulated.	  Such	  changes	  seem	  to	  be	  the	  results	  of	  diabetic	  TCFs	  mainly	  
FOXO1,	   PPARα,	   PPARγ,	   and	   NFKB1	   that	   controls	   those	   three	   diabetic	   genes.	   These	  findings	   may	   lead	   to	   novel	   therapeutic	   strategies	   for	   mobilization	   of	   EPCs	   and	   the	  treatment	  of	  diabetic	  vascular	  complications	  such	  as	  diabetic	  retinopathy,	  nephropathy	  and	  cardiovascular	  disease.	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8. WGS	  and	  DNA	  microarray	  
phylotyping	  of	  MRSA	  strains	  	  	  	  This	  chapter	  is	  a	  shortened	  version	  of	  the	  following	  publication:	  	  





On	   the	   genomic	   mutation	   regards,	   we	   also	   presented	   an	   NGS	   pipeline	   to	   identify	   core-­‐
genome	  SNPs	  and	  genetic	  variations	  between	  two	  phenotypic	  groups	  in	  a	  similar	  analogy	  
to	   somatic	   mutations	   between	   the	   healthy	   and	   disease	   cohorts.	   Since	   Whole	   Genome	  
Sequencing	   data	   of	   tumor	   and	   healthy	   human	   samples	   were	   not	   accessible,	   the	   NGS	  
pipeline	   was	   utilized	   on	   two	   groups	   of	   MRSA	   bacterial	   isolates	   (nasal	   and	   invasive)	   to	  
investigate	  the	  phylogenetic	  positions	  of	  the	  recently	  emerged	  t504	  clone	  (Spa-­‐type	  t504)	  
in	  the	  Saarland	  province	  of	  Germany	  and	  to	  better	  understand	  the	  infectivity	  mechanism	  
of	  the	  invasive	  group	  as	  a	  prototype	  example	  for	  “from	  genotype	  to	  phenotype”	  studies.	  	  	  
	  	  
	  	  
Chapter	  8	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  WGS	  and	  DNA	  microarray	  phylotyping	  of	  MRSA	  strains	  	  	  
	  	   122	  
Abstract	  	  Hospital-­‐associated	   methicillin	   resistant	   Staphylococcus	   aureus	   (MRSA)	   is	   frequently	  caused	   by	   predominant	   clusters	   of	   closely	   related	   isolates	   unresolvable	   by	   routine	  diagnostic	   typing	   methods.	   Whole	   genome	   sequencing	   (WGS)	   and	   DNA	   microarray	  (MA)	  now	  allow	  for	  better	  discrimination	  within	  a	  prevalent	  clonal	  complex	  (CC).	  This	  single	   center	   exploratory	   study	   aims	   to	   distinguish	   invasive	   and	   non-­‐invasive	   MRSA	  isolates	   with	   similar	   genetic	   background	   into	   phylogenetic-­‐	   and	   virulence-­‐associated	  genotypic	  subgroups	  by	  WGS	  and	  MA.	  A	  cohort	  of	  twelve	  blood	  stream	  and	  fifteen	  nasal	  MRSA	  isolates	  of	  clonal	  complex	  5	  (CC5)	  (spa-­‐types	  t003	  and	  t504)	  was	  selected.	  Rooted	   phylotyping	   based	   on	   core-­‐genome	   SNP	   WGS	   data	   revealed	   the	   regional	  clustering	   of	   two	   closely	   related	   CC5	   isolate	   subgroups	   (clade	   t504	   and	   clade1	   t003)	  which	   could	   be	   discriminated	   from	   other	   regional	   t003	   isolates	   and	   also	   from	  geographically	   unrelated	   CC5	   MRSA	   reference	   isolates.	   However,	   phylogenetic	  subtyping	   was	   not	   associated	   with	   invasiveness	   when	   comparing	   blood	   stream	   and	  nasal	  isolates.	  	  Clustering	   of	   MA	   profiles	   was	   not	   concordant	   with	   WGS	   phylotyping	   of	   CC5	   MRSA	  isolates,	  but	  MA	  could	  discriminate	  subgroups	  of	  nasal	  and	  blood	  stream	  origin.	  Among	  the	   new	   putative	   virulence	   associated	   genes	   identified	   by	   WGS,	   the	   strongest	  association	  with	  invasiveness	  of	  blood	  stream	  infections	  was	  shown	  for	  ebhB	  gene.	  Integrated	  analysis	  of	  core-­‐genome	  in	  combination	  with	  accessory	  genome	  data	  enables	  in	  depth	  analysis	  of	  highly	  related	  MRSA	  isolates	  with	  subtyping	  according	  to	  phylogeny	  and	  presumable	  also	  to	  virulence	  and	  invasiveness	  in	  vivo.	  
8.1 Background	  	  Approximately	  20%	  of	  the	  healthy	  population	  is	  intermittently	  or	  persistently	  colonized	  with	   Staphylococcus	   aureus	   which	   is	   a	   well-­‐known	   facultative	   pathogen	   causing	  localized	  and	  also	  generalized	  invasive	  infections	  [339].	  Transition	  from	  colonization	  to	  invasive	   infection	   is	   associated	  with	   disruption	   of	   barrier	   and	   immune	   functions	   and	  also	   with	   the	   presence	   of	   bacterial	   virulence	   factors	   and	   mutations	   of	   its	   genetic	  determinants	  [340].	  Especially,	  infections	  due	  to	  methicillin-­‐resistant	  S.	  aureus	  (MRSA)	  cause	   a	   significant	   disease	   burden	   and	   also	   increased	   hospital	   costs	   [341,	   342].	  Prevention	   of	   MRSA	   infections	   requires	   early	   MRSA	   detection,	   decolonization,	   and	  appropriate	  infection	  control	  policies.	  Since	  the	  1990’s	  MRSA	  is	  further	  responsible	  for	  a	   growing	  number	   of	   community-­‐acquired	   infections	   [343,	   344].	  Most	   invasive	  MRSA	  infections	   are	   related	   to	   previous	   colonization	   with	   the	   same	   strain	   [345],	   however,	  detailed	   knowledge	   of	   the	   genetic	   background	   related	   to	   transition	   of	   nasal	   MRSA	  carriage	  to	  invasive	  MRSA	  blood	  stream	  infections	  is	  still	  limited.	  	  Various	   molecular	   typing	   methods	   have	   been	   developed	   to	   discriminate	   epidemic	  strains	   for	   outbreak	   control,	   epidemiological	   surveillance,	   and	   also	   for	   prevention	   of	  further	   transmission	   [346,	   347].	   Highly	   discriminative	   techniques	   are	   required	   for	  detailed	   analysis	   of	   local	   outbreaks	   because	   MRSA	   infections	   are	   dominated	   in	   each	  region	   by	   few	   phylogenetically	   related	   clones	   of	   the	   same	   clonal	   complex	   (CC)	   and	  sequence	   type	   (ST)	   [348].	   Phylogeny	   is	   regularly	   analyzed	   to	   the	   CC	   and	   ST	   level	   by	  multilocus-­‐sequence	   typing	   (MLST);	   however,	   this	   method	   is	   cumbersome	   and	   not	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discriminative	   between	   closely	   related	   strains.	   Alternatively,	   single	   locus	   sequence	  typing,	   i.e.	   spa-­‐typing	   [349,	   350],	   allows	   for	   discrimination	   of	   S.	   aureus	   isolates;	  however,	   also	   spa-­‐typing	   is	   not	   very	   discriminative	   for	   hospital-­‐associated	   infections	  and	   is	   not	   directly	   linked	   to	   phylogeny	   of	   isolates.	   The	  majority	   of	   MRSA	   isolates	   in	  German	  hospitals	  were	  assigned	  to	  spa-­‐type	  t003	  isolates	  of	  CC5	  [351,	  352]	  which	  limits	  application	   of	   standard	   typing	   methods	   for	   detailed	   epidemic	   investigation	   and	   the	  indexing	   of	   variations	   for	   phylogenetic	   arrangements	   and	   population	   based	  examination	   [353].	   Recently,	   the	   appearance	   of	   a	   new	   highly	   prevalent	   CC5	   spa-­‐type	  (t504)	   was	   detected	   apart	   from	   spa-­‐type	   t003	   in	   a	   hospital	   admission	   prevalence	  screening	  study	  in	  the	  State	  of	  Saarland	  in	  Southwest	  Germany	  [354].	  The	  structure	  of	  repeat	   elements	   was	   similar	   between	   local	   t504	   and	   t003	   strains;	   however,	   the	  phylogenetic	   relationship	   between	   the	   local	   t504	   and	   other	   CC5	   German	   isolates	  remains	  still	  to	  be	  elucidated	  by	  more	  detailed	  broad-­‐range	  phylogenetic	  analysis.	  	  Compared	   to	   MLST	   and	   spa-­‐typing,	   microarray	   (MA)	   and	   whole	   genome	   sequencing	  (WGS)	   dramatically	   enhanced	   discriminatory	   power	   of	   genotyping,	   and	   recently	   both	  technologies	  have	  become	  accessible	  also	  for	  larger	  scale	  typing	  purposes.	  For	  example,	  WGS	  gives	  valuable	   insight	   into	  MRSA	   transmission	   chains	  e.g.	   in	   intensive	   care	  units	  [355]	  and	  has	  already	  been	  used	  for	  the	  characterization	  of	  outbreaks	  	  [346,	  356,	  357].	  It	  can	  also	  be	  implemented	  for	  detection	  of	  phenotypic	  properties	  on	  a	  genotypic	  base	  such	  as	  antibiotic	  resistance	  [358].	  Although	  new	  broad-­‐range	  genetic	  techniques	  may	  now	  allow	  for	  virulence	  assignment	  of	  clinical	  isolates	  [359],	  the	  knowledge	  for	  defined	  virulence-­‐associated	  genotyping	  is	  still	  limited.	  MRSA	  virulence	  is	  caused	  by	  known	  and	  presumably	   also	   by	   still	   unknown	   virulence	   determinants	   and	   also	   by	   regulatory	  processes	   [360].	   In	   particular,	   MRSA	   strains	   of	   the	   same	   CC	  may	   contain	   pathogenic	  patterns	   in	   a	   very	   similar	   genetic	   context,	   and	   these	   genotypic	   differences	   may	  contribute	   to	   variable	   virulence	   of	   invasive	   and	   non-­‐invasive	   MRSA	   strains	   [361].	   In	  line,	  several	  virulence	  factor	  (VF)	  online	  catalogs	  (such	  as	  the	  PATRIC	   [362]	  and	  VFDB	  [363]	   databases)	   were	   developed	   to	   affiliate	   information	   on	   the	   virulence	   factors	   in	  numerous	  organisms,	  species	  and	  related	  strains	  with	  whole	  genome	  sequence	  analysis	  of	  clinical	  isolates	  [364].	  	  The	   goal	   of	   the	   present	   single	   center	   study	   was	   to	   compare	   nasal	   and	   blood	   stream	  MRSA	   isolates	   of	   the	   predominant	   CC5	   by	   genotyping	   using	  WGS	   and	  MA.	   The	   study	  design	   included	   a	   dual	   approach	   using	   the	   core-­‐genome	   single	   nucleotide	  polymorphism	  (SNP)	  WGS	  approach	  [353,	  365]	  as	  well	  as	  a	  MA	  approach	  with	  a	  specific	  focus	  on	  the	  presence	  or	  absence	  of	  accessory	  gene	  signals.	  Application	  of	  WGS	   led	  to	  the	   clear	   discrimination	   of	   regional	   phylogenetic	   clades	   distinct	   from	   geographically	  unrelated	   strains	   of	   the	   same	   CC.	   However,	   invasiveness	   was	   not	   associated	   with	  phylogeny	   but	   with	   mutations	   of	   virulence	   factors	   in	   the	   core	   and	   the	   accessory	  genome.	  
8.2 	  Methods	  
8.2.1 MRSA	  CC5	  isolates.	  	  Fifteen	  nasal	  colonization	  isolates	  [366],	  and	  twelve	  invasive	  blood	  stream	  isolates	  from	  patients	  of	  the	  University	  of	  Saarland	  Medical	  Center	  (subsequently	  referred	  to	  as	  nasal	  [NAS]	   and	   invasive	   [INV]	   isolates,	   respectively)	   were	   included;	   WGS	   results	   were	  compared	   also	   to	   four	   German	   CC5	   t003	  MRSA	   reference	   isolates	   provided	   by	   the	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German	  Reference	   Laboratory	   for	   Staphylococcus	   aureus	   infections;	   all	   clinical	  MRSA	  isolates	  belonged	  to	  spa-­‐types	  t003	  and	  t504	  of	  CC5.	  	  
8.2.2 Whole	  genome	  sequencing	  	  	  Whole	  genome	  sequencing	  of	  MRSA	  DNA	  was	  performed	  using	  an	  Illumina	  MiSeq	  (HZI	  in	  Braunschweig,	  Germany)	  producing	  paired-­‐end	   reads	  of	  251	  basepair	   lengths	  with	  an	   average	   coverage	   of	   110-­‐fold.	   In-­‐depth	   bioinformatics	   analysis	   of	   this	   data	   was	  performed	  using	   the	  developed	  automated	  pipeline	  described	  previously	   in	   chapter	  3	  (Figure	  3-­‐19).	  Briefly,	  reads	  were	  mapped	  against	  the	  complete	  reference	  genome	  of	  S.	  
aureus	   CC5	   strain	   NC_017340.1	   (http://www.ncbi.nlm.nih.gov/nuccore/NC_017340)	  using	   the	   short	   read	   alignment	   version	   of	   the	   Burrows-­‐wheeler	   Aligner	   (BWA)	  algorithm	  [175].	  Both	  duplicate	  reads	  and	  reads	  with	  low	  mapping	  quality	  (<	  30)	  were	  filtered	  out	  and	  the	  final	  alignments	  were	  sorted.	  Genetic	  mutations	  were	  called	  using	  the	  VarScan2	  tool	  [177].	  Phylogenetic	  analysis	  was	  restricted	  to	  the	  consensus	  sequence	  of	   the	   highly	   conserved	   core-­‐genome.	   Therefore,	   variants	   that	   occurred	   in	   repetitive	  sequences	  and	  mobile	  genetic	  regions	  were	  masked	  for	  phylogenetic	  analysis.	  	  
8.2.3 Phylogeny	  construction	  	  Core-­‐genome	  SNPs	   from	  coding	  and	  non-­‐coding	  genomic	  regions	  were	  extracted	   from	  the	  consensus	  sequences	  and	  a	  phylogenetic	  representative	  SNP	  matrix	  was	  generated.	  Subsequently,	   a	   phylogenetic	   tree	   was	   constructed	   using	   the	   Maximum	   Likelihood	  method	   as	   implemented	   in	   SeaView	   [178]	   and	   rooted	   using	   the	   CC5	   ST5	   reference	  genome	   N315	   (http://www.ncbi.nlm.nih.gov/nuccore/NC_002745).	   Trees	   were	  displayed	  and	  annotated	  using	  FigTree	  (http://tree.bio.ed.ac.uk/software/figtree/).	  For	  comparison,	   four	   representative	   German	   CC5	   isolates	   were	   also	   included	   for	   direct	  comparison	   with	   the	   local	   strains	   and	   in	   order	   to	   enrich	   the	   phylogenetic	   tree.	   The	  dendrograms	  of	   the	  DNA	  microarray	  were	  produced	  using	   the	  hierarchical	   clustering	  algorithm	  using	  average	  linkage	  and	  Euclidian	  distance	  in	  the	  R	  suite	  [173].	  
8.2.4 Genetic	  variations	  between	  invasive	  and	  nasal	  samples	  	  	  The	  significance	  of	  the	  genetic	  variations	  between	  each	  isolate	  pair	  (invasive	  and	  nasal)	  was	  evaluated	  by	  VarScan	  on	  the	  basis	  of	  the	  sequence	  reads	  through	  Fisher’s	  exact	  test	  using	  a	  significance	  level	  or	  p-­‐value	  threshold	  of	  0.05.	  Successfully	  passed	  variants	  were	  collected	   and	   annotated	   to	   the	   corresponding	   genes	   in	   the	   reference	   genome.	  Subsequently,	   the	   variants	   were	   grouped	   by	   position,	   and	   the	   occurrence	   of	   each	  variant	  was	  noted.	  The	   identities	  of	  548	  known	  virulence-­‐related	  genes	  were	  derived	  from	   the	   virulence	   factor	   (VF)	   databases	  NIAID	   Pathogen	   Annotation	   Browser	   [367],	  
PATRIC	   [362]	   ,	   and	   VFDB	   [363].	   Over	   representation	   analysis	   for	   enrichment	   with	  functional	  GO	   terms,	  KEGG	  pathways,	   and	   INTERPRO	  protein	   families	  was	  performed	  using	  the	  DAVID	  tool	  [367].	  
8.2.5 DNA	  microarray	  analysis	  	  DNA	  extraction	  (Qiagen,	  Hilden,	  Germany),	  and	  microarray	  analysis	  using	  IdentiBAC	  MA	  (Alere,	   Jena,	  Germany)	  was	  performed	  according	   to	   the	  manufacturer´s	   instruction	  as	  previously	  described	  [366].	  Data	  processing	  and	  bioinformatics	  grouping	  according	  to	  similarity	  of	  genetic	  profiles	  was	  done	  accordingly.	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8.3 Results	  	  Whole	  genome	  sequencing	  produced	  paired-­‐end	  reads	  of	  251	  bp	   length	  at	  about	  110-­‐fold	  coverage.	  81-­‐87%	  of	  the	  sample	  reads	  could	  be	  mapped	  against	  the	  reference	  CC5	  genome	   NC_017340.1	   (http://www.ncbi.nlm.nih.gov/nuccore/NC_017340)	   (spa-­‐type	  
t003)	  with	  a	  maximal	  possible	  mapping	  error	  of	  0.1	  %.	  By	  masking	  repetitive	  sequences	  and	  mobile	  genetic	  regions,	  the	  first	  part	  of	  our	  analysis	  focused	  on	  the	  so-­‐called	  core-­‐genome	  region	  and	  included	  reconstruction	  of	  the	  strain	  phylogeny	  and	  SNP	  analysis.	  
8.3.1 Phylogenetic	  analysis	  	  Phylogenetic	  analysis	  based	  on	  the	  1112	  core-­‐genome	  SNPs	  of	  WGS	  data	  showed	  that	  all	   isolates	   with	   spa-­‐type	   t504	   clustered	   separately	   from	   type	   t003	   forming	   a	   single	  clade	   (Clade	   t504)	   (Figure	   8-­‐1).	   The	   phylogenetic	   distribution	   of	   t003	   was	   generally	  more	   diverse	   but	   cluster	   analysis	   revealed	   a	   distinct	   clade	   of	   nine	   local	   t003	   isolates	  	  (Clade1	   t003)	   without	   direct	   connection	   to	   geographical	   unrelated	   German	   reference	  isolates.	   Also,	   the	   remaining	   eight	   local	   isolates	   without	   particular	   clustering	   were	  distributed	  without	  direct	  link	  to	  the	  geographical	  unrelated	  German	  reference	  isolates	  (Other	   t003).	   This	   confirms	   high	   diversity	   in	   phylogenetic	   arrangements	   of	   the	   t003	  strain	  in	  geographically	  distinct	  regions	  [352,	  353].	  	  
8.3.2 SNP	  analysis	  	  SNP	   calling	   of	   the	   WGS	   data	   identified	   genetic	   variations	   in	   535	   unique	   genomic	  positions	  outside	  of	  mobile	  genetic	  elements	  and	  repetitive	  sequences	  between	  all	  pairs	  of	  the	  12	  invasive	  isolates	  and	  the	  15	  nasal	  ones.	  These	  535	  positions	  include	  479	  SNPs	  and	  56	  Indels.	  Clade	  t504	  (36	  ±	  7	  mutations)	  and	  clade1	  t003	  (43	  ±	  8)	  isolates	  contained	  fewer	  mutations	  than	  other	  regional	  t003	  isolates	  (56	  ±	  11)	  (Figure	  8-­‐2).	  However,	  only	  40%	   of	   genetic	   mutations	   occurred	   in	   annotated	   regions	   and	   involved	   176	   genes.	  Among	  these	  genes,	  18	  genes	  containing	  24	  variants	  were	  previously	  characterized	  as	  virulence–related	  genes	   in	   the	  VF	  catalogs	  (tcaA,	  rnr,	  saeS,	  sasA,	  msrR,	  ssaA,	  capA,	  arlS,	  
hlgB,	  sdrD,	  aur,	  hysA,	  isdE,	  isdF,	  hlb,	  essA,	  atl,	  and	  lip).	  Interestingly,	  all	  of	  these	  18	  known	  virulence-­‐related	   genes	   had	   variants	   in	   at	   least	   one	   invasive	   sample;	   yet,	   no	   such	  variants	   were	   recorded	   in	   the	   nasal	   isolates	   with	   according	   genes.	   Twenty	   genes	  showed	   variants	   in	   at	   least	   two	   invasive	   isolates,	   yet	   again,	   in	   genes	   from	   strains	   of	  nasal	  origin	  these	  variations	  were	  absent.	  In	  the	  following,	  we	  will	  refer	  to	  such	  genes	  as	  ‘twice	  mutated	  genes’.	  Such	  twice	  mutated	  genes	  of	  invasive	  isolates	  include	  two	  known	  virulence-­‐related	   genes	   (atl,	   hlb)	   and	   18	   genes	   that	   have	   not	   been	   associated	   with	  virulence	  so	  far	  (ebhB,	  pfoS/R,	  glpF,	  feoB,	  yvcP,	  sbnD,	  mutS2,	  prkC,	  miaA,	  thrC,	  trpD,	  gnd,	  
sodA,	  tagG,	  kdpD,	  metT,	  tcaB,	  opp-­‐1F)	  (Supplementary	  Table	  E-­‐2).	  	  	  Yet,	   twice	   mutated	   gene	   variants	   of	   invasive	   versus	   nasal	   strains	   failed	   to	   reach	  statistical	  significance	  (P-­‐values	  of	  0.20	  and	  0.07,	  Fisher’s	  exact	  test);	  only	  the	  gene	  ebhB	  (coding	   for	   a	  putative	   Staphylococcal	   surface	   anchored	  giant	  protein)	   showed	  genetic	  variations	  at	  7	  positions	   (1482083,	  1484403,	  1487821,	  1491377,	  1499271,	  1502542,	  1503065)	  thus	  covering	  most	  of	  the	  entire	  gene.	  Each	  of	  these	  mutations	  occurred	  in	  at	  least	   2	   out	   of	   12	   invasive	   strains,	   but	   not	   in	   nasal	   strain.	   The	   difference	   of	   ebhB	  mutations	  between	  invasive	  (7	  out	  of	  12	  invasive	  strains)	  and	  nasal	  isolates	  (0	  out	  of	  15	  nasal	  strains)	  was	  statistically	  highly	  significant	  (Fisher´s	  exact	  test,	  P-­‐value	  =	  0.0009).	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Figure	  8-­‐1	  Phylogenetic	   tree	  of	  27	   invasive	  and	  nasal	  S.	  aureus	  CC5	  strains	  collected	   in	  Saarland	  as	  well	  as	  
four	   representative	   S.	   aureus	   reference	   isolates	   in	  Germany	  based	  on	   the	   core-­‐genome	  SNP	  approach.	  The	  tree	  was	  rooted	  with	  the	  genome	  sequence	  from	  isolate	  N315	  (ST5;	  NCBI	  accession	  no.	  NC_002745).	  	  To	  get	  further	  insight	  in	  the	  genomic	  location	  of	  the	  twice	  mutated	  genes,	  we	  analyzed	  their	  genomic	  distance	  to	  known	  virulence-­‐associated	  genes	  by	  use	  of	  a	  Manhattan	  plot	  (Figure	  8-­‐3).	  Mutations	   in	  genes	  of	  candidate	  virulence	  variants	  (twice	  mutated	  genes	  marked	   in	   green)	   were	   significantly	   closer	   to	   variants	   in	   18	   known	   virulence	   genes	  (marked	  in	  red)	  than	  to	  random	  SNP	  positions	  (P-­‐value	  =	  0.035).	  	  	  The	  18	  at	  least	  twice	  mutated	  genes	  were	  related	  to	  metabolic	  pathways	  and	  functional	  biological	   process	   terms	   of	   the	   Gene	   Ontology	   and	   tested	   their	   affiliation	   to	   protein	  families	  using	  statistical	  term	  over	  representation	  analysis.	  The	  gene	  products	  of	  sbnD	  and	   tcaB	   belong	   to	   protein	   family	   tetracycline	   resistance	   protein,	   TetA/multidrug	  resistance	   protein	   MdtG	   (INTERPRO:	   IPR001958)	   that	   prevents	   the	   antibiotic	  tetracycline	   from	  inhibiting	  bacterial	  protein	  synthesis.	  The	  genes	  trpD	  and	  kdpD	  take	  part	  in	  the	  KEGG	  pathway	  two	  component	  system.	  However,	  the	  majority	  of	  these	  genes	  are	  not	  characterized	  so	  far	  in	  the	  annotation	  databases	  (Supplementary	  Table	  E-­‐1).	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Figure	  8-­‐2	  Heatmap	  showing	  the	  number	  of	  genetic	  variations	  between	  each	  pair	  of	  isolates.	  	  The	  highest	   similarity	  was	   found	   for	   clade	   t504	   followed	  by	   t003	   clade	   I.	   A	   direct	   comparison	   of	   groups	   revealed	  higher	  similarity	  between	  t003	  clade	  I	  and	  t504	  as	  compared	  to	  t003	  clade	  I	  and	  other	  t003	  isolates.	  	  
8.3.3 Clustering	  based	  on	  DNA	  microarray	  	  Hierarchical	   clustering	  analysis	  of	   the	  entire	   set	  of	  330	  MA	  probes	  yielded	   five	  major	  clusters	  with	   at	   least	   three	   isolates	   (Figure	   8-­‐4a).	   Among	   them,	   cluster	   A1	   contained	  only	   invasive	   blood	   stream	   isolates	   (P-­‐value	   =0.01,	   Fisher	   exact	   test)	   and	   was	  characterized	   by	   positive	   signals	   of	   hsdSx.CC15	   (allelic	   variant	   of	   type	   I	   site-­‐specific	  deoxyribonuclease	  subunit),	  and	  Q2YUB3	  (unspecific	  efflux	  transporter).	  Cluster	  A2	  (P-­‐
value=0.23)	   contained	   only	   ccrB.4	   positive	   (cassette	   chromosome	   recombinase)	   nasal	  isolates	   whereas	   clusters	   A3	   to	   A5	   were	   without	   clear	   predisposition	   to	   invasive	   vs.	  nasal	   isolates.	   When	   grouping	   was	   restricted	   to	   virulence	   genes	   annotated	   in	   the	  virulence	   factor	   (VF)	   catalogues	   (174	   genetic	   probes),	   six	   clusters	   were	   identified	  (Figure	  8-­‐4,	  B1-­‐6).	  B3	  (P-­‐value	  =0.08)	  is	  characterized	  by	  positive	  hybridization	  signals	  of	   ssl01.set6_probe2_11	  and	   ssl01.set6..MRSA252	   (allelic	   variants	   of	   the	   staphylococcal	  superantigen-­‐like	  protein	  1	  termed	  set6)	  and	  encompasses	  only	  invasive	  strains.	  B2	  (P-­‐




































































































0 28 36 34 40 44 41 48 45 49 43 47 43 42 43 46 40 35 62 49 48 46 56 52 50 51 63
28 0 28 28 29 32 32 48 44 49 43 47 43 41 43 46 40 35 62 40 39 46 55 50 39 41 63
36 28 0 40 43 46 46 47 45 49 43 46 43 42 43 46 40 35 62 53 53 46 56 51 55 56 63
34 28 40 0 47 50 51 48 45 49 43 47 43 42 43 46 40 35 62 58 57 46 56 52 58 61 63
40 29 43 47 0 56 50 49 45 50 44 48 44 43 44 47 41 36 63 58 62 47 56 52 59 70 64
44 32 46 50 56 0 23 51 49 49 43 47 43 42 43 46 40 35 62 63 62 46 56 52 63 70 62
41 32 46 51 50 23 0 51 49 49 43 47 43 42 43 46 40 35 62 61 61 46 55 52 61 70 62
48 48 47 48 49 51 51 0 46 49 43 45 43 58 56 58 40 35 57 59 58 57 59 58 60 61 63
45 44 45 45 45 49 49 46 0 50 44 46 44 56 56 56 41 36 56 57 56 47 55 51 57 57 64
49 49 49 49 50 49 49 49 50 0 20 35 31 45 37 46 36 31 37 50 49 49 50 50 51 52 51
43 43 43 43 44 43 43 43 44 20 0 35 31 39 31 40 36 32 31 44 43 43 44 44 45 46 45
47 47 46 47 48 47 47 45 46 35 35 0 31 43 33 44 36 31 35 48 47 47 48 48 49 50 49
43 43 43 43 44 43 43 43 44 31 31 31 0 39 31 40 40 40 13 44 42 43 44 44 45 46 45
42 41 42 42 43 42 42 58 56 45 39 43 39 0 38 43 36 31 58 43 42 46 56 51 43 45 63
43 43 43 43 44 43 43 56 56 37 31 33 31 38 0 43 36 31 50 44 43 46 56 52 45 46 63
46 46 46 46 47 46 46 58 56 46 40 44 40 43 43 0 37 32 43 47 46 46 56 52 47 49 63
40 40 40 40 41 40 40 40 41 36 36 36 40 36 36 37 0 0 36 41 40 40 41 41 42 43 42
35 35 35 35 36 35 35 35 36 31 32 31 40 31 31 32 0 0 31 36 36 35 36 36 37 38 37
62 62 62 62 63 62 62 57 56 37 31 35 13 58 50 43 36 31 0 63 61 46 56 52 64 64 63
49 40 53 58 58 63 61 59 57 50 44 48 44 43 44 47 41 36 63 0 62 47 57 52 71 71 64
48 39 53 57 62 62 61 58 56 49 43 47 42 42 43 46 40 36 61 62 0 11 56 52 63 70 63
46 46 46 46 47 46 46 57 47 49 43 47 43 46 46 46 40 35 46 47 11 0 47 47 48 49 63
56 55 56 56 56 56 55 59 55 50 44 48 44 56 56 56 41 36 56 57 56 47 0 49 57 57 64
52 50 51 52 52 52 52 58 51 50 44 48 44 51 52 52 41 36 52 52 52 47 49 0 53 53 64
50 39 55 58 59 63 61 60 57 51 45 49 45 43 45 47 42 37 64 71 63 48 57 53 0 61 61
51 41 56 61 70 70 70 61 57 52 46 50 46 45 46 49 43 38 64 71 70 49 57 53 61 0 63
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clusters	   represent	   both	   invasive	   and	   nasal	   isolates.	   For	   comparison,	   read	   counts	   for	  these	  genes	  were	  related	  to	  those	  found	  in	  the	  WGS	  data.	  
	  
Figure	   8-­‐3	   Manhattan	   Plot	   showing	   the	   genomic	   distribution	   of	   the	   535	   variants	   between	   each	   pair	   of	  
isolates.	   Related	   genes	   of	   24	   variants	   occurring	   in	   known	   virulence	   are	   marked	   in	   red.	   54	   variants	   that	   occur	  exclusively	   in	   at	   least	   two	  virulent	   isolates	   are	  marked	   in	   green.	  By	   testing	   against	   randomized	  SNP	  positions,	  we	  showed	   that	   mutated	   still	   undefined	   genes	   (green)	   are	   significantly	   closer	   to	   known	   virulence	   genes	   (red)	   than	  expected	  by	  chance	  (P-­‐value	  =	  0.035).	  	  Two	   out	   of	   these	   four	   genes	   (hsdSx.CC15,	   and	   Q2YUB3)	   were	   not	   annotated	   in	   the	  reference	  genome.	  Gene	  set6	  has	  10	  allelic	  variants;	  thus,	  a	  simple	  comparison	  of	  read	  numbers	  across	   isolates	  was	  not	  helpful.	  Gene	  ccrB	  had	  on	  average	  an	  about	   two-­‐fold	  coverage	   in	   strains	  NAS22-­‐NAS24	   belonging	   to	   cluster	   A2	   (maximal	   read	   coverage	   is	  about	  200,	  average	  read	  coverage	  is	  176)	  compared	  to	  the	  strains	  INV4,	  INV6,	  and	  INV8	  forming	  cluster	  B3	  (maximal	  read	  coverage	  is	  about	  120,	  average	  read	  coverage	  is	  93).	  This	  result	  matches	  the	  exclusively	  positive	  signal	  for	  this	  gene	  in	  strains	  of	  cluster	  A2	  based	  on	  the	  MA	  experiment.	   	  Next,	  the	  interrelation	  between	  the	  phylogenetic	  clades,	  dendrogram	   groups	   and	   mutations	   occurring	   in	   known	   virulence	   genes	   and	   at	   least	  twice-­‐mutated	  genes	  was	  addressed.	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Figure	  8-­‐4	  Dendrogram	  based	  on	  hierarchical	  clustering	  of	  DNA	  microarray	  (MA).	  Invasive	   (INV)	  and	  nasal	   (NAS)	   isolates	  were	   indicated	  and	  also	  strain	  assignment	  by	  spa-­‐typing	  and	  core-­‐genome	  SNP	  analysis	  into	  phylogenetic	  clades	  was	  indicated.	  (a)	  Genetic	  profiles	  of	  all	  MA	  genes/alleles	  were	  used	  (n	  =	  330)	  while	  (b)	  alternative	  analysis	  was	  restricted	  to	  174	  probes	  of	  annotated	  genes	  in	  the	  virulence	  catalogs.	  	  
8.4 Discussion	  	  Here	  we	  confirm	  that	  WGS	  with	  core-­‐genome	  SNP	  analysis	   is	  applicable	   for	  analyzing	  the	   evolutionary	   distance	   between	   closely	   related	   CC5	   MRSA	   strains.	   Using	   less	  discriminatory	  methods	  the	  provenience	  of	  the	  recently	  evolved	  regional	  spa-­‐type	  t504	  strains	   remained	   elusive	   [354,	   366].	   Based	   on	  WGS	  we	   can	   now	   prove	   that	   the	   t504	  strains	  were	  of	  clonal	  origin	  with	  common	  ancestors	  to	  the	  highly	  abundant	  t003	  group.	  Interestingly,	   a	   second	   clade	   of	   CC5	   isolates	   was	   identified	   by	   WGS	   without	   direct	  association	   to	   other	   t003	   strains	   including	   German	   reference	   strains	   of	   other	  provenience.	   Therefore	  we	   hypothesize	   that	   –	   similarly	   to	   the	   t504	  clade	   –	   a	   second	  clade	  of	  CC5	  isolates	  evolved	  in	  the	  region	  of	  Saarland	  (t003	  clade	  1)	  which	  has	  not	  been	  identified	  before	  by	   less	  discriminatory	   typing	  methods.	   In	   the	  present	  study	  regional	  clades	   (t504	   and	   t003	   clade	   1)	   were	   detected	   in	   the	   population	   during	   a	   hospital	  admission	  study	  [354]	  and	  not	  following	  MRSA	  transmission	  in	  the	  same	  hospital	  [355].	  The	   appearance	  of	   regional	   clades	   argues	   for	  MRSA	   spreading	   in	   regional	  health-­‐care	  associated	  networks.	   The	  phylogenetic	   tree	   revealed	   that	   the	   t003	   strains	  were	  more	  diverse	  than	  the	  t504	  strains.	  However,	  the	  close	  distance	  between	  clade	  t504	  and	  clade	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Although	  WGS	  is	  able	  to	  determine	  genome	  sequences	  at	  fast	  pace	  and	  affordable	  costs	  it	   has	   argued	   that	   bioinformatics	   techniques	   are	   still	   lacking	   that	   enable	   to	   extract	  information	  about	  the	  true	  virulence	  potential	  of	  an	  organism	  from	  sequence	  data	  alone	  [368].	   As	   a	   possible	   means	   to	   detect	   functional	   relevant	   mutations,	   they	   proposed	  setting	   up	   a	   virulence-­‐assaying	   framework	   based	   on	  medium-­‐throughput	   phenotypic	  characterization	  of	   candidate	   strains,	  e.g.	   by	   assaying	   their	   adhesion	   to	   fibronectin	  or	  cytolytic	   activity.	   Applying	  WGS	   to	   RN4220	   strains	   could	   identify	   a	   number	   of	   SNPs	  affecting	   the	   general	   fitness	   of	   the	   bacteria	   [369].	  Most	   relevant	   to	   the	   present	  work	  were	   the	   recent	   studies	   based	   on	  WGS	  who	  were	   able	   to	   associate	   the	   toxicity	   of	   90	  
MRSA	   ST239	   isolates	  with	   around	  100	   statistically	   significant	   SNPs	   [359]	   and	   studies	  investigating	   the	   evolutionary	   dynamics	   of	   S.	   aureus	   during	   long-­‐term	   carriage	   and	  transition	  from	  nasal	  carriage	  to	  invasive	  infection	  	  [340,	  360,	  370,	  371].	  
	  
Table	  8-­‐1	  Association	  of	  phylogenetic	  clades	  to	  the	  known	  virulence	  factor	  genes	  and	  the	  twice	  mutated	  
genes	  (that	  have	  variants	  in	  at	  least	  two	  invasive	  isolates	  but	  none	  in	  isolates	  of	  nasal	  origin)	  	  
	  
Mutated	  genes	  detected	  by	  WGS	  
	  
Phylogenetic	  groups	  (WGS)	   Known	  virulence	  genes	   Twice	  mutated	  genes	  	  
Clade1	  t003	  	   sdrD,	  msrR,	  hysA,	  tcaA,	  ssaA,	  sasA	   	  
Clade	  t504	  	   essA,	  saeS,	  atl,	  isdF,	  hlb,	  lip	  
sbnD,	  mutS2,	  prkC,	  glpF,	  miaA,	  thrC,	  trpD,	  ebhB,	  
sodA,pfoS/R,	   tagG,	   kdpD,	   metT,	   tcaB,	   opp-­‐1F,	  
yvcP	  
Other	  t003	  	  
capA,	   rnr,	   isdE,	   arlS,	  hlb,	  hlgB,	  aur,	  
sasA	   gnd,	  feoB	  	  	  Here,	   we	   followed	   a	   similar	   strategy	   that	   is	   based	   on	   identifying	   genetic	   variations	  occurring	   exclusively	   either	   in	   the	   group	   of	   invasive	   blood	   stream	   or	   in	   the	   group	   of	  colonizing	  nasal	  isolates.	  We	  identified	  the	  genetic	  variations	  between	  all	  pairs	  of	  blood	  stream	  and	  nasal	   isolates	   and	  we	  demonstrated	   that	   invasiveness	  was	  not	   associated	  with	   phylotyping	   (core-­‐genome	   SNP	   analysis)	   but	   with	   characteristic	   mutations	   of	  known	  and	  presumed	  new	  candidate	  virulence	  genes.	  	  We	  identified	  SNPs	  between	  blood	  stream	  and	  nasal	  isolates	  (twice	  mutated	  genes),	  but	  for	  most	  mutated	  genes	  the	  difference	  was	  not	  significant	  presumably	  due	  to	  the	  limited	  number	  of	  isolates	  in	  present	  exploratory	  study.	  However,	  a	  significant	  association	  with	  invasiveness	  was	  detected	  for	  mutations	  in	  the	  giant	  protein	  ebhB	  gene.	  The	  ebh	  gene	  is	  the	   largest	   open	   reading	   frame	   on	   the	   S.	   aureus	   (33kb)	   encoding	   for	   the	   Giant	  Staphylococcal	  Surface	  Protein	  (GSSP)	  which	  is	  a	  membrane	  anchored	  protein	  capable	  for	  binding	  of	  matrix	  components,	  to	  protect	  the	  cell	  against	  osmotic	  pressure	  changes	  and	   to	   control	   agglutination	   [370,	   372].	   Analysis	   of	   ebhA	   and	   ebhB	   in	   some	   genomes	  (Mu50,	  N315)	  showed	  that	   the	  original	  single	  open	  reading	   frame	  was	  disrupted	  by	  a	  frameshift	  mutation	  leading	  to	  their	  permanent	  separation	  [373].	  	  The	   genetic	   vicinity	   between	   known	   virulence	   factors	   and	   twice	   mutated	   genes	   of	  unknown	   pathogenicity	   could	   be	   interpreted	   as	   a	   sign	   of	   functional	   relatedness	   in	  respect	   to	   pathogenicity;	   however,	   this	   hypothesis	   remains	   to	   be	   confirmed	   by	  experimental	   studies.	   Mutations	   in	   pathogenicity-­‐associated	   genes	   may	   become	  selected	  due	  to	  enhanced	  infectivity,	  increased	  virulence	  [374]	  or	  increased	  fitness	  and	  better	   adaptation	   processes.	   Routine	   comparison	   of	   WGS	   data	   on	   blood	   stream	   and	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nasal	  CC5	  MRSA	  was	  limited	  in	  the	  present	  study	  because	  SNP	  analysis	  was	  restricted	  to	  mutations	   of	   the	   core	   genome	   due	   to	   technical	   reasons.	   It	   has	   been	   pointed	   out	   that	  mobile	  genetic	  elements	  encoding	  for	  antibiotic	  resistance	  and	  virulence	  [372]	  may	  be	  responsible	   for	   dynamic	   phenotypic	   changes.	   Hence,	   they	   were	   not	   covered	   in	   the	  present	   SNP	   analysis	   focusing	   on	   virulence-­‐associated	  mutations	   in	   the	   core-­‐genome	  [370].	  In	  contrast	  to	  WGS	  with	  core-­‐genome	  SNP	  approach,	  clustering	  of	  MA	  data	  did	  not	  allow	  sub-­‐clustering	   according	   to	   phylogenetic	   distances	   (Figure	   4a-­‐b).	   Instead,	   cluster	  analysis	   based	   on	   MA	   apparently	   identified	   distinct	   clusters	   of	   invasive	   isolates	  according	   to	   the	   presence	   of	   characteristic	   microarray	   hybridization	   profiles	   in	  accessory	  genes	  outside	   the	  core-­‐genome.	  However,	  discrimination	  of	  most	  MA	  based	  subgroups	  was	  not	  significant	  presumably	  due	  to	  low	  number	  of	  isolates	  in	  the	  present	  exploratory	  study.	  The	  presence	  of	  known	  and	  presumed	  virulence	  genes	  in	  related	  and	  unrelated	  MRSA	   CC5	   subgroups	   strengthens	   the	   hypothesis	   that	  MRSA	   virulence	   and	  invasion	   was	   not	   associated	   with	   phylotyping	   but	   with	   characteristic	   mutations	   of	  genome[359].	  	  In	  conclusion,	  we	  have	  shown	  that	  whole-­‐genome	  sequencing	  analyzed	  by	  phylogeny-­‐oriented	  mapping	   and	   SNP-­‐analysis	   of	   the	   core-­‐genome	  as	  well	   as	  DNA-­‐hybridization	  data	  detected	  by	  microarrays	  are	  able	   to	  provide	   important	   insight	  of	  complementary	  nature	   into	   evolution	   and	   virulence	   of	   MRSA	   CC5.	   This	   approach	   identifies	   potential	  new	   candidate	   virulence	   genes	   requiring	   confirmation	   by	   independent	   experimental	  studies.	   We	   also	   demonstrated	   that	   increased	   virulence	   and	   invasiveness	   was	   not	  associated	  with	  phylogeny.	  Coupled	  core-­‐	  and	  accessory	  genome	  WGS	  analyses	  require	  additional	  tools	  for	  better	  discrimination	  of	  infection	  associated	  and	  commensal	  MRSA	  strains.	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9. Conclusion	  and	  outlook	  	  	  	  	  	  	  
Synopsis	  
	  
In	   this	  chapter,	  we	  summarize	   the	  results	  achieved	   in	   this	   thesis	  and	  discuss	   the	  current	  
limitations	   of	   the	   introduced	   approaches	   and	   directions	   for	   further	   improvements.	  
Moreover,	  we	  shed	   light	  on	  possible	   implications	   for	   future	  research	  and	   follow-­‐up	  work	  
for	  this	  thesis.	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9.1 Accomplished	  work	  	  The	   enormously	   increasing	   availability	   of	   transcriptomic	   and	   epigenomic	   data	   from	  different	  biological	  experiments	  allow	  for	  deep	  and	  comprehensive	  integrative	  analysis.	  Functions	  of	  the	  molecular	  elements	  (genes,	  proteins,	  mutations,	  miRNAs,	  siRNAs,..etc)	  that	   represent	   the	   entities	   of	   such	   genomic	   data	   are	   highly	   connected	   with	   the	  underlying	   cellular	   malfunctions	   and	   disease	   pathways.	   Moreover,	   these	   molecular	  elements	  interact	  with	  each	  other	  forming	  a	  complex	  interwoven	  regulatory	  machinery	  that	  govern	   the	  cellular	  pathways	  of	  biological	   functions	  or	   the	  pathology	  of	  diseases.	  Therefore,	   revealing	   these	   critical	  molecular	   interactions	   in	   complex	   living	   systems	   is	  being	  considered	  as	  one	  of	  the	  major	  goals	  of	  the	  systems	  biology	  revolution	  nowadays.	  	  	  In	   this	   dissertation,	   we	   have	   introduced	   practical	   computational	   approaches	  implemented	   as	   freely	   available	   software	   tools	   to	   integrate	   heterogeneous	   sources	   of	  large-­‐scale	   genomic	   data	   and	   unravel	   the	   combinatorial	   regulatory	   interactions	  between	   different	   molecular	   elements.	   These	   proposed	   approaches	   were	   applied	   to	  investigate	   the	   molecular	   mechanisms	   of	   cellular	   differentiation	   as	   an	   example	   for	  biological	   processes	   and	  human	  breast	   cancer,	   and	  diabetes	   as	   examples	   for	   complex	  diseases.	  	  First,	  the	  automated	  GRN	  pipeline	  constructs	  the	  genomic	  regulatory	  machinery	  of	  a	  cell	  from	  expression,	  sequencing,	  and	  annotation	  datasets	  through	  three	  modules	  (Chapter	  3).	   The	   GRN	   pipeline	   starts	   with	   building	   the	   weighted	   co-­‐expression	   network,	   then	  searches	  for	  TFs	  motifs	   in	  the	  sequences	  of	   the	  network	  genes	  as	  well	  as	  harvests	  the	  known	   interactions	   whose	   source	   and	   end	   nodes	   are	   involved	   in	   the	   co-­‐expression	  networks.	   Next,	   the	   confirmed	   interactions	   between	   the	   two	   previous	   steps	   are	  subjected	   as	   a	   prior	   network	   to	   a	   Bayesian	   learner	   module.	   The	   selection	   of	   the	  Bayesian	   approach	   as	   a	   reconstruction	  method	  was	   based	   on	   the	   question	   of	   how	   to	  infer	   interactions	   while	   making	   use	   of	   what	   is	   already	   known.	   Bayesian	   network	  learning	   algorithms	   allow	   using	   initial	   network	   as	   a	   prior	   knowledge	   to	   guide	   the	  learning	   process.	   Moreover,	   Bayesian	   networks	   enable	   dealing	   with	   noises	   that	   are	  inherent	  in	  microarray	  data	  and	  to	  model	  hidden	  nodes	  in	  the	  network.	  Application	  of	  the	   GRN	   pipeline	   on	   gene	   expression	   and	   sequence	   data	   of	   blood	   cell	   differentiation	  (hematopoiesis,	   chapter	   5),	   mouse	   diabetes	   samples	   (chapter	   7),	   and	   human	   breast	  cancer	  data	  (chapter	  6)	  demonstrated	  its	  usefulness	  in	  unraveling	  the	  architecture	  and	  features	  of	  the	  corresponding	  GRN	  network.	  We	  have	  also	  assessed	  the	  performance	  of	  the	   GRN	   pipeline	   by	   benchmarking	   its	   results	   against	   two	   other	   statistical	   methods	  (chapter	   6)	   and	   found	   plausible	   overlaps	   that	   confirm	   the	   efficacy	   of	   the	   Bayesian	  approach	  in	  learning	  the	  GRN	  topology.	  Nevertheless,	  we	  refer	  to	  important	  limitations	  of	  Bayesian	  learning	  algorithms	  in	  the	  following	  section.	  	  The	   three	   modules	   of	   the	   GRN	   pipeline	   are	   implemented	   as	   separated	   software	  components	   (plugins)	   and	   hosted	   by	   our	   software	   framework	  Mebitoo	   for	   workflow	  automation.	  We	   note	   that	   coupling	   the	   third	  module	   is	   still	   in	   progress.	  Mebitoo	   is	   a	  software	   application	   suite	   written	   in	   Java	   that	   is	   based	   on	   the	   Netbeans	   Rich-­‐Client	  platform	   (RCP)	   project	   that	   can	   easily	   be	   extended	   with	   additional	   functionality	  deployed	   as	   modules.	   Since	   the	   Mebitoo	   framework	   implements	   a	   uniform	   plugin	  interface,	  automated	  data	  processing	  can	  be	  invoked	  using	  a	  task	  execution	  interface	  in	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order	   to	   queue	   multiple	   operations	   of	   different	   modules	   and	   process	   datasets	   in	  parallel.	  Mebitoo	   is	   appropriate	   for	   inexperienced	   users,	   researchers	   without	   programming	  knowledge	   as	  well	   as	   scientific	  programmers,	   and	  developers.	   For	   the	   first	   group,	  we	  provide	  an	  easy	  and	   friendly	  GUI	   that	  guides	   the	  user	   to	   sequentially	  define	  his	   tasks	  (every	  task	  represents	  one-­‐time	  running	  module)	  and	  gets	  the	  final	  results	  in	  one–click	  press	  button.	  	  For	  advanced	  users	  with	  knowledge	  in	  java	  programming,	  Mebitoo	  can	  be	  used	   as	   a	   ready	   hosting	   workflow	   automation	   framework	   for	   coupling	   more	   new	  bioinformatics	  add-­‐on	  plugins	  or	  modules.	  	  While	  the	  capabilities	  of	  the	  GRN	  pipeline	  are	  limited	  to	  capture	  only	  gene	  interaction	  information	   at	   the	   transcriptional	   level	   using	   gene	   expression	   and	   gene	   sequencing	  data,	   we	   further	   extended	   it	   to	   a	   general	   integrative	   network-­‐based	   approach	   that	  involves	   also	  post-­‐transcriptional	   interactions	   and	   reports	   the	   computational	   analysis	  of	   gene	   and	   miRNA	   transcriptomes,	   DNA	   methylome,	   and	   somatic	   mutations.	   This	  aimed	   at	   identifying	   putative	   disease	   drivers	   and	   novel	   targets	   for	   therapeutic	  treatment.	  This	  approach	  has	  been	  applied	  to	  breast	  cancer	  data	  and	  was	  able	  to	  reveal	  the	   strong	   association	  between	   regulatory	   elements	   from	   four	  different	   genomic	  data	  sources.	   This	   integrated	   molecular	   analysis	   enabled	   by	   this	   approach	   substantially	  expands	   our	   knowledge	   base	   of	   prospective	   genomic	   drivers	   of	   genes,	   miRNAs,	   and	  mutations	  highlights	  candidates	  for	  further	  investigation	  in	  the	  wet	  lab	  as	  novel	  targets	  for	  breast	  cancer	  treatment	  (Chapter	  6).	  	  Also	  by	  benchmarking	  the	  provided	  approach,	  it	   can	   be	   applied	   in	   a	   similar	   fashion	   to	   other	   cancer	   types,	   complex	   diseases,	   or	   for	  studying	  cellular	  functions	  where	  such	  multi-­‐dimensional	  datasets	  are	  available.	  	  Regarding	   to	   the	   incorporation	   of	   somatic	  mutations	  with	   other	   genomic	   data	   sets,	   a	  stand-­‐alone	  pipeline	  named	  “SnvDMiR”	  was	   implemented	  to	  explore	  possible	  genomic	  proximity	   relationships	   between	   somatic	   variants	   and	   both	   differentially	   methylated	  CpG	   sites	   as	   well	   as	   differentially	   expressed	   miRNAs.	   Further	   analysis	   on	   somatic	  variants	   that	   occur	   in	   close	   genomic	   vicinity	   to	   the	   deregulated	  miRNAs	   or	   CpG	   sites	  revealed	  mutations	  that	  are	  candidate	  drivers	  of	  oncogenic	  processes	  in	  breast	  cancer.	  With	  respect	   to	  the	  genomic	  mutations,	  we	  also	  presented	  an	  NGS	  pipeline	  to	   identify	  core-­‐genome	  SNPs	  and	  genetic	  variations	  between	   two	  groups	   in	  a	   similar	  analogy	   to	  somatic	   mutations	   between	   the	   healthy	   and	   disease	   cohorts.	   Since	   Whole	   Genome	  Sequencing	   data	   of	   tumor	   and	   healthy	   human	   samples	   were	   not	   accessible,	   the	   NGS	  pipeline	  was	  utilized	  on	  two	  groups	  of	  MRSA	  bacterial	   isolates	  (nasal	  and	   invasive)	   to	  investigate	   the	   phylogenetic	   positions	   of	   the	   recently	   emerged	   t504	   clone	   (Spa-­‐type	  t504)	   in	   the	   Saarland	   province	   of	   Germany	   and	   to	   better	   understand	   the	   infectivity	  mechanism	   of	   the	   invasive	   group	   as	   an	   example	   of	   a	   “from	   genotype	   to	   phenotype”	  study	  (Chapter	  8).	  	  Motivated	  by	   this,	  we	  developed	  TFmiR	  as	  a	   freely	  available	  web	  server	   for	  deep	  and	  integrative	   downstream	   analysis	   of	   combinatorial	   regulatory	   interactions	   between	  TFs/genes	  and	  miRNAs	  that	  are	  involved	  in	  human	  disease	  pathogenesis.	  TFmiR	  helps	  to	  better	  elucidate	  disease	  cellular	  mechanisms	  on	  the	  molecular	  level	  from	  a	  network	  perspective.	  The	  TFmiR	  web	  server	  is	  based	  on	  user-­‐provided	  sets	  of	  deregulated	  genes	  and/or	   miRNAs	   regardless	   of	   the	   data	   producing	   technologies	   of	   either	   microarray	  experiments,	  NGS,	  or	  PCR.	  The	  usefulness	  of	  TFmiR	  was	  confirmed	  by	  constructing	  the	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breast	  cancer–specific	  network	  and	  identifying	  literature-­‐confirmed	  core	  regulators	  as	  well	   as	   novel	   hub	   nodes	   of	   TFs/miRNAs	   that	   could	   be	   further	   experimentally	  investigated	   as	   new	   potential	   drug	   targets.	   TFmiR	   was	   also	   able	   to	   characterize	  important	  TF–miRNA	  co-­‐regulatory	  motifs	  whose	  co-­‐regulated	  genes	  form	  cooperative	  functional	   modules	   in	   breast	   cancerogenesis.	   Our	   web	   server	   showed	   advances	   over	  other	   related	  web	   tools	   in	   terms	  of	   the	   extended	  downstream	  analysis,	   the	   variety	  of	  user	   parameters,	   user	   call	   scenarios,	   and	   in	   terms	   of	   incorporating	   information	   from	  various	  well-­‐established	  regulatory	  databases.	  	  In	  summary,	  the	  work	  presented	  in	  this	  thesis	  has	  led	  to	  the	  development	  of	  interesting	  computational	   approaches	   that	   are	   introduced	   to	   the	   scientific	   literature	   in	   non-­‐commercial	  software	  toolkits.	  The	  provided	  topological	  and	   functional	  analyses	  of	  our	  frameworks	  as	  validated	  on	  cellular	  differentiation	  and	  complex	  diseases	  promotes	  our	  frameworks	   as	   reliable	   systems	   biology	   tools	   for	   researchers	   across	   the	   life	   science	  communities.	  
9.2 Limitations	  of	  this	  work	  	  	  The	  GRN	  pipeline	  utilizing	  a	  Bayesian	   learner	   showed	  a	   remarkable	  potential	   to	   infer	  the	   network	   topology.	   However,	   there	   are	   some	   inherent	   concerns	   that	   need	   to	   be	  mentioned.	   For	   instance,	   the	   Bayesian	   approach	   doesn’t	   allow	   cycles	   or	   loops	   in	   the	  inferred	   networks,	   whereas	   most	   genes	   have	   negative	   feedback	   effect	   on	   their	   own	  expression.	   Furthermore,	   Bayesian	   inference	   algorithms	   require	   sophisticated	  preprocessing	   procedures	   for	   the	   expression	   data	   such	   as	   normalization,	   data	  denoising,	   missing	   value	   imputation,	   and	   discretization.	   We	   didn’t	   encounter	   such	   a	  concern	   in	   any	   of	   our	   datasets	   because	   the	   data	   used	   were	   carefully	   preprocessed.	  Another	  major	   problem	   of	   Bayesian	   networks	   is	   the	   computational	   difficulty	   and	   the	  costly	  processing	  due	  to	  the	  dimensionality	  problem	  of	  the	  input	  microarray	  data.	  The	  Bayesian	  learning	  algorithms	  are	  not	  generally	  suited	  for	  inferring	  larger	  networks	  with	  hundreds	  or	  thousands	  of	  genes.	  However,	  assuming	  a	  sparse	  nature	  of	  the	  GRN	  where	  each	   gene	   is	   regulated	   by	   relatively	   few	   genes,	   data	   partitioning	   methods	   such	   as	  clustering	   and	   biclustering	   techniques	   have	   been	   introduced	   to	   group	   genes	   into	  functionally	  homogenous	  clusters	  before	  applying	  the	  Bayesian	  learner.	  	  	  As	   with	   any	   prediction	   method,	   the	   inferred	   interactions	   require	   experimental	  verification	   such	   as	   the	   standard	   laboratory	   knock-­‐out	   experiments,	   enforced	  expression	   of	   the	   TF	   and	   monitoring	   the	   expression	   pattern	   of	   the	   target	   gene,	   and	  Chipseq	  experiment	   to	  examine	  whether	   the	  binding	  motifs	  of	   the	  TF	  are	  close	   to	   the	  TSS	  of	   the	   target	  gene.	  However,	   this	  was	  not	  established	  parallel	   to	   this	  work	  due	   to	  lack	  of	  resources	  and	  time.	  The	  validation	  in	  this	  work	  was	  mainly	  based	  on	  literature-­‐confirmed	   evidences,	   other	   computational	   and	   statistical	   methods	   such	   as	   statistical	  significance,	   functional	   similarity,	   reporting	   phenotypes	   due	   to	   gene	   knock-­‐outs	   from	  MGI	   database,	   and	   based	   on	   benchmarking	   and	   assessing	   the	   performance	   against	  similar	  approaches.	  Unfortunately,	  gold	  standard	  networks	  for	  hematopoiesis	  or	  human	  cancer	   were	   not	   available	   to	   systematically	   verify	   the	   constructed	   interactions	   using	  AUC	  ROC	  and	  precision	  and	  recall	  curves.	  	  As	  discussed	  in	  Chapter	  6,	  the	  samples	  used	  as	  input	  for	  the	  integrative	  network	  based	  approach	  are	  the	  matched	  and	  common	  ones	  between	  the	  four	  TCGA	  data	  sets	  (mRNA	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Expression,	  DNA	  Methylation,	  miRNA	  expression,	  and	  somatic	  mutations).	  This	  means	  that	  data	  sets	  have	  to	  be	  consistent	  and	  belong	  to	  the	  same	  samples	  (cell	  lines/patients).	  Otherwise,	   technical	   variations	   between	   different	   samples	   cultured	   in	   various	   labs	  could	   lead	   to	   inappropriate	   results.	   A	   serious	   problem	  of	   this	   approach	   is	   the	   lack	   of	  consistent	   data	   as	   was	   reviewed	   in	   the	   blood	   cell	   differentiation	   (chapter	   5).	  Apparently,	   to	  date	  not	  many	  genomic	  data	  repositories	  offer	  such	  consistent	  data	   for	  developmental	   cell	   lines	   or	   diseases.	   Up	   to	   our	   knowledge,	   only	   the	   TCGA	   portal	  provides	   consistent	   data	   for	   normal	   and	   tumor	   samples	   for	   various	   cancer	   types	   in	  human.	  
9.3 Outlook	  	  Although	   heterogeneous	   sources	   of	   genomic	   datasets	   have	   been	   incorporated	   in	   this	  work	   to	   reverse	  engineer	   the	  complex	  regulatory	  networks,	   it	   is	   still	  not	  persuasively	  sufficient	   to	  build	   realistic	  dynamic	  models	   from	   the	  acquired	  GRN	  networks.	   	  This	   is	  due	   to	   the	   role	   of	   other	   cellular	  mechanisms,	  which	   are	   believed	   to	   contribute	   to	   the	  regulatory	  machinery	  in	  the	  cell	  such	  as	  epigenetic	  mechanisms	  (histone	  modifications,	  siRNA	   interference,	   regulated	   degradation	   of	   mRNA)	   and	   post-­‐translational	   events	   (	  protein	  phosphorylation,	  processing,	  or	  localization).	  Hence,	  there	  is	  abundant	  room	  for	  further	   research	   on	   deciphering	   the	   regulatory	   roles	   of	   these	   cellular	   activities	   by	  incorporating	  representing	  data	  sets	  to	  those	  introduced	  in	  this	  work.	  Along	  the	  same	  line,	   the	  biophysics	  nature	  of	   the	  cell	   like	   the	   roughness	  characteristics	  of	   the	   surface	  markers	   attached	   to	   the	   hematopoietic	   stem	   cells	   seemed	   to	   influence	   the	  differentiation	  competency	  of	  stem	  cells.	  This	  opens	  up	  new	  avenues	  for	  future	  research	  areas	  on	  assembling	  these	  biophysics	  properties	   into	   the	   full	  picture	  of	   the	  regulation	  machinery.	   However,	   more	   deep	   research	   on	   the	   regulatory	   role	   of	   biophysics	  characteristics	  of	  the	  cell	  needs	  to	  be	  undertaken	  in	  advance.	  	  	  Once	  the	  roles	  of	  cellular	  mechanisms	  affecting	  the	  regulatory	  machinery	  are	  encoded	  in	  the	  acquired	  network,	  it	  would	  be	  interesting	  to	  stimulate	  the	  network	  and	  study	  the	  network	  dynamics	  to	  identify	  master	  regulatory	  elements	  that	  are	  responsible	  for	  most	  genetic	   diseases	   and	   accordingly	   could	   serve	   as	   a	   commencing	   point	   for	   therapeutic	  treatment.	  Similarly	  in	  cellular	  programming,	  this	  would	  help	  in	  identifying	  key	  driver	  molecules	   and	   their	   interactions,	   which	   determine	   the	   conditions	   at	   which	   the	   cell	  switches	  to	  the	  next	  cell	  stage.	  	  	  On	   the	   other	   hand,	   it	   is	   fairly	   acceptable	   within	   the	   research	   community	   to	   classify	  biological	   networks	   into	   gene	   regulatory	   networks,	   signal	   transduction	   network,	  metabolic	  networks,	   and	  protein-­‐protein	   interaction	  network.	  Though,	   to	  what	   extent	  the	   transcriptional	   regulatory	  network	  can	  be	  decoupled	   from	  the	  other	  networks	   for	  the	  sake	  of	  reducing	  the	  complexity	  of	  biological	  systems.	  Further	  research	  work	  needs	  to	  examine	  more	  closely	  the	  links	  between	  the	  different	  biological	  networks.	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Table	  A-­‐1:	  Imprinted	  Gene	  list.	  The	  last	  column	  indicates	  whether	  the	  maternal	  (M)	  or	  paternal	  (P)	  allele	  is	  
expressed.	  P/M	  means	  that	  the	  gene	  exhibits	  species	  or	  isoform-­‐specific	  patterns	  of	  imprinting:	  human	  COPG2	  was	  reported	  to	  be	  paternally	  expressed,	  while	  this	  gene	  is	  maternally	  expressed	  in	  the	  mouse.	  Human	  ZIM2	  is	  paternally	  expressed,	  whereas	  the	  murine	  Zim2	  gene	  is	  active	  on	  the	  maternal	  chromosome.	  GRB10	  encodes	  maternally,	  and	  paternally	  expressed	  isoforms.	  “?”	  in	  the	  imprinting	  column	  indicates	  genes	  for	  which	  the	  imprinting	  status	  is	  not	  known.	  	  
Gene	  Name	  Description	  Imprinting	  Expressed	  
	  
Allele	  
Human	  (Mouse)	  Human	  Mouse	   ASB4	  (Asb4)	  	  ankyrin	  repeat	  and	  SOCS	  box-­‐containing	  4	  ?	  Y	  M	   ASCL2	  (Ascl2)	  	  achaete-­‐scute	   complex	   homolog	   2	  (Drosophila)	  ?	  Y	  M	   ATP10A	  (Atp10a)	  	  ATPase,	  class	  V,	  type	  10A	  Y	  ?	  M	   BEGAIN	  (Begain)	  brain-­‐enriched	   guanylate	   kinase-­‐associated	  homolog	  (rat)	  ?	  Y	  P	   Blcap	  bladder	  cancer	  associated	  protein	  Y	  Y	  M	   C15ORF2	  chromosome	  15	  open	  reading	  frame	  2	  Y	  (no	  ortholog)	  ?	   CALCR	  (Calcr)	  	  calcitonin	  receptor	  ?	  Y	  M	   CDKN1C	  (Cdkn1c)	  	  cyclin-­‐dependent	   kinase	   inhibitor	   1C	   (p57,	  Kip2)	  Y	  Y	  M	   COMMD1	  (Commd1)	  	  copper	   metabolism	   (Murr1)	   domain	  containing	  1	  N	  Y	  M	   COPG2	  (Copg2)	  	  coatomer	  protein	  complex,	  subunit	  gamma	  2	  ?	  Y	  P/M	   CPA4	  (Cpa4)	  	  carboxypeptidase	  A4	  Y	  ?	  M	   DIO3	  (Dio3)	  deiodinase,	  iodothyronine,	  type	  III	  ?	  Y	  P	   DLGAP2	  (Dlgap2)	  discs,	   large	   (Drosophila)	   homolog-­‐associated	  protein	  2	  Y	  ?	  P	   DLK1	  (Dlk1)	  	  delta-­‐like	  1	  homolog	  (Drosophila)	  Y	  Y	  P	   DLX5	  (Dlx5)	  	  distal-­‐less	  homeobox	  5	  Y	  ?	  M	   GNAS	  (Gnas)	  	  GNAS	  complex	  locus	  Y	  Y	  M	   GRB10	  (Grb10)	  	  growth	  factor	  receptor-­‐bound	  protein	  10	  Y	  Y	  P/M	   H13	  histocompatibility	  13	  ?	  Y	  M	   HTR2A	  (Htr2a)	  	  5-­‐hydroxytryptamine	  (serotonin)	  receptor	  2A	  ?	  Y	  M	   IGF2	  (Igf2)	  	  insulin-­‐like	  growth	  factor	  2	  	  Y	  Y	  P	   IGF2R	  (Igf2r)	  	  insulin-­‐like	  growth	  factor	  2	  receptor	  N	  Y	  M	   IMPACT	  (Impact)	  	  Impact	  homolog	  (mouse)	  no	  ortholog	  Y	  P	   INPP5F	  (Inpp5f)	  	  inositol	  polyphosphate-­‐5-­‐phosphatase	  F	  ?	  Y	  P	   INS	  (Ins2)	  	  insulin	  2	  Y	  Y	  P	   KCNQ1(Kcnq1)	  	  potassium	   voltage-­‐gated	   channel,	   KQT-­‐like	  subfamily,	  member	  1	  Y	  Y	  M	   KLF14	  (Klf14)	  Kruppel-­‐like	  factor	  14	  Y	  Y	  M	   KCNK9	  (Kcnk9)	  potassium	  channel,	  subfamily	  K,	  member	  9	  Y	  Y	  M	   L3MBTL	  (L3mbtl)	  	  lethal(3)malignant	   brain	   tumor-­‐like	   protein-­‐like	  Y	  N	  P	   LRRTM1	  (Lrrtm1)	  leucine	   rich	   repeat	   transmembrane	   neuronal	  1	  Y	  N	  P	   MAGEL2	  (Magel2)	  	  MAGE-­‐like	  2	  Y	  Y	  P	   MCTS2	  (Mcts2)	  malignant	  T	  cell	  amplified	  sequence	  2	  Y	  Y	  P	   MEST	  (Mest,	  Peg1)	  	  mesoderm	   specific	   transcript	   homolog	  (mouse)	  Y	  Y	  P	   MKRN3	  (Mkrn3)	  	  makorin	  ring	  finger	  protein	  3	  Y	  Y	  P	   NAP1L5	  (Nap1l5)	  	  nucleosome	  assembly	  protein	  1-­‐like	  5	  Y	  Y	  P	   NDN	  (Ndn)	  	  necdin	  homolog	  (mouse)	  Y	  Y	  P	   NNAT	  (Nnat)	  	  neuronatin	  Y	  Y	  P	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PEG3	  (Peg3)	  	  paternally	   expressed	   3;	   PEG3	   antisense	   RNA	  (non-­‐protein	  coding);	  zinc	  finger,	  imprinted	  2	  Y	  Y	  P	   PEG10	  (Peg10)	  	  paternally	  expressed	  10	  Y	  Y	  P	   (Peg12)	  	  paternally	  expressed	  12	  no	  ortholog	  Y	  P	   PHLDA2	  (Phlda2)	  	  pleckstrin	   homology-­‐like	   domain,	   family	   A,	  member	  2	  Y	  Y	  M	   PLAGL1	  (Plagl1)	  	  pleiomorphic	  adenoma	  gene-­‐like	  1	  Y	  ?	  P	   PPP1R9A	  (Ppp1r9a)	  	  protein	   phosphatase	   1,	   regulatory	   (inhibitor)	  subunit	  9A	  Y	  Y	  M	   PRIM2	  (Prim2)	  primase,	  DNA,	  polypeptide	  2	  (58kDa)	  Y	  ?	  M	   RASGRF1	  (Rasgrf1)	  	  Ras	   protein-­‐specific	   guanine	   nucleotide-­‐releasing	  factor	  1	  ?	  Y	  P	   SGCE	  (Sgce)	  	  sarcoglycan,	  epsilon	  Y	  Y	  P	   SLC22A18	  (Slc22a18)	  	  solute	  carrier	  family	  22,	  member	  18	  Y	  Y	  M	   SLC22A2	  (Slc22a2)	  	  solute	   carrier	   family	   22	   (organic	   cation	  transporter),	  member	  2	  ?	  Y	  M	   SLC22A3	  (Slc22a3)	  	  solute	   carrier	   family	   22	   (extraneuronal	  monoamine	  transporter),	  member	  3	  ?	  Y	  M	   SLC38A4	  (Slc38a4)	  	  solute	  carrier	  family	  38,	  member	  4	  ?	  Y	  P	   SNURF-­‐SNRPN	  	  small	   nuclear	   ribonucleoprotein	   polypeptide	  N;	  SNRPN	  upstream	  reading	  frame	  Y	  Y	  P	   TCEB3C	  	  transcription	   elongation	   factor	  B	  polypeptide	  3C-­‐like;	  	  Y	  N	  M	   TFPI2	  (Tfpi2)	  tissue	  factor	  pathway	  inhibitor	  2	  Y	  Y	  M	   TP73	  (Trp73)	  	  tumor	  protein	  p73	  Y	  ?	  M	   TRPM5	  (Trpm5)	  	  transient	   receptor	   potential	   cation	   channel,	  subfamily	  M,	  member	  5	  ?	  N	  P	   UBE3A	  (Ube3a)	  	  ubiquitin	  protein	  ligase	  E3A	  Y	  Y	  M	   USP29	  (Usp29)	  	  ubiquitin	  specific	  peptidase	  29	  ?	  Y	  P	   WT1-­‐Alt	  transcript	  (Wt1)	  	  Wilms	  tumor	  1	  Y	  ?	  P	   (Zim1)	  	  zinc	  finger,	  imprinted	  1	  no	  ortholog	  Y	  M	   ZIM2	  (Zim2)	  	  paternally	   expressed	   3;	   PEG3	   antisense	   RNA	  (non-­‐protein	  coding);	  zinc	  finger,	  imprinted	  2	  Y	  Y	  P/M	   ZIM3	  (Zim3)	  	  zinc	  finger,	  imprinted	  3	  ?	  Y	  M	   ZNF264	  (Zfp264)	  	  zinc	  finger	  protein	  264	  ?	  Y	  P	   ZNF331	  	  zinc	  finger	  protein	  331	  Y	  ?	  M	   ZNF597	  (Zfp597)	  zinc	  finger	  protein	  597	  Y	  ?	  M	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Figure	  A-­‐1:	  Heat	  map	  for	  the	  enriched	  transcription	  factor	  targets	  in	  the	  full	  set	  of	  imprinted	  genes	  in	  human	  
(a)	   and	  mouse	   (b)	   at	   p-­‐value	   of	   0.01.	  Marked	   in	   red	  and	  blue	   in	   the	   top	   line	  are	   the	  maternally	   and	  paternally	  expressed	  genes,	  respectively.	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Figure	   B-­‐1	   Heatmaps	   of	   differentially	   expressed	   imprinted	   genes	   (paternally	   expressed	   are	   in	   blue	   and	  
maternally	  expressed	  are	  in	  red),	  pluripotency	  genes	  (cyan),	  and	  hematopoietic	  genes	  (orange)	  along	  three	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Figure	  B-­‐2:	  	  Functional	  similarity	  scores	  computed	  with	  the	  FunSimMat	  tool	  based	  on	  the	  biological	  process	  
GO	   category	   between:	   A)	   imprinted	   and	   hematopoietic	   differentially	   expressed	   genes	   (red)	   compared	   to	   the	  similarity	   of	   the	   other	   genes	   in	   both	   gene	   sets	   (blue)	   and	   B)	   imprinted	   and	   differentially	   expressed	   pluripotency	  genes	  (red)	  compared	  to	  the	  similarity	  of	  the	  other	  genes	  in	  both	  gene	  sets	  (blue).	  In	  A	  the	  differentially	  expressed	  imprinted	  and	  hematopoietic	  genes	  show	  a	  significantly	  higher	  average	  functional	  similarity	  (~0.35	  to	  0.75)	  to	  each	  other	  than	  the	  background	  of	  the	  other	  genes	  in	  the	  two	  gene	  sets	  (about	  0.3).	  P-­‐values	  vary	  between	  0.178	  and	  6.0	  E-­‐237.	   In	   B	   the	   deferentially	   expressed	   imprinted	   and	   pluripotency	   genes	   show	   a	   significantly	   higher	   average	  functional	  similarity	  (~0.38	  to	  0.64)	  to	  each	  other	  than	  the	  background	  (about	  0.3).	  P-­‐values	  vary	  between	  0.006	  and	  4.5	  E-­‐24.	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Table	  B-­‐1.	  List	  of	  lineage-­‐specific	  imprinted,	  pluripotency,	  and	  hematopoietic	  genes	  in	  the	  investigated	  blood	  


















Lineage related phenotypes due to genes knock-
out 
(Not complete) 
Bcell 27 Ppp1r9a, Ndn, Slc22a3, 
Peg12, Sgce, Gatm, 
Cdkn1c, Gab1, Cmah, 
Asb4, Impact, Mkrn3, 
Tspan32, Phlda2, Cd81, 
Ddc, Mcts2, Tfpi2, Airn, 
Kcnq1ot1, Peg3, Sp2, Axl, 
Sfmbt2, Slc22a18, Nap1l4, 
Phf17 
102 Mpl, Smo, Ccnd1, Bmpr2, Relb, Gab1, 
Arid3b, Ctbp2, Rel, Tle2, Spp1, Tcf3, 
Mitf, Tcfeb, Lefty1, Klf2, Akt1, Creb1, 
Hcfc1, Mef2d, Smad1, Klf4, Ewsr1, 
Pik3cd, Tgfb1, Irs1, Pou2f1, Lef1, 
Psen1, Axin1, Rcn2, Dnmt3b, Pim3, 
Smarca4, Dhx9, Ehmt2, Mta2, Hras1, 
Kat5, Rif1, Stk40, Raf1, Sgk1, Myc, 
Zfx, Mbd3, Mapk1, Fgfr1, Hira, 
Smarca2, Zfp143, Carm1, Parp1, 
Acvr1b, Xpo4, Smarcad1, Ssrp1, P4ha1, 
Pias4, Satb2, Id1, Dffa, Paf1, Mycn, 
Ocln, Pbrm1, Rcor2, Wdr61, Fgf4, 
Wwp2, H3f3a, Smarcc1, Rbbp7, Grb2, 
Med12, Mtf2, Dnmt3a, Sumo1, Tcfe3, 
Ehmt1, Aes, Lyar, Smad4, Cdk2ap1, 
Il6st, Terf2, Chd4, Kdm4c, Ddb1, 
Smarca5, Phf17, Zfp57, Hdac1, Rela, 
Cdk2, Utf1, Hdac2, Grsf1, Ipo7, Smad2, 
Dnmt1, Acvr1 
64 Ccr7, Irf4, Meis1, Cd79a, 
Tmem176b, Fzd7, Tmem176a, 
Sox6, Hoxb3, Vnn1, Rbp1, 
Hoxa9, Ikzf3, Tgfbr3, Nbeal2, 
Prtn3, Dtx1, Pbx1, Dnaja3, Id2, 
Cd27, Polm, Pdgfrb, Dyrk3, 
Ccl5, Il7r, Fut7, Relb, Card11, 
Thsd1, Myo1e, Klf1, Il15, Rag2, 
Cxcr5, Slc40a1, Cebpa, Ahsp, 
Gfi1b, Gpr183, Flt3, Ccl3, Lta, 
Cd83, Lilrb3, Chd7, Il18r1, 
Angpt1, Tal1, Gata3, Kit, Spib, 
Ifnz, Tek, Gata2, H2-Ab1, 
Hdac5, Cd34, Pf4, Thoc5, Srf, 
Clec2i, Hlx, Trf 
MP:0002144-abnormal B cell differentiation 
MP:0004939-abnormal B cell morphology 
MP:0004978-decreased B-1 B cell number 
MP:0005093-decreased B cell proliferation 
MP:0008024-absent lymph nodes 
MP:0008209-decreased pre-B cell number 
MP:0000702-enlarged lymph nodes 
MP:0002023-B cell derived lymphoma 
MP:0002401-abnormal lymphopoiesis 
MP:0010763-abnormal hematopoietic stem cell 
physiology 
MP:0008102-lymph node hyperplasia 
MP:0004810-decreased hematopoietic stem cell 
number 
MP:0010763-abnormal hematopoietic stem cell 
physiology 
MP:0002459-abnormal B cell physiology 
MP:0008174-decreased follicular B cell number 
MP:0008470-abnormal spleen B cell follicle 
morphology 
MP:0005154- increased B cell proliferation 
MP:0004978- decreased B-1 B cell number 
 
Erythrocytes 4 Sgce, Mkrn3, Kcnq1ot1, 
Sfmbt2 
8 Stat3, Rcn2, Mpl, Satb1, Mef2c, 
Acvr1b, Smad1, Hras1 
11 Tek, Add2, Fli1, Crip2, Rbp1, 
Gata2, Satb1, Cd27, Ahsp, 
Mef2c, Acvr1b 
MP:0008973-decreased erythroid progenitor cell 
number 
MP:0009395-increased nucleated erythrocyte cell 
number 
MP:0002875-decreased erythrocyte cell number 
MP:0000245-abnormal erythropoiesis 
MP:0002447-abnormal erythrocyte morphology 
MP:0003656-abnormal erythrocyte physiology 
MP:0003657-abnormal erythrocyte osmotic lysis 
MP:0002416-abnormal proerythroblast 
morphology 
MP:0003131-increased erythrocyte cell number 




Granulocytes 6 Ppp1r9a, Sgce, Ndn, 
Peg12, Impact, Mkrn3 
3 Pml, Tert, Phc1 7 Hoxa5, Gfi1b, Gata3, Rbp1, 
Angpt1, Meis1, Csf1r 
MP:0000334-decreased granulocyte number 
MP:0005072-abnormal hair follicle melanin 
granule morphology 
MP:0000322-increased granulocyte number 
MP:0002396-abnormal hematopoietic system 
morphology/development  
MP:0002123-abnormal hematopoiesis 
MP:0000715-decreased thymocyte number 
Monocytes 9 Sgce, Peg12, Ndn, 
Ppp1r9a, Impact, Klrb1f, 
Mkrn3, Phlda2, Cdkn1c 
6 Mpl, Tle2, Tert, Phc1, Rel, Smad7 19 Cebpa, Csf1r, Egr1, Lgals1, 
Hoxa5, Gfi1b, Car2, Gata3, 
Rbp1, Angpt1, Gimap5, Tgfbr3, 
Pglyrp1, Meis1, Gata2, Sema4a, 
Nrarp, Tek, Junb 
MP:0008112-abnormal monocyte differentiation 
MP:0002445-abnormal mononuclear cell 
differentiation 
MP:0000220-increased monocyte cell number  
MP:0000223-decreased monocyte cell number 
MP:0002123-abnormal hematopoiesis 
Nkcell 12 Klrb1f, Ppp1r9a, Cdkn1c, 
Gab1, Ndn, Slc22a3, Sgce, 
Phlda2, Impact, Mkrn3, 
Cd81, Ampd3 
16 Mpl, Tcf7, Gab1, Relb, Lef1, Smo, Rif1, 
Mitf, Gatad2a, Klf2, Chd4, Rbl2, Sp1, 
Atrx, Axin1, Mycn 
45 Lck, Rbp1, Fzd7, Ccr2, Cd28, 
Id2, Card11, Tcf7, Meis1, Txk, 
Ifng, Vnn1, Tbx21, Sox6, 
Eomes, Tesc, Cd3d, Ikzf3, 
Bcl11a, Prdm1, Relb, Lef1, 
MP:0008040-decreased NK T cell number 
MP:0002339-abnormal lymph node morphology 
MP:0002123-abnormal hematopoiesis 
MP:0008047-absent uterine NK cells 
MP:0008038-abnormal NK T cell number 
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Angpt1, Tiparp, Kit, Ccl3, Tal1, 
Gata2, Sema4a, Zap70, Dyrk3, 
Ccl5, Gab3, Lyl1, Hoxa9, Prtn3, 
Tgfbr3, Tek, Chd7, Dtx1, H2-
Oa, Hdac9, Hlx, Polm, Rsad2 
MP:0008044-increased NK cell number 
MP:0008045-decreased NK cell number  
MP:0008046-absent NK cells 
 
 
Tcell 30 Ndn, Ppp1r9a, Sgce, 
Peg12, Gab1, Asb4, 
Slc22a3, Mkrn3, 
LOC100505359, Cdkn1c, 
Phlda2, Cmah, Gatm, 
Impact, Igf2r, Tfpi2, 
Slc22a18, Nap1l4, Sfmbt2, 
Th, Peg3, Mcts2, Sp2, 
Dhcr7, Plagl1, Ddc, H13, 
Tspan32, Cd81, Xlr4c 
70 Mpl, Tcf7, Ctbp2, Spp1, Gab1, Mef2c, 
Kdm6b, Zfp219, Tle2, Smad3, Lefty1, 
Ccnd1, Rcn2, Satb1, Smad1, Mitf, Lef1, 
Creb1, Pias4, Psen1, Mef2d, Fgfr1, 
Stk40, Klf2, Ocln, Socs1, Hras1, Ewsr1, 
Hdac1, Bmpr2, Mycn, Axin1, Ctcf, Aes, 
Grb2, Mbd3, Pim1, Ercc5, Hcfc1, 
Dnmt3b, Ehmt2, Pik3cd, Paf1, Mta2, 
Dhx9, Terf2, Ddb1, Med12, 
Gadd45gip1, Pim3, Smurf1, Tgfb1, 
Arid3b, Cdk2, Hira, Id1, Prkaca, Foxd3, 
Notch1, Hif1a, Il6st, Leo1, Tcf3, 
Smad2, Kat5, Acvr1b, Trp53, Atf2, 
Kdm6a, Dnmt3l 
53 Lck, Fzd7, Rbp1, Tcf7, Gata2, 
Dtx1, Prtn3, Tek, Tnfsf11, Il15, 
Meis1, Zap70, Bcl11b, Cd3e, 
Kit, Srf, Cd3d, Vnn1, Car2, 
Tal1, Dyrk3, Tirap, Lyl1, Pf4, 
Tesc, Sema4a, Anxa1, Hoxa9, 
Mef2c, Angpt1, Il7r, Gfi1b, 
Themis, Lta, Hdac9, Gata3, Itk, 
Ctla4, Tnf, Cd34, Hhex, Hlx, 
Gpr183, Ccr7, Cd4, Tcra, Nkap, 
Thoc5, Il2ra, Trf, Il4, Tbx21, 
Eomes 
MP:0002145-abnormal T cell differentiation 
MP:0005018-decreased T cell number 
MP:0008075-decreased CD4-positive T cell 
number  
MP:0008079-decreased CD8-positive T cell 
number 
MP:0008083-decreased single-positive T cell 
number 
MP:0002123-abnormal hematopoiesis 
MP:0008051-abnormal memory T cell physiology 
MP:0002024-T cell derived lymphoma 
MP:0008070-absent T cells 
 
Shared by all Lymphoid lineages:      Ppp1r9a, Ndn, Slc22a3, Sgce, Cdkn1c, Gab1, Impact, Mkrn3, Phlda2, Cd81, Meis1, Fzd7, Vnn1, Rbp1, Hoxa9, Prtn3, Dtx1, Dyrk3, Angpt1, Tal1, Kit, Tek, Gata2, Hlx, Mpl, Mitf, Klf2, 
Lef1, Axin1, Mycn 
Shared by all Myeloid lineages:       Sgce, Mkrn3, Rbp1 
Exclusive in Lymphoid Lineages:  Slc22a3, Gatm, Gab1, Cmah, Asb4, Tspan32, Cd81, Ddc, Mcts2, Tfpi2, Airn, Peg3, Sp2, Axl, Slc22a18, Nap1l4, Phf17, Ampd3, LOC100505359, Igf2r, Th, Dhcr7, Plagl1, H13, Xlr4c, 
Ccr7, Irf4, Cd79a, Tmem176b, Fzd7, Tmem176a, Sox6, Hoxb3, Vnn1, Hoxa9, Ikzf3, Nbeal2, Prtn3, Dtx1, Pbx1, Dnaja3, Id2, Polm, Pdgfrb, Dyrk3, Ccl5, Il7r, Fut7, Relb, Card11, Thsd1, Myo1e, Klf1, Il15, Rag2, Cxcr5, 
Slc40a1, Gpr183, Flt3, Ccl3, Lta, Cd83, Lilrb3, Chd7, Il18r1, Tal1, Kit, Spib, Ifnz, H2-Ab1, Hdac5, Cd34, Pf4, Thoc5, Srf, Clec2i, Hlx, Trf, Lck, Ccr2, Cd28, Tcf7, Txk, Ifng, Tbx21, Eomes, Tesc, Cd3d, Bcl11a, Prdm1, Lef1, 
Tiparp, Zap70, Gab3, Lyl1, H2-Oa, Hdac9, Rsad2, Tnfsf11, Bcl11b, Cd3e, Tirap, Anxa1, Themis, Itk, Ctla4, Tnf, Hhex, Cd4, Tcra, Nkap, Il2ra, Il4, Smo, Ccnd1, Bmpr2, Arid3b, Ctbp2, Spp1, Tcf3, Mitf, Tcfeb, Lefty1, Klf2, 
Akt1, Creb1, Hcfc1, Mef2d, Klf4, Ewsr1, Pik3cd, Tgfb1, Irs1, Pou2f1, Psen1, Axin1, Dnmt3b, Pim3, Smarca4, Dhx9, Ehmt2, Mta2, Kat5, Rif1, Stk40, Raf1, Sgk1, Myc, Zfx, Mbd3, Mapk1, Fgfr1, Hira, Smarca2, Zfp143, 
Carm1, Parp1, Xpo4, Smarcad1, Ssrp1, P4ha1, Pias4, Satb2, Id1, Dffa, Paf1, Mycn, Ocln, Pbrm1, Rcor2, Wdr61, Fgf4, Wwp2, H3f3a, Smarcc1, Rbbp7, Grb2, Med12, Mtf2, Dnmt3a, Sumo1, Tcfe3, Ehmt1, Aes, Lyar, Smad4, 
Cdk2ap1, Il6st, Terf2, Chd4, Kdm4c, Ddb1, Smarca5, Zfp57, Hdac1, Rela, Cdk2, Utf1, Hdac2, Grsf1, Ipo7, Smad2, Dnmt1, Acvr1, Gatad2a, Rbl2, Sp1, Atrx, Kdm6b, Zfp219, Smad3, Socs1, Ctcf, Pim1, Ercc5, Gadd45gip1, 
Smurf1, Prkaca, Foxd3, Notch1, Hif1a, Leo1, Trp53, Atf2, Kdm6a, Dnmt3l 
Exclusive in Myeloid Lineages: Add2, Fli1, Crip2, Hoxa5, Csf1r, Egr1, Lgals1, Gimap5, Pglyrp1, Nrarp, Junb, Stat3, Pml, Tert, Phc1, Smad7 
 	  
Table	  B-­‐2.	  Gene	  sets	  studied	  in	  this	  work.	  	  
Gene set Count Annotated in MS4302.0 array Description 
Imprinted genes 120 86 Imprinted genes selected from the Imprinting catalogs as 
described in methods 
Pluripotency genes 274 272 Genes involved in the PluriNetwork 
Hematopoietic genes 615 562 Genes annotated for GO:0048534: “hematopoietic or lymphoid 
organ development”  
Ign genes 169 155 Imprinted genes plus additional genes regulating the imprinted 
genes 
Ignpluri genes 20 20 Genes involved in both Ign and PluriNetwork 
Ignhema genes 17 17 Genes involved in both Ign and hematopoietic genes 
Ignshared genes 32 32 Combined list of genes shared between 1- Ign and 
hematopoietic genes. And 2- Ign and pluripotency genes 
Gene population (Total number of genes in the array) = 21390 
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Figure C-2. Proximity analysis of somatic mutations with the up-and down-methylated genes. Ideogram 
plots showing the genomic distributions of the somatic mutations occurring at promoter regions of (a) the up-
methylated genes (234 cases), and (b) down-methylated genes (113 cases). The outer green circle shows the 
entire set of differentially methylated genes, whereas the next highlighted red lines refer to the identified cases 
adjacent to the somatic mutations. The inner blue circle represents the entire set of somatic SNVs and the next 
highlighted red lines depict the matched SNVs in the identified cases. The plot illustrates also the fractions of 
the three considered types of mutations (C->T, C->G and C->A) showing the occurrence frequency for each. 
Obviously the C->T mutations for the up-methylated genes occur at a higher rate than its peers in the down-




Table	  C-­‐1.	  Ten	  most	  significant	  GO	  terms	  and	  KEGG	  pathways	  enriched	  in	  the	  list	  of	  the	  73	  candidate	  driver	  
genes.	  	  
Category Enriched term P-value 
GO functional 
terms 
GO:0006357~regulation of transcription from RNA polymerase II promoter 6.67E-09 
GO:0006355~regulation of transcription, DNA-dependent 1.15E-07 
GO:0006350~transcription 1.59E-07 
GO:0051252~regulation of RNA metabolic process 1.75E-07 
GO:0045449~regulation of transcription 1.96E-07 
GO:0034645~cellular macromolecule biosynthetic process 1.08E-06 
GO:0019219~regulation of nucleobase, nucleoside, nucleotide and nucleic acid 
metabolic process 1.10E-06 
GO:0010556~regulation of macromolecule biosynthetic process 1.24E-06 
GO:0009059~macromolecule biosynthetic process 1.26E-06 
GO:0051171~regulation of nitrogen compound metabolic process 1.33E-06 
   
KEGG pathways 
hsa05223:Non-small cell lung cancer 2.48E-03 
hsa04110:Cell cycle 3.42E-03 
hsa05215:Prostate cancer 1.01E-02 
hsa05219:Bladder cancer 1.91E-02 
hsa05200:Pathways in cancer 2.32E-02 
hsa05214:Glioma 4.06E-02 
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Table	  C-­‐2.	  A	  list	  of	  the	  33	  genes	  whose	  gene	  products	  are	  targeted	  by	  anti-­‐cancer	  drugs,	  characterized	  from	  
the	   three	  considered	  drug	  databases,	  CTD,	  PharmGKB,	  and	  Cancer	  resource.	  (1)	  means	  that	  at	  least	  one	  drug	  that	   targets	   this	  gene	  product	   is	  reported	   in	  this	  database,	  and	  (0)	  means	  no	  drugs	  are	  reported	  for	  the	  respective	  gene	  in	  this	  database.	  Not	  included	  are	  substances	  that	  are	  known	  to	  be	  cancerogenous	  or	  mutagenic.	  
 
Target gene Drug and antineoplastic agents CTD PharmGKB Cancer Resource 
ABCB8 docetaxel; Cyclosporine; Progesterone 1 0 0 
ABCG4 indole-3 carbinol; Methotrexate; exemestane; Vincristine 1 0 0 
AHCTF1 Methotrexate; bisphenol A 1 0 0 
AKT1 U 0126;tyrphostin AG 1478; Ursodeoxycholic Acid;Valproic Acid;tyrphostin AG 1024; trametinib; Tretinoin 1 0 1 
APOC1 tanshinone; Quercetin; Fluorouracil; bexarotene; Cisplatin; Tamoxifen 1 0 1 
AR Dihydrotestosterone; Acetylcysteine; celecoxib 1 0 0 
ATF6 Nelfinavir; Tretinoin;bisphenol A; Cyclosporine; Curcumin 1 0 0 
ATG4C epigallocatechin gallate 1 0 0 
ATP1B1 resveratrol; Ranitidine; vorinostat; Genistein; Progesterone; epigallocatechin gallate 1 0 0 
B4GALT7 Cytarabine; Cyclosporine 1 0 0 
BIRC6 Dieldrin; Cyclosporine; Cisplatin; Fluorouracil; Doxorubicin; Epirubicin;Estradiol; zoledronic acid; bisphenol A 1 0 0 
BRCA1 Tretinoin; trichostatin A; Estradiol; transplatin; troglitazone; Tunicamycin; fulvestrant 1 0 1 
CA6 Tretinoin;Carmustine 1 0 0 
CCDC130 Quercetin;Tamoxifen;Cyclosporine;bisphenol A 1 0 0 
CCDC92 Quercetin; Folic Acid 1 0 0 
CD2 Dexamethasone; Methotrexate; Cyclophosphamide 1 0 0 
CD79B Cyclophosphamide 1 0 0 
CDC34 Estradiol; bortezomib; Fluorouracil; Tamoxifen 1 0 0 
DAPK1 paclitaxel;gemcitabine 0 1 0 
EGR1 Fluorouracil; gemcitabine 0 0 1 
ESR1 exemestane;tamoxifen 0 1 1 
JUN andrographolide; cinnamic aldehyde; Daunorubicin; decitabine; Cisplatin;Doxorubicin 0 0 1 
LRRC28 gemcitabine 0 0 1 
MYB Fluorouracil;gemcitabine;Quercetin 0 0 1 
MYC alitretionoin; Amsarcine; bicalutamide; Camtothecin; decitabine; Cisplatin; Doxorubicin 0 0 1 
NFKB1 Curcumin; decitabine; Doorubicin; Echinomycin; Fluorouracil; gefitinib; indole-3-carbinol; parthenolide 0 0 1 
NQO2 doxorubicin; cyclophosphamide 0 1 0 
OS9 alitretionoin 0 0 1 
SP1 Etoposide; indole-3-carbinol; Ionidamine; Quercetin; Adaphostin 0 0 1 
STAT3 azaspirane; bisphenol A; Capsaicin; Fluorouracil; interferon alfacon-1; resveratrol;sulindac sulfide; Tamoxifen 0 0 1 
TGFB1 Doxorubicin; Fluorouracil; Thalidomide; Entinostat; Hyaluronidase 0 0 1 
TP53 4-biphenylmine; alliin; Apigenin; Atropine;bicalutamide;butylidenephthalide 0 0 1 
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Table	  D-­‐1:	  Final	  list	  of	  58	  GRN	  module	  genes	  and	  transcription	  factors.	  
Symbol	   Entrez	  Gene	  ID	   Definition	   LFC	  (ratio)	   P-­‐value	   Regulation	  
ABCC2	   12780	   Mus	   musculus	   ATP-­‐binding	   cassette,	   sub-­‐family	   C	  
(CFTR/MRP),	  member	  2	  (Abcc2),	  mRNA.	  
0.9920	   0.0111	   DOWN	  
AHR	   11622	   Mus	  musculus	  aryl-­‐hydrocarbon	  receptor	  (Ahr),	  mRNA.	   1.0029	   0.3787	   UP	  
ALX1	   216285	   Mus	  musculus	  ALX	  homeobox	  1	  (Alx1),	  mRNA.	   1.0025	   0.2549	   UP	  
AP1S1	   11769	   Mus	   musculus	   adaptor	   protein	   complex	   AP-­‐1,	   sigma	   1	  
(Ap1s1),	  mRNA.	  
0.9886	   0.3645	   DOWN	  
AR	   11835	   Mus	  musculus	  androgen	  receptor	  (Ar),	  mRNA.	   1.0027	   0.4901	   UP	  
ASPSCR1	   68938	   Mus	   musculus	   alveolar	   soft	   part	   sarcoma	   chromosome	  
region,	   candidate	   1	   (human)	   (Aspscr1),	   transcript	   variant	  
2,	  mRNA.	  
1.0093	   0.0419	   UP	  
BMF	   NA	   NA	   1.0324	   0.0001	   UP	  
CASP3	   NA	   NA	   0.9910	   0.0208	   DOWN	  
CCT7	   12468	   Mus	  musculus	  chaperonin	  containing	  Tcp1,	  subunit	  7	  (eta)	  
(Cct7),	  mRNA.	  
0.9792	   0.0020	   DOWN	  
CDS1	   74596	   Mus	   musculus	   CDP-­‐diacylglycerol	   synthase	   1	   (Cds1),	  
mRNA.	  
0.9952	   0.7725	   DOWN	  
CEBPA	   12606	   Mus	   musculus	   CCAAT/enhancer	   binding	   protein	   (C/EBP),	  
alpha	  (Cebpa),	  mRNA.	  
0.9868	   0.3237	   DOWN	  
CLCNKA	   12733	   Mus	  musculus	  chloride	  channel	  Ka	  (Clcnka),	  mRNA.	   0.9908	   0.0089	   DOWN	  
DR1	   13486	   Mus	   musculus	   down-­‐regulator	   of	   transcription	   1	   (Dr1),	  
mRNA.	  
0.9984	   0.7765	   DOWN	  
FOXA1	   15375	   Mus	  musculus	  forkhead	  box	  A1	  (Foxa1),	  mRNA.	   0.9948	   0.1571	   DOWN	  
FOXA2	   15376	   Mus	  musculus	  forkhead	  box	  A2	  (Foxa2),	  mRNA.	   0.9991	   0.6021	   DOWN	  
FOXD3	   15221	   Mus	  musculus	  forkhead	  box	  D3	  (Foxd3),	  mRNA.	   1.0019	   0.5498	   UP	  
FOXF2	   14238	   Mus	  musculus	  forkhead	  box	  F2	  (Foxf2),	  mRNA.	   0.9998	   0.9395	   DOWN	  
FOXI1	   14233	   Mus	  musculus	  forkhead	  box	  I1	  (Foxi1),	  mRNA.	   1.0043	   0.0695	   UP	  
FOXJ1	   15223	   Mus	  musculus	  forkhead	  box	  J1	  (Foxj1),	  mRNA.	   0.9964	   0.2217	   DOWN	  
FOXJ2	   60611	   Mus	  musculus	  forkhead	  box	  J2	  (Foxj2),	  mRNA.	   1.0160	   0.1175	   UP	  
FOXL1	   14241	   Mus	  musculus	  forkhead	  box	  L1	  (Foxl1),	  mRNA.	   1.0023	   0.4621	   UP	  
FOXO1	   NA	   NA	   1.0125	   0.3555	   UP	  
FOXO4	   54601	   Mus	  musculus	  forkhead	  box	  O4	  (Foxo4),	  mRNA.	   1.0003	   0.9086	   UP	  
FOXQ1	   15220	   Mus	  musculus	  forkhead	  box	  Q1	  (Foxq1),	  mRNA.	   1.0081	   0.3548	   UP	  
GATA1	   14460	   Mus	  musculus	  GATA	  binding	  protein	  1	  (Gata1),	  mRNA.	   0.9974	   0.8083	   DOWN	  
HNF4A	   15378	   Mus	   musculus	   hepatic	   nuclear	   factor	   4,	   alpha	   (Hnf4a),	  
mRNA.	  
0.9990	   0.7515	   DOWN	  
HNF4G	   30942	   Mus	   musculus	   hepatocyte	   nuclear	   factor	   4,	   gamma	  
(Hnf4g),	  mRNA.	  
1.0041	   0.1770	   UP	  
IKZF1	   22778	   Mus	   musculus	   IKAROS	   family	   zinc	   finger	   1	   (Ikzf1),	  
transcript	  variant	  1,	  mRNA.	  
1.0018	   0.8153	   UP	  
MAX	   17187	   Mus	  musculus	  Max	  protein	  (Max),	  mRNA.	   1.0166	   0.3979	   UP	  
MAZ	   17188	   Mus	  musculus	  MYC-­‐associated	  zinc	  finger	  protein	  (purine-­‐
binding	  transcription	  factor)	  (Maz),	  mRNA.	  
0.9978	   0.4452	   DOWN	  
MEF2C	   NA	   	   1.0114	   0.6041	   UP	  
NFATC2	   18019	   Mus	   musculus	   nuclear	   factor	   of	   activated	   T-­‐cells,	  
cytoplasmic,	   calcineurin-­‐dependent	   2	   (Nfatc2),	   transcript	  
variant	  2,	  mRNA.	  
0.9993	   0.6261	   DOWN	  
NFE2	   18022	   Mus	  musculus	   nuclear	   factor,	   erythroid	   derived	   2	   (Nfe2),	  
mRNA.	  
1.0174	   0.1184	   UP	  
NFKB1	   NA	   	   1.0048	   0.6109	   UP	  
NFYA	   18044	   Mus	  musculus	  nuclear	   transcription	   factor-­‐Y	  alpha	   (Nfya),	  
mRNA.	  
0.9975	   0.5666	   DOWN	  
NKX6-­‐2	   14912	   Mus	  musculus	  NK6	  homeobox	  2	  (Nkx6-­‐2),	  mRNA.	   0.9985	   0.4802	   DOWN	  
NR2F2	   11819	   Mus	   musculus	   nuclear	   receptor	   subfamily	   2,	   group	   F,	  
member	  2	  (Nr2f2),	  transcript	  variant	  2,	  mRNA.	  
0.9998	   0.8905	   DOWN	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PIK3C2A	   NA	   NA	   1.0080	   0.0003	   UP	  
POU6F1	   19009	   Mus	  musculus	  POU	  domain,	  class	  6,	  transcription	  factor	  1	  
(Pou6f1),	  mRNA.	  
1.0155	   0.0961	   UP	  
PPARA	   19013	   Mus	  musculus	  peroxisome	  proliferator	  activated	   receptor	  
alpha	  (Ppara),	  mRNA.	  
1.0015	   0.5671	   UP	  
PPARG	   19016	   Mus	  musculus	  peroxisome	  proliferator	  activated	   receptor	  
gamma	  (Pparg),	  mRNA.	  
0.9966	   0.2365	   DOWN	  
PTF1A	   NA	   NA	   1.0064	   0.0099	   UP	  
RUNX1	   12394	   Mus	  musculus	  runt	  related	  transcription	  factor	  1	   (Runx1),	  
mRNA.	  
0.9954	   0.5370	   DOWN	  
SLC12A1	   NA	   NA	   1.0026	   0.0054	   UP	  
SLC16A4	   229699	   Mus	   musculus	   solute	   carrier	   family	   16	   (monocarboxylic	  
acid	  transporters),	  member	  4	  (Slc16a4),	  mRNA.	  
0.9898	   0.0008	   DOWN	  
SLC22A1	   20517	   Mus	   musculus	   solute	   carrier	   family	   22	   (organic	   cation	  
transporter),	  member	  1	  (Slc22a1),	  mRNA.	  
1.0006	   0.7509	   UP	  
SPI15	   NA	   NA	   1.0020	   0.4474	   UP	  
SREBF1	   20787	   Mus	  musculus	   sterol	   regulatory	   element	   binding	   factor	   1	  
(Srebf1),	  mRNA.	  
0.9965	   0.2896	   DOWN	  
SRY	   21674	   Mus	   musculus	   sex	   determining	   region	   of	   Chr	   Y	   (Sry),	  
mRNA.	  
1.0003	   0.9368	   UP	  
TBP	   21374	   Mus	  musculus	  TATA	  box	  binding	  protein	  (Tbp),	  mRNA.	   0.9860	   0.0673	   DOWN	  
TCF3	   21415	   Mus	   musculus	   transcription	   factor	   3	   (Tcf3),	   transcript	  
variant	  1,	  mRNA.	  
1.0010	   0.6035	   UP	  
TCF7	   21414	   Mus	  musculus	  transcription	  factor	  7,	  T-­‐cell	  specific	   (Tcf7),	  
mRNA.	  
0.9992	   0.9032	   DOWN	  
TEF	   21685	   Mus	   musculus	   thyrotroph	   embryonic	   factor	   (Tef),	  
transcript	  variant	  1,	  mRNA.	  
1.0029	   0.4737	   UP	  
VDR	   22337	   Mus	  musculus	  vitamin	  D	  receptor	  (Vdr),	  mRNA.	   1.0022	   0.6336	   UP	  
ZEB1	   21417	   Mus	   musculus	   zinc	   finger	   E-­‐box	   binding	   homeobox	   1	  
(Zeb1),	  mRNA.	  
1.0110	   0.4390	   UP	  
E4BP4	   NA	   Unannotated	  in	  the	  microarray	  chip	   NA	   NA	   NA	  
TCF11MAFG	   NA	   Unannotated	  in	  the	  microarray	  chip	   NA	   NA	   NA	  
AHRARNT	   NA	   Unannotated	  in	  the	  microarray	  chip	   NA	   NA	   NA	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Table	  E-­‐1.	  List	  of	  the	  twice-­‐mutated	  genes	  and	  the	  associated	  functional	  terms.	  
Gene	  Name	   Gene	  Symbol	   Description	   Functional	  /	  metabolic	  /protein	  family	  group	  
SA2981_1390	   ebhB	   Putative	   Staphylococcal	   surface	   anchored	   protein;	  adhesin	  emb	   N.A	  
SA2981_1815	   pfoS/R	   Regulatory	  protein	   N.A	  
SA2981_1256	   glpF	   Glycerol	  uptake	  facilitator	  protein	   N.A	  
SA2981_2486	   feoB	   Ferrous	  iron	  transport	  protein	  B	   N.A	  
SA2981_2564	   yvcP	   Two-­‐component	  response	  regulator	  YvcP	   N.A	  
SA2981_0120	   sbnD	   Siderophore	   staphylobactin	   biosynthesis	   protein	  SbnD	  
Tetracycline	  resistance	  protein,	  TetA	  	  	  (INTERPRO)	  
	  	  
tetracycline	  transport	  (GO:0015904)	  
antibiotic	  transport	  (GO:0042891)	  
drug:hydrogen	  antiporter	  activity	  (GO:0015307)	  
response	  to	  stimulus	  (GO:0050896)	  
SA2981_1100	   mutS2	   Recombination	  inhibitory	  protein	  MutS2	   response	  to	  stimulus	  (GO:0050896)	  
SA2981_1178	   prkC	   Serine/threonine	   protein	   kinase	   PrkC,	   regulator	   of	  stationary	  phase	   N.A	  
SA2981_1260	   miaA	   tRNA	   delta(2)-­‐isopentenylpyrophosphate	  transferase	   N.A	  
SA2981_1284	   thrC	   Threonine	  synthase	   N.A	  
SA2981_1323	   trpD	   Anthranilate	  phosphoribosyltransferase	   Two-­‐component	  system	  (KEGG)	  
SA2981_1468	   gnd	   6-­‐phosphogluconate	   dehydrogenase,	  decarboxylating	   N.A	  
SA2981_1511	   sodA	   Manganese	   superoxide	   dismutase;	   Superoxide	  dismutase	  (Fe)	   response	  to	  stimulus	  (GO:0050896)	  
SA2981_1826	   tagG	   Teichoic	  acid	  translocation	  permease	  protein	  TagG	   N.A	  
SA2981_2019	   kdpD	   Osmosensitive	  K+	  channel	  histidine	  kinase	  KdpD	   Two-­‐component	  system	  (KEGG:)	  
SA2981_2265	   metT	   Methionine	  transporter	  MetT	   N.A	  
SA2981_2294	   tcaB	   Teicoplanin	   resistance	   associated	   membrane	  protein	  TcaB	  
Tetracycline	  resistance	  protein,	  TetA	  (INTERPRO:)	  
	  	  
tetracycline	  transport	  (GO:0015904)	  
antibiotic	  transport	  (GO:0042891)	  
drug:hydrogen	  antiporter	  activity	  (GO:0015307)	  
response	  to	  stimulus	  (GO:0050896)	  
SA2981_2400	   opp-­‐1F	   Oligopeptide	   transporter	   putative	   ATPase	   domain	  protein	   N.A	  
	  
	  
Table	  E-­‐2.	  	  List	  of	  the	  SNPs	  occurring	  in	  at	  least	  2	  invasive	  strains	  but	  in	  none	  of	  the	  nasal	  strains,	  their	  genes,	  
and	  the	  resulting	  amino	  acid	  change.	  For	  the	  amino	  acid	  change	  in	  the	  five	  cases	  of	  insertions,	  the	  original	  reading	  frame	  (ORF)	  is	  shifted	  leading	  to	  a	  wide	  change	  in	  the	  amino	  acid	  chain.  















SA2981_0120	   sbnD	   Siderophore staphylobactin biosynthesis protein SbnD 131858	   G	   T	   W	  to	  C	   4.05E-­‐51	  
SA2981_0148	   -­‐	   	  	   162408	   T	   C	   none	  (D)	   2.21E-­‐50	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SA2981_0542	   -­‐	   	  	   616048	   A	   G	   none	  (G)	   2.83E-­‐52	  
SA2981_0561	   -­‐	   	  	   631881	   G	   A	   R	  to	  K	   3.54E-­‐53	  
SA2981_0710	   -­‐	   	  	   783925	   T	   C	   none	  (I)	   1.36E-­‐48	  
SA2981_0711	   -­‐	   	  	   784904	   A	   G	   Q	  to	  R	   2.83E-­‐61	  
SA2981_0724	   -­‐	   	  	   797606	   G	   GA	   ORF	  shifted	   1.81E-­‐47	  
SA2981_0874	   -­‐	   	  	   921757	   G	   A	   G	  to	  D	   2.97E-­‐53	  
SA2981_0978	   -­‐	   	  
1035879	   A	   G	   I	  to	  V	   4.15E-­‐40	  
1036742	   G	   A	   M	  to	  I	   1.86E-­‐70	  
SA2981_1074	   -­‐	   	  	   1131989	   C	   T	   T	  to	  I	   3.51E-­‐44	  
SA2981_1100	   mutS2	   Recombination inhibitory protein MutS2 1157221	   C	   T	   none	  (S)	   9.61E-­‐67	  
SA2981_1178	   prkC	  
Serine/threonine protein kinase 
PrkC, regulator of stationary 
phase 
1237441	   G	   T	   A	  to	  S	   2.81E-­‐52	  
SA2981_1251	   -­‐	   	  	   1324647	   C	   A	   T	  to	  N	   2.45E-­‐37	  
SA2981_1256	   glpF	   Glycerol uptake facilitator protein 1331327	   C	   CT	  
ORF	  
shifted	   2.41E-­‐29	  




1336837	   A	   G	   D	  to	  G	   8.05E-­‐45	  
SA2981_1284	   thrC	   Threonine synthase 1361487	   C	   T	   S	  to	  F	   1.61E-­‐30	  
SA2981_1288	   -­‐	   	  	   1365826	   T	   C	   T	  to	  A	   1.59E-­‐26	  
SA2981_1323	   trpD	   Anthranilate phosphoribosyltransferase 1409763	   T	   C	   R	  to	  R	   2.78E-­‐38	  
SA2981_1390	   ebhB	   Putative Staphylococcal surface anchored protein; adhesin emb 1503065	   C	   T	   S	  to	  N	   7.67E-­‐41	  
SA2981_1468	   gnd	   6-phosphogluconate dehydrogenase, decarboxylating 1585512	   G	   A	   none	  (F)	   2.40E-­‐23	  




1622766	   C	   T	   G	  to	  D	   2.46E-­‐33	  
SA2981_1815	   pfoS/R	   Regulatory protein 1946895	   C	   CAAT	   add	  R	   1.93E-­‐31	  
SA2981_1826	   tagG	   Teichoic acid translocation permease protein TagG 1967972	   A	   T	   F	  to	  Y	   2.88E-­‐51	  
SA2981_2019	   kdpD	   Osmosensitive K+ channel 
histidine kinase KdpD 
2151346	   G	   GA	   ORF	  shifted	   1.37E-­‐53	  
SA2981_2265	   metT	   Methionine transporter MetT 2394447	   A	   T	   none	  (G)	   5.88E-­‐62	  
SA2981_2284	   -­‐	   	  	   2414503	   G	   A	   A	  to	  T	   7.91E-­‐77	  
SA2981_2294	   tcaB	  
Teicoplanin resistance 
associated membrane protein 
TcaB 
2424068	   A	   G	   I	  to	  T	   1.70E-­‐62	  
SA2981_2329	   -­‐	   	  	   2462332	   C	   T	   none	  (L)	   1.14E-­‐59	  
SA2981_2366	   -­‐	   	  	   2504026	   G	   A	   P	  to	  S	   8.70E-­‐67	  
SA2981_2367	   -­‐	   	  	   2504949	   A	   G	   I	  to	  V	   3.05E-­‐58	  
SA2981_2370	   -­‐	   	  	   2507139	   C	   CA	   ORF	  shifted	   1.69E-­‐24	  
SA2981_2400	   opp-­‐1F	  
Oligopeptide transporter 
putative ATPase domain protein 
2541624	   C	   T	   A	  to	  T	   4.11E-­‐76	  
SA2981_2486	   feoB	   Ferrous iron transport protein B 2637050	   C	   T	   V	  to	  M	   3.31E-­‐61	  
SA2981_2556	   -­‐	   	  	   2710563	   T	   C	   none	  (K)	   2.77E-­‐50	  
SA2981_2564	   yvcP	   Two-component response regulator YvcP 2721091	   G	   T	   P	  to	  T	   2.38E-­‐71	  
SA2981_2642	   -­‐	   	  	   2812721	   G	   T	   R	  to	  L	   3.21E-­‐48	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